

0001213900-24-09196110-Q CorMedix Inc. 2024103020241030082035082035082035 0 0001213900-24-091961 10-Q 54 20240930 20241030 20241030 CorMedix Inc. 0001410098 2834 0000000000 DE 1231 10-Q 34 001-34673 241407530 300 CONNELL DRIVE SUITE 4200 BERKELEY HEIGHTS NJ 07922 908-517-9500 300 CONNELL DRIVE SUITE 4200 BERKELEY HEIGHTS NJ 07922 10-Q 1 ea0218371-10q cormedix.htm QUARTERLY REPORT A A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 A FORM 10-Q A (Mark One) A QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 A For the quarterly period ended September 30, 2024 A TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 A For the transition period from to A Commission file number 001-34673 A CORMEDIX INC. (Exact Name of Registrant as Specified in Its Charter) A Delaware A 20-5894890 (State or Other Jurisdiction of Incorporation or Organization) A (I.R.S. Employer Identification No.) A A 300 Connell Drive, Suite 4200, Berkeley Heights, NJ A 07922 (Address of Principal Executive Offices) A (Zip Code) A (908) 517-9500A (Registrant's Telephone Number, Including Area Code) A Securities registered pursuant to Section 12(b) of the Act: A Title of each class A Trading Symbol(s) A Name of each exchange on which registered Common stock, \$0.001 par value A CRMD A Nasdaq Global Market A Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes A No A Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (A\$232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes A No A Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of A large accelerated filer, A accelerated filer, A smaller reporting company, and A emerging growth company in Rule 12b-2 of the Exchange Act. A Large accelerated filer A Accelerated filer A Non-accelerated filer A Smaller reporting company A Emerging Growth Company A A A If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. A A Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes A No A The number of shares outstanding of the issuer's common stock, as of October 28, 2024 was 60,677,204. A A A A A CORMEDIX INC. AND SUBSIDIARIES A INDEX A A Page PART I FINANCIAL INFORMATION A A Item 1. Unaudited Condensed Consolidated Financial Statements A A A Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 A A A Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023 A A A A Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Nine Months Ended September 30, 2024 and 2023 A A A A Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 A A A Notes to Unaudited Condensed Consolidated Financial Statements A A A Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations A A A Item 3. Quantitative and Qualitative Disclosure About Market Risk A A A A Item 4. Controls and Procedures A A A PART II OTHER INFORMATION A A A Item 1. Legal Proceedings A A A A Item 1A. Risk Factors A A A A Item 2. Unregistered Sales of Equity Securities and Use of Proceeds A A A A Item 3. Defaults Upon Senior Securities A A A A Item 4. Mine Safety Disclosure A A A A Item 5. Other Information A A A A Item 6. Exhibits A A A A SIGNATURES A A A A PART I FINANCIAL INFORMATION A A A Item 1. Unaudited Condensed Consolidated Financial Statements. A CorMedix Inc. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS A A September 30, 2024 (Unaudited) A December 31, 2023 A ASSETS A A A A Current assets A A A A Cash and cash equivalents A \$35,286,138 A \$43,642,684 A Restricted cash A A A A 77,453 A Short-term investments A A 10,743,562 A A 32,388,130 A Trade receivables, net A 17,387,446 A A Inventories, net A 6,649,495 A A 2,106,345 A Prepaid research and development expenses A A 170,739 A A 353,574 A Other prepaid expenses and current assets A 2,916,889 A A 882,214 A Total current assets A 73,154,269 A A 79,450,400 A Property and equipment, net A 1,899,875 A A 1,866,224 A License intangible asset, net A 1,896,104 A A A Restricted cash, long-term A 105,084 A A 103,055 A Operating lease right-of-use asset A 530,862 A A 640,278 A TOTAL ASSETS A \$77,586,194 A \$82,059,957 A A A A A LIABILITIES AND STOCKHOLDERS' EQUITY A A A A Current liabilities A A A A Accounts payable A \$1,343,833 A \$4,279,679 A Accrued expenses A 16,973,677 A A 6,970,217 A Operating lease liability, short-term A 163,449 A A 150,619 A Total current liabilities A 18,480,959 A A 11,400,515 A Operating lease liability, net of current portion A 392,967 A A 517,013 A TOTAL LIABILITIES A 18,873,926 A A 11,917,528 A A A A A COMMITMENTS AND CONTINGENCIES (Note 5) A A A A A A A A A A STOCKHOLDERS' EQUITY A A A A Preferred stock - \$0.001 par value: 2,000,000 shares authorized; 181,622 shares issued and outstanding at September 30, 2024 and December 31, 2023 A 182 A A 182 A Common stock - \$0.001 par value: 160,000,000 shares authorized; 57,887,149 and 54,938,258 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively A 57,886 A A 54,938 A Accumulated other comprehensive gain A 89,120 A A 94,108 A Additional paid-in capital A 411,659,517 A A 391,693,214 A Accumulated deficit A (353,094,437) A (321,700,013) TOTAL STOCKHOLDERS' EQUITY A 58,712,268 A A 70,142,429 A TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY A \$77,586,194 A \$82,059,957 A See Accompanying Notes to Unaudited Condensed Consolidated Financial Statements. A A A CorMedix Inc. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) A A For the Three Months Ended September 30, 2024 A For the Nine Months Ended September 30, 2024 A 2024 A 2023 A 2024 A 2023 A Revenue A A A A A A A A Net sales A \$11,456,115 A \$- A \$12,262,234 A \$- A Cost of sales A (686,598) A A A (2,014,975) A A Gross profit A 10,769,517 A A A 10,247,259 A A Operating Expenses A A A A A A A A Research and development A (727,119) A (2,663,976) A (2,215,551) A (10,866,236) Selling and marketing A (6,748,900) A (4,058,428) A (20,472,961) A (9,955,651) General and administrative A (6,580,834) A (3,744,879) A (22,851,144) A (12,467,157) Total Operating Expenses A (14,056,853) A (10,467,283) A (45,539,656) A (33,289,044) Loss From Operations A (3,287,336) A (10,467,283) A (35,292,397) A (33,289,044) Other Income (Expense): A A A A A A A A Interest income A 553,856 A A 765,241 A A 2,068,407 A A 1,761,808 A Foreign exchange transaction loss A (33,325) A A (29,199) A A (38,806) A A A A A A Other income A A A A A A 500,000 A A Interest expense A (10,007) A A (13,113) A A (26,398) A A (27,740) Total Other Income A 510,524 A A 722,929 A A 2,503,203 A A 1,703,846 A Loss before income taxes A (2,776,812) A (9,744,354) A (32,789,194) A (31,585,198) Tax benefit A A A A A A 1,394,770 A A Net Loss A (2,776,812) A (9,744,354) A (31,394,424) A (31,585,198) Other Comprehensive Income (Loss): A A A A A A A A Unrealized gain (loss) from investments A 5,040 A A (4,571) A A (3,832) A A 1,090 A Foreign currency translation (loss) gain A (1,651) A A (1,727) A A (1,156) A A 566 A Total Other Comprehensive Income (Loss) A 3,389 A A (6,298) A A (4,988) A A 1,656 A Comprehensive Loss A (2,773,423) A (9,750,652) A (31,399,412) A (31,583,542) Net Loss Per Common Share A Basic and Diluted A (0.05) A (0.17) A (0.54) A (0.65) Weighted Average Common Shares Outstanding A Basic and Diluted A 58,225,221 A A 56,553,174 A A 57,986,190 A A 48,715,585 A See Accompanying Notes to Unaudited Condensed Consolidated Financial Statements. A A A CorMedix Inc. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) A For the three months ended September 30, 2024 A A Common Stock A Preferred Stock - Series C-3, Series E and Series G A Accumulated Other Comprehensive A Additional Paid-in A Accumulated A Total Stockholders' A A Shares A Amount A Shares A Amount A Income A Capital A Deficit A Equity A Balance at July 1, 2024 A 55,274,791 A \$55,274 A 181,622 A A 182 A \$85,731 A \$396,360,369 A \$350,317,625 A \$46,183,931 A Stock issued in connection with ATM sale of common stock, net A 2,290,024 A A 2,290 A A A A A 12,364,191 A A A 12,366,481 A Stock issued in connection with options exercised A 322,334 A A 322 A A A A A A 1,707,481 A A A 1,707,803 A Stock-based compensation A A A A A A A A 1,227,476 A A A 1,227,476 A Other comprehensive gain A A A A A A A A 3,389 A A A A 3,389 A Net loss A A A A A A A A (2,776,812) A A (2,776,812) A Balance at September 30, 2024 A 57,887,149 A \$57,886 A 181,622 A 182 A \$89,120 A \$411,659,517 A (353,094,437) A For the nine months ended September 30, 2024 A A A Common Stock A Preferred Stock - Series C-3, Series E and Series G A Accumulated Other Comprehensive A Additional Paid-in A Accumulated A Total Stockholders' A A Shares A Amount A Shares A Amount A Income A Capital A Deficit A Equity A Balance at January 1, 2024 A 54,938,258 A \$54,938 A 181,622 A 182 A \$94,108 A \$391,693,214 A (321,700,013) A \$70,142,429 A Stock issued in connection with ATM sale of common stock, net A 2,521,

management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary to fairly state the interim results. Interim operating results are not necessarily indicative of results that may be expected for the full year ending December 31, 2024, or for any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto of the Company which are included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 12, 2024. The accompanying consolidated balance sheet as of December 31, 2023 has been derived from the audited financial statements included in such Annual Report on Form 10-K. A Note 2 - Summary of Significant Accounting Policies and Liquidity and Uncertainties: A Liquidity and Uncertainties A The condensed consolidated financial statements have been prepared in conformity with GAAP which contemplate continuation of the Company as a going concern. To date, the Company's commercial operations have not generated sufficient revenues to enable profitability. The Company's current commercial and development expenses for DefenCath and its other operating requirements are expected to be funded for at least twelve months from the issuance of this Quarterly Report on Form 10-Q by the Company's existing cash, cash equivalents and short-term investments at September 30, 2024 and its expected liquidity from commercial operations. A The Company may raise additional capital through various potential sources, such as equity and/or debt financing, strategic relationships, potential strategic transactions and/or out-licensing. Management can provide no assurances that such financing or strategic relationships will be available on acceptable terms, or at all. As of September 30, 2024, approximately \$36,012,000 of the Company's common stock remains available for sale under the 2024 ATM program, with \$100,000,000 of remaining capacity under the 2024 Shelf Registration Statement for the issuance of Company securities (see Note 6). A The Company's operations are subject to a number of other factors that can affect its operating results and cash flow projections over the next twelve months from the issuance of these financial statements. Such factors include, but are not limited to: the ability to market DefenCath and generate necessary revenue in the time periods required; ability to manufacture successfully; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company products; the Company's ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; and the Company's ability to raise capital to support its operations. A 6 A CORMEDIX INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued) A Use of Estimates A The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Company's consolidated balance sheets and the reported amounts of revenue and expenses reported for each of the periods presented are affected by estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from those estimates. A Reclassifications A Certain reclassifications were made to the prior year's amounts to conform to the 2024 presentation. A Basis of Consolidation A The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. A Trade Accounts Receivable and Allowances A The Company complies with ASU 2016-13, A Measurement of Credit Losses on Financial Instruments, A which requires the Company to recognize an allowance that reflects a current estimate of credit losses expected to be incurred over the life of a financial asset, including trade receivables. The allowance for credit losses reflects the best estimate of expected credit losses of the accounts receivable portfolio determined on the basis of current information, forecasts of future economic conditions, industry knowledge and to some extent our historical experience. The Company determines its allowance methodology by pooling receivable balances at the customer level. The Company considers various factors, including individual credit risk associated with each customer, the current and future condition of the general economy and industry knowledge. These credit risk factors are monitored on a quarterly basis and updated as necessary. To the extent any individual debtor is identified whose credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of such customer. The Company makes concerted efforts to collect all outstanding balances due, however account balances are charged off against the allowance when management believes it is probable the receivable will not be recovered. The Company does not have any off-balance sheet credit exposure related to its customers. There are no significant allowances recorded for credit losses as of September 30, 2024. A Concentrations A The major customers of the Company are defined as those constituting greater than 10% of its total revenue. In the three and nine months ended September 30, 2024, the Company had sales to one customer that accounted for 98% and 92% of its total revenue of \$11,456,000 and \$12,262,000, respectively. This customer also accounts for 100% of the Company's accounts receivable as of September 30, 2024. The Company currently has one FDA approved source for each of its two key active pharmaceutical ingredients for DefenCath, tauridine and heparin sodium. A Financial Instruments A Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, short-term investments and accounts receivable. The Company maintains its cash and cash equivalents in bank deposit and other interest-bearing accounts, the balances of which, at times, may exceed federally insured limits. A The following table is the reconciliation of the accounting standard that modifies certain aspects of the recognition, measurement, presentation and disclosure of financial instruments as shown on the Company's consolidated statement of cash flows: A A September 30, A A 2024 A A 2023 A Cash and cash equivalents A \$35,286,138 A A \$53,313,811 A Restricted cash A \$105,084 A A \$187,210 A Total cash, cash equivalents and restricted cash A \$35,391,222 A A \$53,501,021 A A 7 A CORMEDIX INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued) A The appropriate classification of marketable securities is determined at the time of purchase and revalued as of each balance sheet date. Investments in marketable debt classified as available-for-sale are reported at fair value. Fair value is determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are considered temporary are reported in other comprehensive income. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense). The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. There were no deemed permanent impairments at September 30, 2024 or December 31, 2023. A A The Company's marketable securities are highly liquid and consist of U.S. government agency securities, high-grade corporate obligations and commercial paper with original maturities of more than 90 days. As of September 30, 2024 and December 31, 2023, all of the Company's investments had contractual maturities of less than one year. The following table summarizes the amortized cost, unrealized gains and losses and the fair value at September 30, 2024 and December 31, 2023: A A Amortized Cost A Gross Unrealized Losses A Gross Unrealized Gains A Fair Value A September 30, 2024: A A A A A A Money Market Funds included in Cash Equivalents A \$23,021,807 A A \$- A A \$23,021,807 A U.S. Government Agency Securities A \$9,550,898 A A (254) A A \$4,174 A A \$9,554,818 A Commercial Paper A \$1,187,415 A A \$- A A \$1,187,415 A A 1,329 A A \$1,188,744 A Subtotal A \$10,738,313 A A (254) A A \$5,503 A A \$10,743,562 A Total September 30, 2024 A \$33,760,120 A A (254) A A \$5,503 A A \$33,765,369 A December 31, 2023: A A A A A A A A A A A A Money Market Funds included in Cash Equivalents A \$32,541,230 A A \$- A A \$32,541,230 A U.S. Government Agency Securities A \$9,701,677 A A \$- A A \$10,506 A A \$29,712,183 A Commercial Paper A \$2,677,372 A A (1,425) A A \$2,675,947 A Subtotal A \$32,379,049 A A (1,425) A A \$10,506 A A \$32,388,130 A Total December 31, 2023 A \$64,920,279 A A (1,425) A A \$10,506 A A \$64,929,360 A Fair Value Measurements A In accordance with Accounting Standards Codification (ASC) 825, Financial Instruments, disclosures of fair value information about financial instruments is required, whether or not recognized in the consolidated balance sheet, for which it is practicable to estimate that value. The Company's financial instruments recorded in the consolidated balance sheets include cash and cash equivalents, accounts receivable, investment securities, accounts payable and accrued expenses. A The carrying value of certain financial instruments, primarily cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their estimated fair values based upon the short-term nature of their maturity dates. A The Company categorizes its financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument. Financial assets recorded at fair value on the Company's condensed consolidated balance sheets are categorized as follows: A 8 A CORMEDIX INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued) A A Level 1 inputs A Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. A A Level 2 inputs A Significant other observable inputs (e.g., quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable such as interest rate and yield curves, and market-corroborated inputs). A A Level 3 inputs A Unobservable inputs for the asset or liability, which are supported by little or no market activity and are valued based on management's estimates of assumptions that market participants would use in pricing the asset or liability. A A The following table provides the carrying value and fair value of the Company's financial assets measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023: A A A Carrying Value A Level 1 A Level 2 A Level 3 A September 30, 2024: A A A A A A A A A A Money Market Funds and Cash Equivalents A \$23,021,807 A A \$23,021,807 A A \$- A A \$- A A U.S. Government Agency Securities A \$9,554,818 A A \$9,554,818 A A \$- A A \$- A A Commercial Paper A \$1,188,744 A A \$1,188,744 A A \$- A A \$- A A Subtotal A \$10,743,562 A A \$9,554,818 A A \$1,188,744 A A \$- A A Total September 30, 2024 A \$33,765,369 A A \$32,576,625 A A \$1,188,744 A A \$- A A December 31, 2023: A A A A A A A A A A A A Money Market Funds and Cash Equivalents A \$32,541,230 A A \$32,541,230 A A \$- A A \$- A A U.S. Government Agency Securities A \$29,712,183 A A \$29,712,183 A A \$- A A \$- A A Commercial Paper A \$2,675,947 A A \$2,675,947 A A \$- A A Subtotal A \$32,388,130 A A \$29,712,183 A A \$2,675,947 A A \$- A A Total December 31, 2023 A \$64,929,360 A A \$62,253,413 A A \$2,675,947 A A \$- A A Inventories A The Company engages third parties to manufacture and package inventory held for sale and warehouse such goods until packaged for final distribution and sale. Costs related to the manufacturing of DefenCath incurred prior to FDA approval in order to support the preparation for commercial launch of its product were expensed as research and development expenses (R&D) as incurred. Upon FDA approval, costs related to the manufacturing of inventory are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis. Remaining pre-commercial inventory previously expensed as R&D prior to FDA approval, consists of certain raw materials and inventory at various stages of completion with a value approximating \$6,177,000 as of September 30, 2024. A Inventory is valued utilizing the standard cost method, which approximates costs determined on the first-in first-out basis. The Company records an inventory reserve for losses associated with dated, expired, excess or obsolete items. This reserve is based on management's current knowledge with respect to inventory levels, planned production and sales volume assumptions. As of September 30, 2024 and December 31, 2023, no reserves were deemed necessary. A Inventories consist of raw materials (including labeling and packaging), work-in-process, and finished goods for DefenCath. Inventories consist of the following: A A September 30, 2024 A A December 31, 2023 A Raw materials A \$603,545 A A \$1,525,420 A Work in progress A \$5,084,583 A A \$80,925 A Finished goods A \$961,367 A A \$- A Total A \$6,649,495 A A \$2,106,345 A A 9 A CORMEDIX INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued) A Revenue Recognition A The Company recognizes revenue from the sale of its product, DefenCath, in accordance with ASC 606, A Revenue from Contracts with Customers (ASC 606). The provisions of ASC 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. A The Company recognizes revenue when it believes that it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer. The Company's product revenue is recognized at a point in time when the performance obligation is satisfied by transferring control of the promised goods or services to a customer. In accordance with the Company's contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is received by a customer. The Company's customers are located in the United States and consist primarily of outpatient service providers and wholesale distributors. A Variable Consideration A The Company includes an estimate of variable consideration in its transaction price at the time of sale when control of the product transfers to the customer. Variable consideration includes: A A Distribution service fees; A A Prompt pay and other discounts; A A Product returns; A A Chargebacks; A A Rebates; A A Volume incentive rebates; A The Company assesses whether or not an estimate of variable consideration is constrained based on the probability that a significant reversal in the amount of cumulative revenue may occur in the future when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may vary from our estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect product sales and earnings in the period such variances become

and the wholesale distributor purchase price of WAC will be charged back to the Company. The Company estimates the amount in chargebacks based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Estimated chargebacks are recorded as contra accounts receivable on the balance sheet.    Rebatesâ€” The Company is or may become subject to negotiated discount obligations to different GPO, direct purchasers, other commercial organizations or government programs. The rebate amounts for these programs are determined by statutory requirements or contractual arrangements. Rebates are owed after the product has been dispensed to an end user and the Company has been invoiced. Rebates are typically invoiced in arrears. The Companyâ€™s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter based on expected product utilization, and estimated future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel at the end of each reporting period. Rebate estimates are recorded as accrued expenses on the balance sheet.    Volume Incentive Rebatesâ€” The Company is subject to negotiated volume incentive rebates with certain direct and indirect customers (primarily outpatient service providers). Rebates are owed based on predetermined volume levels and payable per the terms in the customer contracts. The Company estimates and records volume incentive rebates based on anticipated purchase volume with specific customers based on communications with the customer. Volume incentive rebates are recorded as accrued expenses on the balance sheet. See Note 4 â€” Accrued Expenses.    Provisions for the revenue reserves described above totaled \$6,598,000 and \$6,792,000 for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, total reserves and allowances to accounts receivable on the balance sheet associated with variable consideration were \$6,753,000.    License Agreement    The Companyâ€™s rights under the License and Assignment Agreement with ND Partners, LLP are capitalized and stated at cost and amortizes using the straight-line method over estimated economic life of the intangible asset. The Company will amortize the intangible asset over its useful life, based on its assessment of various factors impacting estimated useful lives and cash flows of the acquired rights. Such factors include the launch date of DefenCath, the strength of the intellectual property protection of DefenCath and various other competitive, developmental and regulatory considerations, and contractual terms. See Note 5 â€” Commitments and Contingencies for further discussion.    Leases    The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (â€œROUâ€) assets, current portion of operating lease liabilities, and operating lease liabilities, net of current portion, on the consolidated balance sheet (see Note 7).    Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Companyâ€™s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Companyâ€™s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.    The Company has elected, as an accounting policy, not to apply the recognition requirements in ASC 842 to short-term leases. Short-term leases are leases that have a term of 12 months or less and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes the lease payments for short-term leases on a straight-line basis over the lease term.    The Company has also elected, as a practical expedient, by underlying class of asset, not to separate lease components from non-lease components and, instead, account for them as a single component.    11    A    CORMEDIX INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)    Loss Per Common Share    A Basic loss per common share excludes dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period. The weighted average number of common shares outstanding during the period included 2,500,625 shares underlying outstanding pre-funded warrants. Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company.    The Companyâ€™s outstanding shares of Series E preferred stock entitle the holders to receive dividends on a basis equivalent to the dividends paid to holders of common stock. As a result, the Series E preferred stock meet the definition of participating securities requiring the application of the two-class method. Under the two-class method, earnings available to common shareholders, including both distributed and undistributed earnings, are allocated to each class of common stock and participating securities according to dividends declared and participating rights in undistributed earnings, which may cause diluted earnings per share to be more dilutive than the calculation using the treasury stock method. No loss has been allocated to these participating securities since they do not have contractual obligations that require participation in the Companyâ€™s losses.    A Since the Company has only incurred losses, potentially dilutive securities are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive, and therefore basic and diluted loss per share are the same for all periods presented. The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:    A    A    Nine Months Ended September 30,    A    A    2024    A    2023    A    A (Number of Shares of Common Stock Issuable)    A    Series C non-voting preferred stock    A    4,000    A    A    4,000    A    Series E non-voting preferred stock    A    391,953    A    A    391,953    A    Series G non-voting preferred stock    A    5,004,069    A    A    5,004,069    A    Shares issuable for payment of deferred board compensation    A    48,909    A    A    48,909    A    Shares underlying outstanding stock options    A    7,675,277    A    A    5,876,007    A    Shares underlying restricted stock units    A    303,994    A    A    103,735    A    Total potentially dilutive shares    A    13,428,202    A    A    11,428,673    A    Stock-Based Compensation    A    Stock-based compensation cost is measured at grant date, based on the estimated fair value of the award using the Black-Scholes option pricing model for options with service or performance-based conditions. Stock-based compensation is recognized as expense over the requisite service period on a straight-line basis or when the achievement of the performance condition is probable.    A Research and Development    A Research and development costs are charged to expense as incurred. Research and development include fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated executive, human resources and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial and the invoices received from its external service providers. As actual costs become known, the Company adjusts its accruals in the period when actual costs become known. Costs related to the acquisition of technology rights and patents for which development work is still in process are charged to operations as incurred and considered a component of research and development expense.    A    12    A    CORMEDIX INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)    Recent Accounting Pronouncements    A From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (â€œFASBâ€) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe the adoption of recently issued standards have or may have a material impact on its consolidated financial statements or disclosures.    ASU No. 2023-09    A In December 2023, the FASB issued Accounting Standards Update (â€œASUâ€) No. 2023-09,    A Income Taxes - Improvements to Income Tax Disclosures (â€œTopic 740â€). The standard requires disaggregation of the effective rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. The standard will be effective for CorMedix beginning in annual reporting period ending December 31, 2025, with early adoption permitted. CorMedix is currently assessing the impact of adopting this guidance on its consolidated financial statements.    ASU No. 2023-07    A In November 2023, the FASB issued ASU No. 2023-07    A Segment Reporting - Improving Reportable Segment Disclosures (â€œTopic 280â€). The standard requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker (â€œCODMâ€), a description of other segment items by reportable segment, and any additional measures of a segmentâ€™s profit or loss used by the CODM when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. The standard is effective for CorMedix beginning in annual reporting period ending December 31, 2024 and interim periods beginning in fiscal year 2025, with early adoption permitted and requires retrospective application to all prior periods presented in the financial statements. CorMedix is currently assessing the impact of adopting this guidance on its consolidated financial statements.    A    Note 3    â€” Other Prepaid Expenses and Current Assets:    A Other Prepaid Expenses and Current Assets    A Other prepaid expenses and current assets consist of the following:    A    A    September    A 30, 2024    A    A    December    A 31, 2023    A    API deposits    A \$1,066,987    A    A    FDA filing fee    A \$599,411    A    A    Commercial    A \$505,627    A    A    171,393    A    Subscriptions    A \$301,291    A    A    466,114    A    Medical affairs    A \$198,048    A    A    A    Insurance    A \$94,246    A    A    126,616    A    Other    A \$151,279    A    A    118,091    A    Total    A \$2,916,889    A    A    \$882,214    A    A    Note 4 - Accrued Expenses:    A Accrued Expenses    A Accrued expenses consist of the following:    A    A    A    September    A 30, 2024    A    A    December    A 31, 2023    A    Accrued gross-to-net deductions    A \$6,371,043    A    A    Accrued payroll and payroll taxes    A \$4,788,529    A    A    2,718,770    A    Manufacturing related    A \$3,037,736    A    A    1,835,101    A    License agreement payable (see Note 5 â€” Commitments and Contingencies)    A \$2,000,000    A    A    Professional and consulting fees    A \$584,374    A    A    2,270,022    A    Other    A \$191,995    A    A    146,324    A    Total    A \$16,973,677    A    A    \$6,970,217    A    A    13    A    CORMEDIX INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)    Note 5 - Commitments and Contingencies:    A Contingency Matters    A In re CorMedix Inc. Securities Litigation, Case No. 2:21-cv-14020 (D.N.J.)    A On October 13, 2021, the United States District Court for the District of New Jersey consolidated into In re CorMedix Inc. Securities Litigation, Case No. 2:21-cv-14020-JXN-CLW, two putative class action lawsuits filed on or about July 22, 2021 and September 13, 2021, respectively, and appointed lead counsel and lead plaintiff, a purported stockholder of the Company. The lead plaintiff filed a consolidated amended class action complaint on December 14, 2021, alleging violations of Sections 10(b) and 20(a) of the Exchange Act, along with Rule 10b-5 promulgated thereunder, and Sections 11 and 15 of the Securities Act of 1933. On October 10, 2022, the lead plaintiff filed a second amended consolidated complaint that superseded the original complaints in In re CorMedix Securities Litigation. On March 21, 2024, the court denied Defendantâ€™s motion to dismiss without prejudice and granted lead plaintiff leave to amend the complaint. On April 22, 2024, lead plaintiff filed a third amended consolidated complaint that superseded the second amended consolidated complaint. In the third amended complaint, the lead plaintiff seeks to represent a class of shareholders who purchased or otherwise acquired CorMedix securities between October 16, 2019 and August 8, 2022, inclusive. The third amended complaint names as defendants the Company and six (6) current and former officers of CorMedix, namely Khoso Baluch, Robert Cook, Matthew David, Phoebe Mounts, John L. Armstrong, and Joseph Todisco (the â€œOfficer Defendantsâ€ and collectively with CorMedix, the â€œCorMedix Defendantsâ€). The third amended complaint alleges that the CorMedix Defendants violated Section 10(b) of the Exchange Act (and Rule 10b-5) and that the Officer Defendants violated Section 20(a). In general, the purported bases for these claims are allegedly false and misleading statements and omissions related to the NDA submissions to the FDA for DefenCath, subsequent complete response letters, as well as communications from the FDA related and directed to the Companyâ€™s contract manufacturing organization and heparin supplier. The Company intends to vigorously contest such claims. The Company filed its motion to dismiss the third amended complaint on June 6, 2024, and received from Plaintiffs their opposition to the Companyâ€™s motion to dismiss on July 22, 2024. The Company filed its response on August 21, 2024.    A In re CorMedix Inc. Derivative Litigation, Case No. 2:21-cv-18493-JXN-LDW (D.N.J.)    A On or about October 13, 2021, a purported shareholder, derivatively and on behalf of the Company, filed a shareholder derivative complaint in the United States District Court for the District of New Jersey, in a case entitled Voter v. Baluch, et al., Case No. 2:21-cv-18493-JXN-LDW (the â€œDerivative Litigationâ€). The complaint names as defendants Khoso Baluch, Janet Dillione, Alan W. Dunton, Myron Kaplan, Steven Lefkowitz, Paulo F. Costa, Greg Duncan, Matthew David, Phoebe Mounts and Joseph Todisco along with the Company as Nominal Defendant. The complaint alleges breaches of fiduciary duties, abuse of control, and waste of corporate assets against the defendants and a claim for contribution for purported violations of Sections 10(b) and 21D of the Exchange Act against certain defendants. The individual defendants intend to vigorously contest such claims. On January 21, 2022, pursuant to a stipulation between the parties, the Court entered an order staying the case while the motion to dismiss the class action lawsuit described in the foregoing paragraph is pending. The stay may be terminated before the motion to dismiss is resolved according to certain circumstances described in the stipulation available on the Courtâ€™s public docket.    A On or about January 13, 2023, another purported shareholder, derivatively and on behalf of the Company, filed a shareholder derivative complaint in the United States District Court for the District of New Jersey, in a case entitled DeSalvo v. Costa, et al., Case No. 2:23-cv-00150-JXN-CLW. Defendants Paulo F. Costa, Janet D. Dillione, Greg Duncan, Alan Dunton, Myron Kaplan, Steven Lefkowitz, Joseph Todisco, Khoso Baluch, Robert Cook, Matthew David, Phoebe Mounts, and John L. Armstrong along with the Company as Nominal Defendant. The complaint alleges breaches of fiduciary duty and unjust enrichment against the individual defendants.    A On or about January 25, 2023, another purported shareholder, derivatively and on behalf of the Company, filed a shareholder derivative complaint in the United States District Court for the District of New Jersey, in a case entitled Scullion v. Baluch, et al., Case No. 2:23-cv-00406-ES-ESK. Defendants Khoso Baluch, Janet Dillione, Alan W. Dunton, Myron Kaplan, Steven Lefkowitz, Paulo F. Costa, Gregory Duncan, Matthew David, and Phoebe Mounts, along with the Company as Nominal Defendant. The complaint alleges breaches of fiduciary duties.    A    14    A    CORMEDIX INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)    On or about April 18, 2023, the Court entered an order consolidating the above-mentioned shareholder derivative complaints for all purposes, including pretrial proceedings, trial and appeal. The consolidated derivative action is entitled, In re CorMedix Inc. Derivative Litigation, C.A. No. 2:21-cv-18493-JXN-LDW. The individual defendants intend to vigorously contest the claims set forth in the consolidated derivative action. The provisions of the Order to Stay entered in the Voter Action on January 21, 2022, apply to the consolidated derivative action. On April 20, 2023, the consolidated derivative action was administratively terminated and removed from the Courtâ€™s docket until the motion to dismiss the class action is resolved and the Private Securities Litigation Reform Act, or PSLRA, stay is lifted. On April 22, 2024, the lead plaintiff in the class action filed a third amended complaint. The class action remains stayed under the PSLRA.    Demand Letter    A On or about June 23, 2022, the Companyâ€™s Board received a letter demanding it investigate and pursue causes of action, purportedly on behalf of the Company, against certain current and former directors, officers, and/or other employees of the Company (the â€œLetterâ€), which the Board believes are duplicative of the claims already asserted in the Derivative Litigation. As set forth in the Boardâ€™s response to the Letter, the Board will consider the Letter at an appropriate time, as circumstances warrant, as it continues to monitor the progress of the Derivative Litigation.    A    License and Assignment Agreement    A In 2008, the Company entered into a License and Assignment Agreement (the â€œND License Agreementâ€) with ND Partners, LLP (â€œNDPâ€). Pursuant to the ND License Agreement, NDP granted the Company exclusive, worldwide licenses for certain antimicrobial catheter lock solutions, processes for treating and inhibiting infections, a biocidal lock system and a tauridine delivery apparatus, and the corresponding United States and foreign patents and applications (the â€œNDP Technologyâ€). As consideration in part for the rights to the NDP Technology, upon execution of the ND License Agreement, the Company paid NDP an initial licensing fee of \$325,000 and granted NDP a 5% equity interest in the Company, consisting of 7,996 shares of the Companyâ€™s common stock.    A Under the ND License Agreement, the Company is required to make cash and equity payments to NDP upon the achievement of certain milestones. In 2014, a certain milestone was achieved resulting in the release of

7,277 shares held in escrow. As of December 31, 2022, the shares remaining in escrow were cancelled in accordance with the terms of the escrow agreement. Under the ND License Agreement, the maximum aggregate amount of cash payments due upon achievement of milestones was \$3,000,000, with the balance being \$2,000,000 as of September 30, 2024 and December 31, 2023. The initial licensing fee of \$325,000, the fair value of the 5% equity interest (7,996 shares of the Company's common stock) and an additional \$500,000, as a result of the achievement of one milestone, were recognized on the Company's statement of operations in R&D in prior periods, as the related milestones were achieved by the Company prior to the FDA approval. During the three months ended March 31, 2024, the Company determined it was probable that the net sales milestones would be achieved in future periods and, as a result, the Company recorded a license intangible asset of \$2,000,000 and a license agreement liability of \$2,000,000, which is included within accrued expenses in the Company's condensed consolidated balance sheet as of September 30, 2024. These sales milestones were met during the three month period ended September 30, 2024. The Company anticipates payment will be due in accordance with the agreement terms at the end of the twelve month period post attainment. Beginning in the second quarter of 2024, the license intangible asset is amortized as cost of goods sold over its estimated economic life of approximately 10 years. The amortization start period correlates with the product launch of DefenCath and the first period in which revenue will be recognized. Amortization expense of approximately \$52,000 and \$104,000 was recorded during the three and nine month periods ending September 30, 2024, respectively. A

15 A CORMEDIX INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued) A The ND License Agreement will expire on a country-by-country basis upon the earlier of (i) the expiration of the last patent claim under the ND License Agreement in a given country, or (ii) the payment of all milestone payments. Upon the expiration of the ND License Agreement in each country, we will have an irrevocable, perpetual, fully paid-up, royalty-free exclusive license to the NDP Technology in such country. The ND License Agreement also may be terminated by NDP if the Company materially breaches or defaults under the ND License Agreement and that breach is not cured within 60 days following the delivery of written notice to the Company, or by the Company on a country-by-country basis upon 60 days prior written notice in the event the Company's Board determines not to proceed with the development of the NDP Technology. If the ND License Agreement is terminated by either party, the Company's rights to the NDP Technology will revert back to NDP. A

Note 6 - Stockholders' Equity: A Common Stock A On June 28, 2023, the Company entered into an underwriting agreement (the "Underwriting Agreement") with RBC Capital Markets, LLC and Truist Securities, Inc., as representatives of the several underwriters named therein, relating to the issuance and sale of an aggregate of 7,500,000 shares of the Company's common stock, and in lieu of common stock to certain investors, pre-funded warrants to purchase 2,500,625 shares of common stock to the underwriters. Pursuant to the Underwriting Agreement, the Company also granted the underwriters a 30-day option to purchase up to 1,500,093 additional shares of common stock. The offering pursuant to the 2021 Shelf Registration Statement closed on July 3, 2023. Upon closing, the Company issued and sold an aggregate of 7,500,000 shares of its common stock at a public offering price of \$4.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 2,500,625 shares of its common stock at a price of \$3.999 per pre-funded warrant. The Company realized net proceeds of approximately \$37,300,000 from the sale of its common stock and the pre-funded warrants. On July 26, 2023, the underwriters' representatives fully exercised the option to purchase additional shares of the Company's common stock, and on July 28, 2023, the Company issued and sold an aggregate of 1,500,093 shares of its common stock at the public offering price of \$4.00 per share, less underwriting discounts and commissions, and the Company realized net proceeds of approximately \$5,600,000. In October 2024, the pre-funded warrants were exercised resulting in the issuance of 2,500,625 shares of common stock by the Company. Due to the pricing of the pre-funded warrants, net proceeds related to this transaction are de minimis. A

On May 9, 2024, the Company filed a shelf registration statement (the "2024 Shelf Registration Statement") for the issuance of up to \$150,000,000 of Company securities. Also on May 9, 2024, the Company entered into an At-The-Market Issuance Sales Agreement with Leerink Partners LLC, as sales agent, pursuant to which the Company may sell, from time to time, an aggregate of up to \$50,000,000 of its common stock through the sales agent under the 2024 Shelf Registration Statement, subject to limitations imposed by the Company and subject to the sales agent's acceptance (the "2024 ATM program"). The sales agent is entitled to a commission of up to 3% of the gross proceeds from the sale of common stock sold under the 2024 ATM program. As of September 30, 2024, approximately \$36,012,000 of the Company's common stock remains available for sale under its 2024 ATM program, with \$100,000,000 of capacity remaining under its 2024 Shelf Registration Statement for the issuance of Company securities. A

During the three and nine months ended September 30, 2024, the Company sold an aggregate of 2,290,024 and 2,521,121 shares of its common stock, respectively, under the 2024 ATM program and realized an aggregate net proceeds of approximately \$12,367,000 and \$13,376,000, respectively. For the three months ended September 30, 2023, there were no sales under the Company's previous at-the-market program, and for the nine months ended September 30, 2023, the Company sold an aggregate of 2,866,421 shares of its common stock and realized net proceeds of approximately \$12,515,000. A

Restricted Stock Units A In January 2024, the Company granted 283,333 restricted stock units (the "RSUs") to its executive officers under its Amended and Restated 2019 Omnibus Stock Incentive Plan with a weighted average grant date fair value of \$3.47 per share. The fair market value of the RSUs was estimated to be the closing price of the Company's common stock on the date of grant. These RSUs vest 25% on the grant date and 25% each on the first, second and third anniversaries of the grant date, subject to continued service as an employee or consultant through the applicable vesting date. During the nine months ended September 30, 2024, the Company issued 42,844 shares upon the vesting of 25% of these RSUs on the grant date and 27,989 shares were withheld in lieu of withholding taxes. A

16 A CORMEDIX INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued) A In May 2024 and 2023, 62,241 and 103,734 RSUs vested, respectively, pursuant to a grant made to the Company's chief executive officer, of which 35,259 and 66,291 shares of common stock were issued by the Company, respectively, and 26,982 and 37,443 shares, respectively, were withheld in lieu of withholding taxes. A

As of September 30, 2024, the Company has 303,994 outstanding RSUs. The Company recorded \$107,000 and \$583,000 compensation expense for the three and nine months ended September 30, 2024, respectively, and \$53,000 and \$207,000 for the three and nine months ended September 30, 2023, respectively. As of September 30, 2024, unrecognized compensation expense for these RSUs amounted to \$778,000 and the expected weighted average period for the expense to be recognized is 1.6 years. A

Preferred Stock A The Company is authorized to issue up to 2,000,000 shares of preferred stock in one or more series without stockholder approval. The Company's board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. Of the 2,000,000 shares of preferred stock authorized, the Company's board of directors has designated (all with par value of \$0.001 per share) the following: A

A As of September 30, 2024 and December 31, 2023: A Preferred Shares Outstanding A Liquidation Preference (Per Share) A Total Liquidation Preference A Series C-3A A 2,000A A 10.00A A \$20,000A Series EA A 89,623A A \$49.20A A \$4,409,452A Series GA A 89,999A A \$187.36A A \$16,862,213A Total A A 181,622A A A A A \$21,291,665A A Stock Options A During the three and nine months ended September 30, 2024, the Company granted ten-year qualified and non-qualified stock options covering an aggregate of 132,500 and 2,176,167 shares, respectively, of the Company's common stock under the Amended and Restated 2019 Omnibus Stock Incentive Plan. The weighted average exercise price of these options is \$5.72 and \$3.75 per share, respectively. For the three and nine months ended September 30, 2023, the Company granted ten-year qualified and non-qualified stock options covering an aggregate of 120,000 and 2,021,200 shares, respectively, and the weighted average exercise price of these options is \$3.90 and \$4.40 per share, respectively. A

During the three and nine months ended September 30, 2024, the Company issued 322,334 and 371,499 shares of common stock, respectively, as a result of the exercise of stock options. The Company realized net proceeds of \$1,708,000 and \$1,894,000 from these exercises for the three and nine months ended September 30, 2024, respectively. During the three and nine months ended September 30, 2023, the Company issued 6,666 and 64,041 shares of common stock, respectively, as a result of the exercise of stock options. The Company realized net proceeds of \$20,000 and \$254,000 from these exercises for the three and nine months ended September 30, 2023, respectively. A

Subsequent to September 30, 2024, through the filing of this Quarterly Report on Form 10-Q for the period ended September 30, 2024, the Company issued 289,430 shares of common stock as a result of the exercise of stock options, from which the Company realized net proceeds of approximately \$2,123,000. A

During the three and nine months ended September 30, 2024, stock-based compensation expense for stock options issued to employees, directors, officers and consultants was \$1,120,000 and \$4,352,000, respectively, and \$950,000 and \$4,069,000 for the three and nine months ended September 30, 2023, respectively. A

As of September 30, 2024, there was approximately \$7,470,000 in total unrecognized compensation expense related to stock options granted, which will be recognized over an expected remaining weighted average period of 1.4 years. A

17 A CORMEDIX INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued) A The fair value of each stock option award estimated on the grant date is determined using the Black-Scholes option pricing model. The following assumptions were used for the Black-Scholes option pricing model for the stock options granted during the nine months ended September 30, 2024: A Expected term (in years) A 5.99A Volatility weighted average A 98.85% Dividend yield weighted average A 0% Risk-free interest rate weighted average A 4.15% Weighted average grant date fair value of options granted during the period A 3.00A A A The Company uses the simplified method to calculate the expected term which takes into account the vesting term and the expiration date of the stock options. The expected term of the stock options granted to consultants, if any, is based upon the full term of the respective option agreements. The expected stock price volatility for the Company's stock options is calculated based on the historical volatility of the Company's stock price for the expected term. The expected dividend yield of 0% reflects the Company's current and expected future policy for dividends on the Company's common stock. To determine the risk-free interest rate, the Company utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of the Company's awards. A

Note 7 - Leases: A The Company entered into a seven-year operating lease agreement in March 2020 for an office space at 300 Connell Drive, Berkeley Heights, New Jersey 07922. The lease agreement, with a monthly average cost of approximately \$17,000, commenced on September 16, 2020. A

The Company entered into an operating lease for its office space in Germany that began in July 2017 and terminated in June 2024. The agreement had a monthly cost of 400 Euros. A

Operating lease expense in the Company's condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 was approximately \$51,000 and \$153,000, respectively, and \$52,000 and \$155,000 for the three and nine months ended September 30, 2023, respectively, which includes costs associated with leases for which ROU assets have been recognized as well as short-term leases. A

At September 30, 2024, the Company has a total operating lease liability of \$556,000, of which \$163,000 was classified as operating lease liabilities, short-term and \$393,000 was classified as operating lease liabilities, net of current portion, on the condensed consolidated balance sheet. At December 31, 2023, the Company's total operating lease liability was \$668,000, of which \$151,000 was classified as operating lease liabilities, short-term and \$517,000 was classified as operating lease liabilities, net of current portion, on the condensed consolidated balance sheet. Operating ROU assets as of September 30, 2024 and December 31, 2023 were \$531,000 and \$640,000, respectively. A

For each of the three and nine months ended September 30, 2024, cash paid for amounts included in the measurement of lease liabilities in operating cash flows from operating leases was \$51,000 and \$153,000, respectively, and \$50,000 and \$150,000 for the three and nine months ended September 30, 2023, respectively. A

The weighted average remaining lease term as of September 30, 2024 and 2023 was 3.0 and 4.1 years, respectively, and the weighted average discount rate for operating leases was 9% at September 30, 2024 and 2023. A

As of September 30, 2024, maturities of lease liabilities were as follows: A 2024 (excluding the nine months ended September 30, 2024) A \$51,000 A 2025 A \$208,000 A 2026 A \$211,000 A 2027 A \$169,000 A Total future minimum lease payments A \$639,000 A Less imputed interest A (83,000) A Total A \$556,000 A A 18 A Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. A The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report on Form 10-Q and our audited 2023 Annual Report on Form 10-K, filed with the Securities and Exchange Commission, or the SEC, on March 12, 2024. A

Forward Looking Statements A This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "will," "plan," "project," "seek," "target," "will," "would," and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or CorMedix's prospects should be considered forward-looking statements. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in Part II, Item 1A of this Quarterly Report on Form 10-Q and in CorMedix's other filings with the SEC, including its most recent Annual Report on Form 10-K, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from CorMedix, and a summary of which is copied below. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law. A

Risks Related to our Financial Position and Need for Additional Capital A We have a history of operating losses, may incur additional operating losses in the future and may never be profitable. A We may need to finance our future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, which may not be on terms favorable to us or our stockholders and may require us to relinquish valuable rights. A

Risks Related to the Commercialization of DefenCath A We are highly dependent on the successful commercialization of our only approved product, DefenCath. A The successful commercialization of DefenCath will depend on obtaining coverage and reimbursement for use of DefenCath from third-party payors. A Our current sales of DefenCath is highly concentrated with one customer. A We have signed additional agreements with new customers that have not yet begun purchasing DefenCath. A The failure of one or more of these customers to purchase the product may adversely impact the commercial success of DefenCath. See the risk factor under the heading "We have significant customer concentration, with a limited number of customers accounting for a large portion of our revenues" in Part II, Item 1A of this Quarterly Report on Form 10-Q for additional information. A If we are unable to effectively retain and equip our sales force, our ability to successfully commercialize DefenCath will be harmed. A

Risks Related to the Development and Commercialization of our Other Products A Successful development and commercialization of our product candidates is uncertain. A Final approval by regulatory authorities of our product candidates for commercial use may be delayed, limited or prevented, any of which would adversely affect our ability to generate operating revenues. A 19 A Risks Related to Healthcare Regulatory and Legal Compliance Matters A DefenCath, and our product candidates (if approved), will be subject to extensive post-approval regulation. A Current

healthcare laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. healthcare system may affect our ability to commercialize DefenCath and future marketed products profitably. **Á Á** **á**— We are subject to laws and regulations relating to privacy, data protection and the collection and processing of personal data. Failure to maintain compliance with these regulations could create additional liabilities for us. **Á Á** **á**— Clinical trials required for our new product candidates or for expanded uses of DefenCath will be expensive and time-consuming, and their outcome is uncertain. **Á Risks Related to Our Business and Industry** **Á á**— Healthcare institutions, physicians and patients may not accept or use our products. **Á Á** **á**— Competition and technological change may make our products and technologies less attractive or obsolete. **Á Á** **á**— Healthcare policy changes, including reimbursement policies for drugs and medical devices, may have an adverse effect on our business, financial condition and results of operations. **Á Á** **á**— If we lose key management or scientific personnel, cannot recruit qualified employees, directors, officers, or other personnel or experience increases in compensation costs, our business may materially suffer. **Á Á** **á**— Changes in funding for the FDA and other government agencies or future government shutdowns or disruptions could cause delays in the submission and regulatory review of marketing applications, including supplements, which could negatively impact our business or prospects. **Á Á** **á**— If we are unable to hire additional qualified personnel or maintain existing personnel, our ability to grow our business may be harmed. **Á Á** **á**— We may not successfully manage our growth. **Á Á** **á**— We face the risk of product liability claims and the amount of insurance coverage we hold now or in the future may not be adequate to cover all liabilities we might incur. **Á Á** **á**— We may be exposed to liability claims associated with the use of hazardous materials and chemicals. **Á Á** **á**— If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business. **Á Á** **á**— Negative U.S. and global economic conditions may pose challenges to our business strategy, which relies on funding from the financial markets or collaborators. **Á Risks Related to Our Intellectual Property** **Á á**— If we materially breach or default under the ND License Agreement with NDP, NDP would have the right to terminate the ND License Agreement, which would materially harm our business. **Á Á** **—** If we do not obtain protection for and successfully defend our respective intellectual property rights, competitors may be able to take advantage of our research and development efforts to develop competing products. **Á Á** **á**— Intellectual property disputes could require us to spend time and money to address such disputes and could limit our intellectual property rights. **Á Á** **20 Á Á** **á**— If we infringe the rights of third parties, we could be prevented from selling products and forced to pay damages and defend against litigation. **Á Risks Related to Dependence on Third Parties** **Á á**— If we or our collaborators are unable to manufacture our products in sufficient quantities or experience quality or manufacturing problems, we may be unable to meet demand for our products and we may lose potential revenues. **Á Á** **á**— We depend on third party suppliers and contract manufacturers for the manufacturing of DefenCath and all key active pharmaceutical ingredients (á€œAPISá€), which subjects us to potential cost increases and manufacturing delays that are not within our control. **Á Á** **á**— We currently have one FDA approved supplier for each of our key APIs, taurolidine and heparin, respectively, as well as two currently FDA approved manufacturing sites for DefenCath finished dosage. **Á Á** **á**— Corporate and academic collaborators may take actions that delay, prevent, or undermine the success of new development products or expanded uses of DefenCath. As our product is a new chemical entity (á€œNCEá€) and the first and only in its class, we may depend on nationally-recognized disease management guidelines to assist in the adoption and implementation of DefenCath. **Á Á** **á**— Data provided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading or incomplete. **Á Á** **á**— We may rely on third parties to conduct our clinical trials and pre-clinical studies. If those parties do not successfully carry out their contractual duties or meet expected deadlines, our product candidates may not advance in a timely manner or at all. **Á Risks Related to Our Common Stock** **Á á**— Our executive officers and directors may sell shares of their stock, and these sales could adversely affect our stock price. **Á Á** **á**— Our common stock price has fluctuated considerably and is likely to remain volatile, and you could lose all or a part of your investment. **Á Á** **á**— A significant number of additional shares of our common stock may be issued at a later date, and their sale could depress the market price of our common stock. **Á Á** **á**— Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult. **Á Á** **á**— If we fail to comply with the continued listing standards of the Nasdaq Global Market, it may result in a delisting of our common stock from the exchange. **Á Á** **á**— Laws, rules and regulations relating to public companies may be costly and impact our ability to attract and retain directors and executive officers. **Á Á** **á**— Our internal control over financial reporting and our disclosure controls and procedures may not prevent all possible errors that could occur. **Á Á** **á**— Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer. **Á Á** **á**— We do not currently pay dividends on our common stock so any returns on our common stock may be limited to the value of our common stock. **Á Á** **á**— We are a á€œsmaller reporting companyá€ and we cannot be certain if the reduced reporting requirements applicable to such companies could make our common stock less attractive to investors. **Á 21 Á Á** **Overview** **Á** CorMedix Inc. (collectively, with our wholly owned subsidiaries, referred to herein as á€œwe, á€ œus, á€ œourá€ or the á€œCompanyá€) is a biopharmaceutical company focused on developing and commercializing therapeutic products of life-threatening diseases and conditions. **Á** Our primary focus is on commercializing our lead product, DefenCathá® (taurolidine and heparin), in the U.S. The name DefenCath is the U.S. proprietary name approved by the FDA. **Á** DefenCath is an antimicrobial catheter lock solution (á€œCLSAá€) (a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL) indicated to reduce the incidence of catheter-related bloodstream infections (á€œCRBSIá€) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (á€œCVCá€). It is indicated for use in a limited and specific population of patients. CRBSIs can lead to treatment delays and increased costs to the healthcare system when they occur due to hospitalizations, need for IV antibiotic treatment, long-term anticoagulation therapy, removal/replacement of the CVC, related treatment costs, as well as increased mortality. We believe DefenCath can address a significant unmet medical need. **Á** On November 15, 2023, we announced that the FDA approved the NDA for DefenCath to reduce the incidence of CRBSI in adult patients with kidney failure receiving chronic hemodialysis through a CVC. DefenCath is indicated for use in a limited and specific population of patients. DefenCath is the first and only FDA-approved antimicrobial CLS in the U.S. and was shown to reduce the risk of CRBSI by up to 71% in a Phase 3 clinical study. **Á** As a result of the November 2023 FDA approval, CorMedix launched the product commercially in April 2024 in the inpatient setting and July 2024 in the outpatient hemodialysis setting. **Á** DefenCath is listed in the Orange Book as having NCE exclusivity (5 years) expiring on November 15, 2028, and the Generating Antibiotic Incentives Now or GAIN exclusivity extension of the NCE exclusivity (an additional 5 years) expiring on November 15, 2033. The GAIN exclusivity extension of 5 years is the result of the January 2015 designation of DefenCath as a Qualified Infectious Disease Product (á€œQIDPAá€). **Á** We announced on April 26, 2023 that following the submission of a duplicate New Technology Add-On Payment (á€œNTAPá€) application in the fourth quarter of 2022 to Centers for Medicare and Medicaid Services (á€œCMSá€), CMS has subsequently issued the Inpatient Prospective Payment System (á€œIPPSá€) 2024 proposed rule that includes a NTAP per hospital stay for DefenCath. This NTAP represents reimbursement to inpatient facilities of 75% of the wholesaler acquisition cost (á€œWACá€) price per 3 mL vial, and an average utilization of 19.5 vials per hospital stay. The final IPPS rule was published in early August 2023 and subsequently amended as of October 1, 2024 to reflect the current WAC of \$249.99 per 3ml vial. **Á** On January 25, 2024, CMS determined that DefenCath should be classified as a renal dialysis service that is subject to the Medicare end-stage renal disease prospective payment system (á€œESRD PPSá€). The ESRD PPS provides bundled payment for renal dialysis services, but also affords a transitional drug add-on payment adjustment, or TDAPA, which provides temporary, additional payments for certain new drugs and biologicals. We submitted an application for TDAPA on January 26, 2024, and received confirmation that our application was approved on April 18, 2024. We also submitted a HCPCS application for a J-code to CMS on December 8, 2023, for DefenCath, which is relevant to billing and the TDAPA application. The HCPCS J-code for DefenCath was published by CMS on April 2, 2024. TDAPA reimbursement is calculated based on 100 percent ASP (or 100 percent of wholesale acquisition price or manufacturersá€™ list price, respectively, if such data is unavailable). TDAPA and post-TDAPA add-on payment adjustments for DefenCath apply for five years (with such add-on payments applying to all ESRD PPS payments for years three through five). CMS confirmed a July 1, 2024 implementation date for HCPCS and TDAPA. **Á** We announced on June 6, 2024 that the CMS has determined that DefenCath qualified for pass-through status under the hospital Out-Patient Prospective Payment System (á€œOPPSá€). Pass-through status provides for separate payment under Medicare Part B for the utilization of DefenCath in the outpatient ambulatory setting for a period of at least two years, and up to a maximum of three years. While vascular access for hemodialysis can be initiated in an inpatient setting, ambulatory surgical centers or vascular access centers offer a less-invasive, outpatient-based alternative for patients. We estimate that up to 100,000 HD-CVC placements occur each year, and pass-through status offers providers a separate reimbursement mechanism in this setting of care administration of DefenCath. **Á 22 Á Á** **Subsequent to the launch of DefenCath in April 2024, the Company announced U.S.-based multi-year commercial supply agreements consisting of a large and several mid-sized dialysis organizations. Each provider has customized an implementation plan to provide access to patients based on a variety of clinical and other factors. The Company believes the currently contracted customer base represents roughly 60% of the outpatient dialysis centers in the U.S. **Á** We may pursue additional indications for DefenCath use as a CLS in populations with unmet medical needs that may also represent potentially significant market opportunities. While we are continuing to assess these areas, potential future indications may include use as a CLS to reduce CRBSIs in total parenteral nutrition patients using a central venous catheter and in certain oncology patients using a central venous catheter. In June 2024, we announced that the FDA provided feedback to our request to discuss development plans for additional indications for DefenCath. In response to these comments, we created and submitted three clinical protocols specifically, the post-marketing requirement of a pediatric hemodialysis (á€œHDá€) study as an obligation under the Pediatric Research Equity Act (á€œPREAá€) a Phase 3 study protocol to reduce the risk of central-line associated bloodstream infections (á€œCLABSIá€) for adult patients receiving total parenteral nutrition (á€œTPNá€) through a CVC and Expanded Access Program (á€œEAPá€) to FDA that allows for pediatric and adult patients, utilizing a CVC for the treatment or maintenance of many serious illness, to access DefenCath to protect their central line from serious infection. The Company expects the EAP to be available to patients at the end of 2024 and to begin enrollment for the adult TPN and pediatric HD studies in early 2025. **Á** We currently have one FDA approved source for each of our two key APIs for DefenCath, taurolidine and heparin sodium, respectively. With regards to taurolidine, we have a drug master file (á€œDMFá€) filed with the FDA. There is a master commercial supply agreement between a third-party manufacturer which has been in place since August 2018. We are currently in the process of identifying potential alternate third-party manufacturers for taurolidine under our existing DMF. In addition, we are working with our existing manufacture to source sufficient quantities of taurolidine API to cover at least 24 months of potential future demand. With respect to heparin sodium API, we have identified an alternate third-party supplier and intend to qualify such supplier under the DefenCath NDA over the next twelve months. **Á** We received FDA approval of DefenCath with finished dosage production from our European based contract manufacturing organization (á€œCMOá€) Rovi Pharma Industrial Services. We believe this CMO has adequate capacity to produce the volumes needed to meet near-term projected demand for the commercial launch of DefenCath. We have also qualified Siegfried Hameln as an alternate finished dosage manufacturing site. **Á** We announced on May 1, 2023 that the USPTO allowed our patent application directed to a locking solution composition for treating and reducing infection and flow reduction in central venous catheters. This application was granted on August 29, 2023 as U.S. Patent No. 11,738,120. **Á** Our newly granted U.S. Patent reflects the unique and proprietary formulation of our product, DefenCath, for which we received FDA approval on November 15, 2023. This patent supplements the coverage of our existing licensed U.S. Patent No. 7,696,182, and has the potential to provide an additional layer of patent protection for DefenCath through 2042. **Á** **Á** As part of the DefenCath approval letter, the FDA communicated the existence of a required pediatric assessment under the PREA. PREA requires sponsors to conduct pediatric studies for, among other things, NDAs for a new active ingredient, such as taurolidine in DefenCath, unless a waiver or deferral is obtained from the FDA. A deferral acknowledges that a pediatric assessment is required but permits the applicant to submit the pediatric assessment after the submission of an NDA. FDA deferred submission of the pediatric study for DefenCath because the product is ready for approval for use in adults and the pediatric study has not been completed. We are currently obligated to conduct the study communicated in the approval letter: an open-label, two-arm (DefenCath vs. standard of care) study to assess safety and time to CRBSI in subjects from birth to less than 18 years of age with kidney failure receiving hemodialysis via a central venous catheter. We announced in June 2024 that the FDA confirmed its requirement that we conduct a study in pediatric HD patients under the PREA. Because this is a required post-marketing study, we would be required to make annual reports to the FDA. Pediatric studies for an approved product conducted under PREA may qualify for pediatric exclusivity, which, if granted, provides an additional six months of exclusivity that attaches to the end of existing marketing exclusivity and patent periods for DefenCath. Depending on the timing of final report submission, DefenCath could potentially receive a total marketing exclusivity period of 10.5 years. However, there are factors that could affect whether this exclusivity is received or the duration of exclusivity, and DefenCath may or may not ultimately be eligible for the additional 0.5 years of exclusivity associated with this pediatric study. **Á** We previously marketed and sold Neutrolin, a CLS product where we received CE-Mark approval for commercial distribution in the EU and other territories. We previously elected to discontinue sales of Neutrolin for lack of commercial viability. The winding down of our operations in the EU is nearly complete and Neutrolin sales in both the EU and the Middle East have been discontinued since 2022. **Á 23 Á Á** **Financial Operations Overview** **Á** **Revenues** **Á** Our ability to continue to generate revenue and become profitable depends on our ability to successfully commercialize DefenCath and achieve gross profits from DefenCath sales that are greater than our ongoing operating costs. If we fail to successfully commercialize DefenCath, or any other product candidates we advance in a timely manner or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, could be adversely affected. Through September 30, 2024, we have funded our operations primarily through equity financings. **Á** **Cost of Revenues** **Á** Cost of revenues include direct and indirect costs related to the manufacturing and distribution of DefenCath, including product cost, **Á** packaging services, freight, amortization of the license intangible asset and an allocation of overhead costs that are primarily fixed such as salaries, benefits and insurance. **Á** Research and Development Expense **Á** Research and development, or R&D, expense consists of: (i) internal costs associated with our development activities; (ii) payments we make to third party contract research organizations, contract manufacturers, investigative sites, and consultants; (iii) technology and intellectual property license costs; (iv) manufacturing development costs; (v) personnel related expenses, including salaries, stocká€based compensation expense, benefits, travel and related costs for the personnel involved in drug development; (vi) activities relating to regulatory filings and pre-clinical studies and clinical trials; (vii) facilities and other allocated expenses, which include direct and allocated expenses for rent, facility maintenance, as well as laboratory and other supplies; and (viii) comparative period costs include certain pre-NDA manufacturing-related costs expensed as R&D. All R&D is expensed as incurred. **Á** The process of conducting pre-clinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming. The probability of success for each product candidate and clinical trial may be affected by a variety of factors, including, among others, the quality of the product candidateá€™s early clinical data, investment in the program, competition, manufacturing capabilities and commercial viability. As a result of the uncertainties associated with clinical trial enrollments and the risks inherent in the development process, we are unable to determine the duration and completion costs of future clinical stages of our product**

candidates or when, or to what extent, we will generate revenues from the commercialization and sale of any of our future product candidates. A Development timelines, probability of success and development costs vary widely. We are currently focused on the commercialization of DefenCath in the U.S. A Selling and Marketing Expense A Selling and marketing, or S&M, expense includes the cost of salaries and related costs for personnel in sales and marketing, brand building, advocacy, market research and consulting. Selling and marketing expenses are expensed as incurred. A General and Administrative Expense A General and administrative, or G&A, expenses consist principally of salaries and related costs for personnel in executive, finance and administrative functions including payroll taxes and health insurance, stock-based compensation and travel expenses. Other general and administrative expenses include facility-related costs, insurance and professional fees for legal, patent review, consulting, and accounting services. General and administrative expenses are expensed as incurred. A Foreign Currency Exchange Transaction Gain (Loss) A Foreign currency exchange transaction gain (loss) is the result of re-measuring transactions denominated in a currency other than our functional currency and is reported in the consolidated statement of operations as a separate line item within other income (expense). The intercompany loans outstanding between our New Jersey-based company and our subsidiaries will not be repaid and the nature of the funding advanced was of a long-term investment nature. As such, unrealized foreign exchange movements related to long-term intercompany loans are recorded in other comprehensive income (loss). A 24 A Interest Income A Interest income consists of interest earned on our cash and cash equivalents and short-term investments. A Interest Expense A Interest expense consists of interest incurred on financing of expenditures. A Results of Operations A Comparison of the Three and Nine Months Ended September 30, 2024 and 2023 A The following is a tabular presentation of our consolidated operating results for the three months ended September 30, 2024 and 2023 (in thousands): A A For the Three Months Ended September 30, A % Increase A For the Nine Months Ended September 30, A % Increase A A 2024 A 2023 A (Decrease) A 2024 A 2023 A (Decrease) A Revenue A \$11,456 A \$- A A \$12,262 A \$- A A Cost of sales A (686) A A A (2,015) A A A Gross profit A 10,770 A A A A 10,247 A A A Operating Expenses: A A A A A A A A Research and development A (727) A (2,664) A (73)% A (2,215) A (10,866) A (80)% Selling and marketing A (6,749) A (4,058) A 66)% A (20,473) A (9,956) A 106)% General and administrative A (6,581) A (3,745) A 76)% A (22,851) A (12,467) A 83)% Total operating expenses A (14,057) A (10,467) A 34)% A (45,539) A (33,289) A 37)% Loss from operations A (3,287) A (10,467) A (69)% A (35,292) A (33,289) A 6)% Interest income A 553 A A 765 A A (28)% A 2,068 A A 1,762 A A 17)% Foreign exchange transaction loss A (33) A (29) A 14)% A (39) A (30) A 28)% Other Income A A A A A A 500 A A A A Interest expense A (10) A (13) A (24)% A (26) A (28) A (5)% Total other income A 510 A A 723 A A (29)% A 2,503 A A 1,704 A A 47)% Loss before income taxes A (2,777) A (9,744) A (72)% A (32,789) A (31,585) A 4)% Tax benefit A A A A A A A A Net loss A (2,777) A (9,744) A (72)% A (31,394) A (31,585) A (1)% Other comprehensive (loss) income A 4 A A (6) A A (154)% A (5) A 2 A A (401)% Comprehensive loss A \$(2,773) A \$(9,750) A (72)% A \$(31,399) A \$(31,583) A (1)% A Revenues. Revenue increased by \$11.5 million and \$12.3 million for the three and nine months ended September 30, 2024. Revenue consists of sales of DefenCath, which was approved by the FDA in November 2023 and launched in the U.S in April 2024 and reflects the shipment of DefenCath to direct customers and specialty distributors, net of estimates for applicable variable consideration, which consists primarily of distribution service fees, prompt pay and other discounts, product returns, chargebacks, rebates and volume incentive rebates. A Cost of Revenues. Cost of revenues include direct and indirect costs related to the manufacturing and distribution of DefenCath, including product cost, packaging services, freight, amortization of the license intangible asset and an allocation of overhead costs that are primarily fixed such as salaries, benefits and insurance. We expect these relatively fixed costs to become less significant as a percentage of net sales with anticipated sales volume increases. Direct costs of product sales during the three and nine months ended September 30, 2024 are minimal as DefenCath sold to date, represents validation lot units previously expensed as R&D. The pre-approval validation batch product previously expensed as R&D will positively impact margins throughout 2024 or until such inventory is depleted. Indirect costs of approximately \$0.6 million for the three months and \$1.9 million for the nine months ended September 30, 2024, respectively, represent the proportion of salaries, benefits and insurance expenses representing excess capacity pertaining to pre-launch related activities. Included in the indirect costs previously expensed as a component of R&D were \$0.2 million and \$0.7 million of personnel expenses for the three and nine months ended September 30, 2023, respectively. A 25 A Research and Development Expense. R&D expense was \$0.7 million for the three months ended September 30, 2024, a decrease of \$2.0 million, or 73%, from \$2.7 million for the same period in 2023. For the nine months ended September 30, 2024, R&D expense was \$2.2 million, compared to \$10.9 million for the nine months ended September 30, 2023, a decrease of \$8.7 million, or 80%. The decrease for both comparison periods was driven by the approval of DefenCath. As a result of the post FDA approval commercial operations, costs related to medical affairs and certain personnel expenses that supported R&D efforts prior to the FDA approval of DefenCath have been recognized in cost of revenue or general and administrative expense during the three and nine months ended September 30, 2024, as compared to the same period last year that were recognized in R&D. In the prior three and nine month periods, there were \$0.1 million and \$1.5 million, respectively, of costs related to the manufacturing of DefenCath validation batches previously expensed as a component of R&D prior to the FDA approval. These types of costs are now capitalized in inventory as DefenCath is a commercialized product. Additionally, there were \$1.9 million and \$5.8 million in personnel and consulting expenses for the three and nine months ended September 30, 2023, respectively, previously expensed as a component of R&D prior to FDA approval, are now expensed in cost of revenue and G&A. A Selling and Marketing Expense. S&M expense was \$6.7 million for the three months ended September 30, 2024, an increase of \$2.7 million, or 66%. For the nine months ended September 30, 2024, S&M expense increased \$10.5 million to \$20.5 million, an increase of 106%. The increase in both periods was due primarily to increased marketing efforts and new personnel, inclusive of our sales force and support for the commercial launch of DefenCath in the third quarter of 2024. A General and Administrative Expense. G&A expense was \$6.6 million for the three months ended September 30, 2024, an increase of \$2.9 million, or 76%, from \$3.7 million for the same period in 2023. For the nine months ended September 30, 2024, G&A expense was \$22.9 million, compared to \$12.5 million for the nine months ended September 30, 2023, an increase of \$10.4 million, or 83%. The increase for both comparison periods was driven by the approval of DefenCath. As a result of the post FDA approval commercial operations, certain personnel and consulting expenses that supported R&D efforts prior to the FDA approval of DefenCath have been recognized in G&A expense during the three months and nine months ended September 30, 2024, as compared to the same period last year that were recognized in R&D. In the prior three and nine month periods, certain personnel and consulting expenses previously expensed as a component of R&D prior to the FDA approval of \$1.7 million and \$5.1 million, respectively, are now expensed in G&A. Additionally, there were increases in personnel expenses of \$0.7 million and \$2.6 million for the three and nine months ended September 30, 2024, respectively, in preparation for support activities pertaining to commercial launch, as well as increases in legal and compliance of \$0.2 million and \$1.5 million and, consulting fees of \$0.1 million and \$0.6 million for the three and nine month periods ended September 30, 2024, respectively. A Interest Income. Interest income for the three months ended September 30, 2024 was \$0.6 million a decrease of \$0.2 million, or 28%, compared to \$0.8 million for the same period last year, due to lower short-term investments. For the nine months ended September 30, 2024, interest income was \$2.1 million compared to \$1.8 million for the same period last year, an increase of \$0.3 million, or 17%, attributable to higher interest rates in short-term investments during this period as compared to the same period last year. A Foreign Exchange Transaction Loss. Foreign exchange transaction losses were due to the re-measuring of transactions denominated in a currency other than our functional currency. Balances and changes were immaterial for all periods presented. A Other Income. Other income relates to a settlement with a previously utilized vendor, occurring during the nine month period ended September 30, 2024. A Interest Expense. Interest expense pertains to certain liabilities we chose to finance. Balances and changes were immaterial for all periods presented. A Other Comprehensive (Loss) Income. Unrealized foreign exchange movements related to long-term intercompany loans, the translation of the foreign affiliate financial statements to U.S. dollars and unrealized movements related to short-term investment are recorded in other comprehensive (loss) income. Income and (loss) is considered immaterial for all periods presented. A 26 A Liquidity and Capital Resources A Sources of Liquidity A As a result of our R&D, S&M and G&A expenditures and the lack of substantial product sales revenue, our ongoing operations have not been profitable since our inception. During the nine months ended September 30, 2024, we received net proceeds of \$13.4 million from the issuance of 2,521,121 shares of common stock under our at-the-market-issuance sales agreement, or ATM program, as compared to \$12.5 million net proceeds for the same period in 2023 from the issuance of 2,866,421 shares of common stock. Also, for the same period in 2023, we received net proceeds of \$42.0 million from the issuance of 9,000,093 shares of common stock and pre-funded warrants to purchase 2,500,625 shares of common stock in connection with the public offering. We may continue to be reliant on external sources of cash until we are able to generate sufficient working capital to fund operations. A In March 2024, we received \$1.4 million, net of expenses, from the sale of our unused New Jersey net operating losses (â€œNOLâ€), that was eligible for sale under the State of New Jerseyâ€™s Economic Development Authorityâ€™s New Jersey Technology Business Tax Certificate Transfer program (â€œNJEDA Programâ€). The NJEDA Program allowed us to sell our available NOL tax benefits for the state fiscal year 2023 in the amount of approximately \$1.5 million. A Net Cash Used in Operating Activities A Net cash used in operating activities for the nine months ended September 30, 2024, was \$45.0 million compared to \$27.7 million for the same period in 2023, an increase of \$17.3 million. The increase is primarily driven by an increase in trade receivables of \$17.4 million and inventories of \$4.5 million offset by a net increase in the change of accrued expenses and accounts payable of \$3.7 million. A Net Cash Provided by (Used in) Investing Activities A Net cash provided by investing activities for the nine months ended September 30, 2024, was \$21.5 million as compared to \$17.7 million of net cash used in investing activities for the same period in 2023. The net cash provided during the nine months ended September 30, 2024, was mainly driven by an increase in maturity of the amount invested in short-term investments to help fund operations, partially offset by lower purchase of short-term investments in 2024 as compared to the same period in 2023. A Net Cash Provided by Financing Activities A Net cash provided by financing activities for the nine months ended September 30, 2024, was \$15.0 million as compared to \$55.4 million for the same period in 2023, a decrease of \$40.4 million. The decrease was mainly attributable to \$42.9 million of net proceeds from a public offering completed in the three month period ended September 30, 2023 offset by increased ATM net proceeds of \$0.9 million and increases in proceeds from the exercise of stock options of \$1.6 million during the nine month period ended September 30, 2024. A Funding Requirements and Liquidity A Our total cash, cash equivalents and short-term investments as of September 30, 2024, was \$46.0 million, excluding restricted cash of \$0.1 million, compared with \$76.0 million for the year ended December 31, 2023, excluding restricted cash of \$0.2 million. As of September 30, 2024, \$36.0 million of the Companyâ€™s common stock remains available for sale under the ATM program. Additionally, we have \$100 million of remaining capacity available under our 2024 Shelf Registration Statement for the issuance of Company securities. A Because our business has not generated positive operating cash flow, we may need to raise additional capital in order to continue to fund our research and development activities, as well as to fund operations generally. Our continued operations are focused on the commercial launch of DefenCath and we can provide no assurances that financing or strategic relationships will be available on acceptable terms, or at all, if additional funds are needed. A We expect to continue to fund operations from cash collections from accounts receivable, plus cash, cash equivalents and short-term investments and through capital raising sources as previously described, which may be dilutive to existing stockholders. In May 2024, we implemented an ATM program, which may be utilized to support our ongoing funding requirements. Additionally, we may enter into a credit facility in case necessary to support ongoing working capital needs. We may seek to sell additional equity or debt securities through one or more discrete transactions, or enter into a strategic alliance arrangement, but can provide no assurances that any such financing or strategic alliance arrangement will be available on acceptable terms, or at all. Moreover, the incurrence of indebtedness would result in increased fixed obligations and could contain covenants that would restrict our operations. Raising additional funds through strategic alliance arrangements with third parties may require significant time to complete and could force us to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or to grant licenses on terms that may not be favorable to us or our stockholders. Our actual cash requirements may vary materially from those now planned due to a number of factors, including any change in the timing of the commercial launch of DefenCath or the focus and direction of our research and development programs, any acquisition or pursuit of development of new product candidates, competitive and technical advances, the costs of commercializing any of our product candidates, and costs of filing, prosecuting, defending and enforcing any patent claims and any other intellectual property rights. A 27 A We expect to generate product sales for DefenCath in the U.S. In the absence of significant revenue, we may continue generating operating cash flow deficits. We will continue to use cash as we increase other activities relating to the commercialization of DefenCath and pursue business development activities. A We currently estimate that as of September 30, 2024, we have sufficient cash, cash equivalents and short-term investments to fund operations for at least twelve months from the issuance of this Quarterly Report on Form 10-Q. These estimates are based upon the Companyâ€™s base case assumptions for market penetration, average selling price, gross-to-net discounts, research and development expense and commercial infrastructure cost. Additional financing may be needed to build out our commercial infrastructure and to continue our operations. If we are unable to raise additional funds when needed, we may be forced to slow or discontinue the commercial launch of DefenCath. We may also be required to delay, scale back or eliminate some or all of our anticipated research and development programs. Each of these alternatives would likely have a material adverse effect on our business. A Contractual Obligations A We entered into a seven-year operating lease agreement in March 2020 for our office space at 300 Connell Drive, Berkeley Heights, New Jersey 07922. The lease agreement, with a monthly average cost of approximately \$17,000, commenced on September 16, 2020. A Critical Accounting Estimates A Our managementâ€™s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities, and revenues and expenses that are not readily apparent from other sources. Actual results and experiences may differ materially from these estimates. While our significant accounting policies are described in more detail in â€œNote 2 â€ Summary of Significant Accounting Policies and Liquidity and Uncertainties,â€ to our consolidated financial statements included in Item 1, â€œUnaudited Condensed Consolidated Financial Statements,â€ of this Quarterly Report on Form 10-Q, we believe that the following accounting policies require the application of significant judgments and estimates. A For the nine months period ended September 30, 2024, there were no significant changes to our critical accounting estimates as identified in our Annual Report on Form 10-K for the year ended December 31, 2023, except as noted below: A A Litigation contingencies are assessed to determine if an unfavorable outcome is reasonably possible, and if so, the contingency is disclosed along with an estimate of the possible loss or range of loss. If a liability is possible or probable, but no reasonable estimation of loss can be made, we will disclose the

of the contingency and state that such an estimate cannot be made. A A A The assessment of going concern uncertainty in our consolidated financial statements to determine if we have sufficient cash and cash equivalents on hand and working capital, including available loans or lines of credit, if any, to operate for a period of at least one year from the date our condensed consolidated financial statements are issued (the "look-forward period"). As part of this assessment, based on conditions that are known and reasonably knowable to us, we consider various scenarios, forecasts, projections, and estimates, and we make certain key assumptions, including the uptake of our product in the inpatient and outpatient settings and commercial contract terms that align with our internal assumptions. Based on this assessment, as necessary or applicable, we make certain assumptions around revenue, gross profit, operating expenses, inventory build and working capital needs to the extent we deem probable those implementations can be achieved within the look-forward period. For additional information, refer to Note 2 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. A 28 A A We account for product revenue from the sale of our product, DefenCath, in accordance with ASC 606, A Revenue from Contracts with Customers (ASC 606). The provisions of ASC 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. We only recognize revenue when we believe that it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services that will be transferred to the customer. In accordance with ASC 606, revenue is recognized at a point in time when the performance obligation is satisfied by transferring control of the promised goods or services to a customer. In accordance with our contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is received by a customer. Our customers are located in the United States and consist primarily of wholesale distributors and outpatient service providers. A We include an estimate of variable consideration in our transaction price at the time of sale when control of the product transfers to the customer. Variable consideration includes: A Distribution service fees; A Prompt pay and other discounts; A Product returns; A Chargebacks; A Rebates; A Volume incentive rebates. A We assess whether or not an estimate of our variable consideration is constrained based on the probability that a significant reversal in the amount of cumulative revenue may occur in the future when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may vary from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect product sales and earnings in the period such variances become known. A The specific considerations that we use in estimating certain amounts related to variable considerations are as follows: A Distribution services fees A We pay distribution service fees primarily to our wholesale distributors. We reserve these fees based on actual net sales and the contractual fee rates negotiated with the customers in the distribution channel. A Prompt pay and other discounts A We provide customers with prompt pay discounts. The specific prompt pay terms vary by customer and are contractually fixed. Prompt pay discounts are expected to be taken by our customers, so an estimate of the discount is recorded at the time of sale based on the invoice price. A Product returns A Customers have the right to return the product that is within six months or less of the labeled expiration date or that is past the expiration date by no more than six months. An estimate for product returns is made based on: (i) data provided to us from our distributors and (ii) the estimated remaining shelf life of DefenCath previously shipped and currently being shipped to distributors. A Chargebacks A Certain covered entities, group purchasing organizations (GPOs) and government entities will be able to purchase the product at a discounted price. The difference between the GPO, government or covered entity purchase price and the wholesale distributor purchase price will be charged back to us. We estimate the amount in chargebacks based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. A Rebates A We are subject to negotiated discount obligations to different GPOs, direct purchasers, other commercial organizations or government programs. The rebate amounts for these programs are determined by statutory requirements or contractual arrangements. Our liability for these rebates consists of invoices received for claims that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter are based on expected product utilization, and estimated future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel at the end of each reporting period. A 29 A Volume Incentive Rebates A Volume incentive rebates are provided to certain customers. Rebates are owed based on predetermined volume levels and payable per the terms in the customer contracts. We estimate and record volume incentive rebates based on anticipated purchase volume with specific customers based on communications with the customer. A Item 3. Quantitative and Qualitative Disclosure about Market Risk. A The Company is not required to provide the information called for in this item due to its status as a Smaller Reporting Company. A Item 4. Controls and Procedures. A Disclosure controls and procedures are designed only to provide reasonable assurance that information to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) as of September 30, 2024. Based on the foregoing evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, to allow timely decisions regarding required disclosures. A Changes in Internal Control Over Financial Reporting A There were no changes in our internal control over financial reporting that occurred during the period covered by this report, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. A 30 A PART II OTHER INFORMATION A Item 1. Legal Proceedings. A For information regarding our legal proceedings, see Note 5, Commitments and Contingencies, included in Part I, Item 1, Financial Statements, in this Quarterly Report on Form 10-Q, which is incorporated into this item by reference. A Item 1A. Risk Factors. A We have significant customer concentration, with a limited number of customers accounting for a large portion of our revenues. A We derive a large portion of our revenues from a few major customers. These customers have no purchase commitments and may cancel, change or delay purchases with little or no notice or penalty. As a result of these customer concentrations, our revenue could fluctuate materially and could be materially and disproportionately impacted by purchasing decisions of these customers or any other significant customer. These customers may decide to purchase less DefenCath from us than management anticipates, may alter purchasing patterns at any time with limited notice, or may decide not to continue to purchase DefenCath at all, any of which could cause our revenue to decline materially and materially harm our financial condition and results of operations. If we are unable to diversify and grow our customer base, we will continue to be susceptible to risks associated with customer concentration. A See Part I, Item 1A, Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023. A Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. A None. A Item 3. Default Upon Senior Securities. A None. A Item 4. Mine Safety Disclosures. A Not applicable. A Item 5. Other Information. A None. A Item 6. Exhibits. A The exhibit index set forth below is incorporated by reference in response to this Item 6. A Exhibit Number A Description 31.1\* A Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2\* A Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1\* A Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2\* A Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS A Inline XBRL Instance Document. 101.SCH A Inline XBRL Taxonomy Extension Schema Document. 101.CAL A Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF A Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB A Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE A Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 A Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). A \* Filed herewith. A + Indicates management contract or compensation plan. A 31 A SIGNATURES A Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto fully authorized. A CORMEDIX INC. A Date: October 30, 2024 By: /s/ Joseph Todisco A Name: A Joseph Todisco A Title: Chief Executive Officer A (Principal Executive Officer) A 32 A false -12-31 Q3 0001410098 0001410098 2024-01-01 2024-09-30 0001410098 2024-10-28 0001410098 2024-09-30 0001410098 2023-12-31 0001410098 2024-07-01 2024-09-30 0001410098 2023-07-01 2023-09-30 0001410098 2023-01-01 2023-09-30 0001410098 us-gaap:CommonStockMember 2024-06-30 0001410098 us-gaap:PreferredStockMember 2024-06-30 0001410098 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001410098 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001410098 us-gaap:RetainedEarningsMember 2024-06-30 0001410098 2024-06-30 0001410098 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001410098 us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001410098 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001410098 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001410098 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001410098 us-gaap:CommonStockMember 2024-09-30 0001410098 us-gaap:PreferredStockMember 2024-09-30 0001410098 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001410098 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001410098 us-gaap:RetainedEarningsMember 2024-09-30 0001410098 us-gaap:CommonStockMember 2023-12-31 0001410098 us-gaap:PreferredStockMember 2023-12-31 0001410098 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001410098 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001410098 us-gaap:RetainedEarningsMember 2023-12-31 0001410098 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001410098 us-gaap:PreferredStockMember 2024-01-01 2024-09-30 0001410098 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0001410098 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001410098 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001410098 us-gaap:CommonStockMember 2023-06-30 0001410098 us-gaap:PreferredStockMember 2023-06-30 0001410098 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001410098 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001410098 us-gaap:RetainedEarningsMember 2023-06-30 0001410098 2023-06-30 0001410098 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001410098 us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001410098 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001410098 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001410098 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001410098 us-gaap:CommonStockMember 2023-09-30 0001410098 us-gaap:PreferredStockMember 2023-09-30 0001410098 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001410098 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001410098 us-gaap:RetainedEarningsMember 2023-09-30 0001410098 2023-09-30 0001410098 us-gaap:CommonStockMember 2022-12-31 0001410098 us-gaap:PreferredStockMember 2022-12-31 0001410098 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001410098 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001410098 us-gaap:RetainedEarningsMember 2022-12-31 0001410098 2022-12-31 0

gaap:FairValueMeasurementsRecurringMember crmd:USGovernmentAgencySecuritiesMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember crmd:USGovernmentAgencySecuritiesMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember crmd:USGovernmentAgencySecuritiesMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember crmd:USGovernmentAgencySecuritiesMember 2023-12-31 0001410098 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001410098 us-gaap:FairValueMeasurementsRecurringMember crmd:DebtSecuritiesExcludingMoneyMarketFundsMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember crmd:DebtSecuritiesExcludingMoneyMarketFundsMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember crmd:DebtSecuritiesExcludingMoneyMarketFundsMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001410098 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 2023-09-30 0001410098 us-gaap:SeriesEPreferredStockMember 2024-01-01 2024-09-30 0001410098 us-gaap:SeriesEPreferredStockMember 2023-01-01 2023-09-30 0001410098 us-gaap:SeriesEPreferredStockMember 2024-01-01 2024-09-30 0001410098 us-gaap:SeriesEPreferredStockMember 2023-01-01 2023-09-30 0001410098 us-gaap:DeferredCompensationShareBasedPaymentsMember 2024-01-01 2024-09-30 0001410098 us-gaap:DeferredCompensationShareBasedPaymentsMember 2023-01-01 2023-09-30 0001410098 us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001410098 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001410098 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001410098 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001410098 crmd:NDPartnersLLPMember 2024-09-30 0001410098 crmd:NDPTechnologyMember 2024-01-01 2024-09-30 0001410098 crmd:NDLicenseAgreementMember 2024-01-01 2024-09-30 0001410098 crmd:NDPartnersLLPMember crmd:NDLicenseAgreementMember 2024-09-30 0001410098 us-gaap:LicenseMember 2024-09-30 0001410098 us-gaap:LicenseMember 2024-07-01 2024-09-30 0001410098 us-gaap:LicenseMember 2024-01-01 2024-09-30 0001410098 crmd:UnderwritingAgreementMember 2023-06-28 0001410098 us-gaap:CommonStockMember 2023-06-28 2023-06-28 0001410098 us-gaap:CommonStockMember us-gaap:IPOMember 2023-07-03 0001410098 us-gaap:WarrantMember us-gaap:CommonStockMember 2023-06-28 0001410098 crmd:PreFundedWarrantsMember 2023-07-03 2023-07-03 0001410098 us-gaap:CommonStockMember 2023-07-28 0001410098 us-gaap:IPOMember 2023-07-28 2023-07-28 0001410098 us-gaap:SubsequentEventMember crmd:PreFundedWarrantsMember 2024-10-31 0001410098 2024-05-09 2024-05-09 0001410098 crmd:LeeringPartnersLLCMember 2024-05-09 2024-05-09 0001410098 crmd:TwoThousandAndTwentyFourATMPProgramMember 2024-01-01 2024-09-30 0001410098 us-gaap:RestrictedStockUnitsRSUMember crmd:TwoThousandAndNineteenOmnibusStockIncentivePlanMember srt:ChiefExecutiveOfficerMember 2024-01-01 2024-01-31 0001410098 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-01-31 0001410098 us-gaap:RestrictedStockUnitsRSUMember crmd:FirstAnniversaryMember 2024-01-01 2024-01-31 0001410098 us-gaap:RestrictedStockUnitsRSUMember crmd:ThirdAnniversaryMember 2024-01-01 2024-01-31 0001410098 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001410098 2024-05-31 2024-05-31 0001410098 2023-05-31 2023-05-31 0001410098 srt:ChiefExecutiveOfficerMember 2024-05-31 0001410098 srt:ChiefExecutiveOfficerMember 2023-05-31 2023-05-31 0001410098 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001410098 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001410098 srt:BoardOfDirectorsChairmanMember 2024-09-30 0001410098 us-gaap:StockOptionMember 2024-07-01 2024-09-30 0001410098 us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001410098 us-gaap:StockOptionMember crmd:TwoThousandAndNineteenOmnibusStockIncentivePlanMember us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001410098 us-gaap:StockOptionMember crmd:TwoThousandAndNineteenOmnibusStockIncentivePlanMember us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001410098 us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001410098 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001410098 us-gaap:StockOptionMember us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001410098 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001410098 us-gaap:StockOptionMember us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001410098 us-gaap:StockOptionMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001410098 crmd:EmployeesAndDirectorsMember 2024-07-01 2024-09-30 0001410098 srt:DirectorMember 2024-01-01 2024-09-30 0001410098 srt:OfficerMember 2023-07-01 2023-09-30 0001410098 crmd:ConsultantsMember 2023-01-01 2023-09-30 0001410098 us-gaap:EmployeeStockOptionMember 2024-09-30 0001410098 crmd:SeriesC3Member 2024-09-30 0001410098 crmd:SeriesC3Member 2023-12-31 0001410098 us-gaap:SeriesEPreferredStockMember 2023-12-31 0001410098 us-gaap:SeriesEPreferredStockMember 2024-09-30 0001410098 us-gaap:SeriesGPreferredStockMember 2023-12-31 0001410098 us-gaap:SeriesGPreferredStockMember 2024-09-30 0001410098 2020-09-16 2020-09-16 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:EUR EX-31.1 2 ea021837101ex31-1 cormedix.htm CERTIFICATION Exhibit 31.1 A CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 A I, Joseph Todisco, certify that: A 1.I have reviewed this Quarterly Report on Form 10-Q of CorMedix Inc.; A 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; A 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; A 4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: A a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared; A b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; A c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and A d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and A 5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): A a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and A b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. A c)Any incidents of cybersecurity that have a significant impact on internal controls over financial reporting and financial statements. A Date: October 30, 2024 By: /s/ Joseph Todisco A Name: A Joseph Todisco A Title: Chief Executive Officer (Principal Executive Officer) EX-31.2 3 ea021837101ex31-2 cormedix.htm CERTIFICATION Exhibit 31.2 A CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 A I, Matthew David, certify that: A 1.I have reviewed this Quarterly Report on Form 10-Q of CorMedix Inc.; A 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; A 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; A 4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: A e)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared; A f)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; A g)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and A h)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and A 5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): A d)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and A e)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. A f)Any incidents of cybersecurity that have a significant impact on internal controls over financial reporting and financial statements. A Date: October 30, 2024 By: /s/ Matthew David A Name: Matthew David A Title: Chief Financial Officer (Principal Financial Officer) EX-32.1 4 ea021837101ex32-1 cormedix.htm CERTIFICATION Exhibit 32.1 A CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 A In connection with the Quarterly Report of CorMedix Inc., a Delaware corporation (the "Company"), on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Joseph Todisco, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. A 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: A 1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and A 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. A Date: October 30, 2024 By: /s/ Joseph Todisco A Name: A Joseph Todisco A Title: Chief Executive Officer (Principal Executive Officer) EX-32.2 5 ea021837101ex32-2 cormedix.htm CERTIFICATION Exhibit 32.2 A CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 A In connection with the Quarterly Report of CorMedix Inc., a Delaware corporation (the "Company"), on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Matthew David, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. A 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: A 1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and A 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. A Date: October 30, 2024 By: /s/ Matthew David A Name: A Matthew David A Title: Chief Financial Officer (Principal Financial Officer) A EX-101.SCH 6 crmd-20240930.xsd XBRL SCHEMA FILE 995301 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 995303 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995304 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995306 - Disclosure - Organization, Business and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 995307 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties link:presentationLink link:definitionLink link:calculationLink 995308 - Disclosure - Other Prepaid Expenses and Current Assets link:presentationLink link:definitionLink link:calculationLink 995309 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 995310 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 995311 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 995312 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Tables) link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Other Prepaid Expenses and Current Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - Organization, Business and Basis of Presentation (Details) link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - Summary of Significant Accounting

Policies and Liquidity and Uncertainties (Details) - Schedule of consolidated statement of cash flows link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Amortized Cost, Unrealized Gains and Losses and the Fair Value link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Carrying and Fair Value of Financial Assets link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Inventories link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share link:presentationLink link:definitionLink link:calculationLink 996013 - Disclosure - Other Prepaid Expenses and Current Assets (Details) - Schedule of Other Prepaid Expenses and Current Assets link:presentationLink link:definitionLink link:calculationLink 996014 - Disclosure - Accrued Expenses (Details) - Schedule of Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 996015 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 996016 - Disclosure - Stockholdersâ€™ Equity (Details) link:presentationLink link:definitionLink link:calculationLink 996017 - Disclosure - Stockholdersâ€™ Equity (Details) - Schedule of Preferred Stock link:presentationLink link:definitionLink link:calculationLink 996018 - Disclosure - Stockholdersâ€™ Equity (Details) - Schedule of Black-Scholes Option Pricing Model link:presentationLink link:definitionLink link:calculationLink 996019 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 996020 - Disclosure - Leases (Details) - Schedule of Maturities of Lease Liabilities link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 crmd-20240930\_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 crmd-20240930\_def.xml XBRL DEFINITION FILE EX-101.LAB 9 crmd-20240930\_lab.xml XBRL LABEL FILE Total current assets TOTAL ASSETS Total current liabilities TOTAL LIABILITIES TOTAL STOCKHOLDERSâ€™ EQUITY Balance Balance TOTAL LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Total Operating Expenses Loss From Operations Total Other Income Net Loss Net loss Total Other Comprehensive Income (Loss) Other comprehensive gain (loss) Comprehensive Loss Balance (in Shares) Balance (in Shares) Equity Components [Axis] Net cash used in operating activities Net cash provided by (used in) investing activities Net cash provided by financing activities NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS CASH, CASH EQUIVALENTS AND RESTRICTED CASH - BEGINNING OF PERIOD CASH, CASH EQUIVALENTS AND RESTRICTED CASH - END OF PERIOD Total cash, cash equivalents and restricted cash Organization, Business and Basis of Presentation [Abstract] Summary of Significant Accounting Policies and Liquidity and Uncertainties [Abstract] Schedule of Cash and Cash Equivalents [Abstract] Debt Security Category [Axis] Measurement Frequency [Axis] Fair Value Hierarchy and NAV [Axis] Schedule of Inventories [Abstract] Total Inventories, net Antidilutive Securities [Axis] Other Prepaid Expenses and Current Assets [Abstract] Schedule of Other Prepaid Expenses and Current Assets [Abstract] Total Other prepaid expenses and current assets Accrued Expenses [Abstract] Schedule of Accrued Expenses [Abstract] Total Accrued expenses Commitments and Contingencies [Abstract] Stockholdersâ€™ Equity [Abstract] Leases [Abstract] Schedule of Maturities of Lease Liabilities [Abstract] Total future minimum lease payments ASSETS Current assets Cash and cash equivalents Restricted cash Short-term investments Trade receivables, net Prepaid research and development expenses Property and equipment, net License intangible asset, net Restricted cash, long-term Operating lease right-of-use asset Operating lease right of use asset LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Current liabilities Accounts payable Operating lease liability, short-term Operating lease liability current Operating lease liability, net of current portion Operating lease liability non current COMMITMENTS AND CONTINGENCIES (Note 5) STOCKHOLDERSâ€™ EQUITY Preferred stock - \$0.001 par value: 2,000,000 shares authorized; 181,622 shares issued and outstanding at September 30, 2024 and December 31, 2023 Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock - \$0.001 par value: 160,000,000 shares authorized; 57,887,149 and 54,938,258 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Common stock, par value (in Dollars per share) Common stock par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Shares of common stock issued Common stock, shares outstanding Accumulated other comprehensive gain Additional paid-in capital Accumulated deficit Revenue: Net sales Total revenue Gross profit Operating Expenses: Other Income (Expense): Interest income Foreign exchange transaction loss Other income Loss before income taxes Other Comprehensive Income (Loss): Unrealized gain (loss) from investments Foreign currency translation (loss) gain Net Loss Per Common Share â€” Basic (in Dollars per share) Net Loss Per Common Share â€” Diluted (in Dollars per share) Weighted Average Common Shares Outstanding â€” Basic (in Shares) Weighted Average Common Shares Outstanding â€” Diluted (in Shares) Stock issued in connection with ATM sale of common stock, net Stock issued in connection with ATM sale of common stock, net (in Shares) Common stock shares issued (in Shares) Stock issued in connection with options exercised Stock issued in connection with options exercised (in Shares) Issuance of exercised stock options Stock-based compensation Issuance of vested restricted stock, net of shares withheld for employee withholding taxes Issuance of vested restricted stock, net of shares withheld for employee withholding taxes (in Shares) Shares of common stock in lieu of withholding taxes Cancellation of shares held in escrow Cancellation of shares held in escrow (in Shares) Stock and pre-funded warrants issued in connection with public offering, net Stock and pre-funded warrants issued in connection with public offering, net (in Shares) CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation Change in right-of-use assets Depreciation Amortization of intangible Amortization expense Changes in operating assets and liabilities: (Decrease) increase in accounts payable Increase in accrued expenses Decrease in operating lease liabilities CASH FLOWS FROM INVESTING ACTIVITIES: Maturity of short-term investments CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from sale of common stock from at-the-market program, net Net proceeds (in Dollars) Proceeds from public offering of common stock and pre-funded warrants, net Proceeds from exercise of stock options Net proceeds of exercised stock options (in Dollars) Foreign exchange effect on cash Cash paid for interest Supplemental Disclosure of Non-Cash Investing Activities: Liability related to license agreement Unrealized gain (loss) from investments Cost of sales Research and development Selling and marketing General and administrative Interest expense Tax benefit Increase in trade receivables Increase in inventory Increase in prepaid expenses and other current assets Purchase of short-term investments Purchase of equipment Payment of employee withholding taxes on vested restricted stock units Common Stock Common Stock [Member] Preferred Stock â€” Series C-3, Series E and Series G Accumulated Other Comprehensive Income Additional Paid-in Capital Accumulated Deficit Organization, Business and Basis of Presentation Summary of Significant Accounting Policies and Liquidity and Uncertainties Schedule of consolidated statement of cash flows Restricted cash Schedule of Amortized Cost, Unrealized Gains and Losses and the Fair Value Amortized Cost Gross Unrealized Gains Fair Value Carrying Value Schedule of Carrying and Fair Value of Financial Assets Schedule of Inventories Raw materials Work in progress Finished goods Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share Total potentially dilutive shares Other Prepaid Expenses and Current Assets Schedule of Other Prepaid Expenses and Current Assets API deposit FDA filing fee Commercial Subscriptions Medical affairs Insurance Other Accrued Expenses Schedule of Accrued Expenses Accrued payroll and payroll taxes Manufacturing related License agreement payable (see Note 5 â€” Commitments and Contingencies) License agreement payable Professional and consulting fees Other Commitments and Contingencies Stockholdersâ€™ Equity Schedule of Preferred Stock Schedule of Black-Scholes Option Pricing Model Expected term (in years) Volatility weighted average Dividend yield weighted average Expected dividend yield, percentage Risk-free interest rate weighted average Weighted average grant date fair value of options granted during the period (in Dollars per share) Leases Schedule of Maturities of Lease Liabilities 2024 (excluding the nine months ended September 30, 2024) 2025 2026 2027 Total Operating lease liability Gross Unrealized Losses Accrued gross-to-net deductions Less imputed interest Money Market Funds included in Cash Equivalents [Member] Money Market Funds and Cash Equivalents [Member] U.S. Government Agency Securities [Member] Commercial Paper [Member] Subtotal [Member] Fair Value, Recurring [Member] Level 1 [Member] Level 2 [Member] Level 3 [Member] Series C-3 non-voting preferred stock [Member] Series E non-voting preferred stock [Member] Series E [Member] Series E Preferred Stock [Member] Series G non-voting preferred stock [Member] Series G [Member] Series G Preferred Stock [Member] Shares issuable for payment of deferred board compensation [Member] Shares underlying outstanding stock options [Member] Equity Option [Member] Shares underlying restricted stock units [Member] Restricted Stock Units [Member] Stock Options [Member] Class of Stock [Axis] Customer [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Investment, Name [Axis] Related Party Transaction [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Product and Service [Axis] Class of Warrant or Right [Axis] Sale of Stock [Axis] Subsequent Event Type [Axis] Related and Nonrelated Parties [Axis] Plan Name [Axis] Title and Position [Axis] Derivative Instrument [Axis] Preferred Stock, Liquidation Preference Per Share Preferred Stock, Liquidation Preference, Value Entity incorporation date Current shelf registration amount Common stock remaining capacity Major customers percentage Inventories expensed as research and development Provisions for the revenue reserves Variable consideration Shares underlying outstanding (in Shares) Amount of initial licensing fee Equity interest percentage Number of shares released in escrow (in Shares) Maximum aggregate amount of cash payments Balance of cash payments Additional amount of achievement milestone License agreement intangible Estimated economic life Warrants purchase shares Purchase of additional shares Common stock per share price (in Dollars per share) Pre-funded warrants to purchase Net proceeds (in Dollars) Common stock available for sale (in Dollars) Sale of common stock (in Dollars) Gross proceeds percentage Capacity remaining program (in Dollars) Sale of stock units Granted shares issued Weighted average grant date fair value (in Dollars per share) RSUs vested percentage RSUs grant percentage Vested shares issued Outstanding RSUs Compensation expense RSUs (in Dollars) Unrecognized compensation expense (in Dollars) Period of unrecognized compensation expense Granted aggregate shares Weighted average exercise price (in Dollars per share) Stock-based compensation (in Dollars) Unrecognized compensation expense (in Dollars) Payments for leasing costs Rental agreement expense (in Euro) Operating lease expense Operating leases Weighted average remaining lease term Weighted average discount rate Liquidity and Uncertainties Use of Estimates Reclassifications Basis of Consolidation Trade Accounts Receivable and Allowances Concentrations Financial Instruments Fair Value Measurements Inventories Revenue Recognition Variable Consideration License Agreement Leases Loss Per Common Share Stock-Based Compensation Research and Development Recent Accounting Pronouncements Series C-3 [Member] CorMedix Inc. [Member] One Customer [Member] Revenue Benchmark [Member] Customer Concentration Risk [Member] Accounts Receivable [Member] ND Partners, LLP [Member] NDP Technology [Member] ND License Agreement [Member] License [Member] Underwriting Agreement [Member] IPO [Member] Warrant [Member] Pre-Funded Warrants [Member] Subsequent Event [Member] Leerink Partners LLC [Member] 2024 ATM Program [Member] 2019 Omnibus Stock Incentive Plan [Member] Chief Executive Officer [Member] Executive Officers [Member] Second Anniversary [Member] First Anniversary [Member] Third Anniversary [Member] Board of Directors [Member] Employees [Member] Director [Member] Officer [Member] Consultants [Member] Employee Stock Option [Member] Equity Component [Domain] Statement [Table] Statement [Line Items] InformationByCategoryOfDebtSecurityDomain [Domain] Marketable Securities [Table] Schedule of Marketable Securities [Line Items] Measurement Frequency [Domain] Fair Value Hierarchy and NAV [Domain] Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Carrying and Fair Value of Financial Assets [Table] Schedule of Carrying and Fair Value of Financial Assets [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Security, Excluded EPS Calculation [Table] Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share [Line Items] Stockholdersâ€™ Equity (Details) - Schedule of Black-Scholes Option Pricing Model [Table] Schedule of Black-Scholes Option Pricing Model [Line Items] Organization, Business and Basis of Presentation (Details) [Table] Organization, Business and Basis of Presentation [Line Items] Customer [Domain] Concentration Risk Type [Domain] Concentration Risk Benchmark [Domain] Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) [Table] Summary of Significant Accounting Policies and Liquidity and Uncertainties [Line Items] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Investment, Name [Domain] Related Party Transaction [Domain] Product and Service [Domain] Commitments and Contingencies (Details) [Table] Commitments and Contingencies [Line Items] Sale of Stock [Domain] Class of Stock [Domain] Title and Position [Domain] Subsequent Event Type [Domain] Related and Nonrelated Parties [Domain] Award Type [Domain] Plan Name [Domain] Derivative Contract [Domain] Class of Warrant or Right [Domain] Stockholdersâ€™ Equity (Details) [Table] Stockholders' Equity [Line Items] Stockholdersâ€™ Equity (Details) - Schedule of Preferred Stock [Table] Stockholdersâ€™ Equity (Details) - Schedule of Preferred Stock [Line Items] Accrued gross-to-net deductions. Represents the value of additional amount of achievement of milestones. Amount of initial licensing fee. Balance of cash payments due upon achievement of milestones. Represent the amount of common stock remaining share value available for sale. Amount of food and drug administration filing fee. The gross proceeds sale of common stock percentage. The amount of inventories expensed as research and development. Represents the amount of license agreement payable. Disclosure of accounting policy for license agreement. Disclosure of accounting policy for liquidity and uncertainties. Carrying value as of the balance sheet date of obligations manufacturing development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Maximum aggregate amount of cash payments due upon achievement of milestones. The Number of shares released in escrow. Represents the amount of prepaid medical affairs. Represents the amount of prepaid subscriptions. Provisions for the revenue reserves. Number of purchase of additional shares. Rental agreement expense. Represents the amount of revenue variable consideration. Sale of common stock. Percentage of grant date shares. Percentage of vesting shares. Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Use of Estimates, Policy [Policy Text Block] Assets [Abstract] Commitments and Contingencies Nonoperating Income (Expense) [Abstract] Finite-Lived License Agreements, Gross Restricted Cash, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Common Stock, Value, Issued Proceeds from Issuance of Warrants Debt Securities Excluding Money Market Funds Member Balance Of Cash Payments Due Upon Achievement Of Milestones Earnings Per Share, Diluted Retained Earnings [Member] Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Lessee, Leases [Policy Text Block] Operating Lease, Payments Weighted Average Number of Shares Outstanding, Basic Accrued Professional Fees, Current Rental Agreement Expense Maximum Aggregate Amount Of Cash Payments Due Upon Achievement Of Milestones Leerink Partners LLCMember Increase (Decrease) in Prepaid Expense and Other Assets Restricted Cash, Noncurrent IPO [Member] Schedule Of Black Scholes Option Pricing Model Abstract Officer [Member] Stock Issued During Period, Value, New Issues Series C Preferred Stock [Member] Statement of Stockholders' Equity [Abstract] Increase (Decrease) in Operating Lease Liability Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Gross Proceeds Sale Of Common Stock Percentage Fair Value Measurement, Policy [Policy Text Block] Income Tax Expense (Benefit) Cor Medix Inc Member Amortization of Intangible Assets Income Statement [Abstract] Other Comprehensive Income (Loss), Net of Tax Stock Issued During Period, Shares, New Issues Lessee, Operating

Leases [Text Block] Two Thousand And Twenty Four ATMProgram Member New Accounting Pronouncements, Policy [Policy Text Block] Investment Income, Interest Cash, Cash Equivalents and Investments [Table Text Block] First Anniversary Member Accrued Grosstonet Deduction Additional Paid in Capital Operating Expenses [Abstract] Inventory, Raw Materials, Gross Board of Directors Chairman [Member] Earnings Per Share, Basic Series E Preferred Stock [Member] Net Cash Provided by (Used in) Operating Activities [Abstract] Debt Securities, Available-for-Sale Revenues [Abstract] Assets Liabilities Research and Development Expense Prepaid Subscriptions Current Equity, Attributable to Parent [Abstract] Preferred Stock, Shares Issued Liquidity And Uncertaintie Policy Text Block Accounts Receivable [Member] Prepaid Expense, Current Sharebased Compensation Arrangement By Sharebased Payment Award Options Grantdate Percentage Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Derivative, Underlying Investment, Shares License Agreement Policy Text Block Prepaid Insurance Manufacturing Development Current Common Stock, Shares, Outstanding Stock Issued During Period, Shares, Issued for Services USGovernment Agency Securities Member Retained Earnings (Accumulated Deficit) Increase (Decrease) in Inventories Depreciation Lessee, Operating Lease, Liability, to be Paid, Year Three Finite-Lived Intangible Asset, Useful Life Net Cash Provided by (Used in) Investing Activities Gain (Loss), Foreign Currency Transaction, before Tax Inventory, Finished Goods, Gross Proceeds from Stock Options Exercised Series G Preferred Stock [Member] Inventory, Policy [Policy Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Payments to Acquire Property, Plant, and Equipment Payments to Acquire Short-Term Investments NDPTechnology Member Food And Drug Administration Filling Fee Line of Credit Facility, Remaining Borrowing Capacity Share-Based Payment Arrangement [Policy Text Block] Preferred Stock, Shares Authorized Interest Paid, Excluding Capitalized Interest, Operating Activities Fair Value, Recurring [Member] Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Percentage Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Preferred Stock, Shares Outstanding Fair Value, Inputs, Level 2 [Member] Prepaid Expense and Other Assets, Current Property, Plant and Equipment, Net Liabilities Assumed Net Cash Provided by (Used in) Financing Activities Accounts Payable, Current Restricted Stock, Shares Issued Net of Shares for Tax Withholdings Increase (Decrease) in Accrued Liabilities Debt Securities, Available-for-Sale, Amortized Cost Common Stock, Shares Authorized One Customer Member Proceeds from Issuance or Sale of Equity Operating Lease, Liability, Noncurrent Interest Expense, Nonoperating Accounts Receivable [Policy Text Block] Other Accrued Liabilities, Current Operating Lease, Weighted Average Discount Rate, Percent Subsequent Event [Member] Warrant [Member] Preferred Stock [Member] Concentration Risk, Credit Risk, Policy [Policy Text Block] Third Anniversary Member Schedule of Accrued Liabilities [Table Text Block] Share-Based Payment Arrangement, Expense Increase (Decrease) in Operating Capital [Abstract] Net Cash Provided by (Used in) Financing Activities [Abstract] Common Stock Remaining Share Value Available For Sale Unrealized Gain (Loss) on Investments Additional Paid-in Capital [Member] Restricted Stock or Unit Expense NDPPartners LLPMember Class of Warrant or Right, Number of Securities Called by Warrants or Rights Sale of Stock, Consideration Received on Transaction NDLicense Agreement Member License [Member] Operating Income (Loss) Number of Shares Released In Escrow Selling and Marketing Expense Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Net Cash Provided by (Used in) Investing Activities [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Operating Lease, Liability Underwriting Agreement Member Additional Amount Of Achievement Of Milestones Series C3 Member Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Significant Accounting Policies [Text Block] Revenue from Contract with Customer [Policy Text Block] Common Stock [Member] Reclassification, Comparability Adjustment [Policy Text Block] Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Employees And Directors Member AOCI Attributable to Parent [Member] Statement of Cash Flows [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Class of Warrant or Right, Outstanding Other Prepaid Expense, Current Sale Of Common Stock Operating Lease, Liability, Current Lessee, Operating Lease, Liability, to be Paid, Year Two Comprehensive Income (Loss), Net of Tax, Attributable to Parent Fair Value, Inputs, Level 3 [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Equity Method Investment, Ownership Percentage Chief Executive Officer [Member] Revenue Variable Consideration Money Market Funds [Member] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Materials, Supplies, and Other Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule Of Carrying And Fair Value Of Financial Assets Abstract Liabilities, Current [Abstract] Net Cash Provided by (Used in) Operating Activities Schedule Of Anti Dilutive Securities Excluded From Calculation Of Diluted Net Loss Per Share Abstract Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Accrued Payroll Taxes, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award Equity Option [Member] Stock Issued During Period, Shares, Other Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Right-of-Use Asset, Periodic Reduction Fair Value, Inputs, Level 1 [Member] Fair Value of Financial Instruments, Policy [Policy Text Block] Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Common Stock Remaining Capacity Equity, Attributable to Parent Provisions For The Revenue Reserves Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Schedule of Inventory, Current [Table Text Block] Accumulated Other Comprehensive Income (Loss), Net of Tax Deferred Compensation, Share-Based Payments [Member] Revenues Stock Issued During Period, Value, Stock Options Exercised Restricted Stock Units (RSUs) [Member] Stock Issued During Period, Value, Issued for Services General and Administrative Expense Marketable Securities [Table Text Block] Concentration Risk, Percentage Payments for Leasing Costs Pre Funded Warrants Member Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Common Stock, Par or Stated Value Per Share Earnings Per Share, Policy [Policy Text Block] Common Stock, Shares, Issued Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Revenue Benchmark [Member] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Preferred Stock, Liquidation Preference Per Share Weighted Average Number of Shares Outstanding, Diluted Gross Profit Operating Lease, Expense Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Intangible Assets, Net (Excluding Goodwill) Accounts Receivable, after Allowance for Credit Loss, Current Schedule Of Amortized Cost Unrealized Gains And Losses And The Fair Value Abstract Director [Member] Lessee, Operating Lease, Liability, to be Paid Inventory, Work in Process, Gross Short-Term Investments Prepaid Advertising Inventories Expensed As Research And Development Amount Of Initial Licensing Fee Equity [Text Block] Sale of Stock, Number of Shares Issued in Transaction Assets, Current [Abstract] Payment, Tax Withholding, Share-Based Payment Arrangement Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Liabilities, Current Operating Expenses Increase (Decrease) in Accounts Payable License Agreement Payable Current Restricted Cash and Cash Equivalents Prepaid Medical Affairs Current Statement of Financial Position [Abstract] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Second Anniversary Member Cash and Cash Equivalents, at Carrying Value Accrued Liabilities, Current Other Current Assets [Text Block] Research and Development Expense, Policy [Policy Text Block] Schedule of Preferred Units [Table Text Block] Shares Issued, Price Per Share Consolidation, Policy [Policy Text Block] Liabilities and Equity [Abstract] Shares, Outstanding OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Commitments and Contingencies Disclosure [Text Block] Lessee, Operating Lease, Liability, to be Paid, Year One Customer Concentration Risk [Member] Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Commercial Paper [Member] Increase (Decrease) in Accounts Receivable Proceeds from Issuance of Common Stock Cost of Revenue Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Consultants Member Schedule of Other Current Assets [Table Text Block] Purchase Of Additional Shares Preferred Stock, Value, Issued Other Nonoperating Income Other Comprehensive Income (Loss), Net of Tax [Abstract] Proceeds from Sale of Short-Term Investments Preferred Stock, Liquidation Preference, Value Liabilities and Equity Lessee, Operating Lease, Liability, Undiscounted Excess Amount Nonoperating Income (Expense) Share-Based Payment Arrangement, Noncash Expense Restricted Stock, Value, Shares Issued Net of Tax Withholdings Two Thousand Nineteen Omnibus Stock Incentive Plan Member Preferred Stock, Par or Stated Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Stock Issued During Period, Value, Other Consolidation, Variable Interest Entity, Policy [Policy Text Block] Operating Lease, Right-of-Use Asset Assets, Current Inventory, Net EX-101.PRE 10 crmd-20240930\_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 9 Months Ended Sep. 30, 2024 Oct. 28, 2024 Document Information [Line Items] Å Document Type 10-Q Å Document Quarterly Report true Å Document Transition Report false Å Entity Interactive Data Current Yes Å Amendment Flag false Å Document Period End Date Sep. 30, 2024 Å Document Fiscal Year Focus 2024 Å Document Fiscal Period Focus Q3 Å Entity Information [Line Items] Å Å Entity Registrant Name CORMEDIX INC. Å Entity Central Index Key 0001410098 Å Entity File Number 001-34673 Å Entity Tax Identification Number 20-5894890 Å Entity Incorporation, State or Country Code DE Å Current Fiscal Year End Date --12-31 Å Entity Current Reporting Status Yes Å Entity Shell Company false Å Entity Filer Category Non-accelerated Filer Å Entity Small Business true Å Entity Emerging Growth Company false Å Entity Contact Personnel [Line Items] Å Å Entity Address, Address Line One 300 Connell Drive Å Entity Address, Address Line Two Suite 4200 Å Entity Address, City or Town Berkeley Heights Å Entity Address, State or Province NJ Å Entity Address, Postal Zip Code 07922 Å Entity Phone Fax Numbers [Line Items] Å Å City Area Code (908) Å Local Phone Number 517-9500 Å Entity Listings [Line Items] Å Å Title of 12(b) Security Common stock, \$0.001 par value Å Trading Symbol CRMD Å Security Exchange Name NASDAQ Å Entity Common Stock, Shares Outstanding Å 60,677,204 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei AmendmentFlag Namespace Prefix: dei Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei CityAreaCode Namespace Prefix: dei Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei CurrentFiscalYearEndDate Namespace Prefix: dei Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei DocumentFiscalPeriodFocus Namespace Prefix: dei Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei DocumentFiscalYearFocus Namespace Prefix: dei Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei DocumentInformationLineItems Namespace Prefix: dei Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei DocumentPeriodEndDate Namespace Prefix: dei Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei DocumentQuarterlyReport Namespace Prefix: dei Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei DocumentTransitionReport Namespace Prefix: dei Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei DocumentType Namespace Prefix: dei Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei EntityAddressAddressLine1 Namespace Prefix: dei Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei EntityAddressAddressLine2 Namespace Prefix: dei Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei EntityAddressCityOrTown Namespace Prefix: dei Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei EntityAddressPostalZipCode Namespace Prefix: dei Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei EntityAddressStateOrProvince Namespace Prefix: dei Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityCentralIndexKey Namespace Prefix: dei Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei EntityCommonStockSharesOutstanding Namespace Prefix: dei Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei EntityContactPersonnelLineItems Namespace Prefix: dei Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei EntityCurrentReportingStatus Namespace Prefix: dei Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityEmergingGrowthCompany

Namespace Prefix: dei\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei\_EntityFileNumber Namespace Prefix: dei\_Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: [\hat{A} Cash and cash equivalents \\$ 35,286,138 \\$ 43,642,684 Restricted cash 77,453 Short-term investments 10,743,562 32,388,130 Trade receivables, net 17,387,446 Inventories, net 6,649,495 2,106,345 Prepaid research and development expenses 170,739 353,574 Other prepaid expenses and current assets 2,916,889 882,214 Total current assets 73,154,269 79,450,400 Property and equipment, net 1,899,875 1,866,224 License intangible asset, net 1,896,104 Restricted cash, long-term 105,084 103,055 Operating lease right-of-use asset 530,862 640,278 TOTAL ASSETS 77,586,194 82,059,957 Current liabilities  \$\hat{A}\$  Accounts payable 1,343,833 4,279,679 Accrued expenses 16,973,677 6,970,217 Operating lease liability, short-term 163,449 150,619 Total current liabilities 18,480,959 11,400,515 Operating lease liability, net of current portion 392,967 517,013 TOTAL LIABILITIES 18,873,926 11,917,528 COMMITMENTS AND CONTINGENCIES \(Note 5\) STOCKHOLDERS \$\hat{A}\$  EQUITY  \$\hat{A}\$  Preferred stock - \\$0.001 par value: 2,000,000 shares authorized; 181,622 shares issued and outstanding at September 30, 2024 and December 31, 2023 182,182 Common stock - \\$0.001 par value: 160,000,000 shares authorized; 57,887,149 and 54,938,258 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 57,886 54,938 Accumulated other comprehensive gain 89,120 94,108 Additional paid-in capital 411,659,517 391,693,214 Accumulated deficit \(353,094,437\) \(321,700,013\) TOTAL STOCKHOLDERS \$\hat{A}\$  EQUITY 58,712,268 70,142,429 TOTAL LIABILITIES AND STOCKHOLDERS \$\hat{A}\$  EQUITY  \$\hat{A}\$  Total Carrying value as of the balance sheet date of liabilities incurred \(and for which invoices have typically been received\) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities \(due within one year or within the normal operating cycle if longer\). + ReferencesReference 1:](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: <a href=)

1BReference 25:

Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 27: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference) 28: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference) 29: [http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference) 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference) 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference) 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference) 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference) 6: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference) 7: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(32\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap\\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(21\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference) 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference) 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference) 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference) 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference) 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference) 8: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference> 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference> 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference) 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference) 20: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference) 21: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap LiabilitiesCurrent Namespace Prefix: us-gaap\\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap LiabilitiesCurrentAbstract Namespace Prefix: us-gaap\\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap\\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap\\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock \(or preferred stock redeemable solely at the option of the issuer\). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference> 3: [http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference) 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference</a> 2: <a href=) 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference> 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap PrepaidExpenseCurrent Namespace Prefix: us-gaap\\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-10-1Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-10-1Reference) 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference) 3: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference> 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference) 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference)

URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap\_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap\_ShortTermInvestments Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 12: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 14: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SAB Topic 4.E\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2) + Details Name: us-gaap\_StockholdersEquity Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap\_StockholdersEquityAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parentheticals) - / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position (Abstract) Â Â Preferred stock, par value (in Dollars per share) \$ 0.001 \$ 0.001 Preferred stock, shares authorized 2,000,000 2,000,000 Preferred stock, shares issued 181,622 181,622 Preferred stock, shares outstanding 181,622 181,622 Common stock, par value (in Dollars per share) \$ 0.001 \$ 0.001 Common stock, shares authorized 160,000,000 160,000,000 Common stock, shares issued 57,887,149 54,938,258 Common stock, shares outstanding 57,887,149 54,938,258 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap\_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap\_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1) + Details Name: us-gaap\_CommonStockSharesAuthorized Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap\_CommonStockSharesIssued Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3) + Details Name: us-gaap\_CommonStockSharesOutstanding Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13) + Details Name: us-gaap\_PREFERREDStockParOrStatedValuePerShare Namespace Prefix: us-gaap\_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1) + Details Name: us-gaap\_PREFERREDStockSharesAuthorized Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3) + Details Name: us-gaap\_PREFERREDStockSharesOutstanding Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap\_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD (\$) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue: Â Â Â Â Net sales \$ 11,456,115 \$ 12,262,234 Cost of sales (686,598) (2,014,975) Gross profit 10,769,517 10,247,259 Operating Expenses: Â Â Â Research and development (727,119) (2,663,976) (2,215,551) (10,866,236) Selling and marketing (6,748,900) (4,058,428) (20,472,961) (9,955,651) General and administrative (6,580,834) (3,744,879) (22,851,144) (12,467,157) Total Operating Expenses (14,056,853) (10,467,283) (45,539,656) (33,289,044) Loss From Operations (3,287,336) (10,467,283) (35,292,397) (33,289,044) Other Income (Expense): Â Â Â Interest income 553,856 765,241 2,068,407 1,761,808 Foreign exchange transaction loss (33,325) (29,199) (38,806) (30,222) Other income 500,000 Interest expense (10,007) (13,113) (26,398) (27,740) Total Other Income 510,524 722,929 2,503,203 1,703,846 Loss before income taxes (2,776,812) (9,744,354) (32,789,194) (31,585,198) Tax benefit 1,394,770 Net Loss (2,776,812) (9,744,354) (31,394,424) (31,585,198) Other Comprehensive Income (Loss): Â Â Â Unrealized gain (loss) from investments 5,040 (4,571) (3,832) 1,090 Foreign currency translation (loss) gain (1,651) (1,727) (1,156) 566 Total Other Comprehensive Income (Loss) 3,389 (6,298) (4,988) 1,656 Comprehensive Loss \$ (2,773,423) \$ (9,750,652) \$ (31,399,412) \$ (31,583,542) Net Loss Per Common Share â€œ Basic (in Dollars per share) \$ (0.05) \$ (0.17) \$ (0.54) \$ (0.65) Weighted Average Common Shares Outstanding â€œ Basic (in Shares) 58,825,221 56,553,174 57,986,190 48,715,585 Weighted Average Common Shares Outstanding â€œ Diluted (in Shares) 58,825,221 56,553,174 57,986,190 48,715,585 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(26\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/21474](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)

Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-5> + Details Name: us-gaap ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2>: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7>: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20>: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147480097/470-10-S99-](https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21)

gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9>: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10): [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11): [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12): [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23): [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap\\_GrossProfit Namespace Prefix: us-gaap\\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income \(loss\) from continuing operations, including income \(loss\) from equity method investments, before deduction of income tax expense \(benefit\), and income \(loss\) attributable to noncontrolling interest. + ReferencesReference 1](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1): <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2>: [http://www.xbrl.org/2003/](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3)

S99-1AReference 25:

asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17:

<https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481674/830-30-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481694/830-30-45-17>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-4>Reference 7: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-5>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481694/830-30-45-20>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 12: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482739/220-10-55-15>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A> + Details Name: us-gaap\_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation. + ReferencesNo definition available. + Details Name: us-gaap\_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation. + ReferencesNo definition available. + Details Name: us-gaap\_RestrictedStockValueSharesIssuedNetOfTaxWithholdings Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap\_SharesOutstanding Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap\_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478448/946-505-50-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap\_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap\_StockIssuedDuringPeriodSharesOther Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478009/946-205-45-4>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478448/946-505-50-2>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap\_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap\_StockIssuedDuringPeriodValueOther Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap\_StockholdersEquity Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML T7 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD (\$ ) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: A Net loss \$ (31,394,424) \$ (31,585,198) Adjustments to reconcile net loss to net cash used in operating activities: A Stock-based compensation 4,935,500 4,276,474 Change in right-of-use assets 109,416 99,970 Depreciation 72,210 52,085 Amortization of intangible 103,896 Changes in operating assets and liabilities: A Increase in trade receivables (17,387,446) Increase in inventory (4,543,150) Increase in prepaid expenses and other current assets (1,851,748) (1,756,105) (Decrease) increase in accounts payable (2,935,851) 183,903 Increase in accrued expenses 8,002,696 1,164,571 Decrease in operating lease liabilities (111,216) (99,486) Net cash used in operating activities (45,000,117) (27,663,786) CASH FLOWS FROM INVESTING ACTIVITIES: A Purchase of short-term investments (21,475,457) (60,978,108) Maturity of short-term investments 43,116 192 43,350 Purchase of equipment (105,861) (31,369) Net cash provided by (used in) investing activities 21,534,874 (17,659,477) CASH FLOWS FROM FINANCING ACTIVITIES: A Proceeds from sale of common stock from at-the-market program, net 13,376,081 12,515,209 Payment of employee withholding taxes on vested restricted stock units (236,615) (198,442) Proceeds from public offering of common stock and pre-funded warrants, net 42,878,399 Proceeds from exercise of stock options 1,894,285 253,988 Net cash provided by financing activities 15,033,751 55,449,154 Foreign exchange effect on cash (478) 385 NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (8,431,970) 10,126,276 CASH, CASH EQUIVALENTS AND RESTRICTED CASH - BEGINNING OF PERIOD 43,823,192 43,374,745 CASH, CASH EQUIVALENTS AND RESTRICTED CASH - END OF PERIOD 35,391,222 53,501,021 Cash paid for interest 26,398 27,739 Supplemental Disclosure of Non-Cash Investing Activities: A Liability related to license agreement 2,000,000 Unrealized gain (loss) from investments \$ 3,832 \$ (1,090) X - ReferencesNo definition available. + Details Name: us-gaap\_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUSInOperatingActivitiesAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType

Balance Type: na Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2> + Details Name: us-gaap\_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1) + Details Name: us-gaap\_Depreciation Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap\_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap\_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap\_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap\_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap\_IncreaseDecreaseInInventories Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap\_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2> + Details Name: us-gaap\_InterestPaidNet Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe fair value of liabilities assumed in noncash investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5> + Details Name: us-gaap\_LiabilitiesAssumed1 Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap\_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap\_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap\_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>

14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap\_NetIncomeLoss Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap\_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15) + Details Name: us-gaap\_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13) + Details Name: us-gaap\_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13> + Details Name: us-gaap\_PaymentsToAcquireShortTermInvestments Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap\_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap\_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12> + Details Name: us-gaap\_ProceedsFromSaleOfShortTermInvestments Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap\_ShareBasedCompensation Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap\_UnrealizedGainLossOnInvestments Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Organization, Business and Basis of Presentation 9 Months Ended Sep. 30, 2024 Organization, Business and Basis of Presentation [Abstract] Á Organization, Business and Basis of Presentation Note 1 - Organization, Business and Basis of Presentation: Á Organization and Business Á CorMedix Inc. (áœœCorMedixáœœ or the áœœCompanyáœœ) was incorporated in the State of Delaware on July 28, 2006. The Company is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. Á The Companyáœœ's primary focus is on the commercialization of its lead product, DefenCathÁ® (taurolidine and heparin) in the United States, or U.S. The Company has in-licensed the worldwide rights to develop and commercialize DefenCath. The name DefenCath is the U.S. proprietary name approved by the U.S. Food and Drug Administration, or FDA. Á Basis of Presentation Á The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information and with the instructions for Quarterly Reports on Form 10-Q and Article 8 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary to fairly state the interim results. Interim operating results are not necessarily indicative of results that may be expected for the full year ending December 31, 2024, or for any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto of the Company which are included in the Companyáœœ's Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 12, 2024. The accompanying consolidated balance sheet as of December 31, 2023 has been derived from the audited financial statements included in such Annual Report on Form 10-K. X - ReferencesNo definition available. + Details Name: us-gaap\_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContent>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent> + Details Name: us-gaap\_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies and Liquidity and Uncertainties 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies and Liquidity and Uncertainties [Abstract] Á Summary of Significant Accounting Policies and Liquidity and Uncertainties Note 2 - Summary of Significant Accounting Policies and Liquidity and Uncertainties: Á Liquidity and Uncertainties Á The condensed consolidated financial statements have been prepared in conformity with GAAP which contemplate continuation of the Company as a going concern. To date, the Companyáœœ's commercial operations have not generated sufficient revenues to enable profitability. The Companyáœœ's current commercial and development expenses for DefenCath and its other operating requirements are expected to be funded for at least twelve months from the issuance of this Quarterly Report on Form 10-Q by the Companyáœœ's existing cash, cash equivalents and short-term investments at September 30, 2024 and its expected liquidity from commercial operations. Á The Company may raise additional capital through various potential sources, such as equity and/or debt financing, strategic relationships, potential strategic transactions and/or out-licensing. Management can provide no assurances that such financing or strategic relationships will be available on acceptable terms, or at all. As of September 30, 2024, approximately \$36,012,000 of the Companyáœœ's common stock remains available for sale under the 2024 ATM program, with \$100,000,000 of remaining capacity under the 2024 Shelf Registration Statement for the issuance of Company securities (see Note 6). Á The Companyáœœ's operations are subject to a number of other factors that can affect its operating results and cash flow projections over the next twelve months from the issuance of these financial statements. Such factors include, but are not limited to: the ability to market DefenCath and generate necessary revenue in the time periods required; ability to manufacture successfully; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company products; the Companyáœœ's ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; and the Companyáœœ's ability to raise capital to support its operations. Á Use of Estimates Á The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Companyáœœ's consolidated balance sheets and the reported amounts of revenue and expenses reported for each of the periods presented are affected by estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from those estimates. Á Reclassifications Á Certain reclassifications were made to the prior yearáœœ's amounts to conform to the 2024

presentation. A Basis of Consolidation A The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. A Trade Accounts Receivable and Allowances A The Company complies with ASU 2016-13, A Measurement of Credit Losses on Financial Instruments, which requires the Company to recognize an allowance that reflects a current estimate of credit losses expected to be incurred over the life of a financial asset, including trade receivables. The allowance for credit losses reflects the best estimate of expected credit losses of the accounts receivable portfolio determined on the basis of current information, forecasts of future economic conditions, industry knowledge and to some extent our historical experience. The Company determines its allowance methodology by pooling receivable balances at the customer level. The Company considers various factors, including individual credit risk associated with each customer, the current and future condition of the general economy and industry knowledge. These credit risk factors are monitored on a quarterly basis and updated as necessary. To the extent any individual debtor is identified whose credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of such customer. The Company makes concerted efforts to collect all outstanding balances due, however account balances are charged off against the allowance when management believes it is probable the receivable will not be recovered. The Company does not have any off-balance sheet credit exposure related to its customers. There are no significant allowances recorded for credit losses as of September 30, 2024. A Concentrations A The major customers of the Company are defined as those constituting greater than 10% of its total revenue. In the three and nine months ended September 30, 2024, the Company had sales to one customer that accounted for 98% and 92% of its total revenue of \$11,456,000 and \$12,262,000, respectively. This customer also accounts for 100% of the Company's accounts receivable as of September 30, 2024. The Company currently has one FDA approved source for each of its two key active pharmaceutical ingredients for DefenCath, taurolidine and heparin sodium. A Financial Instruments A Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, short-term investments and accounts receivable. The Company maintains its cash and cash equivalents in bank deposit and other interest-bearing accounts, the balances of which, at times, may exceed federally insured limits. A A The following table is the reconciliation of the accounting standard that modifies certain aspects of the recognition, measurement, presentation and disclosure of financial instruments as shown on the Company's consolidated statement of cash flows: A A September 30, A A 2024A 2023A Cash and cash equivalentsA \$35,286,138A \$53,313,811A Restricted cashA \$105,084A \$187,210A Total cash, cash equivalents and restricted cashA \$35,391,222A \$53,501,021A A The appropriate classification of marketable securities is determined at the time of purchase and reevaluated as of each balance sheet date. Investments in marketable debt classified as available-for-sale are reported at fair value. Fair value is determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are considered temporary are reported in other comprehensive income. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense). The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. There were no deemed permanent impairments at September 30, 2024 or December 31, 2023. A A The Company's marketable securities are highly liquid and consist of U.S. government agency securities, high-grade corporate obligations and commercial paper with original maturities of more than 90 days. As of September 30, 2024 and December 31, 2023, all of the Company's investments had contractual maturities of less than one year. The following table summarizes the amortized cost, unrealized gains and losses and the fair value at September 30, 2024 and December 31, 2023: A A Amortized CostA Gross Unrealized LossesA Gross Unrealized GainsA Fair ValueA September 30, 2024: A A A A A A A A Money Market Funds included in Cash EquivalentsA \$23,021,807A \$-A \$-A \$23,021,807A U.S. Government Agency SecuritiesA \$9,554,898A \$-A (254)A A A 1,474A A \$9,554,818A Commercial PaperA \$1,187,415A \$-A \$-A \$1,187,415A SubtotalA \$10,738,313A \$-A (254)A A \$10,738,313A A A A A A A A A Money Market Funds included in Cash EquivalentsA \$32,541,230A \$-A \$-A \$32,541,230A U.S. Government Agency SecuritiesA \$29,701,677A \$-A \$-A \$29,712,183A Commercial PaperA \$2,677,372A A (1,425)A A \$-A \$2,675,947A SubtotalA \$32,379,049A A (1,425)A A \$10,506A \$32,388,130A Total December 31, 2023: A A \$64,920,279A A (1,425)A A \$10,506A \$64,929,360A A Fair Value Measurements A In accordance with Accounting Standards Codification (ASC) 825, Financial Instruments, disclosures of fair value information about financial instruments is required, whether or not recognized in the consolidated balance sheet, for which it is practicable to estimate that value. The Company's financial instruments recorded in the consolidated balance sheets include cash and cash equivalents, accounts receivable, investment securities, accounts payable and accrued expenses. A The carrying value of certain financial instruments, primarily cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their estimated fair values based upon the short-term nature of their maturity dates. A The Company categorizes its financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument. Financial assets recorded at fair value on the Company's condensed consolidated balance sheets are categorized as follows: A Level 1 inputs Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. A Level 2 inputs Significant other observable inputs (e.g., quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable such as interest rate and yield curves, and market-corroborated inputs). A Level 3 inputs Unobservable inputs for the asset or liability, which are supported by little or no market activity and are valued based on management's estimates of assumptions that market participants would use in pricing the asset or liability. A The following table provides the carrying value and fair value of the Company's financial assets measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023: A A Carrying ValueA Level 1A Level 2A Level 3A September 30, 2024: A A A A A A A A Money Market Funds and Cash EquivalentsA \$23,021,807A \$23,021,807A \$-A \$-A \$-A U.S. Government Agency SecuritiesA \$9,554,818A A \$-A \$-A Commercial PaperA \$1,188,744A A \$-A \$-A SubtotalA \$10,743,562A A \$9,554,818A A \$1,188,744A \$-A Total September 30, 2024: A A \$33,765,369A A \$32,576,625A A \$1,188,744A A \$-A December 31, 2023: A A A A A A A A Money Market Funds and Cash EquivalentsA \$32,541,230A A \$32,541,230A A \$-A \$-A U.S. Government Agency SecuritiesA \$29,712,183A A \$29,712,183A A \$-A \$-A Commercial PaperA \$2,675,947A A \$-A \$-A Inventories A The Company engages third parties to manufacture and package inventory held for sale and warehouse such goods until packaged for final distribution and sale. Costs related to the manufacturing of DefenCath incurred prior to FDA approval in order to support the preparation for commercial launch of its product were expensed as research and development expenses (R&D) as incurred. Upon FDA approval, costs related to the manufacturing of inventory are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis. Remaining pre-commercial inventory previously expensed as R&D prior to FDA approval, consists of certain raw materials and inventory at various stages of completion with a value approximating \$6,177,000 as of September 30, 2024. A Inventory is valued utilizing the standard cost method, which approximates costs determined on the first-in first-out basis. The Company records an inventory reserve for losses associated with dated, expired, excess or obsolete items. This reserve is based on management's current knowledge with respect to inventory levels, planned production and sales volume assumptions. As of September 30, 2024 and December 31, 2023, no reserves were deemed necessary. A Inventories consist of raw materials (including labeling and packaging), work-in-process, and finished goods for DefenCath. Inventories consist of the following: A A September 30, 2024A December 31, 2023A Raw materialsA \$603,545A \$1,525,420A Work in progressA \$5,084,583A \$580,925A Finished goodsA \$961,367A A \$-A TotalA \$6,649,495A \$2,106,345A A Revenue Recognition A The Company recognizes revenue from the sale of its product, DefenCath, in accordance with ASC 606 A Revenue from Contracts with Customers (ASC 606). The provisions of ASC 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. A The Company recognizes revenue when it believes that it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer. The Company's product revenue is recognized at a point in time when the performance obligation is satisfied by transferring control of the promised goods or services to a customer. In accordance with the Company's contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is received by a customer. The Company's customers are located in the United States and consist primarily of outpatient service providers and wholesale distributors. A Variable Consideration A The Company includes an estimate of variable consideration in its transaction price at the time of sale when control of the product transfers to the customer. Variable consideration includes: A A Distribution service fees; A A Prompt pay and other discounts; A A Product returns; A A Chargebacks; A A Rebates; A A Volume incentive rebates; A The Company assesses whether or not an estimate of variable consideration is constrained based on the probability that a significant reversal in the amount of cumulative revenue may occur in the future when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may vary from our estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect product sales and earnings in the period such variances become known. A The specific considerations that the Company uses in estimating these amounts related to variable considerations are as follows: A Distribution services fees A The Company pays distribution service fees primarily to its wholesale distributors. The Company reserves these fees based on actual net sales and the contractual fee rates negotiated with the customers in the distribution channel. The Company records these fees as contra accounts receivable on the balance sheet. A Prompt pay and other discounts A The Company provides customers with prompt pay discounts. The specific prompt pay terms vary by customer and are contractually fixed. Prompt pay discounts are expected to be taken by the Company's customers, so an estimate of the discount is recorded at the time of sale based on the invoice price. Prompt pay discount estimates are recorded as contra accounts receivable on the balance sheet. A Product returns A Customers have the right to return product that is within six months or less of the labeled expiration date or that is past the expiration date by no more than six months. The Company determines its estimate for product returns based on: (i) data provided to the Company by its distributors (including weekly reporting of distributors' sales and inventory held by distributors that provided the Company with visibility into the distribution channel in order to determine what quantities were sold to both inpatient and outpatient facilities), and (ii) the estimated remaining shelf life of DefenCath held by the wholesale distributors and outpatient service providers. Since the returns primarily consist of expired and short dated products that will not be resold, the Company does not record a return asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred due to the anticipated return). Estimated product returns are recorded as accrued expenses on the balance sheet. A Chargebacks A Certain covered entities, group purchasing organizations (GPOs) and government entities will be able to purchase the product at a price discounted below wholesaler acquisition cost (WAC). The difference between the GPO, government or covered entity purchase price and the wholesale distributor purchase price of WAC will be charged back to the Company. The Company estimates the amount in chargebacks based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Estimated chargebacks are recorded as contra accounts receivable on the balance sheet. A Rebates A The Company is or may become subject to negotiated discount obligations to different GPO, direct purchasers, other commercial organizations or government programs. The rebate amounts for these programs are determined by statutory requirements or contractual arrangements. Rebates are owed after the product has been dispensed to an end user and the Company has been invoiced. Rebates are typically invoiced in arrears. The Company's liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter based on expected product utilization, and estimated future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel at the end of each reporting period. Rebate estimates are recorded as accrued expenses on the balance sheet. A Volume Incentive Rebates A The Company is subject to negotiated volume incentive rebates with certain direct and indirect customers (primarily outpatient service providers). Rebates are owed based on predetermined volume levels and payable per the terms in the customer contracts. The Company estimates and records volume incentive rebates based on anticipated purchase volume with specific customers based on communications with the customer. Volume incentive rebates are recorded as accrued expenses on the balance sheet. See Note 4 A Accrued Expenses. A Provisions for the revenue reserves described above totaled \$6,598,000 and \$6,792,000 for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, total reserves and allowances to accounts receivable on the balance sheet associated with variable consideration were \$6,753,000. A License Agreement A The Company's rights under the License and Assignment Agreement with ND Partners, LLP are capitalized and stated at cost and amortizes using the straight-line method over estimated economic life of the intangible asset. The Company will amortize the intangible asset over its useful life, based on its assessment of various factors impacting estimated useful lives and cash flows of the acquired rights. Such factors include the launch date of DefenCath, the strength of the intellectual property protection of DefenCath and various other competitive, developmental and regulatory considerations, and contractual terms. See Note 5 A Commitments and Contingencies for further discussion. A Leases A The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, current portion of operating lease liabilities, and operating lease liabilities, net of current portion, on the consolidated balance sheet (see Note 7). A Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain

Common Share A Basic loss per common share excludes dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period. The weighted average number of common shares outstanding during the period included 2,500,625 shares underlying outstanding pre-funded warrants. Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company. A The Companyâ€™s outstanding shares of Series E preferred stock entitle the holders to receive dividends on a basis equivalent to the dividends paid to holders of common stock. As a result, the Series E preferred stock meet the definition of participating securities requiring the application of the two-class method. Under the two-class method, earnings available to common shareholders, including both distributed and undistributed earnings, are allocated to each class of common stock and participating securities according to dividends declared and participating rights in undistributed earnings, which may cause diluted earnings per share to be more dilutive than the calculation using the treasury stock method. No loss has been allocated to these participating securities since they do not have contractual obligations that require participation in the Companyâ€™s losses. A Since the Company has only incurred losses, potentially dilutive securities are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive, and therefore basic and diluted loss per share are the same for all periods presented. The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: A A Nine Months Ended September 30, A A 2024A A 2023A A (Number of Shares of Common Stock Issuable)A Series C-3 non-voting preferred stockA A 4,000A A A 4,000A Series E non-voting preferred stockA A 391,953A A A 391,953A Series G non-voting preferred stockA A 5,004,069A A A 5,004,069A Shares issuable for payment of deferred board compensationA A 48,909A A A 48,909A Shares underlying outstanding stock optionsA A 7,675,277A A A 5,876,007A Shares underlying restricted stock unitsA A 303,994A A A 103,735A Total potentially dilutive sharesA A 13,428,202A A A 11,428,673A A Stock-Based Compensation A Stock-based compensation cost is measured at grant date, based on the estimated fair value of the award using the Black-Scholes option pricing model for options with service or performance-based conditions. Stock-based compensation is recognized as expense over the requisite service period on a straight-line basis or when the achievement of the performance condition is probable. A Research and Development A Research and development costs are charged to expense as incurred. Research and development include fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated executive, human resources and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial and the invoices received from its external service providers. As actual costs become known, the Company adjusts its accruals in the period when actual costs become known. Costs related to the acquisition of technology rights and patents for which development work is still in process are charged to operations as incurred and considered a component of research and development expense. A A Recent Accounting Pronouncements A From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (â€œFASBâ€) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe the adoption of recently issued standards have or may have a material impact on its consolidated financial statements or disclosures. A ASU No. 2023-09 A In December 2023, the FASB issued Accounting Standards Update (â€œASUâ€) No. 2023-09, A Income Taxes - Improvements to Income Tax Disclosures (â€œTopic 740â€). The standard requires disaggregation of the effective rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. The standard will be effective for CorMedix beginning in annual reporting period ending December 31, 2025, with early adoption permitted. CorMedix is currently assessing the impact of adopting this guidance on its consolidated financial statements. A ASU No. 2023-07 A In November 2023, the FASB issued ASU No. 2023-07A Segment Reporting - Improving Reportable Segment Disclosures (â€œTopic 280â€). The standard requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker (â€œCODMâ€), a description of other segment items by reportable segment, and any additional measures of a segmentâ€™s profit or loss used by the CODM when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. The standard is effective for CorMedix beginning in annual reporting period ending December 31, 2024 and interim periods beginning in fiscal year 2025, with early adoption permitted and requires retrospective application to all prior periods presented in the financial statements. CorMedix is currently assessing the impact of adopting this guidance on its consolidated financial statements. A X - ReferencesNo definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 - SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483426/235-10-50>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/235/tableOfContent> + Details Name: us-gaap SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Other Prepaid Expenses and Current Assets 9 Months Ended Sep. 30, 2024 Other Prepaid Expenses and Current Assets [Abstract] A Other Prepaid Expenses and Current Assets Note 3 â€ Other Prepaid Expenses and Current Assets: A Other Prepaid Expenses and Current Assets A Other prepaid expenses and current assets consist of the following: A A A SeptemberA 30, 2024A A DecemberA 31, 2023A API depositA \$1,066,987A A \$-A FDA filing feeA A 599,411A A A CommercialA A 505,627A A A 171,393A SubscriptionsA A 301,291A A A 466,114A Medical affairsA A 198,048A A A A InsuranceA A 94,246A A A 126,616A OtherA A 151,279A A A 118,091A TotalA \$2,916,889A A \$882,214A X - DefinitionThe entire disclosure for other current assets. + ReferencesNo definition available. + Details Name: us-gaap OtherCurrentAssetsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses 9 Months Ended Sep. 30, 2024 Accrued Expenses [Abstract] A Accrued Expenses Note 4 - Accrued Expenses: A Accrued Expenses A Accrued expenses consist of the following: A A A SeptemberA 30, 2024A A DecemberA 31, 2023A Accrued gross-to-net deductionsA \$6,371,043A A \$-A Accrued payroll and payroll taxesA A 4,788,529A A A 2,718,770A Manufacturing relatedA A 3,037,736A A A 1,835,101A License agreement payable (see Note 5 â€ Commitments and Contingencies)A A 2,000,000A A A -A Professional and consulting feesA A 584,374A A A 2,270,022A OtherA A 191,995A A A 146,324A TotalA \$16,973,677A A \$6,970,217A X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483384/720-30-45-1>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap PayablesAndAccrualsAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies [Abstract] A Commitments and Contingencies Note 5 - Commitments and Contingencies: A Contingency Matters A In re CorMedix Inc. Securities Litigation, Case No. 2:21-cv-14020 (D.N.J.) A On October 13, 2021, the United States District Court for the District of New Jersey consolidated into In re CorMedix Inc. Securities Litigation, Case No. 2:21-cv-14020-JXN-CLW, two putative class action lawsuits filed on or about July 22, 2021 and September 13, 2021, respectively, and appointed lead counsel and lead plaintiff, a purported stockholder of the Company. The lead plaintiff filed a consolidated amended class action complaint on December 14, 2021, alleging violations of Sections 10(b) and 20(a) of the Exchange Act, along with Rule 10b-5 promulgated thereunder, and Sections 11 and 15 of the Securities Act of 1933. On October 10, 2022, the lead plaintiff filed a second amended consolidated complaint that superseded the original complaints in In re CorMedix Securities Litigation. On March 21, 2024, the court denied Defendantâ€™s motion to dismiss without prejudice and granted lead plaintiff leave to amend the complaint. On April 22, 2024, lead plaintiff filed a third amended consolidated complaint that superseded the second amended consolidated complaint. In the third amended complaint, the lead plaintiff seeks to represent a class of shareholders who purchased or otherwise acquired CorMedix securities between October 16, 2019 and August 8, 2022, inclusive. The third amended complaint names as defendants the Company and six (6) current and former officers of CorMedix, namely Khoso Baluch, Robert Cook, Matthew David, Phoebe Mounts, John L. Armstrong, and Joseph Todisco (the â€œOfficer Defendantsâ€ and collectively with CorMedix, the â€œCorMedix Defendantsâ€). The third amended complaint alleges that the CorMedix Defendants violated Section 10(b) of the Exchange Act (and Rule 10b-5) and that the Officer Defendants violated Section 20(a). In general, the purported bases for these claims are allegedly false and misleading statements and omissions related to the NDA submissions to the FDA for DefenCath, subsequent complete response letters, as well as communications from the FDA related and directed to the Companyâ€™s contract manufacturing organization and heparin supplier. The Company intends to vigorously contest such claims. The Company filed its motion to dismiss the third amended complaint on June 6, 2024, and received from Plaintiffs their opposition to the Companyâ€™s motion to dismiss on July 22, 2024. The Company filed its response on August 21, 2024. A In re CorMedix Inc. Derivative Litigation, Case No. 2:21-cv-18493-JXN-LDW (D.N.J.) A On or about October 13, 2021, a purported shareholder, derivatively and on behalf of the Company, filed a shareholder derivative complaint in the United States District Court for the District of New Jersey, in a case entitled Voter v. Baluch, et al., Case No. 2:21-cv-18493-JXN-LDW (the â€œDerivative Litigationâ€). The complaint names as defendants Khoso Baluch, Janet Dillione, Alan W. Dunton, Myron Kaplan, Steven Lefkowitz, Paulo F. Costa, Greg Duncan, Matthew David, Phoebe Mounts and Joseph Todisco along with the Company as Nominal Defendant. The complaint alleges breaches of fiduciary duties, abuse of control, and waste of corporate assets against the defendants and a claim for contribution for purported violations of Sections 10(b) and 21D of the Exchange Act against certain defendants. The individual defendants intend to vigorously contest such claims. On January 21, 2022, pursuant to a stipulation between the parties, the Court entered an order staying the case while the motion to dismiss the class action lawsuit described in the foregoing paragraph is pending. The stay may be terminated before the motion to dismiss is resolved according to certain circumstances described in the stipulation available on the Courtâ€™s public docket. A On or about January 13, 2023, another purported shareholder, derivatively and on behalf of the Company, filed a shareholder derivative complaint in the United States District Court for the District of New Jersey, in a case entitled DeSalvo v. Costa, et al., Case No. 2:23-cv-00150-JXN-CLW. Defendants Paulo F. Costa, Janet D. Dillione, Greg Duncan, Alan Dunton, Myron Kaplan, Steven Lefkowitz, Joseph Todisco, Khoso Baluch, Robert Cook, Matthew David, Phoebe Mounts, and John L. Armstrong along with the Company as Nominal Defendant. The complaint alleges breaches of fiduciary duty and unjust enrichment against the individual defendants. A On or about January 25, 2023, another purported shareholder, derivatively and on behalf of the Company, filed a shareholder derivative complaint in the United States District Court for the District of New Jersey, in a case entitled Scullion v. Baluch, et al., Case No. 2:23-cv-00406-ES-ESK. Defendants Khoso Baluch, Janet Dillione, Alan W. Dunton, Myron Kaplan, Steven Lefkowitz, Paulo F. Costa, Gregory Duncan, Matthew David, and Phoebe Mounts, along with the Company as Nominal Defendant. The complaint alleges breaches of fiduciary duties. A On or about April 18, 2023, the Court entered an order consolidating the above-mentioned shareholder derivative complaints for all purposes, including pretrial proceedings, trial and appeal. The consolidated derivative action is entitled, In re CorMedix Inc. Derivative Litigation, C.A. No. 2:21-cv-18493-JXN-LDW. The individual defendants intend to vigorously contest the claims set forth in the consolidated derivative action. The provisions of the Order to Stay entered in the Voter action on January 21, 2022, apply to the consolidated derivative action. On April 20, 2023, the consolidated derivative action was administratively terminated and removed from the Courtâ€™s docket until the motion to dismiss the class action is resolved and the Private Securities Litigation Reform Act, or PSLRA, stay is lifted. On April 22, 2024, the lead plaintiff in the class action filed a third amended complaint. The class action remains stayed under the PSLRA. A Demand Letter A On or about June 23, 2022, the Companyâ€™s Board received a letter demanding it investigate and pursue causes of action, purportedly on behalf of the Company, against certain current and former directors, officers, and/or other employees of the Company (the â€œLetterâ€), which the Board believes are duplicative of the claims already asserted in the Derivative Litigation. As set forth in the Boardâ€™s response to the Letter, the Board will consider the Letter at an appropriate time, as circumstances warrant, as it continues to monitor the progress of the Derivative Litigation. A A License and Assignment Agreement A In 2008, the Company entered into a License and Assignment Agreement (the â€œND License Agreementâ€) with ND Partners, LLP (â€œNDPâ€). Pursuant to the ND License Agreement, NDP granted the Company exclusive, worldwide licenses for certain antimicrobial catheter lock solutions, processes for treating and inhibiting infections, a biocidal lock system and a taurolidine delivery apparatus, and the corresponding United States and foreign patents and applications (the â€œNDP Technologyâ€). As consideration in part for the rights to the NDP Technology, upon execution of the ND License Agreement, the Company paid NDP an initial licensing fee of \$325,000 and granted NDP a 5% equity interest in the Company, consisting of 7,996 shares of the Companyâ€™s common stock. A Under the ND License Agreement, the Company is required to make cash and equity payments to NDP upon the achievement of certain milestones. In 2014, a certain milestone was achieved resulting in the release of 7,777 shares held in escrow. As of December 31, 2022, the shares remaining in escrow were cancelled in accordance with the terms of the escrow agreement. Under the ND License Agreement, the maximum aggregate amount of cash payments due upon achievement of milestones was \$3,000,000, with the balance being \$2,000,000 as of September 30, 2024 and December 31, 2023. The initial licensing fee of \$325,000, the fair value of the 5% equity interest (7,996 shares of the Companyâ€™s common stock) and an additional \$500,000, as a result of the achievement of one milestone, were recognized on the Companyâ€™s statement of operations in R&D in prior periods, as the related milestones were achieved by the Company prior to the FDA approval. During the three months ended March 31, 2024, the Company determined it was probable that the net sales milestones would be achieved in future periods and, as a result, the Company recorded a license intangible asset of \$2,000,000 and a license agreement liability of \$2,000,000, which is included within accrued expenses in the Companyâ€™s condensed consolidated balance sheet as of September 30, 2024. These sales milestones were met during the three month period ended September 30, 2024. The Company anticipates payment will be due in accordance with the agreement terms at the end of the twelve month period post attainment. A Beginning in the second quarter of 2024, the license intangible asset is amortized as cost of goods sold over its estimated economic life of approximately 10 years. The amortization start period correlates

with the product launch of DefenCath and the first period in which revenue will be recognized. Amortization expense of approximately \$52,000 and \$104,000 was recorded during the three and nine month periods ending September 30, 2024, respectively. The ND License Agreement will expire on a country-by-country basis upon the earlier of (i) the expiration of the last patent claim under the ND License Agreement in a given country, or (ii) the payment of all milestone payments. Upon the expiration of the ND License Agreement in each country, we will have an irrevocable, perpetual, fully paid-up, royalty-free exclusive license to the NDP Technology in such country. The ND License Agreement also may be terminated by NDP if the Company materially breaches or defaults under the ND License Agreement and that breach is not cured within 60 days following the delivery of written notice to the Company, or by the Company on a country-by-country basis upon 60 days prior written notice in the event the Company's Board determines not to proceed with the development of the NDP Technology. If the ND License Agreement is terminated by either party, the Company's rights to the NDP Technology will revert back to NDP. X - ReferencesNo definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 405-SubTopic 30-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/405-30/tableOfContentReference> 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/450/tableOfContentReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/450/tableOfContentReference) 4:

operating cash flows from operating leases was \$51,000 and \$153,000, respectively, and \$50,000 and \$150,000 for the three and nine months ended September 30, 2023, respectively. A The weighted average remaining lease term as of September 30, 2024 and 2023 was 3.0 and 4.1 years, respectively, and the weighted average discount rate for operating leases was 9% at September 30, 2024 and 2023. A As of September 30, 2024, maturities of lease liabilities were as follows: A 2024 (excluding the nine months ended September 30, 2024) A \$ 51,000 A 2025 A 208,000 A 2026 A 211,000 A 2027 A 169,000 A Total future minimum lease payments A 639,000 A Less imputed interest A (83,000 ) Total A \$ 556,000 A X - ReferencesNo definition available. + Details Name: us-gaap\_LeasesAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1:

insured limits. The following table is the reconciliation of the accounting standard that modifies certain aspects of the recognition, measurement, presentation and disclosure of financial instruments as shown on the Company's consolidated statement of cash flows: As of September 30, 2024 and 2023, Cash and cash equivalents \$35,286,138 As of September 30, 2024 and 2023, Restricted cash \$105,084 As of September 30, 2024 and 2023, Total cash, cash equivalents and restricted cash \$35,391,222 As of September 30, 2024 and 2023, The appropriate classification of marketable securities is determined at the time of purchase and reevaluated as of each balance sheet date. Investments in marketable debt classified as available-for-sale are reported at fair value. Fair value is determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are considered temporary are reported in other comprehensive income. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense). The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. There were no deemed permanent impairments at September 30, 2024 or December 31, 2023. The Company's marketable securities are highly liquid and consist of U.S. government agency securities, high-grade corporate obligations and commercial paper with original maturities of more than 90 days. As of September 30, 2024 and December 31, 2023, all of the Company's investments had contractual maturities of less than one year. The following table summarizes the amortized cost, unrealized gains and losses and the fair value at September 30, 2024 and December 31, 2023: As of September 30, 2024 and December 31, 2023, Gross Unrealized Losses \$2,021,807 As of September 30, 2024 and December 31, 2023, Gross Unrealized Gains \$2,021,807 As of September 30, 2024 and December 31, 2023, Money Market Funds included in Cash Equivalents \$23,021,807 As of September 30, 2024 and December 31, 2023, U.S. Government Agency Securities \$9,554,818 As of September 30, 2024 and December 31, 2023, Commercial Paper \$1,188,744 As of September 30, 2024 and December 31, 2023, Subtotal \$10,738,313 As of September 30, 2024 and December 31, 2023, Total September 30, 2024 \$33,760,120 As of September 30, 2024 and December 31, 2023, Total December 31, 2023 \$33,760,120 As of September 30, 2024 and December 31, 2023, Money Market Funds included in Cash Equivalents \$32,541,230 As of September 30, 2024 and December 31, 2023, U.S. Government Agency Securities \$29,701,677 As of September 30, 2024 and December 31, 2023, Commercial Paper \$2,677,372 As of September 30, 2024 and December 31, 2023, Subtotal \$32,379,049 As of September 30, 2024 and December 31, 2023, Total December 31, 2023 \$64,920,279 As of September 30, 2024 and December 31, 2023, Fair Value Measurements Fair Value Measurements in accordance with Accounting Standards Codification (ASC) 825, Financial Instruments, disclosures of fair value information about financial instruments is required, whether or not recognized in the consolidated balance sheet, for which it is practicable to estimate that value. The Company's financial instruments recorded in the consolidated balance sheets include cash and cash equivalents, accounts receivable, investment securities, accounts payable and accrued expenses. The carrying value of certain financial instruments, primarily cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their estimated fair values based upon the short-term nature of their maturity dates. The Company categorizes its financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument. Financial assets recorded at fair value on the Company's condensed consolidated balance sheets are categorized as follows: Level 1 inputs Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 inputs Significant other observable inputs (e.g., quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable such as interest rate and yield curves, and market-corroborated inputs). Level 3 inputs Unobservable inputs for the asset or liability, which are supported by little or no market activity and are valued based on management's estimates of assumptions that market participants would use in pricing the asset or liability. The following table provides the carrying value and fair value of the Company's financial assets measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023: As of September 30, 2024 and December 31, 2023, Level 1 \$2,021,807 As of September 30, 2024 and December 31, 2023, Level 2 \$2,021,807 As of September 30, 2024 and December 31, 2023, Level 3 \$9,554,818 As of September 30, 2024 and December 31, 2023, Commercial Paper \$1,188,744 As of September 30, 2024 and December 31, 2023, Subtotal \$10,738,313 As of September 30, 2024 and December 31, 2023, Total September 30, 2024 \$33,760,120 As of September 30, 2024 and December 31, 2023, Total December 31, 2023 \$33,760,120 As of September 30, 2024 and December 31, 2023, Money Market Funds and Cash Equivalents \$32,541,230 As of September 30, 2024 and December 31, 2023, U.S. Government Agency Securities \$29,701,677 As of September 30, 2024 and December 31, 2023, Commercial Paper \$2,677,372 As of September 30, 2024 and December 31, 2023, Subtotal \$32,379,049 As of September 30, 2024 and December 31, 2023, Total December 31, 2023 \$64,920,279 As of September 30, 2024 and December 31, 2023, Inventories The Company engages third parties to manufacture and package inventory held for sale and warehouse such goods until packaged for final distribution and sale. Costs related to the manufacturing of DefenCath incurred prior to FDA approval in order to support the preparation for commercial launch of its product were expensed as research and development expenses (ASC 730) as incurred. Upon FDA approval, costs related to the manufacturing of inventory are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis. Remaining pre-commercial inventory previously expensed as R&D prior to FDA approval, consists of certain raw materials and inventory at various stages of completion with a value approximating \$6,177,000 as of September 30, 2024. Inventory is valued utilizing the standard cost method, which approximates costs determined on the first-in first-out basis. The Company records an inventory reserve for losses associated with dated, expired, excess or obsolete items. This reserve is based on management's current knowledge with respect to inventory levels, planned production and sales volume assumptions. As of September 30, 2024 and December 31, 2023, no reserves were deemed necessary. Inventories consist of raw materials (including labeling and packaging), work-in-process, and finished goods for DefenCath. Inventories consist of the following: As of September 30, 2024 and December 31, 2023, Raw materials \$603,545 As of September 30, 2024 and December 31, 2023, Work in progress \$5,084,583 As of September 30, 2024 and December 31, 2023, Finished goods \$961,367 As of September 30, 2024 and December 31, 2023, Total \$6,649,495 As of September 30, 2024 and December 31, 2023, Revenue Recognition Revenue Recognition The Company recognizes revenue from the sale of its product, DefenCath, in accordance with ASC 606. Revenue from Contracts with Customers (ASC 606) requires the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes revenue when it believes that it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer. The Company's product revenue is recognized at a point in time when the performance obligation is satisfied by transferring control of the promised goods or services to a customer. In accordance with the Company's contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is received by a customer. The Company's customers are located in the United States and consist primarily of outpatient service providers and wholesale distributors. Variable Consideration Variable Consideration The Company includes an estimate of variable consideration in its transaction price at the time of sale when control of the product transfers to the customer. Variable consideration includes: A Distribution service fees; B Prompt pay and other discounts; C Product returns; D Chargebacks; E Rebates; F Volume incentive rebates; The Company assesses whether or not an estimate of variable consideration is constrained based on the probability that a significant reversal in the amount of cumulative revenue may occur in the future when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may vary from our estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect product sales and earnings in the period such variances become known. The specific considerations that the Company uses in estimating these amounts related to variable considerations are as follows: Distribution services fees The Company pays distribution service fees primarily to its wholesale distributors. The Company reserves these fees based on actual net sales and the contractual fee rates negotiated with the customers in the distribution channel. The Company records these fees as contra accounts receivable on the balance sheet. Prompt pay and other discounts The Company provides customers with prompt pay discounts. The specific prompt pay terms vary by customer and are contractually fixed. Prompt pay discounts are expected to be taken by the Company's customers, so an estimate of the discount is recorded at the time of sale based on the invoice price. Prompt pay discount estimates are recorded as contra accounts receivable on the balance sheet. Product returns Customers have the right to return product that is within six months or less of the labeled expiration date or that is past the expiration date by no more than six months. The Company determines its estimate for product returns based on: (i) data provided to the Company by its distributors (including weekly reporting of distributors' sales and inventory held by distributors that provided the Company with visibility into the distribution channel in order to determine what quantities were sold to both inpatient and outpatient facilities), and (ii) the estimated remaining shelf life of DefenCath held by the wholesale distributors and outpatient service providers. Since the returns primarily consist of expired and short dated products that will not be resold, the Company does not record a return asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred due to the anticipated return). Estimated product returns are recorded as accrued expenses on the balance sheet. Chargebacks Certain covered entities, group purchasing organizations (GPOs) and government entities will be able to purchase the product at a price discounted below wholesaler acquisition cost (WAC). The difference between the GPO, government or covered entity purchase price and the wholesale distributor purchase price of WAC will be charged back to the Company. The Company estimates the amount in chargebacks based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Estimated chargebacks are recorded as contra accounts receivable on the balance sheet. Rebates The Company is or may become subject to negotiated discount obligations to different GPO, direct purchasers, other commercial organizations or government programs. The rebate amounts for these programs are determined by statutory requirements or contractual arrangements. Rebates are owed after the product has been dispensed to an end user and the Company has been invoiced. Rebates are typically invoiced in arrears. The Company's liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter based on expected product utilization, and estimated future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel at the end of each reporting period. Rebate estimates are recorded as accrued expenses on the balance sheet. Volume Incentive Rebates The Company is subject to negotiated volume incentive rebates with certain direct and indirect customers (primarily outpatient service providers). Rebates are owed based on predetermined volume levels and payable per the terms in the customer contracts. The Company estimates and records volume incentive rebates based on anticipated purchase volume with specific customers based on communications with the customer. Volume incentive rebates are recorded as accrued expenses on the balance sheet. See Note 4. Accrued Expenses. Provisions for the revenue reserves described above totaled \$6,598,000 and \$6,792,000 for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, total reserves and allowances to accounts receivable on the balance sheet associated with variable consideration were \$6,753,000. License Agreement License Agreement The Company's rights under the License and Assignment Agreement with ND Partners, LLP are capitalized and stated at cost and amortizes using the straight-line method over estimated economic life of the intangible asset. The Company will amortize the intangible asset over its useful life, based on its assessment of various factors impacting estimated useful lives and cash flows of the acquired rights. Such factors include the launch date of DefenCath, the strength of the intellectual property protection of DefenCath and various other competitive, developmental and regulatory considerations, and contractual terms. See Note 5. Commitments and Contingencies for further discussion. Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, current portion of operating lease liabilities, and operating lease liabilities, net of current portion, on the consolidated balance sheet (see Note 7). Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company has elected, as an accounting policy, not to apply the recognition requirements in ASC 842 to short-term leases. Short-term leases are leases that have a term of 12 months or less and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes the lease payments for short-term leases on a straight-line basis over the lease term. The Company has also elected, as a practical expedient, by underlying class of asset, not to separate lease components from non-lease components and, instead, account for them as a single component. Loss Per Common Share Loss Per Common Share Basic loss per common share excludes dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period. The weighted average number of common shares outstanding during the period included 2,500,625 shares underlying outstanding

based conditions. Stock-based compensation is recognized as expense over the requisite service period on a straight-line basis or when the achievement of the performance condition is probable. Research and Development Research and development costs are charged to expense as incurred. Research and development include fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated executive, human resources and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial and the invoices received from its external service providers. As actual costs become known, the Company adjusts its accruals in the period when actual costs become known. Costs related to the acquisition of technology rights and patents for which development work is still in process are charged to operations as incurred and considered a component of research and development expense. A Recent Accounting Pronouncements Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe the adoption of recently issued standards have or may have a material impact on its consolidated financial statements or disclosures. ASU No. 2023-09 In December 2023, the FASB issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes - Improvements to Income Tax Disclosures (Topic 740). The standard requires disaggregation of the effective rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. The standard will be effective for CorMedix beginning in annual reporting period ending December 31, 2025, with early adoption permitted. CorMedix is currently assessing the impact of adopting this guidance on its consolidated financial statements. ASU No. 2023-07 In November 2023, the FASB issued ASU No. 2023-07A Segment Reporting - Improving Reportable Segment Disclosures (Topic 280). The standard requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker (CODM), a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. The standard is effective for CorMedix beginning in annual reporting period ending December 31, 2024 and interim periods beginning in fiscal year 2025, with early adoption permitted and requires retrospective application to all prior periods presented in the financial statements. CorMedix is currently assessing the impact of adopting this guidance on its consolidated financial statements. X - Definition Disclosure of accounting policy for license agreement. + References No definition available. + Details. Name: crmd\_LicenseAgreementPolicyTextBlock Namespace Prefix: crmd\_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for liquidity and uncertainties. + References No definition available. + Details. Name: crmd\_LiquidityAndUncertaintyPolicyTextBlock Namespace Prefix: crmd\_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - References No definition available. + Details. Name: us-gaap\_AccountingPoliciesAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for credit risk. + References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1) + Details. Name: us-gaap\_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap\_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + References Reference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4) Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1> + Details. Name: us-gaap\_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined). + References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Paragraph 2A -Subparagraph \(a\) -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-2A](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Paragraph 2A -Subparagraph (a) -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-2A) Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4) Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 5A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A) + Details. Name: us-gaap\_ConsolidationVariableInterestEntityPolicy Namespace Prefix: us-gaap\_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2> + Details. Name: us-gaap\_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + References No definition available. + Details. Name: us-gaap\_FairValueMeasurementPolicyTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for determining the fair value of financial instruments. + References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1> + Details. Name: us-gaap\_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap\_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1> Reference 3:

[http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 14.D.2.Q6\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap\\_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for accounts receivable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for accounts receivable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2)Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1>Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15)Reference 6: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B + Details Name: us-gaap TradeAndOtherAccountsReceivablePolicy Namespace Prefix: us-gaap\\_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B + Details Name: us-gaap TradeAndOtherAccountsReceivablePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12>Reference 7: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies and Liquidity and Uncertainties (Tables) 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies and Liquidity and Uncertainties [Abstract] A Schedule of consolidated statement of cash flows The following table is the reconciliation of the accounting standard that modifies certain aspects of the recognition, measurement, presentation and disclosure of financial instruments as shown on the Companyâ€™s consolidated statement of cash flows: A A September 30, A A 2024A A 2023A Cash and cash equivalentsA $35,286,138A A $53,313,811A Restricted cashA A 105,084A A A 187,210A Total cash, cash equivalents and restricted cashA $35,391,222A A $53,501,021A A Schedule of Amortized Cost, Unrealized Gains and Losses and the Fair Value The following table summarizes the amortized cost, unrealized gains and losses and the fair value at September 30, 2024 and December 31, 2023: A A Amortized CostA A Gross Unrealized LossesA A Gross Unrealized GainsA A Fair ValueA A September 30, 2024A A A A A A A A Money Market Funds included in Cash EquivalentsA $23,021,807A A $-A A $23,021,807A U.S. Government Agency SecuritiesA 9,550,898A A (254)A A 4,174A A 9,554,818A Commercial PaperA A 1,187,415A A A -A A 1,329A A A 1,188,744A SubtotalA A 10,738,313A A (254)A A 5,503A A A 10,743,562A Total September 30, 2024A $33,760,120A A (254)A A $5,503A A $33,765,369A December 31, 2023A A A A A A A A A A A A Money Market Funds included in Cash EquivalentsA $32,541,230A A $-A A $-A A $32,541,230A U.S. Government Agency SecuritiesA A 29,701,677A A A -A A A 10,506A A A 29,712,183A Commercial PaperA A 2,677,372A A (1,425)A A A 2,675,947A SubtotalA A 32,379,049A A (1,425)A A 10,506A A A 32,388,130A Total December 31, 2023A $64,920,279A A ($1,425)A A 10,506A A $64,929,360A Schedule of Carrying and Fair Value of Financial Assets The following table provides the carrying value and fair value of the Companyâ€™s financial assets measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023: A A Carrying ValueA A Level 1A A Level 2A A Level 3A A September 30, 2024A A A A A A A A A A Money Market Funds and Cash EquivalentsA $23,021,807A A $-A A $23,021,807A A A A A A A A A U.S. Government Agency SecuritiesA A 9,554,818A A A 9,554,818A A A -A A -A Commercial PaperA A 1,188,744A A A -A A A 1,188,744A A A -A SubtotalA A 10,743,562A A A 9,554,818A A A 1,188,744A A A -A Total September 30, 2024A $33,765,369A A $32,576,625A A $1,188,744A A A December 31, 2023A A A A A A A A A A A A Money Market Funds and Cash EquivalentsA $32,541,230A A $32,541,230A A A $-A U.S. Government Agency SecuritiesA A 29,712,183A A A 29,712,183A A A -A A -A Commercial PaperA A 2,675,947A A A -A A 2,675,947A A A -A SubtotalA A 32,388,130A A A 29,712,183A A A 2,675,947A A A -A Total December 31, 2023A $64,929,360A A $62,253,413A A $2,675,947A A A Schedule of Inventories Inventories consist of the following: A A September 30, 2024A A DecemberA 31, 2023A Raw materialsA $603,545A A $1,525,420A Work in progressA A 5,084,583A A A 580,925A Finished goodsA A 961,367A A A -A TotalA $6,649,495A A $2,106,345A A Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: A A Nine Months Ended September 30, A A 2024A A 2023A A A (Number of Shares of Common Stock Issuable)A Series C-3 non-voting preferred stockA A 4,000A A A 4,000A Series E non-voting preferred stockA A 391,953A A A 391,953A Series G non-voting preferred stockA A 5,004,069A A A 5,004,069A Shares issuable for payment of deferred board compensationA A 48,909A A A 48,909A Shares underlying outstanding stock optionsA A 7,675,277A A A 5,876,007A Shares underlying restricted stock unitsA A 303,994A A A 103,735A Total potentially dilutive sharesA A 13,428,202A A A 11,428,673A X - ReferencesNo definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap\\_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities \(including those issuable pursuant to contingent stock agreements\) that could potentially dilute basic earnings per share \(EPS\) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap\\_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of cash, cash equivalents, and investments. + ReferencesNo definition available. + Details Name: us-gaap ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock Namespace Prefix: us-gaap\\_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets. + ReferencesNo definition available. + Details Name: us-gaap MarketableSecuritiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of cash, cash equivalents, and investments. + ReferencesNo definition available. + Details Name: us-gaap ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4:

Namespace Prefix: us-gaap\_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Tables) 9 Months Ended Sep. 30, 2024 Leases [Abstract] A Schedule of Maturities of Lease Liabilities As of September 30, 2024, maturities of lease liabilities were as follows: 2024 (excluding the nine months ended September 30, 2024) A \$ 51,000 A 2025 A \$ 208,000 A 2026 A \$ 211,000 A 2027 A \$ 169,000 A Total future minimum lease payments A \$ 639,000 A Less imputed interest A (83,000 ) Total A \$ 556,000 X - ReferencesNo definition available. + Details Name: us-gaap\_ LeasesAbstract Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1:

asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748546/942-210-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap RestrictedCashAndCashEquivalents Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Amortized Cost, Unrealized Gains and Losses and the Fair Value - USD (\$ Sep. 30, 2024 Dec. 31, 2023 Schedule of Marketable Securities [Line Items] A A Amortized Cost \$ 33,760,120 \$ 64,920,279 Gross Unrealized Losses (254) (1,425) Gross Unrealized Gains 5,503 10,506 Fair Value 33,765,369 64,929,360 Money Market Funds included in Cash Equivalents [Member] A A Schedule of Marketable Securities [Line Items] A A Amortized Cost 23,021,807 32,541,230 Gross Unrealized Losses Gross Unrealized Gains Fair Value 23,021,807 32,541,230 U.S. Government Agency Securities [Member] A A Schedule of Marketable Securities [Line Items] A A Amortized Cost 9,550,898 29,717,677 Gross Unrealized Losses (254) Gross Unrealized Gains 4,174 10,506 Fair Value 9,554,818 29,712,183 Commercial Paper [Member] A A Schedule of Marketable Securities [Line Items] A A Amortized Cost 1,187,415 2,677,372 Gross Unrealized Losses (1,425) Gross Unrealized Gains 1,329 Fair Value 1,188,744 2,675,947 Subtotal [Member] A A Schedule of Marketable Securities [Line Items] A A Amortized Cost 10,738,313 32,379,049 Gross Unrealized Losses (254) (1,425) Gross Unrealized Gains 5,503 10,506 Fair Value \$ 10,743,562 \$ 32,388,130 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap MarketableSecuritiesLineItems Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap InformationByCategoryOfDebtSecurityAxis=us-gaap\_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap InformationByCategoryOfDebtSecurityAxis=crmd\_USGovernmentAgencySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap InformationByCategoryOfDebtSecurityAxis=us-gaap\_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap InformationByCategoryOfDebtSecurityAxis=crmd\_DebtSecuritiesExcludingMoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Carrying and Fair Value of Financial Assets - Fair Value, Recurring [Member] - USD (\$ Sep. 30, 2024 Dec. 31, 2023 Schedule of Carrying and Fair Value of Financial Assets [Line Items] A A Carrying Value \$ 33,765,369 \$ 64,929,360 Level 1 [Member] A A Schedule of Carrying and Fair Value of Financial Assets [Line Items] A A Carrying Value 32,576,625 62,253,413 Level 2 [Member] A A Schedule of Carrying and Fair Value of Financial Assets [Line Items] A A Carrying Value 1,188,744 2,675,947 Level 3 [Member] A A Schedule of Carrying and Fair Value of Financial Assets [Line Items] A A Carrying Value Money Market Funds and Cash Equivalents [Member] A A Schedule of Carrying and Fair Value of Financial Assets [Line Items] A A Carrying Value 23,021,807 32,541,230 Money Market Funds and Cash Equivalents [Member] | Level 1 [Member] A A Schedule of Carrying and Fair Value of Financial Assets [Line Items] A A Carrying Value 23,021,807 32,541,230 Money Market Funds and Cash Equivalents [Member] | Level 2 [Member] A A Schedule of Carrying and Fair Value of Financial Assets [Line Items] A A Carrying Value Money Market Funds and Cash Equivalents [Member] | Level 3 [Member] A A Schedule of Carrying and Fair Value of Financial Assets [Line Items] A A Carrying Value U.S. Government Agency Securities [Member] A A Schedule of Carrying and Fair Value of Financial Assets [Line Items] A A Carrying Value 9,554,818 29,712,183 U.S. Government Agency Securities [Member] | Level 1 [Member] A A Schedule of Carrying and Fair Value of Financial Assets [Line Items] A A Carrying Value 9,554,818 29,712,183 U.S. Government Agency Securities [Member] | Level 2 [Member] A A Schedule of Carrying and Fair Value of Financial Assets [Line Items] A A Carrying Value U.S. Government Agency Securities [Member] | Level 3 [Member] A A Schedule of Carrying and Fair Value of Financial Assets [Line Items] A A Carrying Value Commercial Paper

gaap\_FairValueByFairValueHierarchyLevelAxis=us-gaap\_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_InformationByCategoryOfDebtSecurityAxis=us-gaap\_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_InformationByCategoryOfDebtSecurityAxis=crmd\_USGovernmentAgencySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_InformationByCategoryOfDebtSecurityAxis=us-gaap\_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_InformationByCategoryOfDebtSecurityAxis=crmd\_DebtSecuritiesExcludingMoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Inventories - USD (\$) Sep. 30, 2024 Dec. 31, 2023 Schedule of Inventories [Abstract] Â Â Raw materials \$ 603,545 \$ 1,525,420 Work in progress 5,084,583 580,925 Finished goods 961,367 Total \$ 6,649,495 \$ 2,106,345 X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap\_InventoryFinishedGoods Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(6\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\) + Details Name: us-gaap\\_InventoryNet Namespace Prefix: us-gaap\\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap\\_InventoryNetAbstract Namespace Prefix: us-gaap\\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: \[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(6\\)\\(a\\)\\(4\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\]\(http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\) + Details Name: us-gaap\\_InventoryRawMaterials Namespace Prefix: us-gaap\\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: \[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(6\\)\\(a\\)\\(3\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\]\(http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\) + Details Name: us-gaap\\_InventoryWorkInProcess Namespace Prefix: us-gaap\\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies and Liquidity and Uncertainties \(Details\) - Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share \[Line Items\] Â Â Total potentially dilutive shares 13,428,202 11,428,673 Series C-3 non-voting preferred stock \[Member\] Â Â Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share \[Line Items\] Â Â Total potentially dilutive shares 4,000 4,000 Series E non-voting preferred stock \[Member\] Â Â Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share \[Line Items\] Â Â Total potentially dilutive shares 391,953 391,953 Series G non-voting preferred stock \[Member\] Â Â Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share \[Line Items\] Â Â Total potentially dilutive shares 5,004,069 5,004,069 Shares issuable for payment of deferred board compensation \[Member\] Â Â Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share \[Line Items\] Â Â Total potentially dilutive shares 48,909 48,909 Shares underlying outstanding stock options \[Member\] Â Â Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share \[Line Items\] Â Â Total potentially dilutive shares 7,675,277 5,876,007 Shares underlying restricted stock units \[Member\] Â Â Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share \[Line Items\] Â Â Total potentially dilutive shares 303,994 103,735 X - DefinitionSecurities \(including those issuable pursuant to contingent stock agreements\) that could potentially dilute basic earnings per share \(EPS\) or earnings per unit \(EPU\) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \\(c\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1\) + Details Name: us-gaap\\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap\\_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap\\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap\\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap\\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap\\_SeriesCPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap\\_SeriesEPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap\\_SeriesGPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap\\_DeferredCompensationShareBasedPaymentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap\\_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap\\_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Other Prepaid Expenses and Current Assets \(Details\) - Schedule of Other Prepaid Expenses and Current Assets - USD \(\\$\) Sep. 30, 2024 Dec. 31, 2023 Schedule of Other Prepaid Expenses and Current Assets \[Abstract\] Â Â API deposit \\$ 1,066,987 FDA filing fee 599,411 Commercial 505,627 171,393 Subscriptions 301,291 466,114 Medical affairs 198,048 Insurance 94,246 126,616 Other 151,279 118,091 Total \\$ 2,916,889 \\$ 882,214 X - DefinitionAmount of food and drug administration filling fee. + ReferencesNo definition available. + Details Name: crmd\\_FoodAndDrugAdministrationFillingFee Namespace Prefix: crmd\\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the amount of prepaid medical affairs. + ReferencesNo definition available. + Details Name: crmd\\_PrepaidMedicalAffairsCurrent Namespace Prefix: crmd\\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the amount of prepaid subscriptions. + ReferencesNo definition available. + Details Name: crmd\\_PrepaidSubscriptionsCurrent Namespace Prefix: crmd\\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: crmd\\_ScheduleOfOtherPrepaidExpensesAndCurrentAssetsAbstract Namespace Prefix: crmd\\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe carrying amount of capitalized costs of materials, supplies, and other assets, which are not included in inventory but used in production. + ReferencesNo definition available. + Details Name: us-gaap\\_MaterialsSuppliesAndOther Namespace Prefix: us-gaap\\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: \[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(7\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1> + Details Name: us-gaap\\\_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap\\\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of consideration paid in advance for advertising that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: \\[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 2: \\\[http://www.xbrl.org/2003/role/exampleRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \\\\(g\\\\)\\\\(6\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1\\\]\\\(http://www.xbrl.org/2003/role/exampleRef-Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph \\\(f\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 3:\\\) + Details Name: us-gaap\\\\_PrepaidAdvertising Namespace Prefix: us-gaap\\\\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: \\\[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\\(SX 210.5-02\\\\(9\\\\)\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\\\]\\\(http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\(SX 210.5-02\\\(9\\\)\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\\\) + Details Name: us-gaap\\\\_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap\\\\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: \\\[http://www.xbrl.org/2003/role/exampleRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \\\\(g\\\\)\\\\(1\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: \\\\[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph \\\\\(f\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 3: \\\\\[http://www.xbrl.org/2003/role/exampleRef-Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph \\\\\\(f\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 3: \\\\\\[http://www.xbrl.org/2003/role/exampleRef-Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph \\\\\\\(f\\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5\\\\\\]\\\\\\(http://www.xbrl.org/2003/role/exampleRef-Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph \\\\\\(f\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5\\\\\\) + Details Name: us-gaap\\\\\\\_PrepaidInsurance Namespace Prefix: us-gaap\\\\\\\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses \\\\\\(Details\\\\\\) - Schedule of Accrued Expenses - USD \\\\\\(\\\\\\\$\\\\\\) Sep. 30, 2024 Dec. 31, 2023 Schedule of Accrued Expenses \\\\\\[Abstract\\\\\\] Â Â Accrued gross-to-net deductions \\\\\\\$ 6,371,043 Accrued payroll and payroll taxes 4,788,529 2,718,770 Manufacturing related 3,037,736 1,835,101 License agreement payable \\\\\\(see Note 5 â€ Commitments and Contingencies\\\\\\) 2,000,000 Professional and consulting fees 584,374 2,270,022 Other 191,995 146,324 Total \\\\\\\$ 16,973,677 \\\\\\\$ 6,970,217 X - DefinitionAccrued gross-to-net deductions. + ReferencesNo definition available. + Details Name: crmd\\\\\\\_AccruedGrossToNetDeduction Namespace Prefix: crmd\\\\\\\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the amount of license agreement payable. + ReferencesNo definition available. + Details Name: crmd\\\\\\\_LicenseAgreementPayableCurrent Namespace Prefix: crmd\\\\\\\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations manufacturing development. Used to reflect the current portion of the liabilities \\\\\\(due within one year or within the normal operating cycle if longer\\\\\\). + ReferencesNo definition available. + Details Name: crmd\\\\\\\_ManufacturingDevelopmentCurrent Namespace Prefix: crmd\\\\\\\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: crmd\\\\\\\_ScheduleOfAccruedExpensesAbstract Namespace Prefix: crmd\\\\\\\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities \\\\\\(due within one year or within the normal operating cycle if longer\\\\\\). + ReferencesReference 1: \\\\\\[http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\\\\\(SX 210.5-02\\\\\\\(20\\\\\\\)\\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\\\\\\]\\\\\\(http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\\\\(SX 210.5-02\\\\\\(20\\\\\\)\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\\\\\\) + Details Name: us-gaap\\\\\\\_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap\\\\\\\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities \\\\\\(due within one year or within the normal operating cycle if longer\\\\\\). + ReferencesReference 1: \\\\\\[http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\\\\\(SX 210.5-02\\\\\\\(20\\\\\\\)\\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\\\\\\]\\\\\\(http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\\\\(SX 210.5-02\\\\\\(20\\\\\\)\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\\\\\\) + Details Name: us-gaap\\\\\\\_AccruedPayrollTaxesCurrent Namespace Prefix: us-gaap\\\\\\\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities \\\\\\(due within one year or within the normal operating cycle if longer\\\\\\). + ReferencesReference 1: \\\\\\[http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\\\\\(SX 210.5-02\\\\\\\(20\\\\\\\)\\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\\\\\\]\\\\\\(http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\\\\(SX 210.5-02\\\\\\(20\\\\\\)\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\\\\\\) + Details Name: us-gaap\\\\\\\_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap\\\\\\\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: \\\\\\[http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\\\\\(SX 210.5-02\\\\\\\(20\\\\\\\)\\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\\\\\\]\\\\\\(http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\\\\(SX 210.5-02\\\\\\(20\\\\\\)\\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\\\\\\) + Details Name: us-gaap\\\\\\\_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap\\\\\\\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies \\\\\\(Details\\\\\\) - USD \\\\\\(\\\\\\\$\\\\\\) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Commitments and Contingencies \\\\\\[Line Items\\\\\\] Â Â A Amount of initial licensing fee Â \\\\\\\$ 325,000 Â A Number of shares released in escrow \\\\\\(in Shares\\\\\\) Â 7,277 Â A Maximum aggregate amount of cash payments Â \\\\\\\$ 3,000,000 Â A Balance of cash payments Â 2,000,000 Â A Additional amount of\\\\\]\\\\\(http://www.xbrl.org/2003/role/exampleRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \\\\\(g\\\\\)\\\\\(6\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1\\\\\)\\\\]\\\\(http://www.xbrl.org/2009/role/commonPracticeRef-Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3:\\\\)\\\]\\\(http://www.xbrl.org/2003/role/exampleRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \\\(g\\\)\\\(1\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2:\\\)\\]\\(http://www.xbrl.org/2009/role/commonPracticeRef-Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 2:\\)\]\(http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2:\)](http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2:)

achievement milestone \$ 500,000 License agreement payable \$ 2,000,000 2,000,000 \$ Amortization expense \$ 103,896 License [Member] Commitments and Contingencies [Line Items] License Agreement intangible \$ 2,000,000 \$ 2,000,000 \$ Estimated economic life 10 years 10 years \$ Amortization expense \$ 52,000 \$ 104,000 \$ NDP Technology [Member] Commitments and Contingencies [Line Items] Common stock shares issued (in Shares) 7,996 \$ ND Partners, LLP [Member] Commitments and Contingencies [Line Items] Equity interest percentage 5.00% 5.00% ND License Agreement [Member] Commitments and Contingencies [Line Items] Amount of initial licensing fee \$ 325,000 Common stock shares issued (in Shares) 7,996 \$ ND License Agreement [Member] ND Partners, LLP [Member] Commitments and Contingencies [Line Items] Equity interest percentage 5.00% 5.00% X - DefinitionRepresents the value of additional amount of achievement of milestones. + ReferencesNo definition available. + Details Name: crmd\_AchievementOfMilestones Namespace Prefix: crmd\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of initial licensing fee. + ReferencesNo definition available. + Details Name: crmd\_AmountOfInitialLicensingFee Namespace Prefix: crmd\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionBalance of cash payments due upon achievement of milestones. + ReferencesNo definition available. + Details Name: crmd\_BalanceOfCashPaymentsDueUponAchievementOfMilestones Namespace Prefix: crmd\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the amount of license agreement payable. + ReferencesNo definition available. + Details Name: crmd\_LicenseAgreementPayableCurrent Namespace Prefix: crmd\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum aggregate amount of cash payments due upon achievement of milestones. + ReferencesNo definition available. + Details Name: crmd\_MaximumAggregateAmountOfCashPaymentsDueUponAchievementOfMilestones Namespace Prefix: crmd\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe Number of shares released in escrow. + ReferencesNo definition available. + Details Name: crmd\_NumberOfSharesReleasedInEscrow Namespace Prefix: crmd\_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap\_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap\_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap\_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap\_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap\_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionGross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap\_FiniteLivedLicenseAgreementsGross Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap\_LossContingenciesLineItems Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap\_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt\_ProductOrServiceAxis=us-gaap\_LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_RelatedPartyTransactionAxis=crmd\_NDPTechnologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=crmd\_NDPartnersLLPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=crmd\_NDLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (USD (\$) 1 Months Ended 3 Months Ended 9 Months Ended May 31, 2024 May 09, 2024 Jul. 03, 2023 Jun. 28, 2023 May 31, 2023 Jan. 31, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Oct. 31, 2024 Dec. 31, 2023 Stockholders Equity [Line Items] Shares of common stock issued \$ 57,887,149 \$ 57,887,149 \$ 54,938,258 Net proceeds (in Dollars) \$ 13,376,081 \$ 12,515,209 \$ Common stock par value (in Dollars per share) \$ 0.001 \$ 0.001 \$ 0.001 Net proceeds (in Dollars) \$ 13,376,000 \$ 13,376,000 \$ Common stock available for sale (in Dollars) \$ 150,000,000 \$ 150,000,000 \$ Gross proceeds percentage \$ 3.00% \$ Capacity remaining program (in Dollars) \$ 100,000,000 \$ 100,000,000 \$ Sale of stock units \$ 2,290,024 \$ 2,521,121 \$ Vested shares issued 62,241 \$ 103,734 \$ Compensation expense RSUs (in Dollars) \$ 107,000 \$ 53,000 \$ 583,000 207,000 \$ Period of unrecognized compensation expense \$ 1 year 4 months 24 days \$ Preferred stock, shares authorized \$ 2,000,000 \$ 2,000,000 \$ Preferred stock, par value (in Dollars per share) \$ 0.001 \$ 0.001 \$ 0.001 Net proceeds of exercised stock options (in Dollars) \$ 1,894,285 \$ 253,988 \$ Expected dividend yield, percentage \$ 0.00% \$ Underwriting Agreement [Member] \$ Stockholders Equity [Line Items] Shares of common stock issued \$ 7,500,000 \$ 7,500,000 \$ Warrants purchase shares \$ 2,500,625 \$ Equity Option [Member] \$ Stockholders Equity [Line Items] Net proceeds (in Dollars) \$ 2,123,000 \$ Granted aggregate shares \$ 132,500 120,000 2,176,167 2,021,200 \$ Weighted average exercise price (in Dollars per share) \$ 3.9 \$ 4.4 \$ Issuance of exercised stock options \$ 289,430 \$ Net proceeds of exercised stock options (in Dollars) \$ 1,708,000 \$ 20,000 \$ 1,894,000 \$ 254,000 \$ 2024 ATM Program [Member] \$ Stockholders Equity [Line Items] Common stock available for sale (in Dollars) \$ 36,012,000 \$ Common Stock [Member] \$ Stockholders Equity [Line Items] Shares of common stock issued \$ 1,500,093 \$ Purchase of additional shares \$ 1,500,093 \$ Common stock par value (in Dollars per share) \$ 4 \$ Net proceeds (in Dollars) \$ 12,515,000 \$ Sale of stock units \$ 2,866,421 \$ Shares of common stock in lieu of withholding taxes \$ 78,103 66,291 \$ Issuance of exercised stock options \$ 322,334 6,666 371,499 64,041 \$ Common Stock [Member] | Warrant [Member] \$ Stockholders Equity [Line Items] Common stock per share price (in Dollars per share) \$ 3.999 \$ Pre-funded warrants to purchase \$ 2,500,625 \$ Common Stock [Member] | Equity Option [Member] \$ Stockholders Equity [Line Items] Issuance of exercised stock options \$ 322,334 6,666 371,499 64,041 \$ Stock Options [Member] \$ Stockholders Equity [Line Items] RSUs vested percentage \$ 25.00% \$ Outstanding RSUs \$ 303,994 \$ 303,994 \$ Unrecognized compensation expense (in Dollars) \$ 778,000 \$ 778,000 \$ Period of unrecognized compensation expense \$ 1 year 7 months 6 days \$ Stock Options [Member] | Second Anniversary [Member] \$ Stockholders Equity [Line Items] RSUs grant percentage \$ 25.00% \$ Stock Options [Member] | First Anniversary [Member] \$ Stockholders Equity [Line Items] RSUs grant percentage \$ 25.00% \$ Stock Options [Member] | Third Anniversary [Member] \$ Stockholders Equity [Line Items] RSUs grant percentage \$ 25.00% \$ Employee Stock Option [Member] \$ Stockholders Equity [Line Items] Unrecognized compensation expense (in Dollars) \$ 7,470,000 \$ 7,470,000 \$ Leerink Partners LLC [Member] \$ Stockholders Equity [Line Items] Sale of common stock (in Dollars) \$ 50,000,000 \$ Executive Officers [Member] | Stock Options [Member] | 2019 Omnibus Stock Incentive Plan [Member] \$ Stockholders Equity [Line Items] Granted shares issued \$ 283,333 \$ \$ Weighted average grant date fair value (in Dollars per share) \$ 3.47 \$ Executive Officers [Member] \$ Stockholders Equity [Line Items] Shares of common stock issued 35,259 \$ 66,291 \$ Shares of common stock in lieu of withholding taxes 26,982 \$ 37,443 \$ Executive Officers [Member] | Stock Options [Member] \$ Stockholders Equity [Line Items] RSUs vested percentage \$ 25.00% \$ Vested shares issued \$ 42,844 \$ Shares of common stock in lieu of withholding taxes \$ 27,989 \$ Board of Directors [Member] \$ Stockholders Equity [Line Items] Preferred stock, shares authorized \$ 2,000,000 \$ 2,000,000 \$ Employees [Member] \$ Stockholders Equity [Line Items] Stock-based compensation (in Dollars) \$ 1,120,000 \$ Director [Member] \$ Stockholders Equity [Line Items] Stock-based compensation (in Dollars) \$ 4,352,000 \$ Officer [Member] \$ Stockholders Equity [Line Items] Stock-based compensation (in Dollars) \$ 950,000 \$ Consultants [Member] \$ Stockholders Equity [Line Items] Stock-based compensation (in Dollars) \$ 4,069,000 \$ Common Stock [Member] | 2019 Omnibus Stock Incentive Plan [Member] | Equity Option [Member] \$ Stockholders Equity [Line Items] Weighted average exercise price (in Dollars per share) \$ 5.72 \$ 3.75 \$ IPO [Member] \$ Stockholders Equity [Line Items] Net proceeds (in Dollars) \$ 5,600,000 \$ IPO [Member] | Common Stock [Member] \$ Stockholders Equity [Line Items] Shares of common stock issued \$ 7,500,000 \$ Common stock per share price (in Dollars per share) \$ 4 \$ Pre-Funded Warrants [Member] \$ Stockholders Equity [Line Items] Net proceeds (in Dollars) \$ 37,300,000 \$ Pre-Funded Warrants

[Member] | Subsequent Event [Member] A A A A A A A A A A Stockholders Equity [Line Items] A A A A A A A A A A Warrants purchase shares A A A A A A A A A A 2,500,625 X - DefinitionThe gross proceeds sale of common stock percentage. + ReferencesNo definition available. + Details Name: crmd\_GrossProceedsSaleOfCommonStockPercentage Namespace Prefix: crmd\_Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of purchase of additional shares. + ReferencesNo definition available. + Details Name: crmd\_PurchaseOfAdditionalShares Namespace Prefix: crmd\_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionSale of common stock. + ReferencesNo definition available. + Details Name: crmd\_SaleOfCommonStock Namespace Prefix: crmd\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of grant date shares. + ReferencesNo definition available. + Details Name: crmd\_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantdatePercentage Namespace Prefix: crmd\_Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of vesting shares. + ReferencesNo definition available. + Details Name: crmd\_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPercentage Namespace Prefix: crmd\_Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1:

www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap\_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - Definition Number of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition Number of shares purchased for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition Per share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap\_SharesIssuedPricePerShare Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - Definition Number of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap\_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap\_ClassOfWarrantOrRightAxis=crmd\_UnderwritingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_DerivativeInstrumentRiskAxis=us-gaap\_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_PlanNameAxis=crmd\_TwoThousandAndTwentyFourATMProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_StatementEquityComponentsAxis=us-gaap\_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_ClassOfWarrantOrRightAxis=us-gaap\_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_AwardTypeAxis=us-gaap\_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_RelatedPartyTransactionAxis=crmd\_SecondAnniversaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_RelatedPartyTransactionAxis=crmd\_FirstAnniversaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_RelatedPartyTransactionAxis=crmd\_ThirdAnniversaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_AwardTypeAxis=us-gaap\_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis=crmd\_LeerinkPartnersLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis=srt\_ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_PlanNameAxis=crmd\_TwoThousandNineteenOmniBusStockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_TitleOfIndividualAxis=srt\_ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_TitleOfIndividualAxis=srt\_BoardOfDirectorsChairmanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_TitleOfIndividualAxis=crmd\_EmployeesAndDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_TitleOfIndividualAxis=srt\_DirectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_TitleOfIndividualAxis=srt\_OfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_TitleOfIndividualAxis=crmd\_ConsultantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: Name: X - Details Name: us-gaap\_StatementClassOfStockAxis=us-gaap\_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_SubsidarySaleOfStockAxis=us-gaap\_IPOMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_SubsidarySaleOfStockAxis=crmd\_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap\_SubsequentEventTypesAxis=us-gaap\_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Equity (Details) - Schedule of Preferred Stock - USD (\$ Sep. 30, 2024 Dec. 31, 2023 Stockholdersâ€™ Equity (Details) - Schedule of Preferred Stock [Line Items] Å Á Preferred Stock, Shares Outstanding 181,622 181,622 Preferred Stock, Liquidation Preference, Value \$ 21,291,665 \$ 21,291,665 Series C-3 [Member] Å Á Stockholdersâ€™ Equity (Details) - Schedule of Preferred Stock [Line Items] Å Á Preferred Stock, Shares Outstanding 2,000 2,000 Preferred Stock, Liquidation Preference Per Share \$ 10 \$ 10 Preferred Stock, Liquidation Preference, Value \$ 20,000 \$ 20,000 Series E Preferred Stock [Member] Å Á Stockholdersâ€™ Equity (Details) - Schedule of Preferred Stock [Line Items] Å Á Preferred Stock, Shares Outstanding 89,623 89,623 Preferred Stock, Liquidation Preference Per Share \$ 49.2 \$ 49.2 Preferred Stock, Liquidation Preference, Value \$ 4,409,452 \$ 4,409,452 Series G Preferred Stock [Member] Å Á Stockholdersâ€™ Equity (Details) - Schedule of Preferred Stock [Line Items] Å Á Preferred Stock, Shares Outstanding 89,999 89,999 Preferred Stock, Liquidation Preference Per Share \$ 187.36 \$ 187.36 Preferred Stock, Liquidation Preference, Value \$ 16,862,213 \$ 16,862,213 X - ReferencesNo definition available. + Details Name: crmd\_StockholdersEquityDetailsScheduleOfPreferredStockLineItems Namespace Prefix: crmd\_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated value of the share. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap\_PREFERREDStockLiquidationPreference Namespace Prefix: us-gaap\_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - Definition Value of the difference between preference in liquidation and the par or stated values of the preferred shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap\_PREFERREDStockLiquidationPreferenceValue Namespace Prefix: us-gaap\_Data Type:

[illegible]

```

http://www.xbrl.org/2003/role/disclosureRef - Topic 842 - SubTopic 2 - Name Accounting Standards Codification - Section 45 - Publisher FASB - URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - ReferencesNone No definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 842 - SubTopic 2 - Name Accounting Standards Codification - Section 45 - Paragraph 1 - Subparagraph (b) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant EXCEL 48 Financial Reporting.Report.xlsx IDEA: XBRL DOCUMENT Began 644 Financial Reporting.Report.xlsx M4$L#10 ("J"7ED04UB00+<0 9&Jc4)0<0",0871P+GAM M,$V./0L",1$ IQO;=IP4)B0+I2L+>[>QLOD&1#LD]>|>OCG|CVX>;QA&WPG M*N*N#BV&5 C(0|I"47BK9.7:-N")=H16-Y<OGDK7A.YNjQ<&4GPZ4A|0W J=0U|RU;EUA 6#M17E!+ P04 M" ?>0EY9;71UX>T K @<0 108U|RU;W!S+V-O&ULS9+! M2Z0P$5(9?17)0JTG%0<CVLN)071!1:2V=U@DX9DI-VVW-7D070P&F GSS M#4QKH<C#PNY+HEOFOLA>4WEFOXM0G?GO MIP3)<17U>T(RJ9;B5SR5K&NM42:AIb&=;=L"/B9<F5#6"~>E$+4 ULT3 MXVGJ6[@<9AAA|OF[@<8E+M4 L4L/V#DY9;>?FQG&LQV)E!T$O<TJ0BSK5YB MTL%<@96=HE/$#;M;?FVVJ|L'UDDN;RO|JX;O&A;22*RG>9J&PO=&AE M;640=&AE64Q+GAM;U:6W/..!1 ">[Z 0->?&V;0O&-H&V/M!S:7;M]F$[4X? MA1#68C6QY9]&?&J[-A#+&E@WMDDVZFSP+&.G|SD5Y'@<X>?>N/+F+HAHB4GA@ MV2 J' UKNW+! ]<[55$D$4SP$>O> ,!4Q>M511 ,X2+&A T9$116F|>(+3&S/XM/F7/Z3H+,%H,M|8B' |..Z?D3EJ(X53"Q|J9S)6;?1 MTDB @LEJE 6Z2?>CTQ4@,@TJ.IU8S9GJ14L3MGXS*VG0T;1K4@ X% X&,+&+THMP M' @<4N>PIWT;@<D00FTHVG09-CVJ7J1J>4T 3JWW?ZYMHG J-6T 3#W= MTXZ)QJW0> V'4<~PZJ)QJO=>M|Jb?|KJFN2D19H0D;CZWH2%;TE0-> @AP M=M;T@<67BGZ=90:V11W|V4<=<#CN.8D1 L;L%1-9|TAF6-59RG9 9#< WQ=; M4'R00;<?X.*2TEROULIM5 :")K|@<? 5'@<6%W* J|9>[R.0S>|UJ|,LYKE'!I MJP&G|N;SYA'<C CDGZ>3UTU"SG"+ CQ-R-88C(CN|JWV6'WV3T=N(|>IP+ BUIY1)&$6?R'VZ MY$XMX4D_A_>|V&F&IO' *D"3<6H8;XM;..L$>3?;>^<?>C8C9JV>|>5>A M62$G|A/@01AKB/GF<I%L'P>E1M'V5;SC MFED)0816!>JAS0'X|JXR">@7QN1X^YIYX'<@6QK0KH|>? 1VC?>J" B"P#E M+GW/I>~>Y|VATK|>A WZGZ$SKYI9+2,6D$N1L$TDN/RJO RQ GH9%LE MOAMNZ$U2I77Y:Y'+>@/6<3IKZ%TBS/>3Q?YI3">#<MW>|ZK:4OK4F.$KT ML@<37|JEUH'>E.70|@<0KX>;=J=W+HXGIB1NOK3 M4!I0P GIQ7?>XCG91+&EJF=>MYV|C1?>OGP5&PH+|EAWB'/B>|>ZAAIC/PT' M>7M2F&5>QE T%&ULK'0L1K=<@<N?> Q+I3<9&U$M'>#<KUS'E|58#<Q;Q<K,D#>)<M3Q(ZQ<GEUQ?X|>Z2JNFX9;5NKRWE&6TB4CQ'>9G39P0'WF60P54=SU5;K'~>M:CVT44|F EFMR|>X46X'Q) (8Y07ID|J|QEQ3ON<?<C*YZ(G;ZEW?I M8+!>|<E'#~4YU T74.NT0?=<I NDSMS(3)QYOI1$=-$4(Y4U~VT%SU&Z.9X|ZSAW;>K'C1-S 6-8>~3+?>7.;MX#7N83 M+&.D7L%|BHJ $<MBOKJO3 DEG>NT>.<I(0)UMND|MW@<'S4J19E9'1/L'TL M?;<~2!F..6 0T7X4J8VFL+V&VC;>8|8APR9C&?AT6;<C/5BZP9Y0C00=5 MY3 J' UH|@TT')$%7C&9MC.CY$X*-/S~|PVPPL2.X>+VOP02P.$S@< MCT>)>69#(T17|J@ QB, !<@<X;|JW;KWTPP9690|LW5TT OON M H(YLSQ21KXDHCWRV7.S;A7'Q8Q5+&'F5Z'2X8W'964J'Y M3K'6)|R).V8& K2L,YXQ&1.1:0>F+>?>3HBCL8T5#MKGVLV@<T?>I8BGU&|WQO8H3$SUWU'7F+WUBA0B_&V|<A B8C3N>7G8G| MR74&NB#<X >+>L3>:Z117AAU|U1M3 |J|C22.B?<6DCB#|JWYJZ-QUDZC? /0 M30&=NG$>|J2|H57,'|S4$>?>P2?>7%YAWADTSE)00G<C 3'.A.YWDL,E? MM.GV|<[R$N59%>KX@<L1+M|WG+3|U>@<6-7%..|J38%=<I>6.7%|7."EH=F0 MUC619'SIV09Q0=>+TR 2F) $BGC|JL&GJ|U33CO|ZSSZT?3;Q'GM'WR H~U|Z2?<~M75&3*SQN6|J0|B2P|B'268%T5@< I2T*XI&SZBERA. HR1/327|JH9X MYP7>>:~L1^8D%$9 L'PAX* ('=1+0&|<5<%1MEZT12$|> MR$T5X5|PF2CPCJW'<~<BAHS#<G$<M)SM'>?>MN)M2|F8+<B^LN' LH90HPJ M5'JG|E/>.<@/O&+KEC.*G40L$95K1%?> D-VRB75J|DZ&PB|A.@K|1>?>Z MZRL<~<4H&E5SEVW.&~WQYHU:30G'?&C;1&4179.F|P|2'>FFOHH?YYXI'7' M6&GO<4OUL4&WV$> T4@|I9&|>+HGD7B|@<AR'Y|N|JZC? Z+I07M|J|U&S2A-R.N0QKAP013U|,YF56<OXK3J9.PW#ULX M' ?K&B-R&=<FE&MFVP~>Z|>JVYMA53B0R'RW:~<N8QM|U| ENJOE&|<B'ET7KBN$5XI M2A0VFI7TUP0(U4D7CQ)OYX(Q)>YU$FHT+!+<#(VX8T$X'>."@E1&1+7*7G M52+4Q|<860 5D&UTJ'P+8J>?>VJ|0JF6UB|RL=<T7YJ|JH9B|B|V|<=>@<L2E1F'8>|<X E T&ISQD:U$'OF@<UGWO|B|<U#HW'I4;B61A6@<CTQ|Y8U !.M*+3Z0: U&M&M MVQ I|QOIQZH$8S|NF1|JDM^H2+<OF$8=05Q$D|+|<6W&XEE|ZE@<[4CIT|YR2 MRN$|J!A9 T~L$>~<NG%L'<J/>+|/V+=6W=ZJ09 R9|J|C|P7|I4|Z M&VWPG<~<WX.A+[*]>=K'CWNV7K0W;SU|WUNGEF6CE;I(7|/0:1-P8%T44Q>?>3R|J|MI|)'<S$MPL?>9 /Z12K;Q.EDCV|L$V6=19F877%F/SZW$ MPO|>80>+>?>1 QM>DA>Z$2Q|@<$9$RYW1'U' M^A32N2J|U3|ZJWGVTSBV=|D|>?>|B4KJ|H03D6A&'2696I2PF|@< FQH !@<X;|JW;W|KPC|JQ M4$E4)=I|JNMW#<N6+5)R6~<0AL63|C.X9D7F1-67ZMD|H|U+<|L%|2J M>#<1:5=>629+QZ|PN1PR|+66980|B6L=KU+U M63Y'<SEM'KHXY7:2J |Z'K2T'<H&A5+9EMG0Q|EN2:3 YJFX@|J'~T.M U1 M1(9H8+711%?>U|@<57?>Q:RD=4:FN(|JW-3>P'>J|6V10=<#<N(GZ,OL KU|>=O12,%%M>LHV&|@<X^8'M,," M,U&0PP/$<74L;A/^<MTO1 3N19GA^<XCH+K2ZW=;1V|=2%<E:7/>J5!<1L M=#;<CMU?ZKZW5<S<C<3:~5;OB|< V.B|4+<J|FQ'E? 5%TJXM40 MCU&D<2W5;+F*7'WLMZ$N|0>NNOQ|RE@<4=8<~|<I[S.R|D1=|<0&Q)WA 5IG MA|J;I1?M951|,K(WX=<X;QM F90BVTW9Q'W/B^XS|@<?>P>W^W'UO^4ITH M468H8=) N)
```

MV\$V"0%565AY?>5]>ZB:3V:G=1M]WA>E">[)]KFWKJER]>F"2'G]XD95;4NX9=- MU>R3%KXVVQ>F;G22T4/[XL5T+Y^L4\_RLKG;^G:^^;UMU77%GFIWS>1Z?;[ MI#F^T45U^ . [Y](F)"?][E]]+UMW6RU?>Z\_5B\_>#1#;"S=>EN]J?;"?C]J] M^>[)]>3EFSG>3S?GNN#?"3Y"NI]U57W+>^&^R]YZ,D21=Z+3%\$1+XZ#O=%( @ M0\$%&GS+FS\$W+S,KT)NF#D^U^"M MZUG@>E&5&L^)=]Q7T^BM;M-MM9>@&8]70+?Y+^PXG1>F,H,4&4Z\*;R]WQ9R M Q&O;IC1\$%=-X-H^'6B]H?<3E6]?"=O KSDU]U^?YV[DUJTG+ +?>G2=E&E MMVE:=-66;E]OH? 57D;:Y-E]19]q?>Y=9>G>+>+>+7AI?&?UW.1^\_7F<[Z\$]>=-C9%3.UBWDDP?!!>UZ-H-HZCZ?G2\_M2V2F6;C?>S) KOV5I&Y^! QGB\$Y^R]?'\*EJ9-4?<-\$%\_HYD\$ \_M>?ZW- WR;7XU>+/-+>+N%CE\_/\_3\_9PEX?.Y?JE9T^>@J^G>+>4&=\$O^QT&W];Z2BM M0-Q^HSA/9+&EUIC9YF911GA21:>\$%&][61+>OD04=KK! M/M-M- L@18%<^C^W3P9;+>#M^JELBXT+?Y;Y&VRS@N@D?3].NI:Q1X6>4S(B;M^\*MO^RH:NI+1+&="70\$31 NBMW?JCR[LS<^("WY<~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e >+6>Z0\_>ZPQG MSX0PR7^>L8 W314#>#N^F]\_>#>#>BJ3(6V^R)A-705ZND^C3#>(^>Q4PL%>[Z:1C M;I&? H#>[HJV/]P]=#>M&S&QT\_>=>[ML^>MXK\_>?7LSI@H>\_>U^>H9^>Q49X M#1+>N>E>1^>@>D>15^9\_>MLV^>+I11\_74H(A!>9QOPL+>W+B^>V^>F&Z.F\$T!>(^>R MZC18 TS^NM^VGZ40S2Z& [^>6\$>^JL3]9P2ZPIKGW^8B)NDZ@>I^>O5^>M^>N(U3L M;1&Z;V)3#>F3R3]X-X&A.8T)]TPK8^UO]98883PG^P8?>M^>[WAS5V^>W.2VLJ[ST^JTN^4KVD8Y]>(^>SLACR F)CJ3N; S'!R\_>NOV MEJ]J^>D&Y^QB^>JGRC&!)T.<7=L3^>Y9@\_>@QIDC@>9AEN+>Q03>#>ISX^<@>=J^C M-.4C(#):#>H=]>8/&X\_>5K#8;02%2T^>AQ ABZ-M4W6U;8?>CLR?>I)3]6\, M\_/JXSJ1B&=>X79.X&U^NDH^JUCVUC(O\$O&K\$>?>Z\_>6\$FQM\$CRO6V9B+>A^>M^>+>6=>@>6^>DDTY^!!Y:8^>FQTAD]0A2LJ^>AT1A(KZ0WL@PZ0]D\_>0>?77;Z MD6G]>@>(!Z?Y@>:HA^>X8-SAM^>@>RY[>^>ABXTO^YR3^3@>8%>^>T^>T^>CX<=>ONZ MTZ49\$>O<0I.9HK1\_#>P>4]>] L6WR5\$!EVP^>M@>X394[RLI&L^>71A)EC\$V3 MIL\$4C\$S7L RASN]19RK9M^>+>QJ^>X&Y+>SR+N^>C2;]>J^>9A44GS3^T]Y1N0&]>3U MYFV1^>1Kj>\_>?Z<6&3W 1^\*V\_H51KE^<(\$>)3BUUY^708\_<@>LX16E6;1\$A3)T^>L^>Y&X3.E-/MOYA^>EXT(!>L^>A^>O\_>>%>MWC@>S^>M+>MWJ^>P<Y^>R^>B^>^>C2;]>[>1^>J^>T^>M^>K\_>=>0N99G^>76FXMX>FYVZ,W3J MWN3%>\_>T]^>DJKW36B]E^>+>4%(O)>1^>L^>Y^>!!A00^>^>V\_>L%>ZL^>R1.EZ^>N^>I^>BZ M^>+>JKSUJ^>MC>\_>WTR^>X^>Y9^>T9\*\*1XUQU. (S/[E4^>@>1M7%]>];%>7@\_>AOHUAX/LS+>\$R0VRAI^>ZM8\_1<3j#>23Si(<^>CD\$S^>C9Z#>P.O)&\_>XTT\_>O MI<+>+CA^>S^>2]SH^>A+N(1X(^>V1^>LXR(Z)!>]>J^>S+>GLJ]IJB^>W M-EIA^>Z^>P^>OY&C]1;5^>Y^>+>@>OYTER;N+=>4^>OMFHP9.W^>#^>U#>^>V8]M.P8[4Z5D+>+V;BR[!>[ HC3\_Q^>29A?>O^>H^>L]>]>]>Q^>Y\_1^>7C^>C^>M^>FGRRV^>QBB M^>J2B#<\_>[R^>H UI1\$^>R]CZ^>H&2X;E9NL>\_>PA1A#1-1K3<51\$E&VW\$0+>Ae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j>\_>?Z<6&3W 1^\*V\_H51KE^<(\$>)3BUUY^708\_<@>LX16E6;1\$A3)T^>L^>Y&X3.E-/MOYA^>EXT(!>L^>A^>O\_>>%>MWC@>S^>M+>MWJ^>P<Y^>R^>B^>^>C2;]>[>1^>J^>T^>M^>K\_>=>0N99G^>76FXMX>FYVZ,W3J MWN3%>\_>T]^>DJKW36B]E^>+>4%(O)>1^>L^>Y^>!!A00^>^>V\_>L%>ZL^>R1.EZ^>N^>I^>BZ M^>+>JKSUJ^>MC>\_>WTR^>X^>Y9^>T9\*\*1XUQU. (S/[E4^>@>1M7%]>];%>7@\_>AOHUAX/LS+>\$R0VRAI^>ZM8\_1<3j#>23Si(<^>CD\$S^>C9Z#>P.O)&\_>XTT\_>O MI<+>+CA^>S^>2]SH^>A+N(1X(^>V1^>LXR(Z)!>]>J^>S+>GLJ]IJB^>W M-EIA^>Z^>P^>OY&C]1;5^>Y^>+>@>OYTER;N+=>4^>OMFHP9.W^>#^>U#>^>V8]M.P8[4Z5D+>+V;BR[!>[ HC3\_Q^>29A?>O^>H^>L]>]>]>Q^>Y\_1^>7C^>C^>M^>FGRRV^>QBB M^>J2B#<\_>[R^>H UI1\$^>R]CZ^>H&2X;E9NL>\_>PA1A#1-1K3<51\$E&VW\$0+>Ae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j>\_>?Z<6&3W 1^\*V\_H51KE^<(\$>)3BUUY^708\_<@>LX16E6;1\$A3)T^>L^>Y&X3.E-/MOYA^>EXT(!>L^>A^>O\_>>%>MWC@>S^>M+>MWJ^>P<Y^>R^>B^>^>C2;]>[>1^>J^>T^>M^>K\_>=>0N99G^>76FXMX>FYVZ,W3J MWN3%>\_>T]^>DJKW36B]E^>+>4%(O)>1^>L^>Y^>!!A00^>^>V\_>L%>ZL^>R1.EZ^>N^>I^>BZ M^>+>JKSUJ^>MC>\_>WTR^>X^>Y9^>T9\*\*1XUQU. (S/[E4^>@>1M7%]>];%>7@\_>AOHUAX/LS+>\$R0VRAI^>ZM8\_1<3j#>23Si(<^>CD\$S^>C9Z#>P.O)&\_>XTT\_>O MI<+>+CA^>S^>2]SH^>A+N(1X(^>V1^>LXR(Z)!>]>J^>S+>GLJ]IJB^>W M-EIA^>Z^>P^>OY&C]1;5^>Y^>+>@>OYTER;N+=>4^>OMFHP9.W^>#^>U#>^>V8]M.P8[4Z5D+>+V;BR[!>[ HC3\_Q^>29A?>O^>H^>L]>]>]>Q^>Y\_1^>7C^>C^>M^>FGRRV^>QBB M^>J2B#<\_>[R^>H UI1\$^>R]CZ^>H&2X;E9NL>\_>PA1A#1-1K3<51\$E&VW\$0+>Ae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j>\_>?Z<6&3W 1^\*V\_H51KE^<(\$>)3BUUY^708\_<@>LX16E6;1\$A3)T^>L^>Y&X3.E-/MOYA^>EXT(!>L^>A^>O\_>>%>MWC@>S^>M+>MWJ^>P<Y^>R^>B^>^>C2;]>[>1^>J^>T^>M^>K\_>=>0N99G^>76FXMX>FYVZ,W3J MWN3%>\_>T]^>DJKW36B]E^>+>4%(O)>1^>L^>Y^>!!A00^>^>V\_>L%>ZL^>R1.EZ^>N^>I^>BZ M^>+>JKSUJ^>MC>\_>WTR^>X^>Y9^>T9\*\*1XUQU. (S/[E4^>@>1M7%]>];%>7@\_>AOHUAX/LS+>\$R0VRAI^>ZM8\_1<3j#>23Si(<^>CD\$S^>C9Z#>P.O)&\_>XTT\_>O MI<+>+CA^>S^>2]SH^>A+N(1X(^>V1^>LXR(Z)!>]>J^>S+>GLJ]IJB^>W M-EIA^>Z^>P^>OY&C]1;5^>Y^>+>@>OYTER;N+=>4^>OMFHP9.W^>#^>U#>^>V8]M.P8[4Z5D+>+V;BR[!>[ HC3\_Q^>29A?>O^>H^>L]>]>]>Q^>Y\_1^>7C^>C^>M^>FGRRV^>QBB M^>J2B#<\_>[R^>H UI1\$^>R]CZ^>H&2X;E9NL>\_>PA1A#1-1K3<51\$E&VW\$0+>Ae >+6>Z0\_>ZPQG MSX0PR7^>L8 W314#>#N^F]\_>#>#>BJ3(6V^R)A-705ZND^C3#>(^>Q4PL%>[Z:1C M;I&? H#>[HJV/]P]=#>M&S&QT\_>=>[ML^>MXK\_>?7LSI@H>\_>U^>H9^>Q49X M#1+>N>E>1^>@>D>15^9\_>MLV^>+I11\_74H(A!>9QOPL+>W+B^>V^>F&Z.F\$T!>(^>R MZC18 TS^NM^VGZ40S2Z& [^>6\$&

[illegible]

[illegible]

[illegible]

Security and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show = {}; Show.LastAR = null; Show.showAR = function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!="TABLE"){d=e.nextSibling;if(!e.nodeName=="TABLE")([var ref=((window)?w.document(document).getElementById(r);if(ref){e=ref.cloneNode(true);e.removeAttribute('id');a.parentNode.appendChild(e)}]} if(e.e.style.display='block';Show.LastAR=e;Show.hideAR=function(){Show.LastAR.style.display='none';Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style.display){}else if(!e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='-'} else {d='none';p='+'} e.style.display=d;if(a.textContent){fa-textContent=p+a.textContent.substring(1)}else{a.innerHTML=p+a.innerHTML.substring(1)}} XML-50-report.css IDEA: XBRL DOCUMENT / Updated 2009-11-04 %v2.2.0.24 % DefRef Styles % .report table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData -hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData -hide a:hover { background-color: #2F4497; } .report table.authRefData -body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table { font-size: 1em; } Report Styles % .pl a, .pl a:visited { color: black; text-decoration: none; } % table % .report { background-color: white; border: 2px solid #ac; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; } .report hr { border: 1px solid #ac; } % Top labels % .report th { background-color: #ac; color: black; font-weight: bold; text-align: center; } .report th:empty { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; } .report -pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; } .report td, .pl a a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td, .pl div a { width: 200px; } .report td, .pl a:over { background-color: #ffe; } % Header rows % .report tr:th { background-color: #ac; color: black; font-weight: bold; } % Calendars % .report -rc { background-color: #f0f0f0; } % Even rows % .report -re, .report -ru { background-color: #def; } .report -reu td { border-bottom: 1px solid black; } % Odd rows % .report -ro, .report -rou { background-color: white; } .report -rou td { border-bottom: 1px solid black; } .report -rou table td, .report -reu table td { border-bottom: 0px solid black; } % styles for footnote marker % .report -fn { white-space: nowrap; } % styles for numeric types % .report -num, .report -nump { text-align: right; white-space: nowrap; } .report -nump { padding-left: 2em; } .report -nump { padding: 0px 0.4em 0px 2em; } % styles for text types % .report -text { text-align: left; white-space: normal; } .report -text big { margin-bottom: 1em; width: 17em; } .report -text more { display: none; } .report -text note { font-style: italic; font-weight: bold; } .report -text small { width: 10em; } .report sup { font-style: italic; } .report -outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3.html 182-246-1 false 53-0 false 5 false false R1.htm 995100 - Document - Cover Sheet http://xbrl.sec.gov/dei/role/document/Cover-Cover-Cover-1-false-false-R2.htm 995301 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.cormedix.com/role/ConsolidatedBalanceSheet-Condensed Consolidated Balance Sheets Statements 2-false-false-R3.htm 995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://www.cormedix.com/role/ConsolidatedBalanceSheet-Parentheticals-Condensed Consolidated Balance Sheets (Parentheticals) Statements 3-false-false-R4.htm 995303 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.cormedix.com/role/ConsolidatedIncomeStatement-Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4-false-false-R5.htm 995304 - Statement - Condensed Consolidated Statements of Changes in Stockholders??? Equity (Unaudited) Sheet http://www.cormedix.com/role/ShareholdersEquityType2or3-Condensed Consolidated Statements of Changes in Stockholders??? Equity (Unaudited) Statements 5-false-false-R6.htm 995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.cormedix.com/role/ConsolidatedCashFlow-Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6-false-false-R7.htm 995306 - Disclosure - Organization, Business and Basis of Presentation Sheet http://www.cormedix.com/role/OrganizationBusinessandBasisofPresentationOrganization, Business and Basis of Presentation Notes 7-false-false-R8.htm 995307 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties Sheet http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesSummary of Significant Accounting Policies and Liquidity and Uncertainties Notes 8-false-false-R9.htm 995308 - Disclosure - Other Prepaid Expenses and Current Assets Sheet http://www.cormedix.com/role/OtherPrepaidExpensesandCurrentAssetsOther Prepaid Expenses and Current Assets Notes 9-false-false-R10.htm 995309 - Disclosure - Accrued Expenses Sheet http://www.cormedix.com/role/AccruedExpensesAccrued Expenses Notes 10-false-false-R11.htm 995310 - Disclosure - Commitments and Contingencies Sheet http://www.cormedix.com/role/CommitmentsandContingenciesCommitments and Contingencies Notes 11-false-false-R12.htm 995311 - Disclosure - Stockholders??? Equity Sheet http://www.cormedix.com/role/StockholdersEquityStockholders??? Equity Notes 12-false-false-R13.htm 995312 - Disclosure - Leases Sheet http://www.cormedix.com/role/LeasesLeases Notes 13-false-false-R14.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance Disclosure Notes 14-false-false-R15.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading Arrangements Notes 15-false-false-R16.htm 996000 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.cormedix.com/role/AccountingPoliciesByPolicyAccounting Policies, by Policy (Policies) Policies http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertainties16-false-false-R17.htm 996001 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Tables) Sheet http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesTablesSummary of Significant Accounting Policies and Liquidity and Uncertainties (Tables) Tables http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertainties17-false-false-R18.htm 996002 - Disclosure - Other Prepaid Expenses and Current Assets (Tables) Sheet http://www.cormedix.com/role/OtherPrepaidExpensesandCurrentAssetsTablesOther Prepaid Expenses and Current Assets (Tables) Tables http://www.cormedix.com/role/OtherPrepaidExpensesandCurrentAssets18-false-false-R19.htm 996003 - Disclosure - Accrued Expenses (Tables) Sheet http://www.cormedix.com/role/AccruedExpensesTablesAccrued Expenses (Tables) Tables http://www.cormedix.com/role/AccruedExpenses19-false-false-R20.htm 996004 - Disclosure - Stockholders??? Equity (Tables) Sheet http://www.cormedix.com/role/StockholdersEquityTablesStockholders??? Equity (Tables) Tables http://www.cormedix.com/role/StockholdersEquity20-false-false-R21.htm 996005 - Disclosure - Leases (Tables) Sheet http://www.cormedix.com/role/LeasesTablesLeases (Tables) Tables http://www.cormedix.com/role/Leases21-false-false-R22.htm 996006 - Disclosure - Organization, Business and Basis of Presentation (Details) Sheet http://www.cormedix.com/role/OrganizationBusinessandBasisofPresentationDetailsOrganization, Business and Basis of Presentation (Details) Details http://www.cormedix.com/role/OrganizationBusinessandBasisofPresentation22-false-false-R23.htm 996007 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) Sheet http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetailsSummary of Significant Accounting Policies and Liquidity and Uncertainties (Details) Details http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesTables23-false-false-R24.htm 996008 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of consolidated statement of cash flows Sheet http://www.cormedix.com/role/ScheduleofconsolidatedstatementofcashflowsTableSummary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of consolidated statement of cash flows Details http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesTables24-false-false-R25.htm 996009 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Amortized Cost, Unrealized Gains and Losses and the Fair Value Sheet http://www.cormedix.com/role/ScheduleofAmortizedCostUnrealizedGainsandLossesandtheFairValueTableSummary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Amortized Cost, Unrealized Gains and Losses and the Fair Value Details http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesTables25-false-false-R26.htm 996010 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Carrying and Fair Value of Financial Assets Sheet http://www.cormedix.com/role/ScheduleofCarryingandFairValueofFinancialAssetsTableSummary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Carrying and Fair Value of Financial Assets Details http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesTables26-false-false-R27.htm 996011 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Inventories Sheet http://www.cormedix.com/role/ScheduleofInventoriesTableSummary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Inventories Details http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesTables27-false-false-R28.htm 996012 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share Sheet http://www.cormedix.com/role/ScheduleofAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareTableSummary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share Details http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesTables28-false-false-R29.htm 996013 - Disclosure - Other Prepaid Expenses and Current Assets (Details) - Schedule of Other Prepaid Expenses and Current Assets Sheet http://www.cormedix.com/role/ScheduleofOtherPrepaidExpensesandCurrentAssetsTableOther Prepaid Expenses and Current Assets (Details) - Schedule of Other Prepaid Expenses and Current Assets Details http://www.cormedix.com/role/OtherPrepaidExpensesandCurrentAssetsTables29-false-false-R30.htm 996014 - Disclosure - Accrued Expenses (Details) - Schedule of Accrued Expenses Sheet http://www.cormedix.com/role/ScheduleofAccruedExpensesTableAccrued Expenses (Details) - Schedule of Accrued Expenses Details http://www.cormedix.com/role/AccruedExpensesTables30-false-false-R31.htm 996015 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.cormedix.com/role/CommitmentsandContingenciesDetailsCommitments and Contingencies (Details) Details http://www.cormedix.com/role/CommitmentsandContingencies31-false-false-R32.htm 996016 - Disclosure - Stockholders??? Equity (Details) Sheet http://www.cormedix.com/role/StockholdersEquityDetailsStockholders??? Equity (Details) Details http://www.cormedix.com/role/StockholdersEquityTables32-false-false-R33.htm 996017 - Disclosure - Stockholders??? Equity (Details) - Schedule of Preferred Stock Sheet http://www.cormedix.com/role/StockholdersEquityDetailsScheduleofPreferredStockStockholders??? Equity (Details) - Schedule of Preferred Stock Details http://www.cormedix.com/role/StockholdersEquityTables33-false-false-R34.htm 996018 - Disclosure - Stockholders??? Equity (Details) - Schedule of Black-Scholes Option Pricing Model Sheet http://www.cormedix.com/role/ScheduleofBlackScholesOptionPricingModelTableStockholders??? Equity (Details) - Schedule of Black-Scholes Option Pricing Model Details http://www.cormedix.com/role/StockholdersEquityTables34-false-false-R35.htm 996019 - Disclosure - Leases (Details) Sheet http://www.cormedix.com/role/LeasesDetailsLeases (Details) Details http://www.cormedix.com/role/LeasesTables35-false-false-R36.htm 996020 - Disclosure - Leases (Details) - Schedule of Maturities of Lease Liabilities Sheet http://www.cormedix.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTableLeases (Details) - Schedule of Maturities of Lease Liabilities Details http://www.cormedix.com/role/LeasesTables36-false-false-All Reports Book All Reports crmd-20240930.xsd crmd-20240930\_cal.xml crmd-20240930\_def.xml crmd-20240930\_lab.xml crmd-20240930\_pre.xml ea0218371-10q cormedix.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 54 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0218371-10q-cormedix.htm": { "nsprefix": "crmd"; "nsuri

"https://xbri.sec.gov/sic/2024/sic-2024.xsd", "https://xbri.sec.gov/stpr/2024/stpr-2024.xsd"}}, "calculationLink": { "local": { "crmd-20240930-cal.xml" } }, "definitionLink": { "local": { "crmd-20240930\_def.xml" } }, "labelLink": { "local": { "crmd-20240930\_lab.xml" } }, "presentationLink": { "local": { "crmd-20240930\_pre.xml" } } }, "inline": { "local": { "ea0218371-10q\_cormedix.htm" } } }, "keyStandard": 222, "keyCustom": 24, "axisStandard": 22, "axisCustom": 0, "memberStandard": 29, "memberCustom": 18, "hidden": { "total": 150, "http://fasb.org/us-gaap/2024": 142, "http://www.cormedix.com/20240930": 4, "http://xbri.sec.gov/dei/2024": 4 }, "contextCount": 182, "entityCount": 1, "segmentCount": 53, "elementCount": 619, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 744, "http://xbri.sec.gov/dei/2024": 31, "http://xbri.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://xbri.sec.gov/dei/role/document/Cover", "longName": "995100 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "b": "p", "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "b": "p", "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.cormedix.com/role/ConsolidatedBalanceSheet", "longName": "995301 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "body", "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:RestrictedCashCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "body", "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "unique": true } }, "R3": { "role": "http://www.cormedix.com/role/ConsolidatedBalanceSheetParentheticals", "longName": "995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "td": "tr", "table": "body", "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "body", "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "unique": true } }, "R4": { "role": "http://www.cormedix.com/role/ConsolidatedIncomeStatement", "longName": "995303 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "body", "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:CostOfRevenue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "body", "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "unique": true } }, "R5": { "role": "http://www.cormedix.com/role/ShareholdersEquityType2or3", "longName": "995304 - Statement - Condensed Consolidated Statements of Changes in Stockholders'2019 Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders'2019 Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c50", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span": "td", "tr", "table": "body", "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c50", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span": "td", "tr", "table": "body", "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.cormedix.com/role/ConsolidatedCashFlow", "longName": "995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "body", "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "body", "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "unique": true } }, "R7": { "role": "http://www.cormedix.com/role/OrganizationBusinessandBasisofPresentation", "longName": "995306 - Disclosure - Organization, Business and Basis of Presentation", "shortName": "Organization, Business and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertainties", "longName": "995307 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties", "shortName": "Summary of Significant Accounting Policies and Liquidity and Uncertainties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.cormedix.com/role/OtherPrepaidExpensesandCurrentAssets", "longName": "995308 - Disclosure - Other Prepaid Expenses and Current Assets", "shortName": "Other Prepaid Expenses and Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.cormedix.com/role/AccruedExpenses", "longName": "995309 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.cormedix.com/role/CommitmentsandContingencies", "longName": "995310 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.cormedix.com/role/StockholdersEquity", "longName": "995311 - Disclosure - Stockholders'2019 Equity", "shortName": "Stockholders'2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.cormedix.com/role/Leases", "longName": "995312 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true } }, "R14": { "role": "http://xbri.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "body", "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "R15": { "role": "http://xbri.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c4", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ecd:Rule10b51ArrTrmtdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmtdFlag", "span": "p", "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ecd:Rule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmtdFlag", "span": "p", "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.cormedix.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "crmd:LiquidityAndUncertainitiePolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:SignificantAccountingPoliciesTextBlock", "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "crmd:LiquidityAndUncertainitiePolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:SignificantAccountingPoliciesTextBlock", "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesTables", "longName": "996001 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Tables)", "shortName": "Summary of Significant Accounting Policies and Liquidity and Uncertainties (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "ix:continuation", "ix:continuation", "body": "html" } }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true } }, "R18": {

"role": "http://www.cormedix.com/role/OtherPrepaidExpensesandCurrentAssetsTables", "longName": "996002 - Disclosure - Other Prepaid Expenses and Current Assets (Tables)", "shortName": "Other Prepaid Expenses and Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:OtherCurrentAssetsTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:OtherCurrentAssetsTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "R19": { "role": "http://www.cormedix.com/role/AccruedExpensesTables", "longName": "996003 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "R20": { "role": "http://www.cormedix.com/role/StockholdersEquityTables", "longName": "996004 - Disclosure - Stockholders'2019 Equity (Tables)", "shortName": "Stockholders'2019 Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfPreferredUnitsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfPreferredUnitsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "R21": { "role": "http://www.cormedix.com/role/LeasesTables", "longName": "996005 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:LesseeOperatingLeasesTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "R22": { "role": "http://www.cormedix.com/role/OrganizationBusinessandBasisofPresentationDetails", "longName": "996006 - Disclosure - Organization, Business and Basis of Presentation (Details)", "shortName": "Organization, Business and Basis of Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "c61", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c61", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "us-gaap:OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "R23": { "role": "http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails", "longName": "996007 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details)", "shortName": "Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "c2", "name": "crmd:CommonStockRemainingShareValueAvailableForSale", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "p", "ix:continuation", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "crmd:CommonStockRemainingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "p", "ix:continuation", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "R24": { "role": "http://www.cormedix.com/role/ScheduleofconsolidatedstatementofcashflowsTable", "longName": "996008 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of consolidated statement of cash flows", "shortName": "Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of consolidated statement of cash flows", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c49", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "R25": { "role": "http://www.cormedix.com/role/ScheduleofAmortizedCostUnrealizedGainsandLossesandtheFairValueTable", "longName": "996009 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Amortized Cost, Unrealized Gains and Losses and the Fair Value", "shortName": "Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Amortized Cost, Unrealized Gains and Losses and the Fair Value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "R26": { "role": "http://www.cormedix.com/role/ScheduleofCarryingandFairValueoffinancialAssetsTable", "longName": "996010 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Carrying and Fair Value of Financial Assets", "shortName": "Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Carrying and Fair Value of Financial Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "c91", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c91", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "R27": { "role": "http://www.cormedix.com/role/ScheduleofInventoriesTable", "longName": "996011 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Inventories", "shortName": "Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "R28": { "role": "http://www.cormedix.com/role/ScheduleofAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareTable", "longName": "996012 - Disclosure - Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share", "shortName": "Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "R29": { "role": "http://www.cormedix.com/role/ScheduleofOtherPrepaidExpensesandCurrentAssetsTable", "longName": "996013 - Disclosure - Other Prepaid Expenses and Current Assets (Details) - Schedule of Other Prepaid Expenses and Current Assets", "shortName": "Other Prepaid Expenses and Current Assets (Details) - Schedule of Other Prepaid Expenses and Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:MaterialsSuppliesAndOther", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:OtherCurrentAssetsTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:MaterialsSuppliesAndOther", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:OtherCurrentAssetsTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "R30": { "role": "http://www.cormedix.com/role/ScheduleofAccruedExpensesTable", "longName": "996014 - Disclosure - Accrued Expenses (Details) - Schedule of Accrued Expenses", "shortName": "Accrued Expenses (Details) - Schedule of Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c2", "name": "crmd:AccruedGrossnetDeduction", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "crmd:AccruedGrossnetDeduction", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "ix:continuation", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "R31": { "role": "http://www.cormedix.com/role/CommitmentsandContingenciesDetails", "longName": "996015 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c0", "name": "crmd:AmountOfInitialLicensingFee", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "p", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "R32": { "role": "http://www.cormedix.com/role/StockholdersEquityDetails", "longName": "996016 - Disclosure - Stockholders'2019 Equity (Details)", "shortName": "Stockholders'2019 Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "ea0218371-10q\_cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-

gaap:SaleOfStockConsiderationReceivedOnTransaction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html", "reportCount": 1, "baseRef": "ea0218371-10q-cormedix.htm", "unique": true }, "R33": { "role": "http://www.cormedix.com/role/StockholdersEquityDetailsScheduleofPreferredStock", "longName": "996017 - Disclosure - Stockholders'2019 Equity (Details) - Schedule of Preferred Stock", "shortName": "Stockholders'2019 Equity (Details) - Schedule of Preferred Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PreferredStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "us-gaap:PreferredStockSharesIssued", "us-gaap:PreferredStockSharesIssued", "td", "tr", "table", "body", "html", "reportCount": 1, "baseRef": "ea0218371-10q-cormedix.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:PreferredStockLiquidationPreferenceValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "us-gaap:PreferredStockLiquidationPreferenceValue", "td", "tr", "table", "ix:continuation", "ix:continuation", "body", "html", "reportCount": 1, "baseRef": "ea0218371-10q-cormedix.htm", "unique": true }, "R34": { "role": "http://www.cormedix.com/role/ScheduleofBlackScholesOptionPricingModelTable", "longName": "996018 - Disclosure - Stockholders'2019 Equity (Details) - Schedule of Black-Scholes Option Pricing Model", "shortName": "Stockholders'2019 Equity (Details) - Schedule of Black-Scholes Option Pricing Model", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "body", "html", "reportCount": 1, "baseRef": "ea0218371-10q-cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "body", "html", "reportCount": 1, "baseRef": "ea0218371-10q-cormedix.htm", "first": true, "unique": true }, "R35": { "role": "http://www.cormedix.com/role/LeasesDetails", "longName": "996019 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c181", "name": "us-gaap:PaymentsForLeasingCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html", "reportCount": 1, "baseRef": "ea0218371-10q-cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c181", "name": "us-gaap:PaymentsForLeasingCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html", "reportCount": 1, "baseRef": "ea0218371-10q-cormedix.htm", "first": true, "unique": true }, "R36": { "role": "http://www.cormedix.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable", "longName": "996020 - Disclosure - Leases (Details) - Schedule of Maturities of Lease Liabilities", "shortName": "Leases (Details) - Schedule of Maturities of Lease Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOffiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html", "reportCount": 1, "baseRef": "ea0218371-10q-cormedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOffiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html", "reportCount": 1, "baseRef": "ea0218371-10q-cormedix.htm", "first": true, "unique": true }, "tag": { "us-gaap:AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies and Liquidity and Uncertainties [Abstract]" } }, "auth\_ref": { "r44", "r47", "r51", "r785" } }, "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": { "http://www.cormedix.com/role/AccruedExpenses": { "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth\_ref": { "r44", "r47", "r51", "r785" } }, "us-gaap:AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth\_ref": { "r44", "r552" } }, "us-gaap:AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": { "http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable [Member]", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth\_ref": { "r517" } }, "us-gaap:AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap:AssetsCurrent", "weight": 1.0, "order": 4.0 }, "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Trade receivables, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth\_ref": { "r735" } }, "crmd:AccruedGrossonnetDeduction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cormedix.com/role/20240930", "localname": "AccruedGrossonnetDeduction", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ScheduleofAccruedExpensesTable": { "parentTag": "us-gaap:AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 }, "presentation": { "http://www.cormedix.com/role/ScheduleofAccruedExpensesTable": { "lang": { "en-us": { "role": { "negatedLabel": "Accrued gross-to-net deductions", "documentation": "Accrued gross-to-net deductions.", "label": "Accrued Grossonnet Deduction" } } }, "auth\_ref": { "us-gaap:AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.cormedix.com/role/ScheduleofAccruedExpensesTable": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "http://www.cormedix.com/role/ScheduleofAccruedExpensesTable": { "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth\_ref": { "r47" } }, "us-gaap:AccruedPayrollTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedPayrollTaxesCurrent", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ScheduleofAccruedExpensesTable": { "parentTag": "us-gaap:AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.cormedix.com/role/ScheduleofAccruedExpensesTable": { "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll and payroll taxes", "label": "Accrued Payroll Taxes, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth\_ref": { "r47" } }, "us-gaap:AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ScheduleofAccruedExpensesTable": { "parentTag": "us-gaap:AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "presentation": { "http://www.cormedix.com/role/ScheduleofAccruedExpensesTable": { "lang": { "en-us": { "role": { "terseLabel": "Professional and consulting fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth\_ref": { "r47" } }, "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive gain", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth\_ref": { "r14", "r15", "r64", "r123", "r404", "r427", "r428" } }, "us-gaap:AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://www.cormedix.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth\_ref": { "r1", "r3", "r15", "r331", "r334", "r382", "r423", "r424", "r713", "r714", "r715", "r723", "r724", "r725", "r727" } }, "ecd:Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth\_ref": { "r628" } }, "crmd:AdditionalAmountOfAchievementOfMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "AdditionalAmountOfAchievementOfMilestones", "crdr": "credit", "presentation": { "http://www.cormedix.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Additional amount of achievement milestone", "documentation": "Represents the value of additional amount of achievement of milestones." } } }, "auth\_ref": { "us-gaap:AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 4.0 }, "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth\_ref": { "r56", "r552", "r845" } }, "us-gaap:AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://www.cormedix.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "terseLabel": "Additional Paid in Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth\_ref": { "r438", "r723", "r724", "r725", "r727", "r791", "r846" } }, "dei:AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462b", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "auth\_ref": { "r684" } }, "dei:AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462bFileNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Additional Securities,

462(b)), "File Number" } } }, "auth\_ref": { "r684" } } }, "dei\_AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecuritiesEffective413b", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } } }, "auth\_ref": { "r682" } } }, "dei\_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Address Type [Domain]" } } }, "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth\_ref": { "r682" } } }, "eecd\_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } } }, "auth\_ref": { "r641" } } }, "eecd\_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "terseLabel": "Adjustment to Compensation." } } }, "auth\_ref": { "r641" } } }, "eecd\_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } } }, "auth\_ref": { "r641" } } }, "eecd\_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Adjustment to PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment to PEO Compensation, Footnote" } } } }, "auth\_ref": { "r641" } } }, "us-gaap\_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": { "http://www.cormedix.com/role/ShareholdersEquityType2or3" }, "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } } }, "auth\_ref": { "r641" } } }, "us-gaap\_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } } }, "auth\_ref": { "r675" } } }, "eecd\_AggtChngPnsnValInSummryCompstnTblForApblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForApblYrMember", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } } }, "auth\_ref": { "r675" } } }, "eecd\_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/eecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } } }, "auth\_ref": { "r591", "r602", "r618", "r653" } } }, "eecd\_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/eecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } } }, "auth\_ref": { "r594", "r605", "r621", "r656" } } }, "eecd\_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } } }, "auth\_ref": { "r676" } } }, "eecd\_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } } }, "auth\_ref": { "r641" } } }, "eecd\_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/eecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } } }, "auth\_ref": { "r648" } } }, "eecd\_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/eecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } } }, "auth\_ref": { "r595", "r606", "r622", "r648", "r657", "r661", "r669" } } }, "eecd\_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/eecd/2024", "localname": "AllTradingArrangementsMember", "presentation": { "http://xbrl.sec.gov/eecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } } }, "auth\_ref": { "r667" } } }, "us-gaap\_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": { "http://www.cormedix.com/role/StockholdersEquityType2or3" }, "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation (in Dollars)", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } } }, "auth\_ref": { "r301", "r307" } } }, "dei\_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } } }, "auth\_ref": { "r682" } } }, "dei\_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } } }, "auth\_ref": { "r682" } } }, "us-gaap\_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap\_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } } }, "presentation": { "http://www.cormedix.com/role/CommitmentsandContingenciesDetails": { "http://www.cormedix.com/role/ConsolidatedCashFlow": { "en-us": { "role": { "terseLabel": "Amortization of intangible", "verboseLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } } }, "auth\_ref": { "r5", "r214", "r215", "r537" } } }, "crmd\_AmountOfInitialLicensingFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "AmountOfInitialLicensingFee", "crdr": "credit", "presentation": { "http://www.cormedix.com/role/CommitmentsandContingenciesDetails": { "en-us": { "role": { "terseLabel": "Amount of initial licensing fee", "documentation": "Amount of initial licensing fee.", "label": "Amount Of Initial Licensing Fee" } } } }, "auth\_ref": { "r5" } } }, "dei\_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } } }, "auth\_ref": { "r598" } } }, "us-gaap\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://www.cormedix.com/role/ScheduleofAntidilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareTable": { "en-us": { "role": { "terseLabel": "Total potentially dilutive shares", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } } }, "auth\_ref": { "r176" } } }, "us-gaap\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://www.cormedix.com/role/ScheduleofAntidilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareTable": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } } }, "auth\_ref": { "r22" } } }, "us-gaap\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": { "http://www.cormedix.com/role/ScheduleofAntidilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareTable": { "en-us": { "role": { "label": "Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth\_ref": { "r22" } } }, "us-gaap\_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": { "http://www.cormedix.com/role/ScheduleofAntidilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareTable": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } } }, "auth\_ref": { "r22" } } }, "dei\_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } } }, "auth\_ref": { "r22" } } }, "us-gaap\_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } } }, "auth\_ref": { "r98", "r98", "r119", "r152", "r179", "r183", "r190", "r191", "r204", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r326", "r328", "r356", "r398", "r472", "r533", "r534", "r552", "r570", "r750", "r751", "r811" } } }, "us-gaap\_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } } }, "auth\_ref": { "r22" } } }, "us-gaap\_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 1.0 } } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } } }, "auth\_ref": { "r115", "r127", "r152", "r204", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r326", "r328", "r356", "r552", "r751", "r811" } } }, "us-gaap\_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": {

"http://www.cormedix.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth\_ref": { "dei": "dei-AuditedAnnualFinancialStatements", "xbrltype": { "booleanItemType": "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "auth\_ref": { "r598" } } }, "dei-AuditorFirmId": { "xbrltype": { "nonemptySequenceNumberItemType": "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": { "http://xbrl.sec.gov/dei/role/document/AuditInformation", "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth\_ref": { "r583", "r586", "r598" } } }, "dei-AuditorLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLineItems", "lang": { "en-us": { "role": { "label": "Auditor [Line Items]" } } }, "auth\_ref": { "dei-AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": { "http://xbrl.sec.gov/dei/role/document/AuditInformation", "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth\_ref": { "r583", "r586", "r598" } } }, "dei-AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": { "http://xbrl.sec.gov/dei/role/document/AuditInformation", "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth\_ref": { "r583", "r586", "r598" } } }, "dei-AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorOpinionTextBlock", "presentation": { "http://xbrl.sec.gov/dei/role/document/AuditInformation", "lang": { "en-us": { "role": { "label": "Auditor Opinion [Text Block]" } } }, "auth\_ref": { "r680" } } }, "dei-AuditorTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorTable", "presentation": { "http://xbrl.sec.gov/dei/role/document/AuditInformation", "lang": { "en-us": { "role": { "label": "Auditor [Table]" } } }, "auth\_ref": { "us-gaap-AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": { "http://www.cormedix.com/role/ScheduleofAmortizedCostUnrealizedGainsandLossesandtheFairValueTable", "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth\_ref": { "r198" } } }, "us-gaap-AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": { "http://www.cormedix.com/role/ScheduleofAmortizedCostUnrealizedGainsandLossesandtheFairValueTable", "lang": { "en-us": { "role": { "negatedLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth\_ref": { "r199" } } }, "us-gaap-AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": { "http://www.cormedix.com/role/ScheduleofAmortizedCostUnrealizedGainsandLossesandtheFairValueTable", "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available for Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth\_ref": { "r196", "r207", "r397" } } }, "us-gaap-AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": { "http://www.cormedix.com/role/ScheduleofAmortizedCostUnrealizedGainsandLossesandtheFairValueTable", "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "verboseLabel": "Carrying Value", "label": "Debt Securities, Available for Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth\_ref": { "r197", "r207", "r341", "r391", "r548", "r550", "r739", "r794", "r795", "r796" } } }, "ecd-AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth\_ref": { "r664" } } }, "ecd-AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth\_ref": { "r665" } } }, "ecd-AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth\_ref": { "r660" } } }, "ecd-AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth\_ref": { "r660" } } }, "ecd-AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth\_ref": { "r660" } } }, "ecd-AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth\_ref": { "r660" } } }, "ecd-AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth\_ref": { "r660" } } }, "ecd-AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth\_ref": { "r660" } } }, "us-gaap-AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth\_ref": { "r272", "r273", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r296", "r297", "r298", "r299", "r300" } } }, "ecd-AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth\_ref": { "r663" } } }, "ecd-AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth\_ref": { "r662" } } }, "ecd-AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth\_ref": { "r661" } } }, "ecd-AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth\_ref": { "r661" } } }, "crmd-BalanceOfCashPaymentsDueUponAchievementOfMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "BalanceOfCashPaymentsDueUponAchievementOfMilestones", "crdr": "credit", "presentation": { "http://www.cormedix.com/role/CommitmentsandContingenciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Balance of cash payments", "documentation": "Balance of cash payments due upon achievement of milestones.", "label": "Balance Of Cash Payments Due Upon Achievement Of Milestones" } } }, "auth\_ref": { "srt-BoardOfDirectorsChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "BoardOfDirectorsChairmanMember", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Board of Directors [Member]", "label": "Board of Directors Chairman [Member]" } } }, "auth\_ref": { "r734" } } }, "dei-BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "BusinessContactMember", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth\_ref": { "r586", "r598" } } }, "us-gaap-CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Abstract]" } } }, "auth\_ref": { "us-gaap-CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet", "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.cormedix.com/role/ScheduleofconsolidatedstatementofcashflowsTable", "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet", "http://www.cormedix.com/role/ScheduleofconsolidatedstatementofcashflowsTable", "lang": { "en-us": { "role": { "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH - BEGINNING OF PERIOD", "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH - END OF PERIOD", "totalLabel": "Total cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth\_ref": { "r18", "r118", "r522" } } }, "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ScheduleofconsolidatedstatementofcashflowsTable", "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow", "http://www.cormedix.com/role/ScheduleofconsolidatedstatementofcashflowsTable", "lang": { "en-us": { "role": { "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH - BEGINNING OF PERIOD", "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH - END OF PERIOD", "totalLabel": "Total cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth\_ref": { "r18", "r73", "r148" } } }, "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedCashFlow", "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "totalLabel": "NET (DECREASE) INCREASE IN CASH AND CASH

EQUIVALENTS", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth\_ref": { "r0", "r73" } } }, "us-gaap\_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "label": "Supplemental Disclosure of Non-Cash Investing Activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth\_ref": { "r161" } } }, "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingEstimateLineItems", "presentation": { "http://www.cormedix.com/role/SummaryOfSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies and Liquidity and Uncertainties [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth\_ref": { "r161" } } }, "ecd\_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth\_ref": { "r639" } } }, "srt\_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "verboseLabel": "Executive Officers [Member]", "label": "Chief Executive Officer [Member]" } } }, "auth\_ref": { "r734" } } }, "ecd\_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth\_ref": { "r636" } } }, "ecd\_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth\_ref": { "r634" } } }, "dei\_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth\_ref": { "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588

"CommonStockSharesIssued", "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet\_Parentheticals",  
"http://www.cormedix.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "verboseLabel": "Shares of common stock issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth\_ref": { "r55" } }, "us-gaap-CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet\_Parentheticals" }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth\_ref": { "r9", "r55", "r460", "r478", "r846", "r847" } }, "us-gaap-CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap\_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "terseLabel": "Common stock - \$0.001 par value: 160,000,000 shares authorized: 57,887,149 and 54,938,258 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth\_ref": { "r55", "r403", "r552" } }, "ecd-CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth\_ref": { "r645" } }, "ecd-CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth\_ref": { "r644" } }, "ecd-CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth\_ref": { "r646" } }, "ecd-CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth\_ref": { "r643" } }, "us-gaap-ComprehensiveIncomeNetOffTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOffTax", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "totalLabel": "Comprehensive Loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth\_ref": { "r16", "r132", "r134", "r140", "r393", "r412", "r413" } }, "us-gaap-ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": { "http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails" }, "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth\_ref": { "r24", "r25", "r40", "r41", "r194", "r517" } }, "us-gaap-ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": { "http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails" }, "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth\_ref": { "r24", "r25", "r40", "r41", "r194", "r517", "r699" } }, "us-gaap-ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": { "http://www.cormedix.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel": "Concentrations", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth\_ref": { "r42", "r107" } }, "us-gaap-ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": { "http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Major customers percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \\benchmark\\ (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth\_ref": { "r24", "r25", "r40", "r41", "r194" } }, "us-gaap-ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": { "http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails" }, "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth\_ref": { "r24", "r25", "r40", "r41", "r194", "r517" } }, "us-gaap-ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": { "http://www.cormedix.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel": "Basis of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth\_ref": { "r34", "r528" } }, "us-gaap-ConsolidationVariableInterestEntityPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationVariableInterestEntityPolicy", "presentation": { "http://www.cormedix.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel": "Variable Consideration", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."} } } }, "auth\_ref": { "r33", "r35", "r36" } }, "crmd-ConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "ConsultantsMember", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Consultants [Member]", "label": "Consultants Member" } } }, "auth\_ref": { } }, "dei-ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelEmailAddress", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth\_ref": { } }, "dei-ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelFaxNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth\_ref": { "r586" } }, "dei-ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelName", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth\_ref": { } }, "dei-ContainedFileInformationFileDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileDescription", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Contained File Information, File Description", "documentation": "The description of the contained file." } } }, "auth\_ref": { } }, "dei-ContainedFileInformationFileName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileName", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Contained File Information, File Name", "documentation": "The name of the contained file." } } }, "auth\_ref": { } }, "dei-ContainedFileInformationFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Contained File Information, File Number", "documentation": "The SEC Document Number of the contained file." } } }, "auth\_ref": { } }, "dei-ContainedFileInformationFileType": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileType", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Contained File Information, File Type", "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."} } } }, "auth\_ref": { } }, "crmd-CorMedixIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "CorMedixIncMember", "presentation": { "http://www.cormedix.com/role/OrganizationBusinessandBasisofPresentationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "CorMedix Inc. [Member]", "label": "Cor Medix Inc Member" } } }, "auth\_ref": { } }, "us-gaap-CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap\_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "negatedLabel": "Cost of sales", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth\_ref": { "r67", "r152", "r204", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r356", "r533", "r750" } }, "dei-CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth\_ref": { } }, "dei-CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth\_ref": { } }, "dei-CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD--"} } }, "auth\_ref": { } }, "us-gaap-CustomerConcentrationRiskMember": { "xbrltype":

"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": {  
"http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails", "lang": { "en-us": { "role": { "terseLabel":  
"Customer Concentration Risk [Member]", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the  
period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The  
risk is the materially adverse effects of loss of a significant customer." } } }, "auth\_ref": { "r77", "r194" } },  
"ermd\_DebtSecuritiesExcludingMoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname":  
"DebtSecuritiesExcludingMoneyMarketFundsMember", "presentation": {  
"http://www.cormedix.com/role/ScheduleofAmortizedCostUnrealizedGainsandLossesandtheFairValueTable",  
"http://www.cormedix.com/role/ScheduleofCarryingandFairValueofFinancialAssetsTable", "lang": { "en-us": { "role": { "terseLabel": "Subtotal [Member]", "label":  
"Debt Securities Excluding Money Market Funds Member" } } }, "auth\_ref": { } }, "us-gaap\_DeferredCompensationShareBasedPaymentsMember": { "xbrltype":  
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationShareBasedPaymentsMember", "presentation": {  
"http://www.cormedix.com/role/ScheduleofAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareTable", "lang": { "en-us": { "role": {  
"terseLabel": "Shares issuable for payment of deferred board compensation [Member]", "label": "Deferred Compensation, Share-Based Payments [Member]",  
"documentation": "Deferred compensation arrangements (such as stock or unit options and share or unit awards) that are equity-based payments with individual  
employees. The arrangements are generally based on employment contracts between the entity and one or more selected officers or key employees, and contain a  
promise by the employer to pay certain amounts or benefits at designated future dates, upon compliance with stipulated requirements. This type of arrangement is  
distinguished from broader based employee benefit plans as it is usually tailored to the employee. Other \"sub-members\" can be added as necessary." } } },  
"auth\_ref": { } }, "dei\_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":  
"DelayedOrContinuousOffering", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Delayed or Continuous  
Offering" } } }, "auth\_ref": { "r610", "r611", "r625" } }, "us-gaap\_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",  
"localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedCashFlow", "parentTag": "us-  
gaap\_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow",  
"lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that  
reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth\_ref": {  
"r5", "r29" } }, "us-gaap\_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":  
"DerivativeContractTypeDomain", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Derivative  
Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the  
contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth\_ref": { "r450", "r451", "r465", "r466", "r467", "r468", "r469", "r470",  
"r471", "r473", "r474", "r475", "r476", "r486", "r487", "r488", "r489", "r492", "r493", "r494", "r495", "r505", "r506", "r507", "r510", "r560", "r562", "r797", "r798",  
"r799", "r800", "r801", "r802", "r803", "r804" } }, "us-gaap\_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",  
"localname": "DerivativeInstrumentRiskAxis", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label":  
"Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth\_ref": { "r37", "r38", "r39", "r86", "r450", "r451", "r465",  
"r466", "r467", "r468", "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r486", "r487", "r488", "r489", "r492", "r493", "r494", "r495", "r505", "r506", "r507",  
"r510", "r527", "r560", "r562", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804" } }, "us-gaap\_DerivativeUnderlyingInvestmentShares": { "xbrltype":  
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeUnderlyingInvestmentShares", "presentation": {  
"http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Shares  
underlying outstanding (in Shares)", "label": "Derivative, Underlying Investment, Shares", "documentation": "Number of shares of underlying investment in  
derivative." } } }, "auth\_ref": { "r505", "r508", "r509" } }, "srt\_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":  
"DirectorMember", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Director [Member]",  
"label": "Director [Member]" } } }, "auth\_ref": { "r734", "r844" } }, "dei\_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri":  
"http://xbrl.sec.gov/dei/2024", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": {  
"en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth\_ref": { "r610", "r611", "r625" } }, "dei\_DocumentAccountingStandard": {  
"xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting  
the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or  
'Other.' } } }, "auth\_ref": { "r586" } }, "dei\_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":  
"DocumentAnnualReport", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Annual Report",  
"documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth\_ref": { "r583", "r586", "r598" } },  
"dei\_DocumentCopyrightInformation": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCopyrightInformation",  
"presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Copyright Information", "documentation": "The  
copyright information for the document." } } }, "auth\_ref": { } }, "dei\_DocumentCreationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",  
"localname": "DocumentCreationDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Creation  
Date", "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the  
recipient, and the document effective date are all potentially different." } } }, "auth\_ref": { } }, "dei\_DocumentDescription": { "xbrltype": "stringItemType", "nsuri":  
"http://xbrl.sec.gov/dei/2024", "localname": "DocumentDescription", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": {  
"label": "Document Description", "documentation": "The description of the document." } } }, "auth\_ref": { } }, "dei\_DocumentDomain": { "xbrltype":  
"domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDomain", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang":  
{ "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming  
convention standards." } } }, "auth\_ref": { } }, "dei\_DocumentEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":  
"DocumentEffectiveDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Effective Date",  
"documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned  
date time value, but it may be declared by the submitter in some cases." } } }, "auth\_ref": { } }, "dei\_DocumentFinStmntErrorCorrectionFlag": { "xbrltype":  
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmntErrorCorrectionFlag", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation":  
"Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth\_ref": { "r583", "r586", "r598",  
"r649" } }, "dei\_DocumentFinStmntRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":  
"DocumentFinStmntRestatementRecoveryAnalysisFlag", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label":  
"Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include  
restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery  
period pursuant to u00a7240.10D-1(b)."} } }, "auth\_ref": { "r583", "r586", "r598", "r649" } }, "dei\_DocumentFiscalPeriodFocus": { "xbrltype":  
"fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY,  
Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having  
FY." } } }, "auth\_ref": { } }, "dei\_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":  
"DocumentFiscalYearFocus", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus",  
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from  
prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth\_ref": { } }, "dei\_DocumentInformationDocumentAxis": { "xbrltype":  
"stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationDocumentAxis", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a  
table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth\_ref": { } },  
"dei\_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems",  
"presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line  
items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one  
or many axes to the table." } } }, "auth\_ref": { } }, "dei\_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",  
"localname": "DocumentInformationTable", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document  
Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a  
submission package." } } }, "auth\_ref": { } }, "dei\_DocumentInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",  
"localname": "DocumentInformationTextBlock", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document  
Information [Text Block]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a  
submission package." } } }, "auth\_ref": { } }, "dei\_DocumentName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":  
"DocumentName", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Name", "documentation":  
"Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the <FILENAME> field of  
EDGAR filings, such as <htm\_25911.htm>, <exhibit1.htm>, <v405727-8k.txt>." } } }, "auth\_ref": { } }, "dei\_DocumentPeriodEndDate": { "xbrltype": "dateItemType",  
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": {  
"role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event  
reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of  
the date is YYYY-MM-DD." } } }, "auth\_ref": { } }, "dei\_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":  
"DocumentPeriodStartDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Period Start Date",  
"documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth\_ref": { } }, "dei\_DocumentQuarterlyReport": {  
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only  
for a form used as an quarterly report." } } }, "auth\_ref": { "r584" } }, "dei\_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri":  
"http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": {  
"role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth\_ref":  
{ "r572" } }, "dei\_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":  
"DocumentShellCompanyEventDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Shell  
Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth\_ref": { "r586" } }, "dei\_DocumentShellCompanyReport": {

"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } },  
"auth\_ref": {  
"r586" } },  
"dei\_DocumentSubtitle": {  
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSubtitle", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Document Subtitle", "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth.'" } } },  
"auth\_ref": {  
"dei\_DocumentSynopsis": {  
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSynopsis", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Document Synopsis", "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period.'" } } },  
"auth\_ref": {  
"dei\_DocumentTitle": {  
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTitle", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Document Title", "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report.'" } } },  
"auth\_ref": {  
"dei\_DocumentTransitionReport": {  
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } },  
"auth\_ref": {  
"r626" } },  
"dei\_DocumentType": {  
"xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.'" } } },  
"auth\_ref": {  
"dei\_DocumentVersion": {  
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentVersion", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Document Version", "documentation": "The version identifier of the document." } } },  
"auth\_ref": {  
"dei\_DocumentsIncorporatedByReferenceTextBlock": {  
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } },  
"auth\_ref": {  
"r575" } },  
"ecdd\_VdddsOrOthrErngsPdOnEqtyAwrdNsNtOthrwsRfctdInTtlCompForCvrdYrMember": {  
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecdd/2024", "localname": "DvdddsOrOthrErngsPdOnEqtyAwrdNsNtOthrwsRfctdInTtlCompForCvrdYrMember", "presentation": {  
"http://xbrl.sec.gov/ecdd/role/PvpDisclosure": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } },  
"auth\_ref": {  
"r638" } },  
"us\_gaap\_EarningsPerShareBasic": {  
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": {  
"http://www.cormedix.com/role/ConsolidatedIncomeStatement": {  
"lang": {  
"en-us": {  
"role": {  
"terseLabel": "Net Loss Per Common Share u2013 Basic (in Dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } },  
"auth\_ref": {  
"r141", "r158", "r159", "r160", "r161", "r162", "r163", "r168", "r170", "r173", "r174", "r175", "r321", "r324", "r338", "r339", "r394", "r414", "r415", "r530" } },  
"us\_gaap\_EarningsPerShareDiluted": {  
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": {  
"http://www.cormedix.com/role/ConsolidatedIncomeStatement": {  
"lang": {  
"en-us": {  
"role": {  
"terseLabel": "Net Loss Per Common Share u2013 Diluted (in Dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } },  
"auth\_ref": {  
"r141", "r158", "r159", "r160", "r161", "r162", "r163", "r170", "r173", "r174", "r175", "r321", "r324", "r338", "r339", "r394", "r414", "r530" } },  
"us\_gaap\_EarningsPerSharePolicyTextBlock": {  
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": {  
"http://www.cormedix.com/role/AccountingPoliciesByPolicy": {  
"lang": {  
"en-us": {  
"role": {  
"terseLabel": "Loss Per Common Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } },  
"auth\_ref": {  
"r22", "r23", "r177" } },  
"us\_gaap\_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {  
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": {  
"http://www.cormedix.com/role/ConsolidatedCashFlow": {  
"parentTag": "us\_gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } },  
"presentation": {  
"http://www.cormedix.com/role/ConsolidatedCashFlow": {  
"lang": {  
"en-us": {  
"role": {  
"terseLabel": "Foreign exchange effect on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } },  
"auth\_ref": {  
"r361" } },  
"dei\_EffectiveAfter60Days486a": {  
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveAfter60Days486a", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Effective after 60 Days, 486(a)", "auth\_ref": {  
"r688" } },  
"dei\_EffectiveOnDate486a": {  
"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486a", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Effective on Date, 486(a)", "auth\_ref": {  
"r688" } },  
"dei\_EffectiveOnDate486b": {  
"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486b", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Effective on Date, 486(b)", "auth\_ref": {  
"r689" } },  
"dei\_EffectiveOnSetDate486a": {  
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486a", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Effective on Set Date, 486(a)", "auth\_ref": {  
"r688" } },  
"dei\_EffectiveOnSetDate486b": {  
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486b", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Effective on Set Date, 486(b)", "auth\_ref": {  
"r689" } },  
"dei\_EffectiveUponFiling462e": {  
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling462e", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Effective Upon Filing, 462(e)", "auth\_ref": {  
"r687" } },  
"dei\_EffectiveUponFiling486b": {  
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling486b", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Effective upon Filing, 486(b)", "auth\_ref": {  
"r689" } },  
"dei\_EffectiveWhenDeclaredSection8c": {  
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveWhenDeclaredSection8c", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Effective when Declared, Section 8(c)", "auth\_ref": {  
"r691" } },  
"us\_gaap\_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {  
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": {  
"http://www.cormedix.com/role/StockholdersEquityDetails": {  
"lang": {  
"en-us": {  
"role": {  
"terseLabel": "Unrecognized compensation expense (in Dollars)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } },  
"auth\_ref": {  
"r302" } },  
"us\_gaap\_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {  
"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": {  
"http://www.cormedix.com/role/StockholdersEquityDetails": {  
"lang": {  
"en-us": {  
"role": {  
"terseLabel": "Period of unrecognized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } },  
"auth\_ref": {  
"r302" } },  
"us\_gaap\_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {  
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": {  
"http://www.cormedix.com/role/StockholdersEquityDetails": {  
"lang": {  
"en-us": {  
"role": {  
"terseLabel": "Unrecognized compensation expense (in Dollars)", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } },  
"auth\_ref": {  
"r783" } },  
"us\_gaap\_EmployeeStockOptionMember": {  
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": {  
"http://www.cormedix.com/role/StockholdersEquityDetails": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } },  
"auth\_ref": {  
"crmd\_EmployeesAndDirectorsMember": {  
"xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "EmployeesAndDirectorsMember", "presentation": {  
"http://www.cormedix.com/role/StockholdersEquityDetails": {  
"lang": {  
"en-us": {  
"role": {  
"terseLabel": "Employees [Member]", "label": "Employees And Directors Member" } } },  
"auth\_ref": {  
"http://xbrl.sec.gov/dei/2024", "localname": "EntitiesTable", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } },  
"auth\_ref": {  
"dei\_EntityAccountingStandard": {  
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAccountingStandard", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Entity Accounting Standard", "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element." } } },  
"auth\_ref": {  
"stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressDescription", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Entity Address, Address Description", "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses." } } },  
"auth\_ref": {  
"dei\_EntityAddressAddressLine1": {  
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": {  
"http://xbrl.sec.gov/dei/role/document/Cover": {  
"lang": {  
"en-us": {  
"role": {  
"label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } },  
"auth\_ref": {  
"dei\_EntityAddressAddressLine2": {  
"xbrltype": "normalizedStringItemType", "nsuri":

"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth\_ref": { } }, "dei\_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth\_ref": { } }, "dei\_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth\_ref": { } }, "dei\_EntityAddressCountry": { "xbrltype": "countryCodeItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code" } } }, "auth\_ref": { } }, "dei\_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth\_ref": { } }, "dei\_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth\_ref": { } }, "dei\_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth\_ref": { } }, "dei\_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesLineItems", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth\_ref": { } }, "dei\_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesTable", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth\_ref": { "r574" } }, "dei\_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth\_ref": { "r578" } }, "dei\_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth\_ref": { "r574" } }, "dei\_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth\_ref": { } }, "dei\_EntityContactPersonnelLineItems": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityContactPersonnelLineItems", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Contact Personnel [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth\_ref": { } }, "dei\_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth\_ref": { } }, "dei\_EntityDomain": { "xbrltype": "domainItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": { "http://xbrl.sec.gov/dei/role/document/AuditInformation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth\_ref": { } }, "dei\_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth\_ref": { "r574" } }, "dei\_EntityExTransitionPeriod": { "xbrltype": "booleanItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth\_ref": { "r690" } }, "dei\_EntityFileNumber": { "xbrltype": "fileNumberItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth\_ref": { } }, "dei\_EntityFilerCategory": { "xbrltype": "filerCategoryItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth\_ref": { "r574" } }, "dei\_EntityHomeCountryISOCode": { "xbrltype": "countryCodeItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityHomeCountryISOCode", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Home Country ISO Code", "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element." } } }, "auth\_ref": { } }, "dei\_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationDateOfIncorporation", "presentation": { "http://www.cormedix.com/role/OrganizationBusinessandBasisofPresentationDetails": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Incorporation date", "documentation": "Date when an entity was incorporated" } } }, "auth\_ref": { } }, "dei\_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth\_ref": { } }, "dei\_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth\_ref": { } }, "dei\_EntityInformationLineItems": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationLineItems", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth\_ref": { } }, "dei\_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth\_ref": { "r679" } }, "dei\_EntityInvCompanyType": { "xbrltype": "invCompanyItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInvCompanyType", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth\_ref": { "r678" } }, "dei\_EntityLegalForm": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityLegalForm", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Legal Form", "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc." } } }, "auth\_ref": { } }, "dei\_EntityListingDepositoryReceiptRatio": { "xbrltype": "pureItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDepositoryReceiptRatio", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Listing, Depository Receipt Ratio", "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'." } } }, "auth\_ref": { } }, "dei\_EntityListingDescription": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDescription", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Listing, Description", "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } }, "auth\_ref": { } }, "dei\_EntityListingForeign": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingForeign", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Listing, Foreign", "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } } }, "auth\_ref": { } }, "dei\_EntityListingParValuePerShare": { "xbrltype": "perShareItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth\_ref": { } }, "dei\_EntityListingPrimary": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingPrimary", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Listing, Primary", "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity." } } }, "auth\_ref": { } }, "dei\_EntityListingSecurityTradingCurrency": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingSecurityTradingCurrency", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover": { "lang": { "en-us": { "role": { "label": "Entity Listing, Security Trading Currency", "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'." } } }, "auth\_ref": { } } }

```

"ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." }, { "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." }, { "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity." }, { "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Entity Number of Employees", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." }, { "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." }, { "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." }, { "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Entity Reporting Currency ISO Code", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: USD." }, { "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Entity Shell Company", "documentation": "A Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." }, { "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." }, { "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Entity Text Block", "documentation": "Container to serve as parent of six Entity related Table concepts." }, { "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." }, { "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Entity Well Known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-KA, 10-QA, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." }, { "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Equity Awards Adj Fn Text Block", "documentation": "Equity Awards Adjustments, Footnote [Text Block]", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Equity Awards Adj Exclg Val Rptd In Summry Compstn Tbl Member", "documentation": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Equity Awards Adj Exclg Val Rptd In Summry Compstn Tbl Member", "documentation": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Equity Abstract", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." }, { "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Equity Valuation Assumption Difference Fn Text Block", "documentation": "Equity Valuation Assumption Difference, Footnote [Text Block]", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "documentation": "Equity Valuation Assumption Difference, Footnote [Text Block]", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "ErrCompAnalysisTextBlock", "documentation": "Erroneous Compensation Analysis [Text Block]", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Erroneous Compensation Analysis [Text Block]", "documentation": "Erroneous Compensation Analysis [Text Block]", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Exchange Domain", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." }, { "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Executive Category Axis", "documentation": "Executive Category Axis", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Exhibits Only, 462(d)", "documentation": "Exhibits Only, 462(d) [File Number]", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Exhibits Only, 462(d) [File Number]", "documentation": "Exhibits Only, 462(d) [File Number]", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Extension", "documentation": "Extension number for local phone number." }, { "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Text Block", "documentation": "Fair Value Assets Measured On Recurring Basis Text Block", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Text Block", "documentation": "Fair Value Assets Measured On Recurring Basis Text Block", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "auth_ref": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": "en-us", "role": "label", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items", "documentation": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation Line Items",
```

"documentation": "Information by measurement frequency." } } }, "auth\_ref": { "r341", "r342", "r343", "r345", "r548", "r795", "r805" } }, "us-gaap\_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": { "http://www.cormedix.com/role/ScheduleofCarryingandFairValueoffFinancialAssetsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth\_ref": { "r233", "r261", "r266", "r342", "r353", "r386", "r544", "r545", "r546", "r548" } }, "us-gaap\_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": { "http://www.cormedix.com/role/ScheduleofCarryingandFairValueoffFinancialAssetsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Level 2 [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth\_ref": { "r233", "r261", "r266", "r342", "r343", "r353", "r387", "r539", "r540", "r544", "r545", "r546", "r548" } }, "us-gaap\_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": { "http://www.cormedix.com/role/ScheduleofCarryingandFairValueoffFinancialAssetsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth\_ref": { "r233", "r261", "r262", "r263", "r264", "r265", "r266", "r342", "r343", "r344", "r345", "r353", "r388", "r539", "r540", "r544", "r545", "r546", "r548", "r550" } }, "us-gaap\_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": { "http://www.cormedix.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth\_ref": { } }, "us-gaap\_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": { "http://www.cormedix.com/role/ScheduleofCarryingandFairValueoffFinancialAssetsTable" }, "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth\_ref": { "r233", "r261", "r262", "r263", "r264", "r265", "r266", "r340", "r342", "r343", "r344", "r345", "r352", "r353", "r355", "r386", "r387", "r388", "r539", "r540", "r544", "r545", "r546", "r548", "r550" } }, "us-gaap\_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": { "http://www.cormedix.com/role/ScheduleofCarryingandFairValueoffFinancialAssetsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring [Member]", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth\_ref": { "r548", "r792", "r793", "r794", "r795", "r796", "r805" } }, "us-gaap\_FairValueOffFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOffFinancialInstrumentsPolicy", "presentation": { "http://www.cormedix.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth\_ref": { "r7" } }, "us-gaap\_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": { "http://www.cormedix.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Estimated economic life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth\_ref": { } }, "us-gaap\_FiniteLivedLicenseAgreementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedLicenseAgreementsGross", "crdr": "debit", "presentation": { "http://www.cormedix.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "License agreement intangible", "label": "Finite-Lived License Agreements, Gross", "documentation": "Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life." } } }, "auth\_ref": { "r703", "r742" } }, "crmd\_FirstAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "FirstAnniversaryMember", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "First Anniversary [Member]", "label": "First Anniversary Member" } } }, "auth\_ref": { } }, "crmd\_FoodAndDrugAdministrationFilingFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "FoodAndDrugAdministrationFilingFee", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ScheduleofOtherPrepaidExpensesandCurrentAssetsTable" }, "parentTag": "us-gaap\_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.cormedix.com/role/ScheduleofOtherPrepaidExpensesandCurrentAssetsTable" }, "lang": { "en-us": { "role": { "terseLabel": "FDA filing fee", "label": "Food And Drug Administration Filing Fee" } } }, "auth\_ref": { } }, "us-gaap\_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement" }, "parentTag": "us-gaap\_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange transaction loss", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth\_ref": { "r357", "r358", "r359", "r360", "r496" } }, "ecd\_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth\_ref": { "r595", "r606", "r622", "r657" } }, "ecd\_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth\_ref": { "r595", "r606", "r622", "r657" } }, "ecd\_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth\_ref": { "r595", "r606", "r622", "r657" } }, "ecd\_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth\_ref": { "r595", "r606", "r622", "r657" } }, "ecd\_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth\_ref": { "r595", "r606", "r622", "r657" } }, "dei\_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerAddressMember", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth\_ref": { "r585", "r609" } }, "dei\_FormerFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerFiscalYearEndDate", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Former Fiscal Year End Date", "documentation": "Former end date of previous fiscal years" } } }, "auth\_ref": { } }, "ecd\_FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCndsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCndsDrngCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth\_ref": { "r637" } }, "us-gaap\_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement" }, "parentTag": "us-gaap\_OperatingExpenses", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "negatedLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth\_ref": { "r69", "r483" } }, "crmd\_GrossProceedsSaleOfCommonStockPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "GrossProceedsSaleOfCommonStockPercentage", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds percentage", "documentation": "The gross proceeds sale of common stock percentage." } } }, "auth\_ref": { } }, "us-gaap\_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement" }, "parentTag": "us-gaap\_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth\_ref": { "r65", "r67", "r97", "r152", "r204", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r356", "r532", "r533", "r729", "r730", "r731", "r732", "r733", "r750" } }, "us-gaap\_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "IPO [Member]", "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth\_ref": { } }, "dei\_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth\_ref": { "r583", "r586", "r598" } }, "us-gaap\_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement" }, "parentTag": "us-gaap\_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth\_ref": { "r66", "r93", "r97", "r395", "r409", "r532", "r533", "r729", "r730", "r731", "r732", "r733" } }, "us-gaap\_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth\_ref": { } }, "us-gaap\_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement" }, "parentTag": "us-

gaap\_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "negatedLabel": "Tax benefit", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth\_ref": { "r102", "r110", "r165", "r166", "r179", "r188", "r191", "r312", "r313", "r316", "r415", "r547" } }, "us-gaap-IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap\_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "terseLabel": "(Decrease) increase in accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth\_ref": { "r4" } }, "us-gaap-IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap\_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "negatedLabel": "Increase in trade receivables", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth\_ref": { "r4" } }, "us-gaap-IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap\_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "terseLabel": "Increase in accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth\_ref": { "r4" } }, "us-gaap-IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap\_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "negatedLabel": "Increase in inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth\_ref": { "r4" } }, "us-gaap-IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth\_ref": { } }, "us-gaap-IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap\_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "terseLabel": "Decrease in operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth\_ref": { "r700", "r718" } }, "us-gaap-IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap\_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "negatedLabel": "Increase in prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth\_ref": { "r4" } }, "ecd-IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual." } } }, "auth\_ref": { "r595", "r606", "r622", "r648", "r657", "r661", "r669" } }, "us-gaap-InformationByCategoryOfDebtSecurityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InformationByCategoryOfDebtSecurityAxis", "presentation": { "http://www.cormedix.com/role/ScheduleofAmortizedCostUnrealizedGainsandLossesandtheFairValueTable", "http://www.cormedix.com/role/ScheduleofCarryingandFairValueofFinancialAssetsTable", "lang": { "en-us": { "role": { "label": "Debt Security Category [Axis]", "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity." } } }, "auth\_ref": { } }, "crmd-InformationByCategoryOfDebtSecurityDomainDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "InformationByCategoryOfDebtSecurityDomainDomain", "presentation": { "http://www.cormedix.com/role/ScheduleofAmortizedCostUnrealizedGainsandLossesandtheFairValueTable", "http://www.cormedix.com/role/ScheduleofCarryingandFairValueofFinancialAssetsTable", "lang": { "en-us": { "role": { "label": "InformationByCategoryOfDebtSecurityDomain [Domain]" } } }, "auth\_ref": { } }, "ecd-InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements." } } }, "auth\_ref": { "r667" } }, "ecd-InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures." } } }, "auth\_ref": { "r587", "r673" } }, "ecd-InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted." } } }, "auth\_ref": { "r587", "r673" } }, "ecd-InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted." } } }, "auth\_ref": { "r587", "r673" } }, "us-gaap-IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "License intangible asset, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth\_ref": { "r213", "r742", "r743" } }, "us-gaap-InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap-NonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth\_ref": { "r187", "r717" } }, "us-gaap-InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth\_ref": { "r144", "r146", "r147" } }, "crmd-InventoriesExpensedAsResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "InventoriesExpensedAsResearchAndDevelopment", "crdr": "debit", "presentation": { "http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Inventories expensed as research and development", "documentation": "The amount of inventories expensed as research and development." }, "label": "Inventories Expensed As Research And Development" } } }, "auth\_ref": { } }, "us-gaap-InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ScheduleofInventoriesTable": { "parentTag": "us-gaap-InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.cormedix.com/role/ScheduleofInventoriesTable", "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth\_ref": { "r707" } }, "us-gaap-InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.cormedix.com/role/ScheduleofInventoriesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "http://www.cormedix.com/role/ConsolidatedBalanceSheet": "http://www.cormedix.com/role/ScheduleofInventoriesTable", "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth\_ref": { "r125", "r523", "r552" } }, "us-gaap-InventoryNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNetAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Inventories [Abstract]" } } }, "auth\_ref": { } }, "us-gaap-InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": { "http://www.cormedix.com/role/AccountingPoliciesByPolicy", "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth\_ref": { "r104", "r117", "r124", "r208", "r209", "r210", "r389", "r529" } }, "us-gaap-InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ScheduleofInventoriesTable": { "parentTag": "us-gaap-InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cormedix.com/role/ScheduleofInventoriesTable", "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth\_ref": { "r709" } }, "us-gaap-InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ScheduleofInventoriesTable": { "parentTag": "us-gaap-InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cormedix.com/role/ScheduleofInventoriesTable", "lang": { "en-us": { "role": { "terseLabel": "Work in progress", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth\_ref": { "r708" } }, "dei-InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActFileNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth\_ref": { "r611", "r612", "r613", "r614" } }, "dei-InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActRegistration", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Investment Company

Act Registration"} }}, {"auth\_ref": {"r627"}}, {"dei\_InvestmentCompanyRegistrationAmendment": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": {"http://xbrl.sec.gov/dei/role/document/Cover"}, "lang": {"en-us": {"role": {"label": "Investment Company Registration Amendment"} }}, {"auth\_ref": {"r627"}}, {"dei\_InvestmentCompanyRegistrationAmendmentNumber": {"xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": {"http://xbrl.sec.gov/dei/role/document/Cover"}, "lang": {"en-us": {"role": {"label": "Investment Company Registration Amendment Number"} }}, {"auth\_ref": {"r627"}}, {"us\_gaap\_InvestmentIncomeInterest": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": {"http://www.cormedix.com/role/ConsolidatedIncomeStatement": {"parentTag": "us-gaap\_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }}, {"presentation": {"http://www.cormedix.com/role/ConsolidatedIncomeStatement"}, "lang": {"en-us": {"role": {"terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." }}, {"auth\_ref": {"r179", "r186", "r191", "r533", "r716"}}, {"us\_gaap\_LeasesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": {"en-us": {"role": {"label": "Leases [Abstract]"} }}, {"auth\_ref": {}}, {"crmd\_LeerinkPartnersLLCMember": {"xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "LeerinkPartnersLLCMember", "presentation": {"http://www.cormedix.com/role/StockholdersEquityDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Leerink Partners LLC [Member]", "label": "Leerink Partners LLC Member"} }}, {"auth\_ref": {}}, {"dei\_LegalEntityAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": {"http://www.cormedix.com/role/OrganizationBusinessandBasisOfPresentationDetails"}, {"http://xbrl.sec.gov/dei/role/document/AuditInformation"}, {"http://xbrl.sec.gov/dei/role/document/Cover"}, "lang": {"en-us": {"role": {"label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." }}, {"auth\_ref": {}}, {"dei\_LegalEntityIdentifier": {"xbrltype": "legalEntityIdentifierItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityIdentifier", "presentation": {"http://xbrl.sec.gov/dei/role/document/Cover"}, "lang": {"en-us": {"role": {"label": "Legal Entity Identifier", "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI." }}, {"auth\_ref": {"r571"}}, {"us\_gaap\_LesseeLeasesPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": {"http://www.cormedix.com/role/AccountingPoliciesByPolicy"}, "lang": {"en-us": {"role": {"terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." }}, {"auth\_ref": {"r376"}}, {"us\_gaap\_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": {"http://www.cormedix.com/role/LeasesTables"}, "lang": {"en-us": {"role": {"terseLabel": "Schedule of Maturities of Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." }}, {"auth\_ref": {"r808"}}, {"us\_gaap\_LesseeOperatingLeaseLiabilityPaymentsDue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": {"http://www.cormedix.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {"parentTag": null, "weight": null, "order": null, "root": true }}, {"presentation": {"http://www.cormedix.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"}, "lang": {"en-us": {"role": {"totalLabel": "Total future minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." }}, {"auth\_ref": {"r380"}}, {"us\_gaap\_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": {"http://www.cormedix.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {"parentTag": "us-gaap\_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }}, {"presentation": {"http://www.cormedix.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"}, "lang": {"en-us": {"role": {"terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} }}, {"auth\_ref": {"r380"}}, {"us\_gaap\_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": {"http://www.cormedix.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {"parentTag": "us-gaap\_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 }}, {"presentation": {"http://www.cormedix.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"}, "lang": {"en-us": {"role": {"terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} }}, {"auth\_ref": {"r380"}}, {"us\_gaap\_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": {"http://www.cormedix.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {"parentTag": "us-gaap\_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 }}, {"presentation": {"http://www.cormedix.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"}, "lang": {"en-us": {"role": {"terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} }}, {"auth\_ref": {"r380"}}, {"us\_gaap\_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": {"http://www.cormedix.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {"parentTag": "us-gaap\_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 }}, {"presentation": {"http://www.cormedix.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"}, "lang": {"en-us": {"role": {"terseLabel": "2024 (excluding the nine months ended September 30, 2024)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." }}, {"auth\_ref": {"r808"}}, {"us\_gaap\_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": {"http://www.cormedix.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"}, "lang": {"en-us": {"role": {"negatedLabel": "Less imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." }}, {"auth\_ref": {"r380"}}, {"us\_gaap\_LesseeOperatingLeasesTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": {"http://www.cormedix.com/role/Leases"}, "lang": {"en-us": {"role": {"terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." }}, {"auth\_ref": {"r371"}}, {"us\_gaap\_Liabilities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet": {"parentTag": "us-gaap\_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 }}, {"presentation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet"}, "lang": {"en-us": {"role": {"totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." }}, {"auth\_ref": {"r12", "r46", "r47", "r48", "r50", "r51", "r52", "r53", "r152", "r204", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r327", "r328", "r329", "r356", "r458", "r531", "r570", "r750", "r811", "r812"}}, {"us\_gaap\_LiabilitiesAndStockholdersEquity": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet": {"parentTag": null, "weight": null, "order": null, "root": true }}, {"presentation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet"}, "lang": {"en-us": {"role": {"totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u00202019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." }}, {"auth\_ref": {"r60", "r90", "r406", "r552", "r722", "r740", "r806"}}, {"us\_gaap\_LiabilitiesAndStockholdersEquityAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet"}, "lang": {"en-us": {"role": {"terseLabel": "LIABILITIES AND STOCKHOLDERS\u00202019 EQUITY", "label": "Liabilities and Equity [Abstract]"} }}, {"auth\_ref": {}}, {"us\_gaap\_LiabilitiesAssumed1": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAssumed1", "crdr": "credit", "presentation": {"http://www.cormedix.com/role/ConsolidatedCashFlow"}, "lang": {"en-us": {"role": {"terseLabel": "Liability related to license agreement", "label": "Liabilities Assumed", "documentation": "The fair value of liabilities assumed in noncash investing or financing activities." }}, {"auth\_ref": {"r19", "r20", "r21"}}, {"us\_gaap\_LiabilitiesCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet": {"parentTag": "us-gaap\_Liabilities", "weight": 1.0, "order": 1.0 }}, {"presentation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet"}, "lang": {"en-us": {"role": {"totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." }}, {"auth\_ref": {"r48", "r116", "r152", "r204", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r327", "r328", "r329", "r356", "r552", "r750", "r811", "r812"}}, {"us\_gaap\_LiabilitiesCurrentAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet"}, "lang": {"en-us": {"role": {"terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]"} }}, {"auth\_ref": {}}, {"crmd\_LicenseAgreementPayableCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "LicenseAgreementPayableCurrent", "crdr": "credit", "calculation": {"http://www.cormedix.com/role/ScheduleofAccruedExpensesTable": {"parentTag": "us-gaap\_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 }}, {"presentation": {"http://www.cormedix.com/role/CommitmentsandContingenciesDetails"}, {"http://www.cormedix.com/role/ScheduleofAccruedExpensesTable"}, "lang": {"en-us": {"role": {"terseLabel": "License agreement payable (see Note 5\u00202013 Commitments and Contingencies)", "verboseLabel": "License agreement payable", "documentation": "Represents the amount of license agreement payable." , "label": "License Agreement Payable Current"} }}, {"auth\_ref": {}}, {"crmd\_LicenseAgreementPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "LicenseAgreementPolicyTextBlock", "presentation": {"http://www.cormedix.com/role/AccountingPoliciesByPolicy"}, "lang": {"en-us": {"role": {"terseLabel": "License Agreement", "documentation": "Disclosure of accounting policy for license agreement." , "label": "License Agreement Policy Text Block"} }}, {"auth\_ref": {}}, {"us\_gaap\_LicenseMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseMember", "presentation": {"http://www.cormedix.com/role/CommitmentsandContingenciesDetails"}, "lang": {"en-us": {"role": {"terseLabel": "License [Member]", "label": "License [Member]", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." }}, {"auth\_ref": {"r755"}}, {"us\_gaap\_LineOfCreditFacilityRemainingBorrowingCapacity": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": {"http://www.cormedix.com/role/StockholdersEquityDetails"}, "lang": {"en-us": {"role": {"terseLabel": "Capacity remaining program (in Dollars)", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."} }}, {"auth\_ref": {"r45", "r49", "r223"}}, {"crmd\_LiquidityAndUncertaintyPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "LiquidityAndUncertaintyPolicyTextBlock", "presentation": {"http://www.cormedix.com/role/AccountingPoliciesByPolicy"}, "lang": {"en-us": {"role": {"terseLabel": "Liquidity and Uncertainties", "documentation": "Disclosure

of accounting policy for liquidity and uncertainties." }, {"label": "Liquidity And Uncertainty Policy Text Block" } } }, {"auth\_ref": {} }, {"dei\_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth\_ref": {} }, {"us\_gaap\_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": { "http://www.cormedix.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth\_ref": { "r219", "r220", "r221", "r222", "r308", "r538", "r746", "r747" } }, {"srt\_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": { "http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails" }, "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth\_ref": { "r194", "r543", "r554", "r557", "r754", "r814", "r815", "r816", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842" } }, {"crmd\_ManufacturingDevelopmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "ManufacturingDevelopmentCurrent", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ScheduleofAccruedExpensesTable" }, {"parentTag": "us-gaap-AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.cormedix.com/role/ScheduleofAccruedExpensesTable" }, "lang": { "en-us": { "role": { "terseLabel": "Manufacturing related", "documentation": "Carrying value as of the balance sheet date of obligations manufacturing development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." }, "label": "Manufacturing Development Current" } } }, {"auth\_ref": {} }, {"us-gaap\_MarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesLineItems", "presentation": { "http://www.cormedix.com/role/ScheduleofAmortizedCostUnrealizedGainsandLossesandtheFairValueTable" }, "lang": { "en-us": { "role": { "label": "Schedule of Marketable Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth\_ref": {} }, {"us-gaap\_MarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTable", "presentation": { "http://www.cormedix.com/role/ScheduleofAmortizedCostUnrealizedGainsandLossesandtheFairValueTable" }, "lang": { "en-us": { "role": { "label": "Marketable Securities [Table]", "documentation": "Disclosure of information about investment in marketable security." } } }, "auth\_ref": {} }, {"us-gaap\_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": { "http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amortized Cost, Unrealized Gains and Losses and the Fair Value", "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, {"auth\_ref": {} }, {"us-gaap\_MaterialsSuppliesAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaterialsSuppliesAndOther", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ScheduleofOtherPrepaidExpensesandCurrentAssetsTable" }, {"parentTag": "us-gaap-PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.cormedix.com/role/ScheduleofOtherPrepaidExpensesandCurrentAssetsTable" }, "lang": { "en-us": { "role": { "terseLabel": "API deposit", "label": "Materials, Supplies, and Other", "documentation": "The carrying amount of capitalized costs of materials, supplies, and other assets, which are not included in inventory but used in production." } } }, {"auth\_ref": {} }, {"crmd\_MaximumAggregateAmountOfCashPaymentsDueUponAchievementOfMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "MaximumAggregateAmountOfCashPaymentsDueUponAchievementOfMilestones", "crdr": "credit", "presentation": { "http://www.cormedix.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Maximum aggregate amount of cash payments", "documentation": "Maximum aggregate amount of cash payments due upon achievement of milestones." }, "label": "Maximum Aggregate Amount Of Cash Payments Due Upon Achievement Of Milestones" } } }, {"auth\_ref": {} }, {"ecd\_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, {"auth\_ref": { "r640" } }, {"ecd\_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, {"auth\_ref": { "r640" } }, {"ecd\_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, {"auth\_ref": { "r660" } }, {"us-gaap\_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": { "http://www.cormedix.com/role/ScheduleofAmortizedCostUnrealizedGainsandLossesandtheFairValueTable" }, "http://www.cormedix.com/role/ScheduleofCarryingandFairValueofFinancialAssetsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds included in Cash Equivalents [Member]", "verboselabel": "Money Market Funds and Cash Equivalents [Member]", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, {"auth\_ref": { "r756" } }, {"ecd\_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, {"auth\_ref": { "r668" } }, {"crmd\_NDLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "NDLicenseAgreementMember", "presentation": { "http://www.cormedix.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "ND License Agreement [Member]", "label": "NDLicense Agreement Member" } } }, {"auth\_ref": {} }, {"crmd\_NDPTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "NDPTechnologyMember", "presentation": { "http://www.cormedix.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "ND Partners, LLP [Member]", "label": "NDPartners LLPMember" } } }, {"auth\_ref": {} }, {"dei\_NameChangeEventDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventDateAxis", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Name Change Event Date [Axis]", "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type." } } }, {"auth\_ref": {} }, {"dei\_NameChangeEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventLineItems", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Name Change Event [Line Items]", "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table." } } }, {"auth\_ref": {} }, {"dei\_NameChangeEventTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventTable", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Name Change Event [Table]", "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period." } } }, {"auth\_ref": {} }, {"srt\_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": { "http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails" }, "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, {"auth\_ref": { "r194", "r543", "r554", "r557", "r754", "r814", "r815", "r816", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842" } }, {"ecd\_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, {"auth\_ref": { "r641" } }, {"us-gaap\_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedCashFlow" }, {"parentTag": "us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, {"auth\_ref": { "r145" } }, {"us-gaap\_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, {"auth\_ref": {} }, {"us-gaap\_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedCashFlow" }, {"parentTag": "us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, {"auth\_ref": { "r145" } }, {"us-gaap\_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, {"auth\_ref": {} }, {"us-gaap\_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.cormedix.com/role/ConsolidatedCashFlow" }, {"parentTag": "us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, {"auth\_ref": { "r73", "r74", "r75" } }, {"us-gaap\_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, {"auth\_ref": {} }, {"us-gaap\_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit",

```

{"calculation": {"http://www.cormedix.com/role/ConsolidatedIncomeStatement": {"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0}, "http://www.cormedix.com/role/ConsolidatedCashFlow": {"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0}, "presentation": {"http://www.cormedix.com/role/ConsolidatedCashFlow": {"http://www.cormedix.com/role/ConsolidatedIncomeStatement", "http://www.cormedix.com/role/ShareholdersEquityType2or3", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": {"en-us": {"role": {"totalLabel": "Net Loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." }}, "auth_ref": {"r68", "r75", "r94", "r114", "r130", "r133", "r137", "r152", "r156", "r158", "r159", "r160", "r161", "r162", "r165", "r166", "r172", "r204", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r321", "r324", "r339", "r356", "r410", "r480", "r497", "r498", "r568", "r750"}}, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": {"http://www.cormedix.com/role/AccountingPoliciesByPolicy": {"lang": {"en-us": {"role": {"terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." }}, "auth_ref": {"}, "dei_NewEffectiveDateForPreviousFiling": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NewEffectiveDateForPreviousFiling", "presentation": {"http://xbrl.sec.gov/dei/role/document/Cover": {"lang": {"en-us": {"role": {"label": "New Effective Date for Previous Filing", "auth_ref": {"r611", "r612", "r613", "r614"}}, "dei_NoSubstantiveChanges462c": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462c", "presentation": {"http://xbrl.sec.gov/dei/role/document/Cover": {"lang": {"en-us": {"role": {"label": "No Substantive Changes, 462(c)", "auth_ref": {"r685"}}, "dei_NoSubstantiveChanges462cFileNumber": {"xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": {"http://xbrl.sec.gov/dei/role/document/Cover": {"lang": {"en-us": {"role": {"label": "No Substantive Changes, 462(c), File Number", "auth_ref": {"r685"}}, "dei_NoTradingSymbolFlag": {"xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": {"http://xbrl.sec.gov/dei/role/document/Cover": {"lang": {"en-us": {"role": {"label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." }}, "auth_ref": {"}, "ecd_NonGaapMeasureDescriptionTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description", "auth_ref": {"r640"}}, "ecd_NonNeosMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs", "auth_ref": {"r595", "r606", "r622", "r648", "r657"}}, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "auth_ref": {"r631"}}, "ecd_NonPeoNeoAvgTotalCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "auth_ref": {"r630"}}, "ecd_NonPeoNeoMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO", "auth_ref": {"r648"}}, "ecd_NonRule10b51ArrAdoptedFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {"lang": {"en-us": {"role": {"label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "auth_ref": {"r668"}}, "ecd_NonRule10b51ArrTrmtdFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {"lang": {"en-us": {"role": {"label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "auth_ref": {"r668"}}, "us-gaap_NonoperatingIncomeExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": {"http://www.cormedix.com/role/ConsolidatedIncomeStatement": {"parentTag": null, "weight": null, "order": null, "root": true}, "presentation": {"http://www.cormedix.com/role/ConsolidatedIncomeStatement": {"lang": {"en-us": {"role": {"totalLabel": "Total Other Income", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "auth_ref": {"r70"}}, "us-gaap_NonoperatingIncomeExpenseAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": {"http://www.cormedix.com/role/ConsolidatedIncomeStatement": {"lang": {"en-us": {"role": {"terseLabel": "Other Income (Expense)", "label": "Nonoperating Income (Expense) [Abstract]", "auth_ref": {"}, crmd_NumberOfSharesReleasedInEscrow": {"xbrltype": "sharesItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "NumberOfSharesReleasedInEscrow", "presentation": {"http://www.cormedix.com/role/CommitmentsandContingenciesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Number of shares released in escrow (in Shares)", "documentation": "The Number of shares released in escrow.", "label": "Number Of Shares Released In Escrow", "auth_ref": {"}, srt_OfficerMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OfficerMember", "presentation": {"http://www.cormedix.com/role/StockholdersEquityDetails": {"lang": {"en-us": {"role": {"terseLabel": "Officer [Member]", "label": "Officer [Member]", "auth_ref": {"r195", "r844"}}, "crmd_OneCustomerMember": {"xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "OneCustomerMember", "presentation": {"http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails": {"lang": {"en-us": {"role": {"terseLabel": "One Customer [Member]", "label": "One Customer Member", "auth_ref": {"}, us-gaap_OperatingExpenses": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": {"http://www.cormedix.com/role/ConsolidatedIncomeStatement": {"parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0}, "presentation": {"http://www.cormedix.com/role/ConsolidatedIncomeStatement": {"lang": {"en-us": {"role": {"negatedTotalLabel": "Total Operating Expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "auth_ref": {"}, us-gaap_OperatingExpensesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": {"http://www.cormedix.com/role/ConsolidatedIncomeStatement": {"lang": {"en-us": {"role": {"terseLabel": "Operating Expenses", "label": "Operating Expenses [Abstract]", "auth_ref": {"}, us-gaap_OperatingIncomeLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": {"http://www.cormedix.com/role/ConsolidatedIncomeStatement": {"parentTag": null, "weight": null, "order": null, "root": true}, "presentation": {"http://www.cormedix.com/role/ConsolidatedIncomeStatement": {"lang": {"en-us": {"role": {"totalLabel": "Loss From Operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "auth_ref": {"r97", "r532", "r729", "r730", "r731", "r732", "r733"}}, "us-gaap_OperatingLeaseExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": {"http://www.cormedix.com/role/LeasesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Operating lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income.", "auth_ref": {"r807"}}, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "lang": {"en-us": {"role": {"label": "Schedule of Maturities of Lease Liabilities [Abstract]", "auth_ref": {"}, us-gaap_OperatingLeaseLiability": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": {"http://www.cormedix.com/role/LeasesDetails": {"http://www.cormedix.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {"lang": {"en-us": {"role": {"terseLabel": "Total", "verboseLabel": "Operating lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "auth_ref": {"r374"}}, "us-gaap_OperatingLeaseLiabilityCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet": {"parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0}, "presentation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet": {"http://www.cormedix.com/role/LeasesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Operating lease liability, short-term", "verboseLabel": "Operating lease liability current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "auth_ref": {"r374"}}, "us-gaap_OperatingLeaseLiabilityNoncurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet": {"parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0}, "presentation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet": {"http://www.cormedix.com/role/LeasesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Operating lease liability, net of current portion", "verboseLabel": "Operating lease liability non current", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present
```

```

http://www.cormedix.com/20240930", "localname": "OrganizationBusinessandBasisofPresentationDetailsTable", "presentation": {
  "http://www.cormedix.com/role/OrganizationBusinessandBasisofPresentationDetails", "lang": { "en-us": { "role": { "label": "Organization, Business and Basis of Presentation (Details) [Table]", "auth_ref": { "us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Business and Basis of Presentation [Abstract]", "auth_ref": { "us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureTextBlock", "presentation": {
    "http://www.cormedix.com/role/OrganizationBusinessandBasisofPresentation", "lang": { "en-us": { "role": { "terseLabel": "Organization, Business and Basis of Presentation", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": { "r43", "r85", "r430", "r431" } }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ScheduleofAccruedExpensesTable": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.cormedix.com/role/ScheduleofAccruedExpensesTable", "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r47" } }, "dei_OtherAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherAddressMember", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Other Address [Member]", "documentation": "Other address for entity" } } }, "auth_ref": { "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation (loss) gain", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth_ref": { "r2", "r411" } }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "terseLabel": "Total Other Comprehensive Income (Loss)", "label": "Other comprehensive income (loss)", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": { "r9", "r11", "r131", "r134", "r139", "r162", "r362", "r363", "r368", "r392", "r411", "r713", "r714" } }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "auth_ref": { "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) from investments", "label": "OCI, Debt Securities, Available for Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax", "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": { "r128", "r129", "r200" } }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsTextBlock", "presentation": { "http://www.cormedix.com/role/OtherPrepaidExpensesandCurrentAssets", "lang": { "en-us": { "role": { "terseLabel": "Other Prepaid Expenses and Current Assets", "label": "Other Current Assets [Text Block]", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": { "us-gaap_OtherNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncome", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other Nonoperating Income", "documentation": "Amount of income related to nonoperating activities, classified as other." } } }, "auth_ref": { "r142" } }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount", "auth_ref": { "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ScheduleofOtherPrepaidExpensesandCurrentAssetsTable": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.cormedix.com/role/ScheduleofOtherPrepaidExpensesandCurrentAssetsTable", "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r710", "r741" } }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "Item 17 or Item 18 specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": { "r586" } }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "auth_ref": { "r593", "r604", "r620", "r655" } }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount", "auth_ref": { "r596", "r607", "r623", "r658" } }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name", "auth_ref": { "r596", "r607", "r623", "r658" } }, "dei_ParentEntityLegalName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ParentEntityLegalName", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Parent Entity Legal Name", "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity" } } }, "auth_ref": { "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure", "auth_ref": { "r629" } }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses [Abstract]", "auth_ref": { "us-gaap_PaymentsForLeasingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLeasingCosts", "crdr": "credit", "presentation": { "http://www.cormedix.com/role/LeasesDetails", "lang": { "en-us": { "role": { "terseLabel": "Payments for leasing costs", "label": "Payments for Leasing Costs", "documentation": "Amount of cash outflow for costs that are essential to originate the lease and would not otherwise have been incurred without the lease agreement. Amount includes, but is not limited to, cash outflows to evaluate the lessee's credit condition, guarantees, and collateral and cash outflows for costs incurred in negotiating, processing, and executing the lease agreement." } } }, "auth_ref": { "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "negatedLabel": "Payment of employee withholding taxes on vested restricted stock units", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": { "r143" } }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "negatedLabel": "Purchase of equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": { "r72" } }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us
```

"lang": {"en-us": {"role": {"label": "PEO [Member]", "terseLabel": "PEO"}}, "auth\_ref": {"r648"}}, "ecd\_PeoName": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": {"en-us": {"role": {"label": "PEO Name", "terseLabel": "PEO Name"}}, "auth\_ref": {"r641"}}, "ecd\_PeoTotalCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": {"en-us": {"role": {"label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount"}}, "auth\_ref": {"r630"}}, "dei\_PhoneFaxNumberDescription": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PhoneFaxNumberDescription", "presentation": {"http://xbrl.sec.gov/dei/role/document/Cover"}, "lang": {"en-us": {"role": {"label": "Phone Fax Number Description", "documentation": "Description of Phone or Fax Number"}}, "auth\_ref": {}}, "us-gaap\_PlanNameAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": {"http://www.cormedix.com/role/StockholdersEquityDetails"}, "lang": {"en-us": {"role": {"label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement."}}}, "auth\_ref": {"r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782"}}, "us-gaap\_PlanNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": {"http://www.cormedix.com/role/StockholdersEquityDetails"}, "lang": {"en-us": {"role": {"label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement."}}}, "auth\_ref": {"r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782"}}, "ecd\_PnsnAdjsPrsSvcCstMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrsSvcCstMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": {"en-us": {"role": {"label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost"}}, "auth\_ref": {"r632"}}, "ecd\_PnsnAdjsSvcCstMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": {"en-us": {"role": {"label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost"}}, "auth\_ref": {"r677"}}, "ecd\_PnsnBnftsAdjFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}, "lang": {"en-us": {"role": {"label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote"}}, "auth\_ref": {"r631"}}, "dei\_PostEffectiveAmendment": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendment", "presentation": {"http://xbrl.sec.gov/dei/role/document/Cover"}, "lang": {"en-us": {"role": {"label": "Post-Effective Amendment"}}, "auth\_ref": {"r572"}}, "dei\_PostEffectiveAmendmentNumber": {"xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendmentNumber", "presentation": {"http://xbrl.sec.gov/dei/role/document/Cover"}, "lang": {"en-us": {"role": {"label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."}}}, "auth\_ref": {"r572"}}, "dei\_PreCommencementIssuerTenderOffer": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": {"http://xbrl.sec.gov/dei/role/document/Cover"}, "lang": {"en-us": {"role": {"label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."}}}, "auth\_ref": {"r579"}}, "dei\_PreCommencementTenderOffer": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": {"http://xbrl.sec.gov/dei/role/document/Cover"}, "lang": {"en-us": {"role": {"label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."}}}, "auth\_ref": {"r581"}}, "dei\_PreEffectiveAmendment": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendment", "presentation": {"http://xbrl.sec.gov/dei/role/document/Cover"}, "lang": {"en-us": {"role": {"label": "Pre-Effective Amendment"}}, "auth\_ref": {"r572"}}, "dei\_PreEffectiveAmendmentNumber": {"xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendmentNumber", "presentation": {"http://xbrl.sec.gov/dei/role/document/Cover"}, "lang": {"en-us": {"role": {"label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."}}}, "auth\_ref": {"r572"}}, "crmd\_PrefundedWarrantsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "PrefundedWarrantsMember", "presentation": {"http://www.cormedix.com/role/StockholdersEquityDetails"}, "lang": {"en-us": {"role": {"label": "Pre-Funded Warrants [Member]", "label": "Pre-Funded Warrants Member"}}, "auth\_ref": {}}, "us-gaap\_PreferredStockLiquidationPreference": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockLiquidationPreference", "presentation": {"http://www.cormedix.com/role/StockholdersEquityDetailsScheduleofPreferredStock"}, "lang": {"en-us": {"role": {"label": "Preferred Stock, Liquidation Preference Per Share", "label": "Preferred Stock, Liquidation Preference Per Share", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."}}}, "auth\_ref": {"r30", "r31", "r54", "r721", "r752"}}, "us-gaap\_PreferredStockLiquidationPreferenceValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockLiquidationPreferenceValue", "crdr": "credit", "presentation": {"http://www.cormedix.com/role/StockholdersEquityDetailsScheduleofPreferredStock"}, "lang": {"en-us": {"role": {"label": "Preferred Stock, Liquidation Preference, Value", "label": "Preferred Stock, Liquidation Preference, Value", "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares."}}}, "auth\_ref": {"r150", "r239", "r251"}}, "us-gaap\_PreferredStockMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": {"http://www.cormedix.com/role/ShareholdersEquityType2or3"}, "lang": {"en-us": {"role": {"label": "Preferred Stock", "label": "Preferred Stock", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."}}}, "auth\_ref": {"r560", "r561", "r564", "r565", "r566", "r567", "r843", "r846"}}, "us-gaap\_PreferredStockParOrStatedValuePerShare": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet\_Parentheticals"}, "lang": {"en-us": {"role": {"label": "Preferred stock, par value (in Dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."}}}, "auth\_ref": {"r54", "r235"}}, "us-gaap\_PreferredStockSharesAuthorized": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet\_Parentheticals"}, "lang": {"en-us": {"role": {"label": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."}}}, "auth\_ref": {"r54", "r460"}}, "us-gaap\_PreferredStockSharesIssued": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet\_Parentheticals"}, "lang": {"en-us": {"role": {"label": "Preferred stock, shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."}}}, "auth\_ref": {"r54", "r235"}}, "us-gaap\_PreferredStockSharesOutstanding": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet\_Parentheticals"}, "lang": {"en-us": {"role": {"label": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."}}}, "auth\_ref": {"r54", "r460", "r478", "r846", "r847"}}, "us-gaap\_PreferredStockValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet": {"parentTag": "us-gaap\_StockholdersEquity", "weight": 1.0, "order": 1.0}}, "presentation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet"}, "lang": {"en-us": {"role": {"label": "Preferred stock - \$0.001 par value: 2,000,000 shares authorized; 181,622 shares issued and outstanding at September 30, 2024 and December 31, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."}}}, "auth\_ref": {"r54", "r402", "r552"}}, "us-gaap\_PrepaidAdvertising": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidAdvertising", "crdr": "debit", "calculation": {"http://www.cormedix.com/role/ScheduleofOtherPrepaidExpensesandCurrentAssetsTable": {"parentTag": "us-gaap\_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0}}, "presentation": {"http://www.cormedix.com/role/ScheduleofOtherPrepaidExpensesandCurrentAssetsTable"}, "lang": {"en-us": {"role": {"label": "Commercial", "label": "Prepaid Advertising", "documentation": "Amount of consideration paid in advance for advertising that provides economic benefits within a future period of one year or the normal operating cycle, if longer."}}}, "auth\_ref": {"r526", "r536", "r741"}}, "us-gaap\_PrepaidExpenseAndOtherAssetsCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet": {"parentTag": "us-gaap\_AssetsCurrent", "weight": 1.0, "order": 7.0}}, "http://www.cormedix.com/role/ScheduleofOtherPrepaidExpensesandCurrentAssetsTable": {"parentTag": null, "weight": null, "order": null, "root": true}}, "presentation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet"}, "http://www.cormedix.com/role/ScheduleofOtherPrepaidExpensesandCurrentAssetsTable"}, "lang": {"en-us": {"role": {"label": "Insurance", "label": "Prepaid Insurance", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."}}}, "auth\_ref": {"r712"}}, "us-gaap\_PrepaidExpenseAndOtherAssetsCurrentAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "lang": {"en-us": {"role": {"label": "Other Prepaid Expenses and Current Assets [Abstract]"}}, "auth\_ref": {}}, "us-gaap\_PrepaidExpenseCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet": {"parentTag": "us-gaap\_AssetsCurrent", "weight": 1.0, "order": 6.0}}, "presentation": {"http://www.cormedix.com/role/ConsolidatedBalanceSheet"}, "lang": {"en-us": {"role": {"label": "Prepaid research and development expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."}}}, "auth\_ref": {"r126", "r211", "r212", "r524"}}, "us-gaap\_PrepaidInsurance": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": {"http://www.cormedix.com/role/ScheduleofOtherPrepaidExpensesandCurrentAssetsTable": {"parentTag": "us-gaap\_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 6.0}}, "presentation": {"http://www.cormedix.com/role/ScheduleofOtherPrepaidExpensesandCurrentAssetsTable"}, "lang": {"en-us": {"role": {"label": "Insurance", "label": "Prepaid Insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."}}}, "auth\_ref": {"r525", "r535", "r741"}}, "crmd\_PrepaidMedicalAffairsCurrent": {"xbrltype":

"monetaryItemType","nsuri":{"http://www.cormedix.com/20240930"},"localname":"PrepaidMedicalAffairsCurrent","crdr":"debit","calculation":{"http://www.cormedix.com/role/ScheduleOfOtherPrepaidExpensesandCurrentAssetsTable":{"parentTag":{"us-gaap\_PrepaidExpenseAndOtherAssetsCurrent","weight":{"1.0,"order":5.0}}},"presentation":{"http://www.cormedix.com/role/ScheduleOfOtherPrepaidExpensesandCurrentAssetsTable"},"lang":{"en-us":{"role":{"terseLabel":"Medical affairs"},"documentation":{"Represents the amount of prepaid medical affairs."},"label":"Prepaid Medical Affairs Current"}}},"auth\_ref":{"}},"crmd\_PrepaidSubscriptionsCurrent":{"xbrltype":"monetaryItemType","nsuri":{"http://www.cormedix.com/20240930"},"localname":"PrepaidSubscriptionsCurrent","crdr":"debit","calculation":{"http://www.cormedix.com/role/ScheduleOfOtherPrepaidExpensesandCurrentAssetsTable":{"parentTag":{"us-gaap\_PrepaidExpenseAndOtherAssetsCurrent","weight":{"1.0,"order":4.0}}},"presentation":{"http://www.cormedix.com/role/ScheduleOfOtherPrepaidExpensesandCurrentAssetsTable"},"lang":{"en-us":{"role":{"terseLabel":"Subscriptions"},"documentation":{"Represents the amount of prepaid subscriptions."},"label":"Prepaid Subscriptions Current"}}},"auth\_ref":{"}}},"us-gaap\_PriorPeriodReclassificationAdjustmentDescription":{"xbrltype":"textBlockItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"PriorPeriodReclassificationAdjustmentDescription"},"presentation":{"http://www.cormedix.com/role/AccountingPoliciesByPolicy"},"lang":{"en-us":{"role":{"terseLabel":"Reclassifications"},"label":"Reclassification, Comparability Adjustment [Policy Text Block]"},"documentation":{"Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."}}},"auth\_ref":{"r701"}}, {"us-gaap\_ProceedsFromIssuanceOfCommonStock":{"xbrltype":"monetaryItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"ProceedsFromIssuanceOfCommonStock","crdr":"debit","calculation":{"http://www.cormedix.com/role/ConsolidatedCashFlow":{"parentTag":{"us-gaap\_NetCashProvidedByUsedInFinancingActivities","weight":{"1.0,"order":1.0}}},"presentation":{"http://www.cormedix.com/role/ConsolidatedCashFlow"},"lang":{"en-us":{"role":{"terseLabel":"Proceeds from sale of common stock from at-the-market program, net"},"verboseLabel":"Net proceeds (in Dollars)"},"label":"Proceeds from Issuance of Common Stock"},"documentation":{"The cash inflow from the additional capital contribution to the entity."}}},"auth\_ref":{"r3"}}, {"us-gaap\_ProceedsFromIssuanceOfWarrants":{"xbrltype":"monetaryItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"ProceedsFromIssuanceOfWarrants","crdr":"debit","calculation":{"http://www.cormedix.com/role/ConsolidatedCashFlow":{"parentTag":{"us-gaap\_NetCashProvidedByUsedInFinancingActivities","weight":{"1.0,"order":2.0}}},"presentation":{"http://www.cormedix.com/role/ConsolidatedCashFlow"},"lang":{"en-us":{"role":{"terseLabel":"Proceeds from public offering of common stock and pre-funded warrants, net"},"label":"Proceeds from Issuance of Warrants"},"documentation":{"The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."}}},"auth\_ref":{"r3"}}, {"us-gaap\_ProceedsFromIssuanceOrSaleOfEquity":{"xbrltype":"monetaryItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"ProceedsFromIssuanceOrSaleOfEquity","crdr":"debit","presentation":{"http://www.cormedix.com/role/StockholdersEquityDetails"},"lang":{"en-us":{"role":{"terseLabel":"Common stock available for sale (in Dollars)"},"label":"Proceeds from Issuance or Sale of Equity"},"documentation":{"The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."}}},"auth\_ref":{"r3","r433"}}, {"us-gaap\_ProceedsFromSaleOfShortTermInvestments":{"xbrltype":"monetaryItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"ProceedsFromSaleOfShortTermInvestments","crdr":"debit","calculation":{"http://www.cormedix.com/role/ConsolidatedCashFlow":{"parentTag":{"us-gaap\_NetCashProvidedByUsedInInvestingActivities","weight":{"1.0,"order":1.0}}},"presentation":{"http://www.cormedix.com/role/ConsolidatedCashFlow"},"lang":{"en-us":{"role":{"terseLabel":"Maturity of short-term investments"},"label":"Proceeds from Sale of Short-Term Investments"},"documentation":{"The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."}}},"auth\_ref":{"r17"}}, {"us-gaap\_ProceedsFromStockOptionsExercised":{"xbrltype":"monetaryItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"ProceedsFromStockOptionsExercised","crdr":"debit","calculation":{"http://www.cormedix.com/role/ConsolidatedCashFlow":{"parentTag":{"us-gaap\_NetCashProvidedByUsedInFinancingActivities","weight":{"1.0,"order":3.0}}},"presentation":{"http://www.cormedix.com/role/ConsolidatedCashFlow"},"lang":{"en-us":{"role":{"terseLabel":"Proceeds from exercise of stock options"},"verboseLabel":"Net proceeds of exercised stock options (in Dollars)"},"label":"Proceeds from Stock Options Exercised"},"documentation":{"Amount of cash inflow from exercise of option under share-based payment arrangement."}}},"auth\_ref":{"r3","r10"}}, {"srt\_ProductOrServiceAxis":{"xbrltype":"stringItemType","nsuri":{"http://fasb.org/srt/2024"},"localname":"ProductOrServiceAxis"},"presentation":{"http://www.cormedix.com/role/CommitmentsandContingenciesDetails"},"lang":{"en-us":{"role":{"label":"Product and Service [Axis]"}}}},"auth\_ref":{"r192","r390","r416","r417","r418","r419","r420","r421","r422","r521","r542","r553","r555","r556","r558","r559","r748","r749","r754","r814","r815","r816","r817","r818","r819","r820","r821","r822","r823","r824","r825","r826","r827","r828","r829","r830","r831","r832","r833","r834","r835","r836","r837","r838","r839","r840","r841","r842"}}, {"srt\_ProductsAndServicesDomain":{"xbrltype":"domainItemType","nsuri":{"http://fasb.org/srt/2024"},"localname":"ProductsAndServicesDomain"},"presentation":{"http://www.cormedix.com/role/CommitmentsandContingenciesDetails"},"lang":{"en-us":{"role":{"label":"Product and Service [Domain]"}}}},"auth\_ref":{"r192","r390","r416","r417","r418","r419","r420","r421","r422","r521","r542","r553","r555","r556","r558","r559","r748","r749","r754","r814","r815","r816","r817","r818","r819","r820","r821","r822","r823","r824","r825","r826","r827","r828","r829","r830","r831","r832","r833","r834","r835","r836","r837","r838","r839","r840","r841","r842"}}, {"us-gaap\_PropertyPlantAndEquipmentNet":{"xbrltype":"monetaryItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"PropertyPlantAndEquipmentNet","crdr":"debit","calculation":{"http://www.cormedix.com/role/ConsolidatedBalanceSheet":{"parentTag":{"us-gaap\_Assets","weight":{"1.0,"order":2.0}}},"presentation":{"http://www.cormedix.com/role/ConsolidatedBalanceSheet"},"lang":{"en-us":{"role":{"terseLabel":"Property and equipment, net"},"label":"Property, Plant and Equipment, Net"},"documentation":{"Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."}}},"auth\_ref":{"r6","r381","r396","r408","r552"}}, {"crmd\_ProvisionsForTheRevenueReserves":{"xbrltype":"monetaryItemType","nsuri":{"http://www.cormedix.com/20240930"},"localname":"ProvisionsForTheRevenueReserves","crdr":"debit","presentation":{"http://www.cormedix.com/role/SummaryOfSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Provisions for the revenue reserves"},"documentation":{"Provisions for the revenue reserves."},"label":"Provisions For The Revenue Reserves"}}},"auth\_ref":{"}}}, {"crmd\_PurchaseOfAdditionalShares":{"xbrltype":"sharesItemType","nsuri":{"http://www.cormedix.com/20240930"},"localname":"PurchaseOfAdditionalShares"},"presentation":{"http://www.cormedix.com/role/StockholdersEquityDetails"},"lang":{"en-us":{"role":{"terseLabel":"Purchase of additional shares"},"documentation":{"Number of purchase of additional shares."},"label":"Purchase Of Additional Shares"}}},"auth\_ref":{"}}}, {"ecd\_PvpTable":{"xbrltype":"stringItemType","nsuri":{"http://xbrl.sec.gov/ecd/2024"},"localname":"PvpTable"},"presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"label":"Pay vs Performance Disclosure [Table]"},"terseLabel":"Pay vs Performance Disclosure"}}},"auth\_ref":{"r629"}}, {"ecd\_PvpTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":{"http://xbrl.sec.gov/ecd/2024"},"localname":"PvpTableTextBlock"},"presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"label":"Pay vs Performance Disclosure, Table"}}},"auth\_ref":{"r629"}}, {"ecd\_RecoveryOfErrCompDisclosureLineItems":{"xbrltype":"stringItemType","nsuri":{"http://xbrl.sec.gov/ecd/2024"},"localname":"RecoveryOfErrCompDisclosureLineItems"},"lang":{"en-us":{"role":{"label":"Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"},"terseLabel":"Recovery of Erroneously Awarded Compensation Disclosure"}}},"auth\_ref":{"r588","r599","r615","r650"}}, {"dei\_RegistrationStatementAmendmentNumber":{"xbrltype":"sequenceNumberItemType","nsuri":{"http://xbrl.sec.gov/dei/2024"},"localname":"RegistrationStatementAmendmentNumber"},"presentation":{"http://xbrl.sec.gov/dei/role/document/Cover"},"lang":{"en-us":{"role":{"label":"Registration Statement Amendment Number"},"documentation":{"Amendment number to registration statement under the Investment Company Act of 1940."}}},"auth\_ref":{"r572"}}, {"us-gaap\_RelatedPartyDomain":{"xbrltype":"domainItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"RelatedPartyDomain"},"presentation":{"http://www.cormedix.com/role/StockholdersEquityDetails"},"lang":{"en-us":{"role":{"label":"Related and Nonrelated Parties [Domain]"},"documentation":{"Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."}}},"auth\_ref":{"r195","r267","r383","r384","r399","r407","r453","r454","r455","r456","r457","r477","r479","r504"}}, {"us-gaap\_RelatedPartyTransactionAxis":{"xbrltype":"stringItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"RelatedPartyTransactionAxis"},"presentation":{"http://www.cormedix.com/role/CommitmentsandContingenciesDetails"},"lang":{"en-us":{"role":{"label":"Related Party Transaction [Axis]"},"documentation":{"Information by type of related party transaction."}}},"auth\_ref":{"r383","r384","r810"}}, {"us-gaap\_RelatedPartyTransactionDomain":{"xbrltype":"domainItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"RelatedPartyTransactionDomain"},"presentation":{"http://www.cormedix.com/role/CommitmentsandContingenciesDetails"},"lang":{"en-us":{"role":{"label":"Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"},"documentation":{"Information by form of arrangement related to research and development."}}},"auth\_ref":{"r311","r786"}}, {"us-gaap\_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain":{"xbrltype":"domainItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"},"presentation":{"http://www.cormedix.com/role/CommitmentsandContingenciesDetails"},"lang":{"en-us":{"role":{"label":"Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"},"documentation":{"Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."}}},"auth\_ref":{"r311","r786"}}, {"us-gaap\_ResearchAndDevelopmentExpense":{"xbrltype":"monetaryItemType","nsuri":{"http://fasb.org/us-gaap/2024"},"localname":"ResearchAndDevelopmentExpense","crdr":"debit","calculation":{"http://www.cormedix.com/role/ConsolidatedIncomeStatement":{"parentTag":{"us-gaap\_OperatingExpenses","weight":{"1.0,"order":1.0}}},"presentation":{"http://www.cormedix.com/role/ConsolidatedIncomeStatement"},"lang":{"en-us":{"role":{"negatedLabel":"Research and development"},"label":"Research and Development Expense"},"documentation":{"Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and

development activity." } } }, "auth\_ref": { "r310", "r519", "r533", "r813" } }, "us-gaap\_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": { "http://www.cormedix.com/role/AccountingPoliciesByPolicy", "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth\_ref": { "r309" } }, "ecd\_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth\_ref": { "r590", "r601", "r617", "r652" } }, "ecd\_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth\_ref": { "r597", "r608", "r624", "r659" } }, "us-gaap\_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ScheduleOfConsolidatedStatementOfCashFlowsTable": { "parentTag": "us-gaap\_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.cormedix.com/role/ScheduleOfConsolidatedStatementOfCashFlowsTable", "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth\_ref": { "r702", "r720" } }, "us-gaap\_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 4.0 }, "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "Restricted cash, long-term", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth\_ref": { "r103", "r704", "r720" } }, "us-gaap\_RestrictedStockExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockExpense", "crdr": "debit", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Compensation expense RSUs (in Dollars)", "label": "Restricted Stock or Unit Expense", "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement." } } }, "auth\_ref": { "r5" } }, "us-gaap\_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "presentation": { "http://www.cormedix.com/role/ShareholdersEquityType2or3", "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Issuance of vested restricted stock, net of shares withheld for employee withholding taxes (in Shares)", "verboseLabel": "Shares of common stock in lieu of withholding taxes", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth\_ref": { "r4" } }, "us-gaap\_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": { "http://www.cormedix.com/role/ScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareTable", "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Shares underlying restricted stock units [Member]", "verboseLabel": "Restricted Stock Units (RSUs) [Member]", "netLabel": "Stock Options [Member]", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth\_ref": { } }, "us-gaap\_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "crdr": "credit", "presentation": { "http://www.cormedix.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Issuance of vested restricted stock, net of shares withheld for employee withholding taxes", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth\_ref": { } }, "us-gaap\_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap\_StockholdersEquity", "weight": 1.0, "order": 5.0 }, "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth\_ref": { "r57", "r82", "r405", "r426", "r428", "r437", "r461", "r552" } }, "us-gaap\_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": { "http://www.cormedix.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth\_ref": { "r113", "r153", "r154", "r155", "r157", "r162", "r164", "r166", "r205", "r206", "r216", "r314", "r315", "r318", "r319", "r320", "r322", "r323", "r324", "r330", "r332", "r333", "r335", "r337", "r370", "r372", "r423", "r425", "r438", "r446" } }, "us-gaap\_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": { "http://www.cormedix.com/role/AccountingPoliciesByPolicy", "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth\_ref": { "r111", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r520" } }, "crmd\_RevenueVariableConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "RevenueVariableConsideration", "crdr": "credit", "presentation": { "http://www.cormedix.com/role/SummaryOfSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Variable consideration", "documentation": "Represents the amount of revenue variable consideration." }, "label": "Revenue Variable Consideration" } } }, "auth\_ref": { } }, "us-gaap\_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap\_GrossProfit", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement", "http://www.cormedix.com/role/SummaryOfSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Net sales", "verboseLabel": "Total revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth\_ref": { "r95", "r96", "r138", "r152", "r179", "r184", "r185", "r189", "r191", "r192", "r193", "r194", "r204", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r356", "r395", "r533", "r750" } }, "us-gaap\_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenues [Abstract]" } } }, "auth\_ref": { } }, "ecd\_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted", "documentation": "Rule 10b5-1 Arrangement Adopted" } } }, "auth\_ref": { "r668" } }, "ecd\_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated", "documentation": "Rule 10b5-1 Arrangement Terminated" } } }, "auth\_ref": { "r668" } }, "crmd\_SaleOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "SaleOfCommonStock", "crdr": "debit", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Sale of common stock (in Dollars)", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth\_ref": { } }, "us-gaap\_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth\_ref": { } }, "us-gaap\_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Sale of stock units", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth\_ref": { } }, "us-gaap\_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": { "http://www.cormedix.com/role/SummaryOfSignificantAccountingPoliciesandLiquidityandUncertaintiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark [Member]", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth\_ref": { "r194", "r698" } }, "srt\_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": { "http://www.cormedix.com/role/ScheduleOfBlackScholesOptionPricingModelTable", "auth\_ref": { "r167", "r268", "r693", "r726" } }, "crmd\_ScheduleOfAccruedExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "ScheduleOfAccruedExpensesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Accrued Expenses [Abstract]" } } }, "auth\_ref": { } }, "us-gaap\_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock" }

"ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": { "http://www.cormedix.com/role/AccruedExpensesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth\_ref": { } }, "crmd\_ScheduleOfAmortizedCostUnrealizedGainsAndLossesAndTheFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "ScheduleOfAmortizedCostUnrealizedGainsAndLossesAndTheFairValueAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Amortized Cost Unrealized Gains And Losses And The Fair Value Abstract" } } }, "auth\_ref": { } }, "crmd\_ScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "ScheduleOfAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Anti-Dilutive Securities Excluded From Calculation Of Diluted Net Loss Per Share Abstract" } } }, "auth\_ref": { } }, "us-gaap\_ScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": { "http://www.cormedix.com/role/ScheduleofAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareTable" }, "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth\_ref": { "r22" } }, "us-gaap\_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": { "http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth\_ref": { "r22" } }, "crmd\_ScheduleOfBlackScholesOptionPricingModelAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "ScheduleOfBlackScholesOptionPricingModelAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Black Scholes Option Pricing Model Abstract" } } }, "auth\_ref": { } }, "crmd\_ScheduleOfCarryingAndFairValueOfFinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "ScheduleOfCarryingAndFairValueOfFinancialAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Carrying And Fair Value Of Financial Assets Abstract" } } }, "auth\_ref": { } }, "us-gaap\_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "presentation": { "http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of consolidated statement of cash flows", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments." } } }, "auth\_ref": { } }, "srt\_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": { "http://www.cormedix.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth\_ref": { "r201", "r202", "r203", "r317", "r694", "r695", "r696", "r787", "r788", "r789", "r790" } }, "us-gaap\_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": { "http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth\_ref": { "r13", "r61", "r62", "r63" } }, "us-gaap\_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": { "http://www.cormedix.com/role/OtherPrepaidExpensesandCurrentAssetsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Prepaid Expenses and Current Assets", "label": "Schedule of Other Current Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth\_ref": { } }, "crmd\_ScheduleOfOtherPrepaidExpensesAndCurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "ScheduleOfOtherPrepaidExpensesAndCurrentAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Other Prepaid Expenses and Current Assets [Abstract]" } } }, "auth\_ref": { } }, "us-gaap\_ScheduleOfPreferredUnitsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPreferredUnitsTextBlock", "presentation": { "http://www.cormedix.com/role/StockholdersEquityTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Preferred Stock", "label": "Schedule of Preferred Units [Table Text Block]", "documentation": "Tabular disclosure of preferred units of master limited partnerships that have priority over limited partner units in areas including liquidation, redemption, conversion, tax status of distribution or sharing in distributions. This schedule ordinarily includes a description of the preferred units that details various rights including redemption, conversion, liquidation, and sharing in distributions; capital contributed by preferred partners; number of preferred units authorized to be issued, issued, and outstanding; aggregate cumulative cash distributions made to the preferred partners; aggregate cumulative net income earned by the preferred partners; capital account balance of the preferred partners." } } }, "auth\_ref": { "r83" } }, "us-gaap\_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": { "http://www.cormedix.com/role/StockholdersEquityTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Black-Scholes Option Pricing Model", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth\_ref": { "r94" } }, "crmd\_SecondAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "SecondAnniversaryMember", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Second Anniversary [Member]", "label": "Second Anniversary Member" } } }, "auth\_ref": { } }, "dei\_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth\_ref": { "r573" } }, "dei\_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth\_ref": { "r577" } }, "dei\_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover" }, "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth\_ref": { "r582" } }, "us-gaap\_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap-OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "negatedLabel": "Selling and marketing", "label": "Selling and Marketing Expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth\_ref": { } }, "crmd\_SeriesC3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "SeriesC3Member", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetailsScheduleofPreferredStock" }, "lang": { "en-us": { "role": { "terseLabel": "Series C-3 [Member]", "label": "Series C3 Member" } } }, "auth\_ref": { } }, "us-gaap\_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesCPreferredStockMember", "presentation": { "http://www.cormedix.com/role/ScheduleofAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareTable" }, "lang": { "en-us": { "role": { "terseLabel": "Series C-3 non-voting preferred stock [Member]", "label": "Series C Preferred Stock [Member]", "documentation": "Series C preferred stock." } } }, "auth\_ref": { "r705", "r706", "r753" } }, "us-gaap\_SeriesEPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesEPreferredStockMember", "presentation": { "http://www.cormedix.com/role/ScheduleofAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareTable", "http://www.cormedix.com/role/StockholdersEquityDetailsScheduleofPreferredStock" }, "lang": { "en-us": { "role": { "terseLabel": "Series E non-voting preferred stock [Member]", "verboseLabel": "Series E [Member]", "netLabel": "Series E Preferred Stock [Member]", "label": "Series E Preferred Stock [Member]", "documentation": "Series E preferred stock." } } }, "auth\_ref": { "r705", "r706", "r753" } }, "us-gaap\_SeriesGPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesGPreferredStockMember", "presentation": { "http://www.cormedix.com/role/ScheduleofAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareTable", "http://www.cormedix.com/role/StockholdersEquityDetailsScheduleofPreferredStock" }, "lang": { "en-us": { "role": { "terseLabel": "Series G non-voting preferred stock [Member]", "verboseLabel": "Series G [Member]", "netLabel": "Series G Preferred Stock [Member]", "label": "Series G Preferred Stock [Member]", "documentation": "Series G preferred stock." } } }, "auth\_ref": { "r705", "r706", "r753" } }, "us-gaap\_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.cormedix.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap\_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth\_ref": { "r4" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Granted shares issued", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth\_ref": { "r287" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value (in Dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the" } } }

period on either than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan." } } },  
"auth\_ref": { "r287" } } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {  
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":  
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": {  
"http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Vested shares issued", "label": "Share-Based Compensation  
Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment  
instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth\_ref": { "r288" } } }, "us-  
gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri":  
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",  
"presentation": { "http://www.cormedix.com/role/ScheduleofBlackScholesOptionPricingModelTable", "http://www.cormedix.com/role/StockholdersEquityDetails",  
"lang": { "en-us": { "role": { "terseLabel": "Dividend yield weighted average", "verboseLabel": "Expected dividend yield, percentage", "label": "Share-Based  
Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a  
percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth\_ref": { "r298" } } }, "us-  
gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri":  
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",  
"presentation": { "http://www.cormedix.com/role/ScheduleofBlackScholesOptionPricingModelTable", "lang": { "en-us": { "role": { "terseLabel": "Volatility weighted  
average", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation":  
"The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted  
measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the  
share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over  
the period." } } }, "auth\_ref": { "r297" } } }, "us-  
gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri":  
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",  
"presentation": { "http://www.cormedix.com/role/ScheduleofBlackScholesOptionPricingModelTable", "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest  
rate weighted average", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk-Free Interest Rate",  
"documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth\_ref": { "r299" } } }, "us-  
gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",  
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": {  
"http://www.cormedix.com/role/ScheduleofBlackScholesOptionPricingModelTable", "lang": { "en-us": { "role": { "label": "Schedule of Black-Scholes Option Pricing  
Model [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information  
associated with domain members defined in one or many axes to the table." } } }, "auth\_ref": { "r270", "r271", "r272", "r273", "r274", "r276", "r277", "r278", "r279",  
"r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r296", "r297", "r298", "r299", "r300" } } }, "us-  
gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype":  
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":  
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": {  
"http://www.cormedix.com/role/ScheduleofBlackScholesOptionPricingModelTable", "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair  
value of options granted during the period (in Dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,  
Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting  
period as calculated by applying the disclosed option pricing methodology." } } }, "auth\_ref": { "r290" } } }, "us-  
gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-  
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": {  
"http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Outstanding RSUs", "label": "Share-Based Compensation  
Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-  
vested options." } } }, "auth\_ref": { "r276", "r277" } } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {  
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":  
"ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "presentation": {  
"http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Granted aggregate shares", "label": "Share-Based  
Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award", "documentation": "Number of shares purchased for issuance under  
share-based payment arrangement." } } }, "auth\_ref": { "r784" } } }, "us-  
gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri":  
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain",  
"presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": {  
"label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth\_ref": { "r272", "r273",  
"r274", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r296", "r297",  
"r298", "r299", "r300" } } }, "us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {  
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":  
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": {  
"http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price (in Dollars per share)",  
"label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation":  
"Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth\_ref": { "r280" } } }, "us-  
gaap\_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":  
"ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": { "http://www.cormedix.com/role/AccountingPoliciesByPolicy", "lang": { "en-us": {  
"role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting  
policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth\_ref": {  
"r269", "r275", "r294", "r295", "r296", "r297", "r300", "r303", "r304", "r305", "r306" } } }, "us-  
gaap\_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri":  
"http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",  
"presentation": { "http://www.cormedix.com/role/ScheduleofBlackScholesOptionPricingModelTable", "lang": { "en-us": { "role": { "terseLabel": "Expected term (in  
years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected  
term of award under share-based payment arrangement, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months,  
and thirteen days." } } }, "auth\_ref": { "r296" } } }, "crmd\_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantdatePercentage": {  
"xbrltype": "percentItemType", "nsuri": "http://www.cormedix.com/20240930", "localname":  
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantdatePercentage", "presentation": {  
"http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "RSUs grant percentage", "documentation": "Percentage of  
grant date shares.", "label": "Sharebased Compensation Arrangement by Sharebased Payment Award Options Grantdate Percentage" } } }, "auth\_ref": { } },  
"crmd\_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPercentage": { "xbrltype": "percentItemType", "nsuri":  
"http://www.cormedix.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPercentage", "presentation":  
{ "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "RSUs vested percentage", "documentation": "Percentage  
of vesting shares.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Percentage" } } }, "auth\_ref": { } }, "us-  
gaap\_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare",  
"presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Common stock per share price (in Dollars  
per share)", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth\_ref": { } }, "us-  
gaap\_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": {  
"http://www.cormedix.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance  
(in Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth\_ref": { } },  
"us-gaap\_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crd": "debit",  
"calculation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet", "parentTag": "us-gaap\_AssetsCurrent", "weight": "1.0", "order": "3.0" }, "presentation": {  
"http://www.cormedix.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term  
Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term  
investments classified as other and current." } } }, "auth\_ref": { "r91", "r92", "r711" } } }, "us-gaap\_SignificantAccountingPoliciesTextBlock": { "xbrltype":  
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": {  
"http://www.cormedix.com/role/SummaryofSignificantAccountingPoliciesandLiquidityandUncertainties", "lang": { "en-us": { "role": { "terseLabel": "Summary of  
Significant Accounting Policies and Liquidity and Uncertainties", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for  
all significant accounting policies of the reporting entity." } } }, "auth\_ref": { "r76", "r149" } }, "dei\_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri":  
"http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": {  
"label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as  
soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth\_ref": { "r580" } } }, "us-gaap\_StatementClassOfStockAxis": { "xbrltype":  
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": {  
"http://www.cormedix.com/role/StockholdersEquityDetails", "http://www.cormedix.com/role/StockholdersEquityDetailsScheduleofPreferredStock", "lang": { "en-  
us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth\_ref": { "r112", "r120",  
"r121", "r122", "r152", "r170", "r171", "r173", "r175", "r181", "r182", "r204", "r224", "r226", "r227", "r228", "r231", "r232", "r235", "r236", "r239", "r242", "r249",  
"r356", "r433", "r434", "r435", "r436", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r460", "r481", "r499", "r511",  
"r512", "r513", "r514", "r515", "r692", "r721", "r728" } } }, "us-gaap\_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-  
gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://www.cormedix.com/role/ShareholdersEquityType2or3",  
"http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by  
component of equity." } } }, "auth\_ref": { "r9", "r55", "r58", "r59", "r113", "r135", "r136", "r137", "r153", "r154", "r155", "r157", "r162", "r164", "r166", "r180",  
"r205", "r206", "r216", "r252", "r314", "r315", "r318", "r319", "r320", "r322", "r323", "r324", "r330", "r331", "r332", "r333", "r334", "r335", "r337", "r362", "r364",

"r365","r366","r367","r368","r370","r372","r382","r411","r423","r424","r425","r438","r499"}}, "us-gaap-StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://www.cormedix.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth\_ref": { "r153","r154","r155","r180","r372","r390","r432","r449","r452","r453","r454","r455","r456","r457","r460","r463","r464","r465","r466","r467","r468","r469","r470","r471","r473","r474","r475","r476","r477","r479","r482","r483","r484","r485","r486","r487","r488","r489","r490","r491","r492","r493","r494","r495","r499","r563"} } }, "us-gaap-StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth\_ref": { } }, "us-gaap-StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth\_ref": { } }, "us-gaap-StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth\_ref": { } }, "srt-StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": { "http://www.cormedix.com/role/ScheduleofBlackScholesOptionPricingModelTable", "auth\_ref": { "r167","r268","r693","r697","r726"} }, "us-gaap-StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://www.cormedix.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth\_ref": { "r153","r154","r155","r180","r195","r372","r390","r432","r449","r452","r453","r454","r455","r456","r457","r460","r463","r464","r465","r466","r467","r468","r469","r470","r471","r473","r474","r475","r476","r477","r479","r482","r483","r484","r485","r486","r487","r488","r489","r490","r491","r492","r493","r494","r495","r499","r563"} } }, "ecd-StkPrCOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrCOrTsrEstimationMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth\_ref": { "r592","r603","r619","r654"} } }, "us-gaap-StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth\_ref": { } }, "us-gaap-StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": { "http://www.cormedix.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Cancellation of shares held in escrow (in Shares)", "label": "Stock Issued During Period, Shares, Issued for Services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth\_ref": { } }, "us-gaap-StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": { "http://www.cormedix.com/role/CommitmentsandContingenciesDetails", "http://www.cormedix.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Stock issued in connection with ATM sale of common stock, net (in Shares)", "verboseLabel": "Common stock shares issued (in Shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth\_ref": { "r9","r54","r55","r82","r433","r499","r512"} } }, "us-gaap-StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": { "http://www.cormedix.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Stock and pre-funded warrants issued in connection with public offering, net (in Shares)", "label": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth\_ref": { } }, "us-gaap-StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": { "http://www.cormedix.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Stock issued in connection with options exercised (in Shares)", "verboseLabel": "Issuance of exercised stock options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth\_ref": { "r9","r54","r55","r82","r281"} } }, "us-gaap-StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "presentation": { "http://www.cormedix.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Cancellation of shares held in escrow", "label": "Stock Issued During Period, Value, Issued for Services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth\_ref": { } }, "us-gaap-StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "presentation": { "http://www.cormedix.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Stock issued in connection with ATM sale of common stock, net", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth\_ref": { "r9","r54","r55","r82","r438","r499","r512","r569"} } }, "us-gaap-StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueOther", "presentation": { "http://www.cormedix.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Stock and pre-funded warrants issued in connection with public offering, net", "label": "Stock Issued During Period, Value, Other", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth\_ref": { } }, "us-gaap-StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "presentation": { "http://www.cormedix.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Stock issued in connection with options exercised", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth\_ref": { "r9","r55","r58","r59","r82"} } }, "us-gaap-StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": { "http://www.cormedix.com/role/ScheduleofAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareTable", "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Shares underlying outstanding stock options [Member]", "verboseLabel": "Equity Option [Member]", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth\_ref": { "r562"} } }, "us-gaap-StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet", "http://parentTag", "us-gaap-LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "calculation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet", "http://www.cormedix.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "totalLabel": "TOTAL STOCKHOLDERS\u00202019 EQUITY", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth\_ref": { "r55","r58","r59","r78","r462","r478","r500","r501","r552","r570","r722","r740","r806","r846"} } }, "us-gaap-StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": { "http://www.cormedix.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS\u00202019 EQUITY", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth\_ref": { } }, "crmd-StockholdersEquityDetailsScheduleofBlackScholesOptionPricingModelTable": { "xbrltype": "stringItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "StockholdersEquityDetailsScheduleofBlackScholesOptionPricingModelTable", "presentation": { "http://www.cormedix.com/role/ScheduleofBlackScholesOptionPricingModelTable", "lang": { "en-us": { "role": { "label": "Stockholders\u00202019 Equity (Details) - Schedule of Black-Scholes Option Pricing Model [Table]" } } }, "auth\_ref": { } }, "crmd-StockholdersEquityDetailsScheduleofPreferredStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "StockholdersEquityDetailsScheduleofPreferredStockLineItems", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetailsScheduleofPreferredStock", "lang": { "en-us": { "role": { "label": "Stockholders\u00202019 Equity (Details) - Schedule of Preferred Stock [Line Items]" } } }, "auth\_ref": { } }, "crmd-StockholdersEquityDetailsScheduleofPreferredStockTable": { "xbrltype": "stringItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "StockholdersEquityDetailsScheduleofPreferredStockTable", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetailsScheduleofPreferredStock", "lang": { "en-us": { "role": { "label": "Stockholders\u00202019 Equity (Details) - Schedule of Preferred Stock [Table]" } } }, "auth\_ref": { } }, "crmd-StockholdersEquityDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "StockholdersEquityDetailsTable", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Stockholders\u00202019 Equity (Details) - Subsequent Event [Member]", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth\_ref": { "r369","r385"} } }, "us-gaap-SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth\_ref": { "r369","r385"} } }, "us-gaap-SubsequentEventDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventDomain", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth\_ref": { "r369","r385"} } }, "us-gaap-SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth\_ref": { } }, "crmd-SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetailsScheduleofCarryingandFairValueofFinancialAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetailsScheduleofCarryingandFairValueofFinancialAssetsTable", "presentation": {

"http://www.cormedix.com/role/ScheduleofCarryingandFairValueoffinancialAssetsTable", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies and Liquidity and Uncertainties (Details) - Schedule of Carrying and Fair Value of Financial Assets [Table]", "auth\_ref": {} }, "crmd\_SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "SummaryofSignificantAccountingPoliciesandLiquidityandUncertaintiesDetailsTable", "presentation": { "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth\_ref": { "r647" } }, "crmd\_ThirdAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "ThirdAnniversaryMember", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Third Anniversary [Member]", "label": "Third Anniversary Member" } } }, "auth\_ref": {} }, "srt\_TitleOffndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOffndividualAxis", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Title and Position [Axis]", "auth\_ref": { "r734", "r809" } }, "srt\_TitleOffndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOffndividualWithRelationshipToEntityDomain", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Title and Position [Domain]", "auth\_ref": {} }, "ecd\_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth\_ref": { "r639" } }, "ecd\_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth\_ref": { "r646" } }, "us-gaap\_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": { "http://www.cormedix.com/role/AccountingPoliciesByPolicy", "lang": { "en-us": { "role": { "terseLabel": "Trade Accounts Receivable and Allowances", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth\_ref": { "r99", "r100", "r101", "r736", "r737", "r738" } }, "ecd\_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement" } } }, "auth\_ref": { "r667" } }, "ecd\_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth\_ref": { "r669" } }, "dei\_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth\_ref": {} }, "ecd\_TrdrArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrAdoptionDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth\_ref": { "r670" } }, "ecd\_TrdrArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrDuration", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth\_ref": { "r671" } }, "ecd\_TrdrArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrExpirationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth\_ref": { "r671" } }, "ecd\_TrdrArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth\_ref": { "r669" } }, "ecd\_TrdrArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndTitle", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth\_ref": { "r669" } }, "ecd\_TrdrArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrSecuritiesAggAvailAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth\_ref": { "r672" } }, "ecd\_TrdrArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrTerminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth\_ref": { "r670" } }, "crmd\_TwoThousandAndTwentyFourATMProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "TwoThousandAndTwentyFourATMProgramMember", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "2024 ATM Program [Member]", "label": "Two Thousand And Twenty Four ATM Program Member" } } }, "auth\_ref": {} }, "crmd\_TwoThousandAndNineteenOmnibusStockIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "TwoThousandAndNineteenOmnibusStockIncentivePlanMember", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "2019 Omnibus Stock Incentive Plan [Member]", "label": "Two Thousand Nineteen Omnibus Stock Incentive Plan Member" } } }, "auth\_ref": {} }, "crmd\_USGovernmentAgencySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "USGovernmentAgencySecuritiesMember", "presentation": { "http://www.cormedix.com/role/ScheduleofAmortizedCostUnrealizedGainsandLossesandtheFairValueTable", "lang": { "en-us": { "role": { "terseLabel": "U.S. Government Agency Securities [Member]", "label": "US Government Agency Securities Member" } } }, "auth\_ref": {} }, "crmd\_UnderwritingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cormedix.com/20240930", "localname": "UnderwritingAgreementMember", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Underwriting Agreement [Member]", "label": "Underwriting Agreement Member" } } }, "auth\_ref": {} }, "ecd\_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth\_ref": { "r666" } }, "us-gaap\_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "presentation": { "http://www.cormedix.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) from investments", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth\_ref": { "r53" } }, "us-gaap\_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": { "http://www.cormedix.com/role/AccountingPoliciesByPolicy", "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth\_ref": { "r26", "r27", "r28", "r105", "r106", "r108", "r109" } }, "ecd\_VstngDtFrValOffEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOffEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth\_ref": { "r635" } }, "us-gaap\_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": { "http://www.cormedix.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Warrant [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth\_ref": { "r560", "r561", "r564", "r565", "r566", "r567" } }, "us-gaap\_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Common Shares Outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth\_ref": { "r169", "r175" } }, "us-gaap\_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": { "http://www.cormedix.com/role/ConsolidatedIncomeStatement", "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Common Shares Outstanding", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth\_ref": { "r168", "r175" } }, "dei-WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": { "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth\_ref": { "r683" } }, "ecd\_YrEndFrValOffEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOffEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth\_ref": { "r633" } }, "std\_ref": { "r0" }, "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1", "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubParagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14", "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "SubParagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "SubParagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1", "r7": {

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

"7B","Subparagraph": "(c)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"},"r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "80","Name": "Accounting Standards Codification","Section": "50","Paragraph": "2","Subparagraph": "(b)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"},"r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "944","SubTopic": "80","Name": "Accounting Standards Codification","Section": "50","Paragraph": "2","Subparagraph": "(c)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"},"r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "946","SubTopic": "205","Name": "Accounting Standards Codification","Section": "45","Paragraph": "4","Subparagraph": "(a)","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"},"r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "946","SubTopic": "210","Name": "Accounting Standards Codification","Section": "S99","Paragraph": "1","Subparagraph": "(SX 210-6-04(12)(b)(1))","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"},"r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "946","SubTopic": "210","Name": "Accounting Standards Codification","Section": "S99","Paragraph": "1","Subparagraph": "(SX 210-6-04(18))","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"},"r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "946","SubTopic": "220","Name": "Accounting Standards Codification","Section": "S99","Paragraph": "3","Subparagraph": "(SX 210-6-09(4)(b))","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"},"r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef","Topic": "946","SubTopic": "220","Name": "Accounting Standards Codification","Section": "S99","Paragraph": "3","Subparagraph": "(SX 210-6-09(7))","Publisher": "FASB","URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"} } ZIP 55 0001213900-24-091961-xbrl.zip IDEAS: XBRL DOCUMENT begin 644 0001213900-24-091961-xbrl.zip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j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j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

[illegible]

[illegible]

J5J)J"J&P!\$XJQLA[0J4I<[I, M7.BWJ/P8 I[(A, I).ENN3K&J D JK'2TVW#IT&G%(770H)YW>= M]=E#G\$UQ0S,2?FEY5WJ&%,CWE<=%#LTZU7VG  
M7LNFN'J'18%=<F<L<=,/:TXB5#.Z&HWXJA,OP8793I\$Y>J4QJLZNVFLI, M5K1ZCHBB,C1JV 3S9<50 QKB%.<XJ>J>L,G7 M=B^&4MCT#3K<3,X 7BHT N9R<46N[KQ%-  
IEY1\$5<S<9+=<GJ>GR<O, M 5<5CH,B<<0>+<JOM&U2S8.RV3\$Y,M,H'ZVG9'2B'Y#<#<82EO F5>^,19,M 40\*0ARF<CG\$>JH9V<X1U2.D4A 16CIE6C<="B'VX 10JE10>1JQ<=HKHJ4I  
MAJ0V.OE3U0<=0<K6F7I EUANU0A, XE9CF<+<G8?<^M'97P'JYUJ>+M.N B MDY!#Z1 KI 'X5<A<1'98\$C'FEU.Y69,97T<V+D6\$W,54ZJ5^A>+<R>AY7 (47 M<^<B<&+<1  
[L7AL%R)5SGY\$?>.>L?=-&B#RKYKJ<TDPR8/7N,9#?BX9 M%?H.4K[I0,7,49C<J. T.A& JQ6DT ML&9P.72VDI?>J4.CJLW2K6Y0\*H,NXO<2Y,Y<^<7.\$=E[QFZ]GP4JK\$E4GJ9  
Mj610GUQA0.O.S3J IQD<16C93<+<S<J'2B3DREATF5\*%K<XX2I<+3IV5. M4C<=<#J KIKRP? S< XPIJLWW.X11 AF3<+<I G,(5ROB5<AZB'XH>GR5TD  
M5.8JEIY.WB.K<EJH2R<IADCSH7+7\$D<WRE!T,Z9X)AOTP80#7UF6QC8C4V<@J<=<61U1<^2+?> MRC>P<1W2GKT,SKWIPV2>BZ1IGYY#<MVB)Y#<+<U(I PK5  
[E0EP1ORJQJORS<P<@<OS&44TB7?F<=J)M5MF8VJ, M(6<LX\$KJ IJUH,(J)J#1+5<7WK<+3M.C8.Z2U>2)R>>+V8FK0<UUVQ X6RTG MCFDY4R2IJ7J\$65  
M<^/BZOE53(4W<CY9<J)Z)B0.#11UE<AS MZ9<560N\$8U<W<JH'7055W'RI9C.16X<=<7Y<FUS4%<531.TF.JQFDVFU<X#<MDJ)U8KE\$<[IMB<=<62F7U?  
BA\$\$(M'D?>J)\$.%\$F6KM8<.\*G'ZONJIF<'S&A[I<MQ.G<3H)SN<GG.48=PO,TK<=<M8<PVTX9'F=L\*3%K%45F6W01FI'N108X MJW<87'.IG.<@!%<+<?>  
Q4\$YVYVJNK7L'UHF'2\*2G1U<J'104W4V8J[3]TXV3RT=<M5?>J>1E=<J'UQZ2A6J?>E3ZJ/U=JR#2#ZWM3<('H4TLPOJGMZB7<KX9 1EXK\$ M1XUOSZ?>HV2S">F9#<8&1W(I\$P<2QW)>D-  
YW<V+VN.E(4I2+U<LJ1,9I\$5J4.M40.L3\$BVUMU\$LS,ZI90J)EG,FG,H 5<5UEI&91#74O.J+>=<B'XV1/I,W2?59I&A0 M8F1M#N%N<X<15>,>Z96EPP6M%J+20N.S\*2BL8 B5MQM#K6ZS%G9B 4R(I"  
<JNC MR.LROL0TKRSM2QCG[0AD)U.I.<I&Q\$.GH,73(QAYSA<4+UNPQQD[BP.PJ

YF%0WDV-MDD3:J1I W+EW=<17Z,7X<ZFO+TJH7LH,.\*=Y,7@8E\*2(CJH,1FP MA.#,D\*^<N+T" G1TET'IS I<^V?0PF>8E L! M?>JYF<=KC9)=<K IT#<  
<TS3W\*2R(N\$<SU01+<M0\*%<.<IK#<J'N1NOOD(Y>>+<J M SLY<2C5H4OQJHLELX\$ 7U3ZJ>+<J#<E(EJN%OP[Q\$ 55+5<=7880J)F, M=<?X>659RA78 14U  
CURLH11V>FQZSFAA4W>Q?>XRJ(B9YF=<B>.>O1RN MLY<ZD7GH8 C.<P23C&G16K26R\$<A>B%<IA +53A4"3YLI.MQ'M<VTS<GQ M\$4+  
[>+DZIKU<=QMCGM4UJYC\$7?<=CPJXYJ'J'>?50D2J4VW)2\$9,S3,W4<M Q=>7>12P<R1+XGIE7N P>=<J#<+ZP4 DG<9%<S1(4Y)>+12 I83Z2T  
M16J16JZ,.\*<AIDYI'U+<\$<S\$<S'R8 OMVXT<+<[WH<=<#M182201H>GV81\$<M'J093J<#<J/I<=<D4GH+W I0&W.7K1M&6[3I9W'MKEI<A>+<I=<TLZ54JWL M\*DUUC<C,Q0W6Y.T\*YI<.  
[SU(67=<+B?53]<CGX1NN 9.72QGM,A%RKF CDM<X(H/ WB8)<J4 U47/IJ.E Y<(<J1NIE\*\*WG60,5K YVY<^W M%EL[TVWT?QPM.YG<AA5(QE2BWY33\$?Z% P MH4,JE%L,+<?>  
NIG(I'>R7?<=<9G240<=<9B>6N'N?<=<#5 M7UHL<J4KRXH<25V1K%1QHJ4Q1 QS=<H6HW\*M7FJA6Z<WX 108XBZ<J4=2#<I MMU7<P<TLOWJXVJ<J+Y+P5TITG2+<JN  
<..J/H#<#F7G<+4 NRU6\$?6>.<P0(B1140?>2A^<WGT8L KI+1> M70I\$5<4C^<J4 T<10,+S7I,G 33C\$5I'<J'FJR XFFZ9C8/8D?>1>L DHB M32,32W4.G YW=<S<+<FB5CE1<(",  
(Q)G4E<J'FL4K6G92<L=<6" ALT\$<Q4< M83K2G<C<."K14A43L&S<@<JL<C@<1.0UFEX2\$<L/EI.WY'14EJ'Y2P JI 2LG M, P3L 44%?27Y<I MQ<L4Y1>  
LM5PZ<[J#<Q4VJC[0J<A<=<SBL6PRHX 6.6 MN2[SKL21NU0\$+<W+LJ4QIKIM<OG8O3<+<=<DYS'E<=79HD?>4>NX8J1>.>YR MGY<+<J.C;ZX8FESN3\$<+1HKT+4J'B'M<^<  
+<PVI'XCLTS#<S+W>>08ISJDG M/AORZJ.YO414B HXI\*.\*=<N^Y3B7L>=<=<(<+<U Q10=Z.IA+C9GLST/P7M4% MYGX AXMUS<=<6.3X.VNZ>BLX=<1'5 MCU#F+<^<J+U #\*AC H4?  
MHC#279=<+<T,8 Y#<C&J<+<UZOJ8KN<Z2C<B<41<ZGV1V'J \$UG<=<^H<00\*%M1JH'J'<J1J6P60?>4.#(2B+34,1ICEE<Y1W0\$KKGU#<J'P<@<HB8R1.MH?  
1E2U4TSW\$<RDR(MK1<=<Y\$5XF218I<0'0CD1<0'<M&B' B ZVND. MTN<F(XI(A0>QRZ9JHMF6D<@<1VVD=<17"X<0'JQEWG10<=<YK%<=<=<KG\$Q'12Z MWC64=<.<Q4&AYHK T&ZL 4=3D?  
<M%\$<U#EM3X<+NLM7GCGUCQJ<5'<5OD<B7YX MP\$3D JTL,=<=<@<J%<P.9DM4<7O+<14\$0XGQ+P6?7JLY8377?>J IJ<+<J JMA40RU.T&B1.TPH8.6<=<42>=<I<^JY2Z<B9UJY<  
M00%0<+6JHJ<+7H M0BT2X8KJA 5EV6&R8'0YD.U>+<K&DJ'CX.P<+<=<69O3J[P4TK6P\$YS2>J>=<M%#<Q<=<J5&4D6<+<3B7'MDIT+8%<T008<+<JL<@D8E<WYF M.UQ,Y<E  
(TQ!:<=<=<=<M0)Y%\*<ACS'BQB6G70R80VB6/7(=#<J.O<C^JZ.DRR<3 M"><=<7V,>8C#7^D+2)<@<ITC\*?P7O3%Y RB B'H[N]\*PK<J4172>W%\*6,J2JN,M:\$7MJN2+J+NV('E  
L8<IM(O<=<C&B?<01Z M4M,5M2?67>,>M2<EB@<I=<BKZ9J<6EH<=<SBHJ\$5<1H2>B(7>O..WB4V/ME #Z1A07\$K\$RTJZ>XRS#<J'<+<#S#HYV "QO>K75QJ?>MG>08B7BH)8#<  
PV9%J/10>J+2<=<AF0S&BH/2L6ZKJ(B1\$<=<=<J>A Y<LO^<H7 L M47>?>#<P&N)DCLJ\$F64Z.00(FN69?>J1.84+<9QZFE#<.<J4V7 T3G#<E9U0U4J4<1'5F27?>=<54XQUF2M4%1,7Z. 3CVDJ9CJQ<  
5I'<R<=<#2M5 ME\$60.0<=<AVUJYJ1(M1.MFPOQ<F<?>7X\*%M MN Q90JWBWF.X3\$OC5JZL3I.E C6 6ZR1A3S<=<J4J7 7D\$F.IR.#ZL4=G M0VPZUJ<=<R/<K<KLAY+08+<J'<U>A3I&UE1#<+?>  
T\$N.A.#<9QJ)DB1<=<NENKC MC7P>=<=<UPL212(6BWMD2C5I<7.H1YH7W?>2XGJ1<49+<9#5>J1 1) B#XJ<@<J4J MJLN=YW4<O'<OCL#2JGX7M,RJ)D.GOGPEQ9?>2\$YJIT%<=<  
{3:<HRNTJ3Z4,<J M6VU=EZM5Z.4O.Y1<W..9\$7+6#K=<9>@80%PI%<+<SKFJ<^8JJU<^B9 I M7Z3JIRMFST8C IP SI417V0.JH%<C5Y41GL<""7."6QC<@<2\*OV<369OTRRLE><=<  
<7,2R,G0@=<=<K40C95W98YU2IG J<=<JN.IU7>>P J MYFF2J2EIV.QX5%+<L+J=<@<V63%<QWL=AW?7Z,<[PC\$GE06B+0<=<+WF0786 M.WUFIJ'CY#<=<3#<#H.ID<L^R15R0?>  
<+<Y>J TJC0\$E J.M<O>XU<+Y I=<GCAI'QJZLU0\$XKR<1'1.4H6WR7.TI2?<KZF<=<C NGAXA<12GL<@BPA MIUUIBUIOG572W&Q6Q A R<J284J C.EROM<P4J+5Y#H6JF/LV&B=X5:1  
M\*+<52A<@8D"WBW\$<V58JQ<2>J"R50P<7?>J MY\*#<C9+IY<=<Q&S<12+V 6J M%7Y>E V."""QQ KJ'Y\$<K GDQD 9U1U&6K.9&1 NRAVU1<Y\$YTS1LT<I<^<=<9S<=<\$ MF<  
A=72IR4WKGXNGNIR4V8\*+<6LQ'F)U486SS8".JIYX<J,GI<F&A%MSC=<M5!GMU'S6[OGQ&KJ'6E A<J'<F4KJ'<F.FA\*#<=<A+C89IEB BF&C<  
M>=<=<E=<5%2J,M6<J<G<=<6%6A=<@<1\$<64K1\$0ZLN&L<CJF,B V7Q3\$HJ<@<+<J M.0258JSHJ'Q<CT24?>#F6IUI#51<^<X.S<^<A#<=<ODB9+57JU<XMXJ>C7)M7 M\$D2\$<B15SG<J7JH+W  
FLK=<=<V4\$<B1EY<CJ87)T2.M2MNH<^IL.LI<^<YPB \*M2>A%<BGP+<O\$[I<C1OM6M5\$7ZE@<+<Y&DNJ09TFF+<=<=<O&W6,7AV\*28).G1 MY<@O3C1>K+UTZ"AAQRY3A44#115+<  
(H+<^PU62J4<O>+<B M\*7J1.D3=<=<JRC3<4TVI<XKN9A)OO<@RVBN&A<URU>2 N<X%?>@<K\$F4&R2.Y6 M76J[0J2]<J#J\$M750LDQJ G&J NAL(\*ZUHO<V123>=<UJJP=344 M<  
JG30\$<^211Z[B&SD7JG)<8+U?2JUL89\$9+<R?>J7\$ 8,5 M\$2NM[<@A.2O>+<J4%<Q0H>ZS>=<JY'<0@<#<=<W,14BB<33RTOPWBLZK.KA 2A  
M%<@<J/9(I<Z5JB&K\$<M\$<J#<QJ)GNMSZQJ<C.#4#1L#B>UO<=<SXTV\$B5%<5 M6%N4A CJQ64\*3,V1O<I<LVXC>1 N<N3<J<^H%<C> M8 HX7(\*V97A<C,)[M201<@<=<JZ6L?>  
>H4&X%594 %NS\$?>7<=<JBF M M'OVX=<[<=<C\$ 1JN17Z<QYN L7?<PHNW\$1.2).S2&K18,VAC6 M1W.9&K.MKF#1,7Y7.  
163>VHC\$1M,W J/G1<=<CUKK.#2EAO67JZT.CP870,S2:R(>?>T0<@<B<NVN MBRJ<@<Q\$?>=<QMJ#<J7R.D85I<7ZBM1<1?R I\$1?>J4JBBQ\$<G'<=<P6F7?>M/U/LAUZIEB&VJMO7\$?>  
>UV\$1FYH<=<@<IUOZRFKM,7I<7GJ1.46 YF(I+1 M&=>>73JXD0=<=<WHYR'<M\$G7<1B<8?<0'Q&5YDJ<C<VD.GX4K\*6G VDU YNU<+<Y MO&P'1<=<X,M,E,D2Q\$XPYEC4628 NIS U  
G1H<CF7J6<G1T\$T1OQ\$2N4LQJ M1.TDQ>#%<S(QQ?>W>=>C F7T3?>T3S<@8HOJ\$S<QE3 O<2)B)W8EK[IA2\$B0E2>M8\$ TJI<=<QJ<@<U ML<I&K&A\*%6ZIHLCF\*=<=<C DY2\$%<@<  
XV.G/OXHA<("GYA3TO>5>M\$W\$3&LS\$E<@C M6K.C,M(J#RXI<LWC.LSC+TRTU<F<CJN<N%JY4C9J /9R7R?>V5?72Y.YG+<+<1J,\* M>JSE<I<=<=<7I)PC<@1E7Y8==WY6Q8\*%QSY@<=<  
Y.6J1NWR<=<GR<28W(G\$+B=F.M I'P2I%3%<FCF3QM<B5FB<(<SX<2<=<Q@<P. @OE3&KJ&E.88>U6&C01RRDM1 M4.  
(N<=<3C V\$<V>=<LDGUT>=<J9&IO&3)Q3UI<@<CGJULOK<I.D2AAT19H.GI9>F&R M+PD.SXTH29&S66<6+3%J0>99N?Q.U<NRO?7G<V D8M1?>3K\$TXAB2T@0\*<R< MHQ\$?>  
#<W64\$<V4778HLQ1.QZUL8BJ1G3 .35VUN\$M'OI<=<8<X7K72QJF93JY MQY'W2FH.<@<5L YJ M3B'<CDI4V&A8KJ7JHHW5<7M8J66\$<M2R&N+I"=<  
<=<JRFM,J<@S\$5=M<IVE<E.B.JZD&))Q"1N%<BFI,Y<@<N)SNZ815B=<MJU.U7F<DYX2ELN#L3JE1\*AXB14E6MEC<QY+<2,0<9\$#1.8"4+<I Z<[S] MXXKIX6 /L7=<#0 JKS!  
US(\$4NFT?H5\*=<IVE90JW<QIRCL)7)FQ)<@<WRZ,R\$E M.J,AIJ<D+JK+V^K'U+80+<J.MGWMO178:WMC4>B2+<@<ADOB>G<Q>0ET?<T,OL M)DPWM)<J[<@M  
12A<C.70<J6Z68L2EK7GVAHJ\$P\$>=<DEO<67I<@<HPX0 M8?>BHH)K4VE@<I=<0\$<9>R<F=M<38FE1L'WK'R78=<=<@<HH<=<=<@<9LPWX,YJY MX+I[<H<@<H!<R>XQHXMK5K5JD?>  
8.WOO<@<M<=<P.W<AC4\$116I<U7Y2X4<=<F.FEJY23C7?1A[L3J\$<=<OYT<P#<I<4XB1C6 ME6(VIYVBJ<@<1T2T<@<J.35E)B'INN%IYQ 3?>VUUV<1Z8\$5<I"Z05+1GY+R1#<  
[H.UY=<VR1<=<CJW<M?>IAMI?>=<IW4ODXJ1M'<JBM2M'.BIXOJJIHTA0B,I=1<L\$<V<1"VLZ1 M2SJ[5D<J7I513BTA,"I#X1 1JTDKAHJN(N4I5)QJDKS<=<4F4(RY6H)G  
MCKSZ64F+QJ7PE65,[NDL3S8X\$<LHR<(<H<^<V=<=<MN%N<90EF5MUT570Z7)%0 M6I1>J1<1RQ0<(<=<9L+5J<=<(<N<@<K<=<9ABD5625,9+0@<U M'TB5 EF=<MNJ6X>=<B\$>=<+<+<=<?>  
<1>+<?>+<G#B<@<3%<K&J+<+<6J4U<XXQ<@<HWWK MEFJOTJ.Z3,V<@<IABVJL<JXW<=<7 GEF=AA\*31TH8Y A13A1K&J)<K&J)<=<=<W6VC M1<2<=<=<Z?>  
\$2FT&E+<#J\$>ZM7JYL=A1D7HNBK>=<?>E746 EWRBPBD,PVT81 M8<1JG<+<+<1VB0\$ 41Q2X6G8M M. AI<=<2VOPCX6.K'SHW<@<1.15X\$J=<M%.POQ<@<C0V55.0\*55CJ05>^<HH0)<  
M2+3 L<P<L7A<QJ>?<=<U<@<N#1<@<R\*QOTPTP87J7B?>XJ,M,M\*%<T,V 6L3 MKV26L3V.0.#1Z<=<IQ4>8&K<L U5(UZ40LL+5Z284Z7JC1AMBZCM<=<  
M79.NTX<F=D DNY<=<=<3J&J<R@<MHP<@<APRU'MAI\*8EGY<4X<=<+<4<V ME\$<=<#11R,701%>TBP(JJ3.YJ)<J9IBJF  
[%H:<JQKMPFB+<1<4&%MAU<=<EZ.Q12@<#<^<TM,2X)<@<BIENG M33V M6]=<E+<D+<I1Y%<SK15=R NTVMPESJN 9IEJ<@<H4.O\*8"106 EW&A/Y1>71: ML\$<+5RK9"G3\$ 6\*3TQ#>J)JL  
<FQJ4PF\$<M7A26JG2S M1Y+Y N03B=<=<L<TN627J2PWCSHRSX,Q586O1Y.6@<J E4=<4LNZEPJ<A'<T'<I'<R M<TR5CI.SV\$V8<+<1L 0.Y<Y>J, VJ<+P1R@<P'N?30M\$<=<L+Q6700U8O<81<^VJ  
MOGZ252298XJ'0UBJ<+<V\$ M073T3G<V<@<N'EF..UHJ3(LR5(17K 9%QZ6<IQ2?>+<D<=<IA4.OZ\$8<=<IF4 M14F6[2KK7J.46UUIJDDQ+5H  
P7U,QUBEA6I<U<I M1<@<N8=<=<X8Z,87J>2BNQM? M084,GPM+<TRO<=<19Y%IU8W<@<UUN\$QX<93GLVY%<H1M<@<O81)2>=<=<SRO\*M JMTD1Z)XIXJ7J2D2<BUJ%<=<  
N7U>UBEG16+<B<0P<=<W<+X<FGR88J8JZJ\$J 1.6I M.<V90U5QCG.LBA\$<TZQ#<=<016JXUNXQ<=<#<6F14GEM<=<=<@<82+4YX<=<J=E<=<M1NN+79UJ+<#<=<2Z8JRTPTIAL[XL1<^<=<R<J  
+15PH.5X3>ZT M1 E7K<@IY6RMBP)<7G8'IO>LE=96DU TIF.9.8TEFMZ=<=<3JJP<@<7%<L852L?>M2 4=<JW\$W<6WC\$Y2X<4V?>L6<,<UG 5<^E YB.570=<JJB<^<=<=<=<M.<@<U&E7#  
M43\$> 3R20% C/7Z9P<=<V77F7J<=<I(YBR P<2FJ2J45D\$2<1V1<+<?>%94I7 MZIG,E&5PCZWB<=<N(FN41+O3S0>J7J67019.L9IG<=<W4A.VA,HAKU<U,4C@<KIN<2EPH9J6LPM&AK61\$<F7  
6NB M09=<9VB1Y&XOUIU9I6>H'LO6<6+<ZH<=<(<B<=<UHTJ3E4F<+<F225<=<(<F M)XLPPE2X4<4CY<+GU<+1.18H112>=<DJ)@<NAY<@<GJ>=<J>X2C/BM1.BFX3J2Y<C1>=<@<  
@<PA06L'N<LU<4<D M1U01P1)<40=<=<706D7442JRT.4X5C\*%<NYUJXUJ0P2J)MIKR<636LEJ1U&XQJY<5&T=<=<F7CY@<Q6 M4+X<S<G&482J JFN,>\_<=<V\$<M0GQ<IC#<=<IM[UK1#<=<  
[B%<=<016060=<2<Q%IRJ1'<N)U5<=<9N<=<6CXTJ.PFR(I MOJ)<N<CUNIE&C6B)8C8.<N\$Y\$HC>0L I<YKUEP=KTC.LB.A7IJBQ6L025G6X  
M1,<@<5BV50SX\$)Y#3.NC.1Q95U)O2U9>=<+<G\*3H.KV7CY#<N8Z?<QV#13Z M.D\$B.U0RX GW'TF\$<9I=<=<78V1%[Q<44N\*2LF S1.AWA% A.C70E DY6H5 M<O5RWL\*G0QB"RC<=<  
#VJ2L<JY&ESA.CK'X&20%Y8J)<M\*F+A06,1GGY<+<A M7<@<JGVGZ8C 6E9851L7.2F%VD<1XQY>=<3K<QD\*GW V'<=<@<=<@<OUL<G<6K(BA.MJ173C0JUAJB<  
S<=<EG9VICUT<=<78Z<QJY<L?>6E@<S F73Z<1UYSJAH9T M4J,6GAHJ7JPLN) L4V73?>NHZ+1HY3329.17J>J)TLN<L4D,3TJ<@<NYSKYI<=<=<RU6 LXB172DAV%Z 32<I824EYD<=<  
M<=<5%<Z5M<+<L&K Y7E05>(<=<=<=<V5JH<@<P.KAU8#QVKM+ 3JHUS<H&HOBQJ'<6% M<U1ZVYR1A8XJ30'J Q<68[B8I'<D\$<O,0+<#<F7Z CMNK156<N)BS#V5CG M.OBI\*FT  
YIRP7\$Q<=<J8FJQ)PJI<@<E?<W7T8ANW&XV<I)M%<5&9GXJ1>=<M<S<L G.R5?<GT<QD2D5\$H2H8G<U=<C0@<2B\$J5Z5GR1#<(<^<=<O VCH3DK  
MHW1A6XLDS(D=<E#<Y#EJ<@<4<=<K\$<@<CT.WWF=<M18B>+I,073/<=<R+<JY<@<N<H MW44HSX%=<B+YQ6J90U.DU2<NL>JZ7P,FKED02HJ\$KJ/34.A<VD2/MGU M%<GDOH  
A1<L2JTGW53J.M#M<=<3J,<S1O/LY94.1+<IOC HK=<=<#>L>J' MKW81M15(R,4<=<J08JE<=<@<Y1611W.NRZDHQJ<@<O<=<=<E6/NXBE>>CGJ\$K M18%<A'N.O8&N<  
@<D1<+<M+AJ<5C.M5ALCJRSW\$1 PK1KJA I=<K\*TTSS\*9C8472UCFBT J\$J+<=<OPI,M.7ZB ESJWJ/GXJYDFP<42.O8MBM16G854+61W7KJ, I=MZR0<I'<HJOLPZ>=<LU  
M<K2Y<=<@<YMO8B.4B #<=<S%<V 2Z@<JW1XJLJLUMLUYK&K'<2>=<I>+<J1R0M.D.[JYTN M92BZ<X.PXAE' L.FHRT(18M)JMNZ,K.P.NW+<@<VSKB<U'1\$5EQB=<8V>.<OZZYUSN  
M<+<H01WC2,2UGP>W+JU<I6PBCD<?>X?>P<=<J4<=<L5V0G<U<LJ1NFDRHQ4 MERO<@<H>=<J4G18MR8'EM4P1JL=7U(LS>=<@<OISPOQ[IA\$89L<=<C;WG0G0GX35%  
M1TSW\$6RA,VUV?7.75F1<=<KJ4N<H1=<D8J9R7EE(B)<=<YN6&C951X7DL<=<=<MDXEJ9JDB<=<PWWOIC1<@<4LIG6 CJAWG7726AG59W<@<=<=<A&4<LV81QJ<IN\$  
M6FK<=<MO<@<P5J.M,7.W=D72(GX98<RV\$<+<I4U<=<=<E?>C7/E55J2L HTQ<=<B B LRN'ENT<(<Q XJ>+PJ8B6 M3XY3>4'<=<WJ2R M7M E8JW#9I (UG<7E22 114'LU4'<H.4=<Q4?>=<51BGY  
M1<OJVJ'X69J7NKA2Q<O 05<7Z.H,EK4<+<1U+WT<BIQ0<=<693CLVTL44<D B)MD<@<P.K C=53XWJ4GJL5EA9E\*6DIFTNCB JYH<K&+<C<TK>=<J M\$B&K51%<MVBMB<=<4P<=<940,7B  
Z&QDU\$<#6<=<EX94<5=<RQ<@6J1<J75,3KL C%<78\$2 M#1.IHWR<=<7JJB/MV1)<2<=<7Z>=<U2 M'B)<JSCVUQMB\$<=<\$IRE<Q0L&=<=<V<T'F<=<U<LXYACJY5<=<=<PUDVGI<=<B?Y3  
MYJ<@<R(I<O0Y<=<1 5U<E1A<=<I6JZ<5&C&FM&H<A> BA'QD'HKD91HN657J)CL MQ9>=<G>J7J0<=<U>+<P<=<I78KY8<=<1N=9TTVWLSW9U>JITQ<@<=<T%<=<LIE<0@<BK<F% M4N1  
(BREGVS<=<VDRO7 M'UO<@<P'IKDUBLVW&HJ[<K'ZKRO<OQ'<REEDUS8U<JURFH8 C4%<HJDI<[NF MJAEIL<=<\$13TI)RI<EG'D<@<R13KD2?<=<1H=<JFQO?>=<S144Z BAE>NE9<=<M3.4  
4=B2,55Y2L 1U<JL<=<GKR508U2M3&4F#199E\$=<PKJ<+<Y+Y/E<=<7 MN'J1<L V4Y'EG 3<=<Q25V78G16M6@<Q,9<=<UBV5KT'J>SDTMMU14A.UW#<81 M\$A4+<F M,H6C  
MK6AF600A4+<7H\$N<N M'<J01 #N\$%<AHJ9J95F\$<E9M4IW9.ZUJ4JHHJ<L\$<R4J'<U>SD,24MWBAU L MC2 A07JHJ 0.01H<=<JXKRM0.7%<5B1M<=<E&E\$+<I>=<  
<=<7@<MY6<=<PD616M14D M<^<@<D&[<S.L T<I'

```

IDAQC&3U>P7E$B.PZU.W88# 6H1" QZ.P.R%ZF7[AS7Q9MJC&KX1.1 M>@ $1RL$R5A>VQD;+1(7 MK:5EF$IRL8P6OS<1>+ZC&JH?>
GCL0HR@|TXB0C|X$S0?|JH<L>F0H3 M|QZSXSZBD3UI<4<L.Y|F">Y|=(4B.NMD51A"GV& ML5E@*9QON<1 V86$UY7(6CPD"U)9KBB:6YA|6MK B*2.>JFF.8CMK$81 M*63?
VJC.BBPQ>TFEY LS7>7D<6A.922DOA<|WF<OS"K8H;4<.B|$.M(L2ONU)=4D) $>?1SSZ7CL+1+D?AAJQNC1 C8H 0LLT;L 6C|Y|Y 0SS|RE
M9M?1J>|OJEQTIXWQ|B/6#21=9)@<8G<4$UX$K|L.VV7Q01% GUY<VXR.MJF>Z|ZVY<^/M^X^E=F<^<(K.M(198N|L.CP|MAV>Z3.=&O|AHQ.C ID2.B&6HA.G
T.NUX|M9+76$.W#>4+1H=|<OY.4 M$+1578.740LKE1 G1= *X0L1M .1JHJG|MKRLRWZBF8GEF<#C$T|LPMU5QK1.7+>1E R$A K
MLW01#>7|AN6H<|$$4<|KT2ECT8IV>L"5$>8+>871>EN=78%W=5;0EVN|TJ.MK<V|MC*AM106H5|."E03| M^>J>Y9LE$V8 N=7EKLGL(%S0&"P2$|f$0_HG&A M>=>
<2|OWD=81<=<RAK*W@>|J20+339VE|($QQ&K$VUUP*FB5)6.S Y=4N.% MKP922(1.PU&T1P% (5ZAI<+1PR|0LR.3)Q^>.<@G7.6Z4$SLM.HCCQ|
M^|HLW^P>QX>T>W"MH0K$HWH*Y?2?>JRN|>8PWO|0K0 Z|Q|FBX4Y13Q| M4^QB^&OE5H%|VD5EQ =WC@3R|(U|H^U8FE^>?>."2X..1|7|M+Z9FKG#
MA|LHB#>10PITZ4|HE.76F?D0G|M$FT<3?9C^LAYLPG.C ID82C6$A5Y9S25 M^=S9LCOR@J5P%$=SOGG?>.(EX@<1&D382VIR>K^<#L/PW@O|$.AAAC^Y;
MUJ>S2^LQ|Q%&W#P9=P<@>YJD|P60+&Q09HLV4H.KU.|TJR&VTCJREPQYVU@U8B|&ICE.E6VZG2T@>@>NV^Q M^J$>J>#&$G7|5>=&59C8QH|WMQY|4V| Y^V$
94<.&D&3=PDT 9|Q.JW9 M^W|>0JG2|@5W|WYD6W;1E8$E+H$7HG%ZX24S>=CD.VFGJZ5@<^BOL@<VVR M
@M&E9H(S9AWOGMA F>3TIG@1|1|VFB9.5J 165=ZIUVZF<86|FPG.Y|/M^CUC^*TZJ#>#S0OZJR>D&TKJH|FDI OS4R 4X|NDSUD;>=&83X*^>V&
MS@<0JH?T56P.FR8DK?>F>XO4>2E<="K$Y&Z1|1|UP2RBFV.F@>M^ARX&6R8? MEZ?QFY1T0J2Y"KK&.&3VVC9 M^>P2@C|<CHMF$JPNY.P9EOP$S=60
ML.HX195|M =EM<2>D>XBXZ.X|B0 L2^KKW+5XM9M.@ F2/R.&+S5=-(|@<G0<Q>T7SVY429C0=1=H<3>W6|>DVA9 S11%>@>.>4T?>
M1.G6D.R1#E44V2|8?ARZ|F><9.B.10.Y|I.V3|F#H|QY3FT& 33M@T 8P.MP1$P.D8SD5P$Q$Q$Q53QV50|> M2+3R.V1#>#>H#2|A R2>>F= MGCG?P?>=YA"(?O3?>
MG.$QF>JL.XY|NT%L+4KHY8 H%INW$<DK IHR2CP MQ+>29|5WE|Q$Q8SU#2?>6_#VJJ=-T.39LL1^CQ+QYB3?D>A 1^V|Z.V MRYPA%6BB9/GZV
CVC9C%YB|<WGBH|.KAN^OV.O.>?>3?>HKO$.64.5E?> M8#>.(PNOZJG8|B|O1^>3.T&M^XA @<AD8K1JT9NH7|XB.IZ5R5Q.K7(VV M^<Z&U0%+MA^=IV$UUV72
FRKU|<?3> 5B5GIDA<=<S^H1AH+PAJ.V+ M DCK&K?K7V2VQ6|AJVZ>X^/O4YCB|4EG1&2LU V.D0+S1| V|F$E+ (OHTM>#>04+829BKVES$6R6)OC1ID86N6DYPE8&&
M>C@<52>B|Z+LE^K?>Q^P$.9L|N1.6/C5(X6.Y@<T70W1Q|<F#9&1 M^..UHK+<=&N^O.CR8Q^O^OR^K.O$S^M^<1>2|5T|XWOW?>52*7|B?>27|BN-S/C<$5 M 2J=
|B7>.&OXVDL1.4=3|CL T1|<QX4A|K&H#B|J=154<@>JBD1J5|<1MTH|H7B$>L12X 2.R0 N<|>S|TCS%<CJY9YB|W0|U$|<$X=XWXBUP?>
M^E=ROF 0^>E9MOS.E3|/6$>)|B|H|^RBU^VSE3^K%BK^EZ^RY 0141>=MX.DBZ02^WJ34$R.7MD4E.&*>+V%M<72K @>|H Z+>DDBMTH |YE00%R MEM_P"4?
S>9%>#|1$|<?>C?>K>U<=>G2Z2|<M.E7?UQZ&Z52609Z.782X5 MM5^0<H^L|<^$>G.FP1M+|S8H.S9+Z<1 M|1|4)5F|CY$MQR|N|&L.BFY05|<|H1+>M|GV#7#
(+C@<M&S|X7H$8$8-J89@JH|Y7L9K73U0ZD|<35$P$U|T WU|W.M|S6^|UN$+TG.Y^X8KPSU7|N3|M.5#5=LGPTH@<Q>G-R7|YBFE|T|XO|K| MB|>#6H>|
P72M|DPIZ|50A_PG#R#1&LV582LP.C& 4.0R1#G<=&S&SR.MX166SF6B|Y7|U75QZ OJH$U=V^V41=RS5N|L6 MC6VBDM+6 W70P$|L>70 1|32>|B?QXG1^|J|X(B_U?P
BYP4ADP.90Q3XS M^P ARD3LWH#87? E1ZQ|PK;+2#>3N."UOG<1K^193.>O.SKJT1T7F.C1&#&+C9A 01^2QNVHMA
VXW>|HVCIXSD0FE(7AS3 |$<NY|:H6D0ZDB4&6@<8.422L|UZ>Z2.F@C^H F$T|>3$>OE1QG|>=>VL M|JH-9|1LGP|U{-0}>0(6RH A3F& G;N|2 W)8F%>=>=>LB M
J%Q^EUG@<V W^<=>?>2^UNPOIQF.QJMW3|/O^U|T^5+78N89%K...T293(M MW MSDT|(TYT7161VU0PIR3+7/3 1|CBGF|GA831|?>UUA.A#8.<3 F<^>."VSP5 BB
18.6T|0<1 L.E|QM< 2.8MH|U@<DE.A0ZP4AAS.<M.(K.T8+L8N|H1|) (K8.9&44M.TV.#>K&C^AF@<C8F|VJE|U|SF4.F9&A7&E M^>#>S.M|6>51>JF BYPZ^M8N?
CP^ETBESF^>|NG.GF$>M|6 1XZ Q1 JXZX3 MP|@C@D.M|U|<S.C|Z33?>3<@?O7K6NS?LP<K^R@N$>1^<6>F1 8B7G?
MTQ=>=<C NDEUQH2.$>028J|F7>0>0>2 T VM^>?>1.7 1DZ>B2X N M^>A|AQF|O$V$4A0$>^>|>#>@E6(H=9+7?>M^TJ MQ6@U577. 6QU<1|H|J -JW&P2FTCOJ
ET_DS@W2I=N%<%%>7M&=<9$Z2% MBT=QB.4AD|@?2?0S^JSHW|H@<2 CUEO3+V^%|MR^N^H&7)SN>IN@<X L8H MF|IFAN%>=ZEVHK|5UPF^YLB^OX^9|>RMP>J@<5&^
XPX6<=&L$N1%P|P^K.M.KW|L|P|<F|B$640 Z7OPB>=>RJM3 M49YUZOXK|7H9D.HI2Q^U>=>NA^|700T52DGU?7CQ|<F03.L^<5(ZCBF7 M5|<B&V.Y|<D5Q|<B|<DBPKE+BU|T1^4F0
U.9H E.Q&LS|>O^M^K1$A8|L M.VLJK<E+EEAM|M6.D.UGR&3J2<C^>9VGR9$7XBSY>P9F.7$>XN.ZYNZ27CV M^26PWVWF7$ 64.O 5%OBQOQ|<J>41&Q|Z+>73S|>6TJC^9F
YQ^M^M<MX.C0.4|8E&C> HZ$<A|JLH.&@<^>9.502E>L/LW4^G$JH16V|AVK 62 M^Y4<A|W^R^7F2I=8+>1KY=>=<Q742Q.7EY|Q<V^VIG<=&U|W<0|1L5>1 ML4
|S^+|EHU7|5<G|9A|3UB4 YW^W5W3PWFL|Q|LV|D^M^<6(43V1^<C^ M$TR|J@<O?VE6?> .9A>A^LW^C+>H^1.GCA1."IXSN#P$S M^K 7CEJ|<QH90WV7PG#<405HAOTXSU!
(4N4L3=6&JY<5U%>7+EP D[A M 77 U6AD 8ZJ#>2A7$SU.SV$YQO|JN&BTM|3XM^!A^T
```

[illegible]

4A8C(U5PX;9WU1VJHH(+YY&T6K<374.9/(E&3%R@8:08A\_9T\_M:F//008C\_UB@((LUHVIX?P...@/TO+ C3 4IOG@&GE;/=>78^OS^Z8IMG4WD\_MBR.8FUBE"FI\*\_(94&3-  
\$561UM#6P1L/M2RQWV1ZL01-C'01-B'+F6H+#+0="5A6.5R079+4-1JY16U&155WFCO-S M"#SX11UDNW6UA56R.X8R.M1'5N  
Q@FBIUTUL915\$T1%\$9HOJN(K25)H:"XM\$0'8009&L)P0/M@L'1&8L>=<<6'D:5T\$.2%47)R1-98<[N#8/3\_=-#1@\_1\_N+201\_#IFE7X\_M.3'7'+?#Q18>N-5K1  
(G1EHDAQ2P2.MYFCFCOD&)1J5@5&L'30\*\$59H\$=0 MB'AW.R#OKF^N^FZZ\_90WV\*6928/(OI\$R=FQF^VI^IKWVI^X7D)JH/Q3.3R  
MC31FV/JLDA1YHCX#E#RADT7F0L0J04LJN1Z=-Z=.IP\*F^3R2+J2&K.G.MMP.&6^PH9NPLBPQ@:3.F9^N/D/G17V/>=<-X/GV1^I=W=87KP\_I9)NWGH.MW5^?  
MQ92#D2OL5L+5F)5198N2A0&H9Y0X5CUA>J2DT5.&IGJLH666.M42Q)/\_?QA9\$.AIR#<IBV@3H1C\_FL^-(0Z2R.9.1#0:N)BAM29.C)OQMGO4=Z  
MZ7.2R.PR.\*IX#<K4T1-L'21#EY1L&-DNW<+A 80%6+H#T.9&A6Q23^&=)M7YD.9G.X? -W=%XUF^KW@+'5XG1OKUB\_4RGK9.CILT.13:5X&7N?)Q8&(&  
M\_GPVT\*!;\$.7)ON<#&1#613W3CZ\_M:U+QIG-BC\$Y8RHBM.#&G.P8B4(W1302F&#^IF7HWHW105HUNC=B\_2R\_V-W.SBF\_M1^Y<-<\_G@WOR\_1L^HWX/  
ZHR\_W32.NEHRQF^Q2OQV+1ZX;K@#<1PQAF5L\_MIP5L.TJ\$9G3C1&1SK-A^6.NED(Q\_NA:HV1=-\$AYB.P%EQ\*1272Q(C\_WO=Y.MPDIU1+1+5;\$E.#Y11F/  
LHV\$ERN0\$W7M^C+FU\_Y-ES317H0.R\_V-1P5^Q2.M#(01.Y)2-21.5^3^P^1\_QOWT73KVIH(+24\_Y97M-MP^4CIR2H6<-+1NXO?  
YK)LG@92.0^F^YK\_KSBQ:1.Z.L\_OB-V^Q\_#?2-180/LUM6+U^27\_1P6K1N"406Q44H@+^JS@49\_MP/KI?  
1^@>X1FO9L#.#AG3?#AWB&S^PKX\$>U^\_1YD.TIYWH.U8\_+1%IA^L\_MKD9KE9L^U^1\_7>CR7\$H\_G0V(^T88W1HWH40N0)DNUCX\_F.L\*BP  
M5O0BQ\_DMP7M#"\$1YD7Y1-L\_1GM<8@CFBQ\_&X%P.&C%QOGI?1>US^D>05%41^VNOLC1^CVR6I/ME/K#APNO\_1\$@A/BK\$M4?7GP.  
\$1X19#.#13U3^R31^0L(Y#Z1?K\_#&C.M.(^XZC1):C^R^17\_28LTWOF+ORT^C(.#^1.WX1\_1"TTTSYYP+S\_#0?N\_MAI<4)R^A\_MW.S0+W.W3\$S^Z-R\$UIKX0H>Z/  
1PA<\_SS@KFO^OKYDU>1.MQ6\$1/Y(\$2B;6+1;"G\_R1SX^&SLXBAX\_MK#DV.HU?ZV^X2)1N\_@2#F@1):1C1F^FABV^#6N1F1/DVP\_AUW82QO^OL\_M51-GN^&-  
%FYO@C.CY@X1+1Y+3BX1\$+1#1\$0BDN^N1).1%14^2AGV\_2KN.M2+WR.EAV77\_XF1@J81@#AYHPH\_X"B1//.5^XV1QX0H7H7&F6==1=OCLMR1=CGN:P..0A"+78@?  
%K>\_1FD3H8D82+\_HH(U11"\$6Z.W1T7F6OKD1DK2&2^MV4U+^N1BGD1&N#.#908F+GEL1A90>BUX=-0SD)X1FL1X^C'6&^07D@\_M08S.  
X9CIRR2)4^NJO1)S?\_6^F^5^X1J01(0.91624TRUJPIP2\$E\_C\$J>FZ.M^3&K1WUP^1)ROA@-1D&0TKF251,5XEP1U;\_Q87+>5^KW2XQ;B\$#H515R:E\_M@+1.5.0LHLW(?  
A>XPC/PYF1J9F.=>U21\_0MWBK\_DGB=N+12C6GHRV8R\_1M@1IPGX#++1\$-77\_9#0-K^76P.Q?A??2=KNM19X6=B.Q3&?.S1Q.SFA\_M/D\$K#DAM1ZR7/  
15L2(HL)HA4H5;6&2WTBG0L.R0SR(PW#1(@\_RA.QW1\_M1&=K4^X;M^34Y10%9V.^XQ//V2F1V>#\_90\$W8.%0GO^PM8D9^S&M(D^1#1V1A\$+>VTZF  
MW11POAH6G6\$>4JHMW\$12W2G1YQAV<217H(F21K\$=E&HIOJUF^1P33JN;H6\_MN>X\_)1#1+1E+9J#^811H>:RY;12E\_-L+>1R)BNN1#T#<  
MC\_KH+0\_0PU48G\*#H"1941'2Q-B"

VA)RXN@0^6RI\_U:LU\_H#WW\_1A1" M#\_10P^2MHC^R7<&KCV&^1T&MKIE471V:86\$%#@0@/(&C1<1)\$B&WY\_MJB\_1^54.&X1\$B@\_E1X&@RDW:3203^HC8\_37-5\*?  
#KG\_N+&#?H031(X1)1\_KYDD1\_P.M2\$62.K1)^2)=JH8:YVT\_ALC:(P#0)TA8P\_Z\_#HO\_<7+2AY#1H\_MG1D^F1\$-#2\_CQGVV^1J^C^A@9LW&WS:L&^1JQ8\_4Z\_U30L  
HO1.0^\$W^1\_MRG9\_6^11/>=>3JZ9-8&5EF\$>W1(C^X>H/L\_MBU:3.Z7V\_P<=&S1E\_A\_@<#.(8C10^0VE\_RN8T^1)Q/CV^>0^T3H^B5M1\_M1^QYP@TS^F7SA\_4R9  
1\$7+JES<"10^@)OB\$WY\$5Z1UCHN^=EY&B++1^BS1\_MH)B\_V9Z\_1#5.1" Z6X\_K^AC#&G&(L^K^>.EENB1+1%>/E^Y9\_M?+^V5L\_M\_OQG/G50N2VL^X^R^RO)=W1  
1NR5H9U0<\_98=>3^2^MNJ9GH^9^KV1^CK6(G\_MHOJ2.B1A9/UOHR^QW0K^&T^SV\_W1^L8/UR41/<+3W:7W3\$>P670WW+BA\_MX:  
610B^36KE\$>1&SKL^EY43EPPB@+1+05A6:ISS\_M@BE+AR^YDKWR8R.MQ^H^6^C.M1:4H1V\_V\_4T^#3+S\_WWE^616R^U.WYHE)N^4#VMW6^0ID6N^  
M#AZRAX7S0^R1M5ILH^C7^ECH:441\_YZ/GOE38\_C1(YLAU7A8(#).9DBPLN^M\$ 2SNFH^S<1<-TG)AB(1Z&745L^A<.F)1TOG.H1N#\_XV2M\_FP1H>?\_U\_MJOQ:  
17FY1=DQ=V\$\_.1N=6EE@>\_1UBX^PDXD(@@OHU\_MP\_7P^F1Q1/@P^R^HY;SINI@14TG6;9L=W+M=E.GY\_V?=>00F1B68  
MU+Q2.3.W2L\_DU>10Y\$E\_M@9A(IEI0D\_6^QV91\$=8%>\_1XG^W^R^J^J^#=&G841\_MMSDE=1U4#4M)8V^W0X\_5^RC2^%T\$F\_1K&L\_R"><5SDF?&Q?  
K<^V14.#\$13B^%1HQ<122Q16#J.O1^M^WRES^S\_D^54^W3R?#52DEUPLSHHE^#CF>=\$^451AGJUI&A.SV216R0L^NN:11C^K8#N  
M91+62+QV^2+17CP7^E0+YR5^5^5^23K4J1@>AB^M1^E^FOV\$PX<#P#P=W1/91<MON/B^B^EY@TK#C9Q\_7&61+1Z6:1UON5&-L24^9B4N6B^>EAL1)<(1Q=HA  
M.AG2ZKR2^M8X151Z^Q\$S1^0HJ^M):TB^X\$^21P^M(W1L1^E1#T^8^M^@SELV^61PYHK4/P1M=OQ1\$5^%A314@>P87:5^%J^C^XANS=Q\_>B\_>8\_>8\_>8\_>7  
M2V+1@E1DL^1.F0?\_55^A^UG+18-A^Q\_&T177K08)ID\$1:XL1C^LE9O1B7D0K(MWTVC0H7@\_K^#EKUM\_LM63\$8Z&8\_GB\$F^9R21&^CBX7P(\$#  
11F31F4H1XX^Y0"#.G=L1E1F3\_MF0UCV\_84RR1ANRY\$1^T^K^A.F1^1\_U^#VYZB<4#\_9(M26Z;1U\_F1^2>1JZ\_Z2\_M:1+>E;S\$UGEKPL1^1-OKKM0U0.NA@QB^T@^"O  
MA#1@U+9\_<A^%8CQCT511^4L\$0B.M7(>5FP\_EY>7.ZBZ\_Q\_#BR>+1.3ZT1+C\_7H1^4EAA^52>1J2\_Q(4:5PZ22^84T^M(1\$Z1\_4D\_1%>7.02M5^2H14Y\$MX1M?  
#&AVKULYZ1+1L1CC+1&55E.#6#UN7^7(A?>B3&91B@3F823477C/R)Q/C&P\_1.O1H4LWQ5@P.MMX;IL\_74\$^AD\_<+1P3ZV%AJT^TZK9Z0@?  
5Q(B\_R#YVH&D6^N5%FI#W1L7\_M2W(1&1U1V^UY7994K@9@ABNV\_2BNPET2\_C\_P1\_7\_H271)YC&+8>80\_STVOB  
M.E6f8>VNOZJ6F2.\$SUZ4;H8/2X#D>32LWT^4@PME1-G>=<19%DI^T^OH29W\_Z3.Y->H3X^+AB\_7^Q#H;ZB>1\_K%&X&H\$C0\_MTK\_1#(V.R.)T&?555C^7FV48M:=  
(X6.PT1@Q5A\_QVEF#1<@F19\$56KCL=)1^M1J1N1SRBBOM^6Q2315LROE13L3\_1^9S8AGOR05L5.C?\_W.Q:(7^1VH#2P\$?M&3.7?  
B31TOR8H2^#62.0.5.15\_UV50URV1^ZQR<8VP1^@\*U^ZWK\_M1H1C^H1WE^&Q+AQOQ@LQ^R=^%USRX^G#\_4T1P1U@GLENF7)(U1#9Y^T^M\_DM4Q1K;Z  
<^M8^02^+SG1BZMB=-;UKYVZO75W^1H0^<N^P+L^R^2K.ID@\_MGA\$18HRFR@CMW140:/E=@FVYJ/S^>9YT(DP\_4%3;Y19\$4H27MG\_P2&^HE  
M3.FM=Y8\$AYC\_FU1+1@U^CYB^M^FJ&+3\$Q/\$5D\$SE<15;UG8^1Z\$5GB5E\_0\_M1>2-R81@FMQ^<8<\_U@181F)BQD\$E^R0T11GD?=>1\$G\$1.  
<5RX7171WG@NW1R\_1U^A<@MN^D1X^5=>=>Y9P#LEHJ@>0%?7ZDL\_XUG38H^CQVQ9PYKQ1^#GHKWOL7N&B\$P\_M1.81KAD6F\_H2U^1M^%9G:  
G.#903J1^R4301HK18+97\$16^10T^M0117Z\_VL056P\_OZ@1^C1H1B1WMOU^A1L6\_NIRK^BFZ^04FY2UC\_>595C3^ZYK\_&^JR9\$?  
M1.HWMPH\$H5-D1Z+P+NZ6GCRYU>1T(UK9D91E^D#FW1L1^108F&5YD=1%W1W16=8VR^M^#K>B^71+>A^P\$>B\_1H^UPL18FG8Q^1(MQ7E1A\_M\$SUI1V1=1T\_>92?^<4  
MU\_.\$T^1(<6>KL>=>9-7^1PAS+X8;EL:P1A70\_1Y^WO?;ZL17S;4HNRY01+>MOR=FD)EEQIV8<1^1^>1^>0E\_1^>=>G^3J=X-0\_M5ILXM^TO^11FAQ0M1#1  
H141FNPY^#8L=>80BM1F1^1QW67\$QB^5HTMY^Y.R.MUE1^YRFPV1E:44A>Y9^C82W^C@+5Y41A@R\_6KXPI19#T^GK^>1^W61\$5^MK\_K2(X+1I&SL^LY@1  
A1@UE7B\_P.5P#K\$W>U1A(A752%BA@A2A1^L91:0)##11\_75M>QYVLM143\_MOI<1929LE1^101V;41<7\_SH1L1M1.MZ^1ESS01E1HFB4^BR\_VYN)X1W  
MZFR3I(L61R&98GBUN&C82.H2CYC8E^/B14MA>Y)1R1>5U.G18^FO351)PPRLK&>1J8&K+V11P#=#J\_M=YBJ1^6(D1+>V%=>H48/7F4M1<2E6-)D?  
44%6SEY1@U+Z1A:NR05ZE06^7\_ME17BW\_0HPAD0^F+AV1E1^&7EZ;01&^FSR&M1\_2^1H>1^H21F1P1MF#18W;80L^POM1X\$1AB0U\_MZYV^&V6N0)LO%L5:  
(144^Y^1K(BB.@1+>4\_95GK3RIPIBM+B->71H0G(D@\_M6ANLHE1FXDQW^HN521)14Y111\$6\_Y^K11NW1D?<  
J12\$UL>=6Q71Z\$S2QXMB^X3+X181E^G551=^#T1\$>0\_MGN\_8X);C7/SBWV2^2DQ@/V4XWE\$;1^PQR1XB\_51D3D1TO/1D3?;BU>1+1S\_M4^1RDDZ);T17B5^O@1  
F0F51VJ6N51MAO:QD\$X\$6W-EZZ.H.C)(R);3M>F\_M3CV&JL91C&PLJ12T1S#\_@M+3^A4B1ES\_4>23V1933=C1:Q.E411^%V>T^W6Z1JXUZFT50&2/5  
M1%+25.5^1VVC15+61^W3<=>G/4251E^XZ&1\_SJA41MCYU1VB1\_1F4M1\_M^\*BT6H1T1@1IG50&UG7.TW01VLGVZ1W=>55HRZ1@\_PM^U1B^G2K9\_P8=MI\_MU7B;^X0Z  
^H31V153^>SY91RT1P1K6M2KZ\_0N^7E1=Z1<@1C1\_6N^7R8\_M2\_K\$U<6H21HD?1W01\_V1S1P\_1YE81CT1BVG.BN41+2&HN-S;P-18P)T1J6UZ>08;P>J;61MS;  
(A1EEWE\_WU\_1M+KM@X5^K<2^COL^M8RN1E1W^?LD7.XG+5D3R1+89V\_+84YAY5UM@WWB+X5&+M1\_M1M^53/Q7N  
U^1&F199HKL149Q5G)H@1M^OHH662M11J\_M1(S1NA@Q\_7#LS7MEN\_#6^C^P33^K%NY>=<9@\_OKXZ^915.1\$6W\_B.N3>+>Z+N\_MB:U1)Z1FEER+71+ZVH3(Q1^6R?1G  
1^51^1@Q0B&A<Z6+G1V\_LC1/Z1YO1Q6^SL8812BZE1P8L^1LZ101K>\_F4P+M\$-<1#N4A\_B:1YV110G^6L1&UDA:1#1#="P19^Q^QWLD^CH<6^8?  
M2\$)S1^XT1H@1H2P-DHD71X@\_Z=AYG+11M1@1Q1M3\$V17WCWA>U1+K\_H\_M=CVQ7^0^#M2^3YU9H1H^1\_21\$Y^T^Z3V1E=ORU\_WG13B8\$41+ZD^A\_U4(@P\_MR^  
1&:R1VRR?1^YAY5>AP.3.V1>7^P2^Y5N1^%K^C1=1S31=QV1Q01\_M@R4L>=>1+1^S0280L^N\$N.C8;U1A+EM%2LXD0^Y)DXSEX&W<1#T1YK%5  
M514^1P021VQ<\_<8IG1T^LB2OF1U^1M^2&54W(RHEH1Q915^91Q1^677+M\_M@D^K41^7N1B1V1&MOA#A6\_U10^5L)M3JXQ#?  
6Z1U41Q1T1C1Z1Y1D\_61(H1U1Y1)=G1S1O&S4AR^89%1N1G^1\_M48W1^S4418X&K1M^L&1B0^CV^HX1^1#XZT^XOH1\_5HRZ@(%%)E\$+O\_11W\_K1W^CH1X^ML&^91  
(G&E1=20K+D=-.S^Q&E&L1BZE1H\_Q@A1^1+Y^R^R^>8(BP^&M1EC71M1?^S^Z1(1OT<\_8W1S70BY<8(9D1OPE^1YD1H&DIOR^N1APB^A@5\_MD=P2^1SRF0@>  
>HN>999U1MOQ:QY/KKRU^#%:(Q14Q61D35A1O=1A(MHZD^1RJGP^D8VL<+A:9L5>M^Q1O^YO<181K\_Z119-QW161O@93%>PMC.MWUR1YN^4Z1RQ1M^5611^1YD  
MG\_TQHE451^1)1YV11^E\_9X01&E=K(E1/H^A6\$4HE1HTEG1H^1LJN\_MY\$S0A1G5GQ1B1Q1Z1F(G191P1H2161F13135W01V541<1G1YHAI9F  
MT7OG1B086B^>1)MMA31^T1%G1DX<+4\_21G97S051%\$A64M1G50KT4F9\_MBE\_11OL^F1G7&U21^P)  
<416>\$5/C1"9AEBA5A13+6\$=2\$Z1+Q41)51^DE1B^XG\_NLK^X^14C171WXH8^GC\_8\_M^B1G8MHJO^A1^6D11+.%TM2Q:(&61O2(D#=-VP1P.C^8(I)=>051H9+9  
MT/4LZN1D1=1601B1N1E14W>1^22>7^2S?E#>1YVT@XZVW^1D4DT6M+>MMP7^CH)5L1/H0\_4C5.W1M+R16@HE1=1UL^DCU^HVGEE7=9U5A11F1M@1#  
1YLAN1@#^T1TFP\_9S\_X-D&=<1B^51^Z1B\_10L8T1%>F+U62\_KG\$M.XH1@MOY#=>B1D)H&1N1Y1N\_18C51J1S=-00&MXQ.UK@QOC\_1YH1#1YBPTF1W^YVW<1  
<^VOL^F&R1^P6TV1R1X<^KOE>\_AU\_M1Z=1\_HDQMV^Y1E1\_Q1GCV^SWR0@&2\_D\_>@&C#H21%>2H12/LMF316&Y1M1.46&  
KUH1=C.KN17@R&8KUG^HOR^<L@^K<=D1CP^M4@0+1#1VFAZ\_M1&+67TP?=<C@G@4:Z>1L6.V4=6+LYWNF\$S;9B5XPH#@DR+3Z\_Q\_212\_MG>1\_POE3K  
W@1>V13+2W3P4^1HAL^W7^S\_1L\$1)K1^1\$1TH@<S72#1RZ18KHPL\$M^C^SWRW194)SUSB@&QW91BYR^3\_>=>QO9SN\_P110#>VX1^1T\_MOX1R;H8@12^A@N2R  
1N#>1Y1P1P1U1J1Q1H1U^611^1S5K1L1RQ^0^1^M1X^618X4^YQ1CDTMS1J1K\$J41TQ1OW1L1F1V1N1W&XK9GB0B>G\$C220K^RQ^7<1@1  
MY\_781NQ31OYF.BB^F1C1A\_Z.P\$1325^1N\$X=4&61B^M1DS51E>?G^61+M\_M\_BVG<1^1MG8^1L>M88Y\$S\_22L1R1BH4E4&(+194030B6MNB:3LY\_MV11\_?>  
>91>1>MK^L7?@1P261VW60+3&BQ:5771N.RD.G4R\_21KO=<^N1D^M+81L=BE1OL^1^1>1N.F1V212<^&EV+9%16/PK1U+Z^11(OLRB525NR  
MN911JG17C1Z5<1K14HERT=JOF\_5&NHEFU1T\_0461K^8518Q>?>MFG1G1M1158Y^>UFV1NVCQ@<3Z>1E1V>0/H1H1TUM=02YD1W3RURM1\$1SK  
MT1\$Y>1O\$PVXQ\_Z17^X1<1>VGP1^06&.9K6G1V41U181M1E1T\$81P1\_V1NC&<M1C1^CHM1D1L1006G1B1G1F=1W\_VA1Y\_M^JA&E/PH+6OBB^K1ZRM1A0U0R6  
M110U1EZ1H1X1E1M1<=>V1Y>7?E1F1Q1T04975G6+1^1L2G1RHAZQ11^1V1LQ1Q612@&#S9>M64N1QSGFAR151Y3M0<^F1J<W:006G^A1S1AHJZ7?  
BWG&E^>OBGLVQ\_XM4)S.DY<W^\*71M96.X12Q1^YC1V>1YHG3S1MD1\_FVP@1^TC#MX1N+M.63XE8P^AE1\$Q1=241WST&84BY1Z1X3#M/@3:E8  
SHA1\$01^MTMR^&1L2^MB8\$7W2LS\_9C3S1U@FY1G\$GNT1G\$H1TAPK2B^CBAAT1B14U2AZ1S1T51Y^MANR6ZK^L1@RHA:X6^1%>0M0.T11)Y<6  
B1#3B=;C4>9X>7#(M5)=6M7\_MN^C26O1H12%5\_9161U1^<0#&#1E1P^Q9M1V11^1CR46R181L>16\_P#P751#  
MDVQ3ZQR1^1)1>11VVMW1JDZ>+VJK=C.=+3.N\$S^GPK1N.BGA0+N@\$4@6\_MH.@^>ZXCP.P5EC48P&2?1H3^1E7((K16:U\_M\_NVB1ST#NU^E6902-  
RO9^C6P1K2<98U1U.AM01UKF1^%51P>Z\_U^M2?>7\_MEEK1GO8F\$;D\$B^C^3^9W@1L>1^6517\_0B5\$UK=Z1E1D1GR=VR1DP@09H1P\_-M1BV919^YBZ\_F1P1A\_R15?  
1HK\$T155K;98\_@>+1SLV1\_M76V0=412127TK1=1B121H2Q1=BOY81L1KDY231+>D12>F1E1H2Q1=OEC1MLQB\$+16CT4\_3RLCQ?  
FRQ7KDB1BN23D17X5UE>1(=AZVUZ2^121<3127\_M\_R@>4ZAT^<#%YQ38.M1@P=>@Y<1^QJ81^>KDU^%T7Z\_V#Z^Q?W>X^7C2^6\_M1PROSR1(>?  
W11^1UM1^FW10116511^3\$9L+@4+>W\$VXSBS<S3NG^\_MS1E^MB41=C1J\_4(O1^3A)@PH6^Y1Z9^C1@BWTG^O=WX<7^1@<@\_U\_1^>214DR^1M^0CN10611^1L?  
6TFVAP^DFS<3>=>H0\$01>2Y1W41K1R1J1LH\$1VSHON1F\_M.2R.5Y4ZU11L12S/^7H2Q1^QE7^B11\_M@3(B^K2XT^>#&1O1X&K1JMG6M\_8>V8^V1MG\$S  
B^<D9\$M1H22^1Y7)Q1M<+32P+^EYG681(1&+>B1&+>3.01\_E1SP#N\_ZR01^1JVVO1H1.G0?>1^Y1Y^M<3P^<@1AK\_N85\_1D>9&2X2^M1M94X1A1NS\_?  
X5ON(EE^Y1+UY>34C=(MBF41^T2DR01BJL1GVW5N3K1^C\_M91L&1D1O41K1D68=VQ9N1M\_B4>11A1E.G^WQ1^71L0\_Z1=6268&2^M\_P161F=1B1YBSBO#\_UL1F5-  
VQ1^F^W9?^E^K^<6#%1^1C.V1^<1>U\_MF8T1Z1G45\$1^%1H^H71LSP1\_6@Q1\_169Q1U^1U19AB15SB@d5VXMN\_SQ/M5&XEV^JBN.T1G\_Y1B7.58AD909@\_M+1  
(B0D02>8D^M^D1Z2A1^1JZ3E41MNA8&41PF11V^81H^H3L^@<81>@1X1YV1W1^1W1BV^R1=51J^G1C\_T\_S0\_@N1K1U1^1G\$54Z^EV1+MAO+1TXO1R1@SD73@30H7\_M  
>17D1\$SS2Q4^%5046V2Z91=HEQ1P17CAGL&SJE1^F6C611125\$U1E^M1Q017^>1E1P\_K012^X^7^51U1U^CMB2\$R92^\_GN&=>121R7^H101AN11<1  
M:=SNE\_JO^V61^Z3V=FQ\_11^?2M+T\_4ZM1K17EO+Y&K=1\_UZFMH3\_X19\_M^="2A>M><136(3V\_NDZL<1%1(1.1H3L^2)2L1N2>S1^B1+T1=OMIP^  
M1DR9C.941G+2B1FN31U@15111^%1X17^1VHW21LTS1U08/Q\_6\$=>1W1RL1OD^M1L^XT80Y1^1JZG1^1\_1@1S1  
P1L1@<6G1K1@SUXE(92\_Q1^YV1R5+H&L1B1@10P+21C330^M^M^ZUX1O1F1V1^1Q1V31N^1WPT81W(ER11)<1GPN651121ON\_T481%\_1XR\_M1T11%1X:38B9<6  
\$E1\$1^M^<1^OHH=73A611M3?1^4YV01H2A3&1P1^4D^1RJ1+49^0Z^F1L1Y1MYR11>21(21^1YX7@\_M1R1+3F2\$1^8:6Q1U7^>K1^&V1Z1N%>62  
8\_7241LHPW1D1R#\_VQ5=DF3H07R1J^M1B<4<D.NB1B^CG1O1HXOLOK6Z1H03P1KZ1%516(S1^"MDH1V+X84&6\_M191^HFLXP211OW4D11M  
M1.9%1F11^VGI&9Q04B964\$78Y\$U1^A1BF20.0SS\_M9=0B>101RDW7^511M1O1E521^P1D1=^C#^S=U13@71DW121H1ASUK>=>OKL6D1M3QW1Z1UTW86CT4C=62<>VIM  
MB&\_K^<S\_V1^1&BX^50>V1^>1%&RMZ4R=Z1(+M\_1E61Q13PM1E1LES\_1^%1U7D11^R10\_HMVQ7KM^P^R0+8YXHP21Y^M^%1XV1  
1Q1^0ZB(KN01^1HP8F\$=F^MMA1Z4U(2^S1^XY@9\_9\_K245=9-NE#C.MK(G21^NY#3E1S7171GN1NH1+NHKS1N551+XFX=1^TN6P7191\_V1L1R@M\$YM51  
MHL1CV7A2A\$YWP31.EMEF^1L\_1^11.CFM71L81#11^N1J\_U\_XKW12^>RBZ\_V11^M1J13^HY18^?K044AV^S1>N+?>9T3DA+Y\_1M^%OXHR^XC\_ZU\_MF6\$R(MHAL3-  
\$FOX112^4^L&R1&O1D1M^M@PB07^X1\$5=1^EK^&491G:511L1V1=1^1UPBN1@U1PPAK1(T^?>7N7XK\$MR1^AGM1S6\_N1J1P10\_R1J1#1Q\$8^#1H0R^C1\_&^&UK\_MX1  
1Y161FN8>N\_OAL^OXT^H^41R1ENRUR^K1Q1LKV11JOU1310183Z^K1H1GBZX1MOMK16^2A1P  
N1Q\$1^1RY0ALC12^2C01R1\_D<#B691P\$<1\$5\_0Q\$D^>ZV@CN&1>0@<1^V1P2\_M1LTA&7^QZKG\_1%F&ZAHK4.@3E1Z1T)<+E^1(4XBRXC&M^M?

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f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fZ9YF2?>RHN;Q9F<10L%R5#>JBIOW\$S=CX%63AQFVOWBF1MOM M/GJ3MW@B+W?0.6<+>\$17.NOH&UOM6 @OP633.1J0KH&O% ME"H#0EM&V"(6L(Y<A\$S"W@C5IUL)Z+R>7(G.<3>5R=4(H+A@<+>V+G9IE! L2.1#>21.45F.618DKCR.YE1%1FTYI8-K1-G1=K#<2M1\$S@X&1C) M0;LDTF<+>I&O?E18C71W1+133N#5.5<06=Z1Y9&INEPR QBI1>4OKYV M<1459J450<#?> U9=EG&G 2H&E86?>XO7A?>A)A11#6C4I&3M043AN 2 M\$<401<HJG22+VZQ6K&W%+X& KR-CU\$)1A32.<+>H>U6L%WZVZSCYH?KI->+W"~F@K1HW8+BG& K18E5YIB+ SWVYJ11Q\$S.MCL.VX+J&XT(4CQ#1%<+>8&1.9A3&1+J&1Z&X%#6LH1>0(1)1Q Y<+>C\$ M(1D-ZO+>YH1YVWOW.Y4&X50EH7004\$)XIT.18G'C(\$<8C" (X<1+1U-MD81HWIZ1Y1-VO1B# S;ZE 671P0CBZ9>%0OYPA1U..H\$\*R01G3PG.# MN>+JF\$P\$H M(1RLI+<+>9N99BD.R>D<D+>28&.4OU)~<+>X~<+> MPOQ M1&E% MFOOSUIG<+>J2HY6G1<+>0 B1DPE1M\$>OE<13X)(M6<+>C<+>YB%VCI(0FP) M1JFY+0%4T8A;~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~WOLA9700.5671+1ZWAE9 R?VF>+>+&DOJ M>Y09<+>RWGIG5.? 01Q13PDJGW7K<+>UAW Z(DE\$=<8L1+V+1&S4<+>KZ>+>M<+>PQD>OZ L.5<+>K3<+>14J1NTX@<+>9<+>GF3Q?4Z8Z@<+>7>+>DO1<+>G14H M3MGU1ICF+ (8MW<+>=<+>VQB@<+>UAW JXN3Y.9@<+>11MRVY6@61<+>6@9> MD<+>C+>Q& H8 L&Z\$<+>1XJ1KEK53IT@KN2HT&J1Q<+>7GKGO1>>1+>1D\$ M6F M1U+<+>W.RB=NE=7?R>9>KKQ.3H(RO?O&160.<+>1@O4Z5<+>1MO/35\$<+>MELX&F.2V8TJZ>2W?D+1XAU7D3-D.U=Z<+>Q(M6>5NSU" G9V=<+>37&Z>~SMN<+> 5PU<+>VW2=S<+>B1J#<+>(3GF82>W@<+>1<3K-V15:L17\$)B42.A?>#7%1E/UT?37C.E146<+>7Z+1?IN:UVSL?OI>VW311F M/MMX<+>1V6VUZCO<+>MTO91C1&GCGG2LW13>+>J9H12D17?>RTO1N3.Q&YK12=<+>ZIO9ZLS(OKAQ?1@<+>ZHMXX5NKU)AEW4GL1O.1=<+>#? M8FZ?JFGV 12.1#>21.45F.618DKCR.YE1%1FTYI8-K1-G1=K#<2M1\$S@X&1C) M0;LDTF<+>I&O?E18C71W1+133N#5.5<06=Z1Y9&INEPR QBI1>4OKYV M<1459J450<#?> U9=EG&G 2H&E86?>X

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e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

*[The content consists of a single, extremely long and dense line of base64-encoded text, which appears to be a corrupted or heavily obfuscated document fragment.]*

xBx03+2?K%DOJE%#BND02W M0+R5L0%K%#@N%A^7,D9;2i5V9;AN"J%B%3.8=8?W-^H\$U%;T,4;I8I;DS M<+T1H?3IY;C;Y  
 ^UJA>#%I8IKD1P^I^WMTAISILIAEG(E05GH6-^P^FKW5^MH1=<^FZKJ^W0I9;IGGYGNAOXEVLWIG>(<MLC;KJ^R8J;B7 D1U^I^MA^675 GL9<6.%&>06-?  
 -76S;WC;D%IMCI@R^M^W2&8^#3\$W^L5%3%12^9?TH-,%P%P%QI^IJBXH^1UE5P9;OB;HH+2V12P2D M5M^83B7J=U^TIEEB?4D.2D%3&>85-ZR4TJ=U^7HA  
 M9%>HG%N>Q%JG%MEEE<L(>^"DIRA181);TY<S MNZOHH?PW3\_YI\_-8S#A5<^SFY3^\_NHL^>4DO/0PYU^UM\_2\_V9^<Q MSOBG8716Q \$4\_?  
 9/K WHH6E^AK\_3MK77H<?P OC/QI8UY76BP1^CGGZ^MOC^N CV15^?PBSZW^I@GGCV8IU8U^#JZ^7@^YI^O^P^S^SAKZN09U =M;# U^O^ZS?H;GWUFVW?  
 CGW1W;EM\_CXJXZ^QIYIN^Y8S1E=OP2P%I MBWZW\_?A^I^/SX\_OWJ#\_TJ#^?\_2TW07P JOWP=20S6^WG=^KH;L^Y\_M^-?  
 -S^T RN7WVW^H^I^/MW^>^H;ZUKOQ^?7==F;F\_OQ SS2IU^W MCIMSR MB?2S19/CQ/19Q0^+^GYI8QM^G^0^<\_<OK9X\_Y  
 MEU^ISN^OMK=C6FN2Z^JZREISNTV0.M5<5N?ZWPIAEV9.M5;ZE9L;+;7K;+0 OH;PZU^XKT(ZIB@N=Q0^=7L6%Q005;G\_EZ<^C9N007/MXX^7DN4J  
 175M0^H(^MAY5W7JZSPBA56P K-6;%RA2O6^%FA=8V1D^E MCU>L\$+>^P6P0IEIKE%?E2VOX+H+3^%8X.D.T.EFJ^I^@H^NM0\_179 M73^  
 IP4P0)DHK01EXIG2W\$+H+^\*1\_88L5L^<G%9YAU5;9-1^%PFM^@TV;DM%;EN=27L1QEMR^VT MN;XC>^UUV6@>W%L^Y^99YX;G^90^AD^%367/  
 13ZERH^NH>4\$A^Y+T M<S WGR0SC2X;EJSR&U^IXHJ343%UV43\_CIG203CM1B0ERMF2F-1^-(6GM0L6IDYFTBG>^%G MM.FE^9+AR^03N^D3JNT?<  
 9M(YW^29U6;W@V^>V&J M^<Q^C^I^/%\_;"SC\$8S%a=>^"OKK16YHXDGKR&7^+R^9FT^5V^M^<AAG;M^#CBIO\_LR^H6N>W>\_7QF^E&ON@CIE113FYA+  
 WF=^<G0Y^VYV0H8 MSYS09N^F8> K9@\_JFBX^R8VG@Y^BH A^I^N^&4^/M^W;265X6^+AC&E^>I0J;I@&^L 1^%\_RH^%P^I^J^+>=6 K;7&17 B^L^<Y9IZ=ID6D^<  
 (M@M9) G1^>\_160S^V0^M1^L6S^ZD^X^LE^X^<(KY);.93^HMEI0^<3P54XG^<2 M8IC^RWTQI^INLU^Y^FZ^5H YHM2JFM^%K%L^+R^6W21=3^\*HRCG-ID^P^MY M68+  
 H8N8J7BFIL+@I^<^T<I9SRP\$92BFY(Q^<C;Q;&^P71^=ORDLEIX M7^#I^HOYHMT^Q7NA^9G&2J WZB2J^PPR<&A^HCUFQQM+L^L;JDH0INT^=663.5?  
 TCFX^7WKNK>^/JM^0^MIOV^I^HIGIA7N M48N5D5YX7RR^8PYR^R^ZH<^<07N^&@=PO\_NG;8;EAB^F&XZ^%JUM^=-0.D9^"IFZE^R^N^J6+I^+I^M2^%&&^&  
 I=TSKSQ^#W5Z^I^UYHBP;P^7FYW;6^V>08^HO2P^>G^CYL^6=6^M;M<^<VG^B=8NCIK^DJOH0F&I^Y6FF^HE^XT6AZM^M6^EBFP7^615\$D^=F3^  
 M=>T.16L^YVWV;K^<=VY=U.Z2\_14JX&Q08^"U^/AIKEC^>F14K^MHJW2A6KB86^>=>CICR^>?^65Y4\_5X2^LR=9BUBGSUNW^5Y9<^I^U01T  
 MMW2ML^GC^DIOBE8^S6BZ;3C^KC14K^MTRE2S5W^42^<@NF^TD412Z2\_ MVT^<2.G2NN6+EL;HP75P^MW0ATP^HYV^WZ7L^M5V5ISGQ1XKP7H2-URM=^/ZIO  
 0%>SY8JN=>\_C1\$19J2FELPCAIO0>SIFT M21Q? 9H8QZ4+UL R;+5+5MC+1^%XB>^I;7^<M^&@;EN;M9NLY5717>0M&^M^5/3F1N9Q8+&W.K6Q8S%6 EC; M3  
 6FIO N21>^%Z%I9L9@&+QZAK9NU M@821H^IG=TWI5Z&5^A84I2GX\_UQ0#5R;2^>B.E^Z+>W^D^J22+Y32A^O@Qf^<  
 MO43HFSQOLEI0>^>Y^HEI^<I^J27;SV3=^W^W4NE^<I^J257&I5A0U^P^Y^PQ^P^L M^<=>62^L6X^IEZ86NR\$=>^I^O^H^X3KU2^T;9Z>  
 N^Y<^P7S^Y^#DOGA^CL^3ILN^8\$ F<8 MC.OW Q102P.\$%>@ CT^>622 @W^C^I^P^DR<^IX IE83 R.3@S S\$P M.65X.S\$M.51C;W)M96H>^"YH=&WM6F%OXK@6\_8I\$?  
 I^=0WJ5; OMIGVH2^I^MS>RPZK9=FGG<6@2^SJOJDX<^<^HUKO^T^ISM^Y^U^C^E0^LZU^76V^>^<^Y  
 MAJN^JWG7KMZJ^0>8GHWI7 L^I^3I7^X3.T^<U>^I^N^OJ;L^2U@AT M^VE^P^E0^B^F2IC8=BMF+&ACGG2= U^JB R&370\$5W07I00D4I^&OD@P%IZY+^E  
 MXBD\_XDI^T210^=YZ>HGD MOQSD26 H\$SX^<E^U<^<2^H^CX^P^T^IH>^#Y^I^@OG0^O^<^I B=^I&V^K^Y^E^#;IZ M0IAS\_VGX^#EIZS^<CGUX^>OWK5;17\_H^GO=6^<AZ  
 I^W<^ISZ\_9I>G>I^<^U^MT6K^4YA<+<F^T^4D428KT^I MW\$?F;TCN43GE^>?^I0I?\_I=^MZ8L0D^%>6.3I&ZL6^VIOQ6-  
 ^IN;G07EvG\_<I^>^I^V>^>^>OY.KXYR MG5K^%@TCG>^%Q5^XAI7M^A86L^LU^TLK1^I2B2ZK5\$H^QOVIDH7^E#B^M3\$1SD5Q%>LZ^"(89;@UP;15:OS28RF^+3TF)\_E  
 #.1B7^46D^L^C1@E.D8Y15^ML23BLZ2D\_615V^6^<=>LRFHIO^HHIQ+H9^IC^6+9^I\$D2B7P^QD^Y3^# M^T^K^2^3^>0^&OYQ^@R21018A^<  
 <15F#0L4GLP6XB;C\$&66R^I^Q9I;EKM^M20.WR;0;=<2HISU^&GD4^<#AD=(S4Y\$A^V^AHQC^DZ;SG.X5VRM^F^I^MV7HWC^I^WB>H2=^T.U\_PP^A3EZZ\$QC<.  
 M@E^F^OHD^U^5Z^A0^>^XP^M^<I^Q^MVCX^W= A0B8D49XK^M \$C^<P^C^I^<M7.F9G6>^GLT4^I^A;Z3^A;D@B^I^E@CM\_VL62^I^>^%>+>6@^>F^>TW^WX9^MDX1^P^LDI  
 BBW7J00A^P^32 MBEL^2^KV52^I^POF@EOYI^U8V^#74\$A21D8TVDR4T&4&(K5C^>M&R&M^>I^H09\_6577=G#9@VE2&1^1DN=<S^F^W^H^O^&S  
 M(3PC4MIKKCC^I^%4^I^3^>H^V^I^70MN^"UO^NF^<E^B6^7W4U^YHK3^6&46 M^#H^I^K0^Y6B;I^H09^IJD25A^"(E\$A)^JB^%5^7HDB^<P^N^X^H^S^N^Q&6^%56&C  
 M+.%^I^&\$NISBW.T6O.V06IOT^9Z^D#\_K>@QEL^?LB^IMW9^1^>I^>@C#^<E MZRB.A^V^HONH^%@X^NC5%U>^<^LGYWJ6^/RKJKH31)^ENBNA6Y="D^O5#2+G<+  
 <I>O^T^I&8^N^W^A=>^I^H2H^E^<P^<\_U70B6\$ M^TXHR&2J5206DCXV^<HIAV81^<KT7^#U^>=>EZZ^&4\_Z^<K^H=^W10^I^>M^VGM^<VHXE^<+>@^>I^F  
 I2-1Q2G6(MM\$>I^>X.DY0F^>+DIB7@ZJHN^M^9<=>^<GV0ELI07@>+ZL0=>440\$1X^F^C^T5Y%&BE>^&K\$@^U^I^ FOH2^MIKE^ZLYS^2^<  
 A^IKL^T^N^X^<P7&PLU;3G;9.2RSW;7N^I^ZM;2^Q^HMJX6I^U2^>^>?^I^6Y+^+W^EM@\_BTYH^M53^O^3&K^G1875^<R^I^T90>^/EX=HZ\$SAOZZ^R^ITFOS^D^R^<

gaap:DebtSecuritiesExcludingMoneyMarketFundsMember 2023-12-31 0001410098 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001410098 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001410098 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001410098 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001410098 us-gaap:FairValueMeasurementsRecurringMember crmd:USGovernmentAgencySecuritiesMember 2024-09-30 0001410098 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember crmd:USGovernmentAgencySecuritiesMember 2024-09-30 0001410098 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember crmd:USGovernmentAgencySecuritiesMember 2024-09-30 0001410098 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember crmd:USGovernmentAgencySecuritiesMember 2024-09-30 0001410098 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-09-30 0001410098 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-09-30 0001410098 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-09-30 0001410098 us-gaap:FairValueMeasurementsRecurringMember crmd:DebtSecuritiesExcludingMoneyMarketFundsMember 2024-09-30 0001410098 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember crmd:DebtSecuritiesExcludingMoneyMarketFundsMember 2024-09-30 0001410098 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember crmd:DebtSecuritiesExcludingMoneyMarketFundsMember 2024-09-30 0001410098 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember crmd:DebtSecuritiesExcludingMoneyMarketFundsMember 2024-09-30 0001410098 us-gaap:FairValueMeasurementsRecurringMember crmd:DebtSecuritiesExcludingMoneyMarketFundsMember 2024-09-30 0001410098 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001410098 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001410098 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001410098 us-gaap:FairValueMeasurementsRecurringMember crmd:USGovernmentAgencySecuritiesMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember crmd:USGovernmentAgencySecuritiesMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember crmd:USGovernmentAgencySecuritiesMember 2023-12-31 0001410098 us-gaap:FairValueMeasurementsRecurringMember crmd:USGovernmentAgencySecuritiesMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001410098 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001410098 us-gaap:FairValueMeasurementsRecurringMember crmd:DebtSecuritiesExcludingMoneyMarketFundsMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember crmd:DebtSecuritiesExcludingMoneyMarketFundsMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember crmd:DebtSecuritiesExcludingMoneyMarketFundsMember 2023-12-31 0001410098 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001410098 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001410098 us-gaap:FairValueMeasurementsRecurringMember us-gaap:SeriesCPreferredStockMember 2024-01-01 2024-09-30 0001410098 us-gaap:SeriesCPreferredStockMember 2023-01-01 2023-09-30 0001410098 us-gaap:SeriesEPreferredStockMember 2024-01-01 2024-09-30 0001410098 us-gaap:SeriesEPreferredStockMember 2023-01-01 2023-09-30 0001410098 us-gaap:SeriesGPreferredStockMember 2024-01-01 2024-09-30 0001410098 us-gaap:SeriesGPreferredStockMember 2023-01-01 2023-09-30 0001410098 us-gaap:DeferredCompensationShareBasedPaymentsMember 2024-01-01 2024-09-30 0001410098 us-gaap:DeferredCompensationShareBasedPaymentsMember 2023-01-01 2023-09-30 0001410098 us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001410098 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001410098 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001410098 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001410098 crmd:NDDPartnersLLPMember 2024-09-30 0001410098 crmd:NDPTechnologyMember 2024-01-01 2024-09-30 0001410098 crmd:NDLicenseAgreementMember 2024-01-01 2024-09-30 0001410098 crmd:NDPartnersLLPMember crmd:NDLicenseAgreementMember 2024-09-30 0001410098 us-gaap:LicenseMember 2024-09-30 0001410098 us-gaap:LicenseMember 2024-07-01 2024-09-30 0001410098 us-gaap:LicenseMember 2024-01-01 2024-09-30 0001410098 crmd:UnderwritingAgreementMember 2023-06-28 0001410098 us-gaap:CommonStockMember 2023-06-28 2023-06-28 0001410098 us-gaap:CommonStockMember us-gaap:IPOMember 2023-07-03 0001410098 us-gaap:WarrantMember us-gaap:CommonStockMember 2023-06-28 0001410098 crmd:PreFundWarrantsMember 2023-07-03 2023-07-03 0001410098 us-gaap:CommonStockMember 2023-07-28 0001410098 us-gaap:IPOMember 2023-07-28 2023-07-28 0001410098 us-gaap:SubsequentEventMember crmd:PreFundWarrantsMember 2024-01-01 2024-09-30 0001410098 2024-05-09 2024-05-09 0001410098 crmd:LeerinkPartnersLLCMember 2024-05-09 2024-05-09 0001410098 crmd:TwoThousandAndTwentyFourATMProgramMember 2024-01-01 2024-09-30 0001410098 us-gaap:RestrictedStockUnitsRSUMember crmd:TwoThousandNineteenOmnibusStockIncentivePlanMember srt:ChiefExecutiveOfficerMember 2024-01-01 2024-01-31 0001410098 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-01-31 0001410098 us-gaap:RestrictedStockUnitsRSUMember crmd:SecondAnniversaryMember 2024-01-01 2024-01-31 0001410098 us-gaap:RestrictedStockUnitsRSUMember crmd:FirstAnniversaryMember 2024-01-01 2024-01-31 0001410098 us-gaap:RestrictedStockUnitsRSUMember crmd:ThirdAnniversaryMember 2024-01-01 2024-01-31 0001410098 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001410098 2024-05-31 2023-05-31 0001410098 srt:ChiefExecutiveOfficerMember 2024-05-31 0001410098 srt:ChiefExecutiveOfficerMember 2023-05-31 0001410098 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001410098 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001410098 srt:BoardOfDirectorsChairmanMember 2024-09-30 0001410098 us-gaap:StockOptionMember 2024-07-01 2024-09-30 0001410098 us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001410098 us-gaap:StockOptionMember crmd:TwoThousandNineteenOmnibusStockIncentivePlanMember us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001410098 us-gaap:StockOptionMember crmd:TwoThousandNineteenOmnibusStockIncentivePlanMember us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001410098 us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001410098 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001410098 us-gaap:StockOptionMember us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001410098 srt:DirectorMember 2024-01-01 2024-09-30 0001410098 srt:OfficerMember 2023-07-01 2023-09-30 0001410098 crmd:ConsultantsMember 2023-01-01 2023-09-30 0001410098 us-gaap:EmployeeStockOptionMember 2024-09-30 0001410098 crmd:SeriesC3Member 202

indicative of results that may be expected for the full year ending December 31, 2024, or for any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto of the Company which are included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 12, 2024. The accompanying consolidated balance sheet as of December 31, 2023 has been derived from the audited financial statements included in such Annual Report on Form 10-K.

**Liquidity and Uncertainties**

The condensed consolidated financial statements included in this Quarterly Report on Form 10-Q by the Company's existing cash, cash equivalents and short-term investments as of September 30, 2024 and its expected liquidity from commercial operations.

The condensed consolidated financial statements have been prepared in conformity with GAAP which contemplate continuation of the Company as a going concern. To date, the Company's commercial operations have not generated sufficient revenues to enable profitability. The Company's current commercial and development expenses for DefenCath and its other operating requirements are expected to be funded for at least twelve months from the issuance of this Quarterly Report on Form 10-Q by the Company's existing cash, cash equivalents and short-term investments as of September 30, 2024 and its expected liquidity from commercial operations.

The Company may raise additional capital through various potential sources, such as equity and/or debt financing, strategic relationships, potential strategic transactions and/or out-licensing. Management can provide no assurances that such financing or strategic relationships will be available on acceptable terms, or at all. As of September 30, 2024, approximately \$36,012,000 of the Company's common stock remains available for sale under the 2024 ATM program, with \$100,000,000 of remaining capacity under the 2024 Shelf Registration Statement for the issuance of Company securities (see Note 6).

The Company's operations are subject to a number of other factors that can affect its operating results and cash flow projections over the next twelve months from the issuance of these financial statements. Such factors include, but are not limited to: the ability to market DefenCath and generate necessary revenue in the time periods required; ability to manufacture successfully; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company products; the Company's ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; and the Company's ability to raise capital to support its operations.

**Use of Estimates**

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Company's consolidated balance sheets and the reported amounts of revenue and expenses reported for each of the periods presented are affected by estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from those estimates.

**Reclassifications**

Certain reclassifications were made to the prior year's amounts to conform to the 2024 presentation.

**Basis of Consolidation**

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

**Trade Accounts Receivable and Allowances**

The Company complies with ASU 2016-13, Measurement of Credit Losses on Financial Instruments, which requires the Company to recognize an allowance that reflects a current estimate of credit losses expected to be incurred over the life of a financial asset, including trade receivables. The allowance for credit losses reflects the best estimate of expected credit losses of the accounts receivable portfolio determined on the basis of current information, forecasts of future economic conditions, industry knowledge and to some extent our historical experience. The Company determines its allowance methodology by pooling receivable balances at the customer level. The Company considers various factors, including individual credit risk associated with each customer, the current and future condition of the general economy and industry knowledge. These credit risk factors are monitored on a quarterly basis and updated as necessary. To the extent any individual debtor is identified whose credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of such customer. The Company makes concerted efforts to collect all outstanding balances due, however account balances are charged off against the allowance when management believes it is probable the receivable will not be recovered. The Company does not have any off-balance sheet credit exposure related to its customers. There are no significant allowances recorded for credit losses as of September 30, 2024.

**Concentrations**

The Company defines as those constituting greater than 10% of its total revenue. In the three and nine months ended September 30, 2024, the Company had sales to one customer that accounted for 98% and 92% of its total revenue of \$11,456,000 and \$12,262,000, respectively. This customer also accounts for 100% of the Company's accounts receivable as of September 30, 2024. The Company currently has one FDA approved source for each of its two key active pharmaceutical ingredients for DefenCath, taurolidine and heparin sodium.

**Financial Instruments**

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, short-term investments and accounts receivable. The Company maintains its cash and cash equivalents in bank deposit and other interest-bearing accounts, the balances of which, at times, may exceed federally insured limits.

The following table is the reconciliation of the accounting standard that modifies certain aspects of the recognition, measurement, presentation and disclosure of financial instruments as shown on the Company's consolidated statement of cash flows:

|                                                  |              |
|--------------------------------------------------|--------------|
| Cash and cash equivalents                        | 105,084      |
| Restricted cash                                  | 187,210      |
| Total cash, cash equivalents and restricted cash | 292,294      |
| Gross                                            | 35,391,222   |
| Unrealized losses                                | (35,391,222) |
| Gross                                            | 53,501,021   |
| Unrealized gains                                 | (53,501,021) |
| Fair Value                                       | 0            |

September 30, 2024

The appropriate classification of marketable securities is determined at the time of purchase and reevaluated as of each balance sheet date. Investments in marketable debt classified as available-for-sale are reported at fair value. Fair value is determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are considered temporary are reported in other comprehensive income. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense). The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. There were no deemed permanent impairments at September 30, 2024 or December 31, 2023.

The Company's marketable securities are highly liquid and consist of U.S. government agency securities, high-grade corporate obligations and commercial paper with original maturities of more than 90 days. As of September 30, 2024 and December 31, 2023, all of the Company's investments had contractual maturities of less than one year. The following table summarizes the amortized cost, unrealized gains and losses and the fair value at September 30, 2024 and December 31, 2023:

|            |              |        |            |
|------------|--------------|--------|------------|
| Gross      | Unrealized   | Losses | Fair Value |
| 35,391,222 | (35,391,222) | 0      | 0          |
| 53,501,021 | (53,501,021) | 0      | 0          |

September 30, 2024

[illegible]

**September 30, 2024:**

| Category        | Quantity           | Unit Cost     | Total Cost              |
|-----------------|--------------------|---------------|-------------------------|
| Raw materials   | 603,545            | \$0.50        | \$301,772.50            |
| Work-in-process | 1,525,420          | \$0.50        | \$762,710.00            |
| Finished goods  | 580,925            | \$0.50        | \$290,462.50            |
| Inventories     | 62,253,413         | \$0.50        | \$31,126,706.50         |
| <b>Total</b>    | <b>609,448,903</b> | <b>\$0.50</b> | <b>\$304,724,450.50</b> |

The Company engages third parties to manufacture and package inventory held for sale and warehouse such goods until packaged for final distribution and sale. Costs related to the manufacturing of DefenCath incurred prior to FDA approval in order to support the preparation for commercial launch of its product were expensed as research and development expenses ("R&D") as incurred. Upon FDA approval, costs related to the manufacturing of inventory are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis. Remaining pre-commercial inventory previously expensed as R&D prior to FDA approval, consists of certain raw materials and inventory at various stages of completion with a value approximating \$6,177,000 as of September 30, 2024.

Inventory is valued utilizing the standard cost method, which approximates costs determined on the first-in-first-out basis. The Company records an inventory reserve for losses associated with dated, expired, excess or obsolete items. This reserve is based on management's current knowledge with respect to inventory levels, planned production and sales volume assumptions. As of September 30, 2024 and December 31, 2023, no reserves were deemed necessary.

Inventories consist of raw materials (including labeling and packaging), work-in-process, and finished goods for DefenCath. Inventories consist of the following:

| Category         | Quantity           | Unit Cost     | Total Cost              |
|------------------|--------------------|---------------|-------------------------|
| Raw materials    | 603,545            | \$0.50        | \$301,772.50            |
| Work-in-progress | 1,525,420          | \$0.50        | \$762,710.00            |
| Finished goods   | 580,925            | \$0.50        | \$290,462.50            |
| <b>Total</b>     | <b>609,448,903</b> | <b>\$0.50</b> | <b>\$304,724,450.50</b> |

**Revenue Recognition**

The Company recognizes revenue from the sale of its product, DefenCath, in accordance with ASC 606. Revenue from Contracts with Customers ("ASC 606"). The provisions of ASC 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

The Company recognizes revenue when it believes that it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer. The Company's product revenue is recognized at a point in time when the performance obligation is satisfied by transferring control of the promised goods or services to a customer. In accordance with the Company's contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is received by a customer. The Company's customers are located in the United States and consist primarily of outpatient service providers and wholesale distributors.

**Variable Consideration**

The Company includes an estimate of variable consideration in its transaction price at the time of sale when control of the product transfers to the customer. Variable consideration includes:

- Prompt pay and other discounts:** The Company provides customers with prompt pay discounts. The specific prompt pay terms vary by customer and are contractually fixed. Prompt pay discounts are expected to be taken by the Company's customers, so an estimate of the discount is recorded at the time of sale based on the invoice price. Prompt pay discount estimates are recorded as contra accounts receivable on the balance sheet.
- Product returns:** Customers have the right to return product that is within six months or less of the labeled expiration date or that is past the expiration date by no more than six months. The Company determines its estimate for product returns based on: (i) data provided to the Company by its distributors (including weekly reporting of distributors' sales and inventory held by distributors that provided the Company with visibility into the distribution channel in order to determine what quantities were sold to both inpatient and outpatient facilities), and (ii) the estimated remaining shelf life of DefenCath held by the wholesale distributors and outpatient service providers. Since the returns primarily consist of expired and short dated products that will not be resold, the Company does not record a return asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred due to the anticipated return). Estimated product returns are recorded as accrued expenses on the balance sheet.
- Chargebacks:** Certain covered entities, group purchasing organizations ("GPO") and government entities will be able to purchase the product at a price discounted below wholesaler acquisition cost ("WAC"). The difference between the GPO, government or covered entity purchase price and the wholesale distributor purchase price of WAC will be charged back to the Company. The Company estimates the amount in chargebacks based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Estimated chargebacks are recorded as contra accounts receivable on the balance sheet.
- Rebates:** The Company is or may become subject to negotiated discount obligations to different GPO, direct purchasers, other commercial organizations or government programs. The rebate amounts for these programs are determined by statutory requirements or contractual arrangements. Rebates are owed after the product has been dispensed to an end user and the Company has been invoiced. Rebates are typically invoiced in arrears. The Company's liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter based on expected product utilization, and estimated future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel at the end of each reporting period. Rebate estimates are recorded as accrued expenses on the balance sheet.
- Volume Incentive Rebates:** The Company is subject to negotiated volume incentive rebates based on predetermined volume levels and payable per the terms in the customer contracts. The Company estimates and records volume incentive rebates based on anticipated purchase volume with specific customers based on communications with the customer. Volume incentive rebates are recorded as accrued expenses on the balance sheet. See Note 4 – Accrued Expenses.

**Provisions for the revenue reserves described above totaled \$6,598,000 and \$6,792,000 for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, total reserves and allowances to accounts receivable on the balance sheet associated with variable consideration were \$6,753,000.**

**License Agreement**

The Company's rights under the License and Assignment Agreement with ND Partners, LLP are capitalized and stated at cost and amortizes using the straight-line method over estimated economic life of the intangible asset. The Company will amortize the intangible asset over its useful life, based on its assessment of various factors impacting estimated useful lives and cash flows of the acquired rights. Such factors include the launch date of DefenCath, the strength of the intellectual property protection of DefenCath and various other competitive, developmental and regulatory considerations, and contractual terms. See Note 5 – Commitments and Contingencies for further discussion.

**Leases**

Operating leases are included in operating lease right-of-use ("ROU") assets, current portion of operating lease liabilities, and operating lease liabilities, net of current portion, on the consolidated balance sheet (see Note 7). Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

The Company has elected, as an accounting policy, not to apply the recognition requirements in ASC 842 to short-term leases. Short-term leases are leases that have a term of 12 months or less and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes the lease payments for short-term leases on a straight-line basis over the lease term.

The Company has also elected, as a practical expedient, by underlying class of asset, not to separate lease components from non-lease components and, instead, account for them as a single component.

**<b><i>Loss Per Common Share</i></b>**

The Company's basic loss per common share excludes dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period. The weighted average number of common shares outstanding during the period included 2,500,625 shares underlying outstanding pre-funded warrants. Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company.

The Company's outstanding shares of Series F preferred stock entitle the holders to receive dividends on a basis equivalent to the dividends paid to holders of common stock. As a result, the Series F preferred stock meet the definition of participating securities requiring the application of the two-class method. Under the two-class method, earnings available to common shareholders, including both distributed and undistributed earnings, are allocated to each class of common stock and participating securities according to dividends declared and participating rights in undistributed earnings, which may cause diluted earnings per share to be more dilutive than the calculation using the treasury stock method. No loss has been allocated to these participating securities since they do not have contractual obligations that require participation in the Company's losses.

Since the Company has only incurred losses, potentially dilutive securities are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive, and therefore basic and diluted loss per share are the same for all periods presented. The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect.

|                                                            | September 30, 2024 | September 30, 2023 |
|------------------------------------------------------------|--------------------|--------------------|
| (Number of Shares of Common Stock Issuable)                | 2,500,625          | 2,500,625          |
| Series C-3 non-voting preferred stock                      | 4,000              | 4,000              |
| Series E non-voting preferred stock                        | 5,004,069          | 5,004,069          |
| Shares issuable for payment of deferred board compensation | 48,909             | 48,909             |
| Shares underlying outstanding stock options                | 7,675,277          | 5,876,007          |
| Shares underlying restricted stock units                   | 1,5pt              | 1,5pt              |
| Total potentially dilutive shares                          | 303,994            | 11,428,673         |

Stock-based compensation cost is measured at grant date, based on the estimated fair value of the award using the Black-Scholes option pricing model for options with service or performance-based conditions. Stock-based compensation is recognized as expense over the requisite service period on a straight-line basis or when the achievement of the performance condition is probable.

**<b><i>Research and Development</i></b>**

Research and development include fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated executive, human resources and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial and the invoices received from its external service providers. As actual costs become known, the Company adjusts its accruals in the period when actual costs become known. Costs related to the acquisition of technology rights and patents for which development work is still in process are charged to operations as incurred and considered a component of research and development expense.

**<b><i>Recent Accounting Pronouncements</i></b>**

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe the adoption of recently issued standards have or may have a material impact on its consolidated financial statements or disclosures.

**ASU No. 2023-09**

In December 2023, the FASB issued Accounting Standards Update ("ASU") No. 2023-09, "Income Taxes - Improvements to Income Tax Disclosures" (Topic 740). The standard requires disaggregation of the effective rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. The standard will be effective for CorMedix beginning in annual reporting period ending December 31, 2025, with early adoption permitted. CorMedix is currently assessing the impact of adopting this guidance on its consolidated financial statements.

**ASU No. 2023-07**

In November 2023, the FASB issued ASU No. 2023-07, "Segment Reporting - Improving Reportable Segment Disclosures" (Topic 280). The standard requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker ("CODM"), a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. The standard is effective for CorMedix beginning in annual reporting period ending December 31, 2024 and interim periods beginning in fiscal year 2025, with early adoption permitted and requires retrospective application to all prior periods presented in the financial statements. CorMedix is currently assessing the impact of adopting this guidance on its consolidated financial statements.

**Liquidity and Uncertainties**

The condensed consolidated financial statements have been prepared in conformity with GAAP which contemplate continuation of the Company as a going concern. To date, the Company's commercial operations have not generated sufficient revenues to enable profitability. The Company's current commercial and development expenses for DefenCath and its other operating requirements are expected to be funded for at least twelve months from the issuance of this Quarterly Report on Form 10-Q by the Company's existing cash, cash equivalents and short-term investments at September 30, 2024 and its expected liquidity from commercial operations.

The Company may raise additional capital through various potential sources, such as equity and/or debt financing, strategic relationships, potential strategic transactions and/or out-licensing. Management can provide no assurances that such financing or strategic relationships will be available on acceptable terms, or at all. As of September 30, 2024, approximately \$36,012,000 of the Company's common stock remains available for sale under the 2024 ATM program, with \$100,000,000 of remaining capacity under the 2024 Shelf Registration Statement for the issuance of Company securities (see Note 6).

The Company's operations are subject to a number of other factors that can affect its operating results and cash flow projections over the next twelve months from the issuance of these financial statements. Such factors include, but are not limited to: the ability to market DefenCath and generate necessary revenue in the time periods required; ability to manufacture successfully; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company products; the Company's ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; and the Company's ability to raise capital to support its operations.

36012000 100000000

**Use of Estimates**

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Company's consolidated balance sheets and the reported amounts of revenue and expenses reported for each of the periods presented are affected by estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from those estimates.

Certain reclassifications were made to the prior year's amounts to conform to the 2024 presentation.

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant

intercompany accounts and transactions have been eliminated in consolidation.

**Trade Accounts Receivable and Allowances**

The Company complies with ASU 2016-13, **Measurement of Credit Losses on Financial Instruments**, which requires the Company to recognize an allowance that reflects a current estimate of credit losses expected to be incurred over the life of a financial asset, including trade receivables. The allowance for credit losses reflects the best estimate of expected credit losses of the accounts receivable portfolio determined on the basis of current information, forecasts of future economic conditions, industry knowledge and to some extent our historical experience. The Company determines its allowance methodology by pooling receivable balances at the customer level. The Company considers various factors, including individual credit risk associated with each customer, the current and future condition of the general economy and industry knowledge. These credit risk factors are monitored on a quarterly basis and updated as necessary. To the extent any individual debtor is identified whose credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of such customer. The Company makes concerted efforts to collect all outstanding balances due, however account balances are charged off against the allowance when management believes it is probable the receivable will not be recovered. The Company does not have any off-balance sheet credit exposure related to its customers. There are no significant allowances recorded for credit losses as of September 30, 2024.

**Concentrations**

The major customers of the Company are defined as those constituting greater than 10% of its total revenue. In the three and nine months ended September 30, 2024, the Company had sales to one customer that accounted for 98% and 92% of its total revenue of \$11,456,000 and \$12,262,000, respectively. This customer also accounts for 100% of the Company's accounts receivable as of September 30, 2024. The Company currently has one FDA approved source for each of its two key active pharmaceutical ingredients for DefenCath, taurolidine and heparin sodium.

**Financial Instruments**

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, short-term investments and accounts receivable. The Company maintains its cash and cash equivalents in bank deposit and other interest-bearing accounts, the balances of which, at times, may exceed federally insured limits.

The following table is the reconciliation of the accounting standard that modifies certain aspects of the recognition, measurement, presentation and disclosure of financial instruments as shown on the Company's consolidated statement of cash flows:

|                                                  | September 30, |            |
|--------------------------------------------------|---------------|------------|
| Cash and cash equivalents                        | 2024          | 2023       |
| Restricted cash                                  | 105,084       | 105,084    |
| Total cash, cash equivalents and restricted cash | 35,391,222    | 35,391,222 |
| Unrealized gains                                 | 23,021,807    | 23,021,807 |
| Unrealized losses                                | 23,021,807    | 23,021,807 |
| Gross unrealized gains                           | 23,021,807    | 23,021,807 |
| Unrealized losses                                | 23,021,807    | 23,021,807 |
| Fair value                                       | 23,021,807    | 23,021,807 |

The appropriate classification of marketable securities is determined at the time of purchase and reevaluated as of each balance sheet date. Investments in marketable debt classified as available-for-sale are reported at fair value. Fair value is determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are considered temporary are reported in other comprehensive income. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense). The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. There were no deemed permanent impairments at September 30, 2024 or December 31, 2023.

The Company's marketable securities are highly liquid and consist of U.S. government agency securities, high-grade corporate obligations and commercial paper with original maturities of more than 90 days. As of September 30, 2024 and December 31, 2023, all of the Company's investments had contractual maturities of less than one year. The following table summarizes the amortized cost, unrealized gains and losses and the fair value at September 30, 2024 and December 31, 2023:

|                        | September 30, 2024 | December 31, 2023 |
|------------------------|--------------------|-------------------|
| Amortized Cost         | 23,021,807         | 23,021,807        |
| Unrealized Gains       | 23,021,807         | 23,021,807        |
| Unrealized Losses      | 23,021,807         | 23,021,807        |
| Gross Unrealized Gains | 23,021,807         | 23,021,807        |
| Unrealized Losses      | 23,021,807         | 23,021,807        |
| Fair Value             | 23,021,807         | 23,021,807        |

**Money Market Funds included in Cash Equivalents**

Commercial Paper

December 31, 2023

Subtotal

Money Market Funds included in Cash Equivalents

December 31, 2023

[illegible]

[illegible]

[illegible]

[illegible]

customer at the time of the initial sale (when recognition of revenue is deferred due to the anticipated return). Estimated product returns are recorded as accrued expenses on the balance sheet.

**Chargebacks** – Certain covered entities, group purchasing organizations (“GPO”) and government entities will be able to purchase the product at a price discounted below wholesaler acquisition cost (“WAC”). The difference between the GPO, government or covered entity purchase price and the wholesale distributor purchase price of WAC will be charged back to the Company. The Company estimates the amount in chargebacks based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Estimated chargebacks are recorded as contra accounts receivable on the balance sheet.

**Rebates** – The Company is or may become subject to negotiated discount obligations to different GPO, direct purchasers, other commercial organizations or government programs. The rebate amounts for these programs are determined by statutory requirements or contractual arrangements. Rebates are owed after the product has been dispensed to an end user and the Company has been invoiced. Rebates are typically invoiced in arrears. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter based on expected product utilization, and estimated future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel at the end of each reporting period. Rebate estimates are recorded as accrued expenses on the balance sheet.

**Volume Incentive Rebates** – The Company is subject to negotiated volume incentive rebates with certain direct and indirect customers (primarily outpatient service providers). Rebates are owed based on predetermined volume levels and payable per the terms in the customer contracts. The Company estimates and records volume incentive rebates based on anticipated purchase volume with specific customers based on communications with the customer. Volume incentive rebates are recorded as accrued expenses on the balance sheet. See Note 4 – Accrued Expenses.

**Provisions for the revenue reserves described above totaled \$6,598,000 and \$6,792,000 for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, total reserves and allowances to accounts receivable on the balance sheet associated with variable consideration were \$6,753,000.**

**License Agreement**

The Company’s rights under the License and Assignment Agreement with ND Partners, LLP are capitalized and stated at cost and amortized using the straight-line method over estimated economic life of the intangible asset. The Company will amortize the intangible asset over its useful life, based on its assessment of various factors impacting estimated useful lives and cash flows of the acquired rights. Such factors include the launch date of DefenCath, the strength of the intellectual property protection of DefenCath and various other competitive, developmental and regulatory considerations, and contractual terms. See Note 5 – Commitments and Contingencies for further discussion.

**Leases**

The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and operating lease liabilities, net of current portion, on the consolidated balance sheet (see Note 7).

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

The Company has elected, as an accounting policy, not to apply the recognition requirements in ASC 842 to short-term leases. Short-term leases are leases that have a term of 12 months or less and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes the lease payments for short-term leases on a straight-line basis over the lease term.

The Company has also elected, as a practical expedient, by underlying class of asset, not to separate lease components from non-lease components and, instead, account for them as a single component.

**Loss Per Common Share**

Basic loss per common share excludes dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period. The weighted average number of common shares outstanding during the period included 2,500,625 shares underlying outstanding pre-funded warrants. Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company.

The Company’s outstanding shares of Series E preferred stock entitle the holders to receive dividends on a basis equivalent to the dividends paid to holders of common stock. As a result, the Series E preferred stock meet the definition of participating securities requiring the application of the two-class method. Under the two-class method, earnings available to common shareholders, including both distributed and undistributed earnings, are allocated to each class of common stock and participating securities according to dividends declared and participating rights in undistributed earnings, which may cause diluted earnings per share to be more dilutive than the calculation using the treasury stock method. No loss has been allocated to these participating securities since they do not have contractual obligations that require participation in the Company’s losses.

Since the Company has only incurred losses, potentially dilutive securities are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive, and therefore basic and diluted loss per share are the same for all periods presented. The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect.

|                                                            | September 30, | September 30, |
|------------------------------------------------------------|---------------|---------------|
|                                                            | 2024          | 2023          |
| Series C-3 non-voting preferred stock                      | 4,000         | 4,000         |
| Series E non-voting preferred stock                        | 391,953       | 391,953       |
| Series G non-voting preferred stock                        | 5,004,069     | 5,004,069     |
| Shares issuable for payment of deferred board compensation | 48,909        | 48,909        |
| Shares underlying outstanding stock options                | 7,675,277     | 5,876,007     |
| Total potentially dilutive shares                          | 3,033,994     | 13,428,202    |
| Weighted average common shares outstanding                 | 2,500,625     | 2,500,625     |

The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect.

[illegible]

**fact-144**

|                                                                        |                   |
|------------------------------------------------------------------------|-------------------|
| Accrued payroll and payroll taxes                                      | 2,718,770         |
| Manufacturing related                                                  | 3,037,736         |
| Professional and consulting fees                                       | 1,835,101         |
| License agreement payable (see Note 5 – Commitments and Contingencies) | 2,000,000         |
| Other                                                                  | 191,995           |
| <b>Total</b>                                                           | <b>16,973,677</b> |

Accrued expenses consist of the following:

|                                                                        |                   |
|------------------------------------------------------------------------|-------------------|
| December 31, 2023                                                      | December 31, 2022 |
| Accrued gross-to-net deductions                                        | 6,371,043         |
| Accrued payroll and payroll taxes                                      | 4,788,529         |
| Manufacturing related                                                  | 2,718,770         |
| Professional and consulting fees                                       | 1,835,101         |
| License agreement payable (see Note 5 – Commitments and Contingencies) | 2,000,000         |
| Other                                                                  | 191,995           |
| <b>Total</b>                                                           | <b>16,973,677</b> |

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about October 13, 2021, the United States District Court for the District of New Jersey consolidated into *In re CorMedix Inc. Securities Litigation*, Case No. 2:21-cv-14020-JXN-CLW, two putative class action lawsuits filed on or about July 22, 2021 and September 13, 2021, respectively, and appointed lead counsel and lead plaintiff, a purported stockholder of the Company. The lead plaintiff filed a consolidated amended class action complaint on December 14, 2021, alleging violations of Sections 10(b) and 20(a) of the Exchange Act, along with Rule 10b-5 promulgated thereunder, and Sections 11 and 15 of the Securities Act of 1933. On October 10, 2022, the lead plaintiff filed a second amended consolidated complaint that superseded the original complaints in *In re CorMedix Securities Litigation*. On March 21, 2024, the court denied Defendant's motion to dismiss without prejudice and granted lead plaintiff leave to amend the complaint. On April 22, 2024, lead plaintiff filed a third amended consolidated complaint that superseded the second amended consolidated complaint. In the third amended complaint, the lead plaintiff seeks to represent a class of shareholders who purchased or otherwise acquired CorMedix securities between October 16, 2019 and August 8, 2022, inclusive. The third amended complaint names as defendants the Company and six (6) current and former officers of CorMedix, namely Khoso Baluch, Robert Cook, Matthew David, Phoebe Mounts, John L. Armstrong, and Joseph Todisco (the "Officer Defendants" and collectively with CorMedix, the "CorMedix Defendants"). The third amended complaint alleges that the CorMedix Defendants violated Section 10(b) of the Exchange Act (and Rule 10b-5) and that the Officer Defendants violated Section 20(a). In general, the purported bases for these claims are allegedly false and misleading statements and omissions related to the NDA submissions to the FDA for DefenCath, subsequent complete response letters, as well as communications from the FDA related and directed to the Company's contract manufacturing organization and heparin supplier. The Company intends to vigorously contest such claims. The Company filed its motion to dismiss the third amended complaint on June 6, 2024, and received from Plaintiffs their opposition to the Company's motion to dismiss on July 22, 2024. The Company filed its response on August 21, 2024.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about October 13, 2021, a purported shareholder, derivatively and on behalf of the Company, filed a shareholder derivative complaint in the United States District Court for the District of New Jersey, in a case entitled *Voter v. Baluch et al.*, Case No. 2:21-cv-18493-JXN-LDW (the "Derivative Litigation"). The complaint names as defendants Khoso Baluch, Janet Dillione, Alan W. Dunton, Myron Kaplan, Steven Lefkowitz, Paulo F. Costa, Greg Duncan, Matthew David, Phoebe Mounts and Joseph Todisco along with the Company as Nominal Defendant. The complaint alleges breaches of fiduciary duties, abuse of control, and waste of corporate assets against the defendants and a claim for contribution for purported violations of Sections 10(b) and 21D of the Exchange Act against certain defendants. The individual defendants intend to vigorously contest such claims. On January 21, 2022, pursuant to a stipulation between the parties, the Court entered an order staying the case while the motion to dismiss the class action lawsuit described in the foregoing paragraph is pending. The stay may be terminated before the motion to dismiss is resolved according to certain circumstances described in the stipulation available on the Court's public docket.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about January 13, 2023, another purported shareholder, derivatively and on behalf of the Company, filed a shareholder derivative complaint in the United States District Court for the District of New Jersey, in a case entitled *DeSalvo v. Costa et al.*, Case No. 2:23-cv-00150-JXN-CLW. Defendants Paulo F. Costa, Janet D. Dillione, Greg Duncan, Alan Dunton, Myron Kaplan, Steven Lefkowitz, Joseph Todisco, Khoso Baluch, Robert Cook, Matthew David, Phoebe Mounts, and John L. Armstrong along with the Company as Nominal Defendant. The complaint alleges breaches of fiduciary duty and unjust enrichment against the individual defendants.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about January 25, 2023, another purported shareholder, derivatively and on behalf of the Company, filed a shareholder derivative complaint in the United States District Court for the District of New Jersey, in a case entitled *Scullion v. Baluch et al.*, Case No. 2:23-cv-00406-ES-ESK. Defendants Khoso Baluch, Janet Dillione, Alan W. Dunton, Myron Kaplan, Steven Lefkowitz, Paulo F. Costa, Gregory Duncan, Matthew David, and Phoebe Mounts, along with the Company as Nominal Defendant. The complaint alleges breaches of fiduciary duties.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about April 18, 2023, the Court entered an order consolidating the above-mentioned shareholder derivative complaints for all purposes, including pretrial proceedings, trial and appeal. The consolidated derivative action is entitled, *In re CorMedix Inc. Derivative Litigation*, C.A. No. 2:21-cv-18493-JXN-LDW. The individual defendants intend to vigorously contest the claims set forth in the consolidated derivative action. The provisions of the Order to Stay entered in the *Voter* Action on January 21, 2022, apply to the consolidated derivative action. On April 20, 2023, the consolidated derivative action was administratively terminated and removed from the Court's docket until the motion to dismiss the class action is resolved and the Private Securities Litigation Reform Act, or PSRA, stay is lifted. On April 22, 2024, the lead plaintiff in the class action filed a third amended complaint. The class action remains stayed under the PSRA.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about June 23, 2022, the Company's Board received a letter demanding it investigate and pursue causes of action, purportedly on behalf of the Company, against certain current and former directors, officers, and/or other employees of the Company (the "Letter"), which the Board believes are duplicative of the claims already asserted in the Derivative Litigation. As set forth in the Board's response to the Letter, the Board will consider the Letter at an appropriate time, as circumstances warrant, as it continues to monitor the progress of the Derivative Litigation.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about June 23, 2022, the Company's Board received a letter demanding it investigate and pursue causes of action, purportedly on behalf of the Company, against certain current and former directors, officers, and/or other employees of the Company (the "Letter"), which the Board believes are duplicative of the claims already asserted in the Derivative Litigation. As set forth in the Board's response to the Letter, the Board will consider the Letter at an appropriate time, as circumstances warrant, as it continues to monitor the progress of the Derivative Litigation.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about June 23, 2022, the Company's Board received a letter demanding it investigate and pursue causes of action, purportedly on behalf of the Company, against certain current and former directors, officers, and/or other employees of the Company (the "Letter"), which the Board believes are duplicative of the claims already asserted in the Derivative Litigation. As set forth in the Board's response to the Letter, the Board will consider the Letter at an appropriate time, as circumstances warrant, as it continues to monitor the progress of the Derivative Litigation.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about June 23, 2022, the Company's Board received a letter demanding it investigate and pursue causes of action, purportedly on behalf of the Company, against certain current and former directors, officers, and/or other employees of the Company (the "Letter"), which the Board believes are duplicative of the claims already asserted in the Derivative Litigation. As set forth in the Board's response to the Letter, the Board will consider the Letter at an appropriate time, as circumstances warrant, as it continues to monitor the progress of the Derivative Litigation.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about June 23, 2022, the Company's Board received a letter demanding it investigate and pursue causes of action, purportedly on behalf of the Company, against certain current and former directors, officers, and/or other employees of the Company (the "Letter"), which the Board believes are duplicative of the claims already asserted in the Derivative Litigation. As set forth in the Board's response to the Letter, the Board will consider the Letter at an appropriate time, as circumstances warrant, as it continues to monitor the progress of the Derivative Litigation.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about June 23, 2022, the Company's Board received a letter demanding it investigate and pursue causes of action, purportedly on behalf of the Company, against certain current and former directors, officers, and/or other employees of the Company (the "Letter"), which the Board believes are duplicative of the claims already asserted in the Derivative Litigation. As set forth in the Board's response to the Letter, the Board will consider the Letter at an appropriate time, as circumstances warrant, as it continues to monitor the progress of the Derivative Litigation.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about June 23, 2022, the Company's Board received a letter demanding it investigate and pursue causes of action, purportedly on behalf of the Company, against certain current and former directors, officers, and/or other employees of the Company (the "Letter"), which the Board believes are duplicative of the claims already asserted in the Derivative Litigation. As set forth in the Board's response to the Letter, the Board will consider the Letter at an appropriate time, as circumstances warrant, as it continues to monitor the progress of the Derivative Litigation.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about June 23, 2022, the Company's Board received a letter demanding it investigate and pursue causes of action, purportedly on behalf of the Company, against certain current and former directors, officers, and/or other employees of the Company (the "Letter"), which the Board believes are duplicative of the claims already asserted in the Derivative Litigation. As set forth in the Board's response to the Letter, the Board will consider the Letter at an appropriate time, as circumstances warrant, as it continues to monitor the progress of the Derivative Litigation.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about June 23, 2022, the Company's Board received a letter demanding it investigate and pursue causes of action, purportedly on behalf of the Company, against certain current and former directors, officers, and/or other employees of the Company (the "Letter"), which the Board believes are duplicative of the claims already asserted in the Derivative Litigation. As set forth in the Board's response to the Letter, the Board will consider the Letter at an appropriate time, as circumstances warrant, as it continues to monitor the progress of the Derivative Litigation.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about June 23, 2022, the Company's Board received a letter demanding it investigate and pursue causes of action, purportedly on behalf of the Company, against certain current and former directors, officers, and/or other employees of the Company (the "Letter"), which the Board believes are duplicative of the claims already asserted in the Derivative Litigation. As set forth in the Board's response to the Letter, the Board will consider the Letter at an appropriate time, as circumstances warrant, as it continues to monitor the progress of the Derivative Litigation.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about June 23, 2022, the Company's Board received a letter demanding it investigate and pursue causes of action, purportedly on behalf of the Company, against certain current and former directors, officers, and/or other employees of the Company (the "Letter"), which the Board believes are duplicative of the claims already asserted in the Derivative Litigation. As set forth in the Board's response to the Letter, the Board will consider the Letter at an appropriate time, as circumstances warrant, as it continues to monitor the progress of the Derivative Litigation.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about June 23, 2022, the Company's Board received a letter demanding it investigate and pursue causes of action, purportedly on behalf of the Company, against certain current and former directors, officers, and/or other employees of the Company (the "Letter"), which the Board believes are duplicative of the claims already asserted in the Derivative Litigation. As set forth in the Board's response to the Letter, the Board will consider the Letter at an appropriate time, as circumstances warrant, as it continues to monitor the progress of the Derivative Litigation.

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in

On or about June 23, 2022, the Company's Board received a letter demanding it investigate and pursue causes of

[illegible]

aggregate of 120,000 and 2,021,200 shares, respectively, and the weighted average exercise price of these options is \$3.90 and \$4.40 per share, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three and nine months ended September 30, 2024, the Company issued 322,334 and 371,499 shares of common stock, respectively, as a result of the exercise of stock options. The Company realized net proceeds of \$1,708,000 and \$1,894,000 from these exercises for the three and nine months ended September 30, 2024, respectively. During the three and nine months ended September 30, 2023, the Company issued 6,666 and 64,041 shares of common stock, respectively, as a result of the exercise of stock options. The Company realized net proceeds of \$20,000 and \$254,000 from these exercises for the three and nine months ended September 30, 2023, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequent to September 30, 2024, through the filing of this Quarterly Report on Form 10-Q for the period ended September 30, 2024, the Company issued 289,430 shares of common stock as a result of the exercise of stock options, from which the Company realized net proceeds of approximately \$2,123,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three and nine months ended September 30, 2024, stock-based compensation expense for stock options issued to employees, directors, officers and consultants was \$1,120,000 and \$4,352,000, respectively, and \$950,000 and \$4,069,000 for the three and nine months ended September 30, 2023, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2024, there was approximately \$7,470,000 in total unrecognized compensation expense related to stock options granted, which will be recognized over an expected remaining weighted average period of 1.4 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of each stock option award estimated on the grant date is determined using the Black-Scholes option pricing model. The following assumptions were used for the Black-Scholes option pricing model for the stock options granted during the nine months ended September 30, 2024:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: left">Expected term (in years)</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">5.99</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right">4.15</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right">3.00</td><td style="text-align: left"></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company uses the simplified method to calculate the expected term which takes into account the vesting term and the expiration date of the stock options. The expected term of the stock options granted to consultants, if any, is based upon the full term of the respective option agreements. The expected stock price volatility for the Company's stock options is calculated based on the historical volatility of the Company's stock price for the expected term. The expected dividend yield of 0% reflects the Company's current and expected future policy for dividends on the Company's common stock. To determine the risk-free interest rate, the Company utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of the Company's awards.</p>7500000 2500625 1500093 7500000 4 2500625 3.999 37300000 1500093 4 5600000 2500625 15000000 50000000 0.03 36012000 100000000 2290024 2521121 12367000 13376000 2866421 12515000 283333 3.47 0.25 0.25 0.25 0.25 42044 0.25 27989 62241 103734 35259 66291 26982 37443 303994 107000 583000 53000 207000 778000 P1Y7M6D 2000000 The Company's board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. Of the 2,000,000 shares of preferred stock authorized, the Company's board of directors has designated (all with par value of \$0.001 per share) the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;><tr style="vertical-align: bottom;"><td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="10" style="border-bottom: 1px solid black; text-align: center">As of September 30, 2024 and<br>December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr style="vertical-align: bottom"><td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="border-bottom: 1px solid black; text-align: center">Preferred<br>Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: 1px solid black; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td colspan="2" style="border-bottom: 1px solid black; text-align: center">Black 1.5pt solid; font-weight: bold; text-align: center">Liquidation<br>Preference<br>(Per Share)</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="border-bottom: 1px solid black; text-align: center">Total<br>Liquidation<br>Preference</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 64%">Series C</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">2,000</td><td style="width: 1%; text-align: left"></td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">10.00</td><td style="width: 1%; text-align: left"></td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">20,000</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right">89.623</td><td style="text-align: left"></td><td style="text-align: left"></td><td style="text-align: left"></td><td style="text-align: right">49.20</td><td style="text-align: left"></td><td style="text-align: left"></td><td style="text-align: right">4,409,452</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 1.5pt">Series G</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: 1px solid black; text-align: right">89,999</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="padding-bottom: 1.5pt; text-align: right">187.36</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="border-bottom: 1px solid black; text-align: right">16,862,213</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: 1px solid black; text-align: right">21,291,665</td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr></table>2000000 0.001 2000 2000 10 10 20000 20000 89623 89623 49.2 49.2 4409452 4409452 89999 89999 187.36 187.36 16862213 16862213 181622 21291665 21291665 132500 276167 5.72 3.75 120000 2021200 3.9 4.4 322334 371499 1708000 1894000 6666 64041 20000 254000 289430 2123000 1120000 4352000 950000 4069000 7470000 P1Y4M24D The fair value of each stock option award estimated on the grant date is determined using the Black-Scholes option pricing model. The following assumptions were used for the Black-Scholes option pricing model for the stock options granted during the nine months ended September 30, 2024:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: left">Expected term (in years)</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">5.99</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right">4.15</td><td style="text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left"></td><td style="text-align: right"></td><td style="text-align: left"></td><td style="text-align: right">3.00</td><td style="text-align: left"></td></tr></table>P5Y11M26D 0.9885 0 0.0415 3 0<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 7 – Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company entered into a seven-year operating lease agreement in March 2020 for an office space at 300 Connell Drive, Berkeley Heights, New Jersey 07922. The lease agreement, with a monthly average cost of approximately \$17,000, commenced on September 16, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company entered into an operating lease for its office space in Germany that began in July 2017 and terminated in June 2024. The agreement had a monthly cost of 400 Euros.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operating lease expense in the Company's condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 was approximately \$51,000 and \$153,000, respectively, and \$52,000 and \$155,000 for the three and nine months ended September 30, 2023, respectively, which includes costs associated with leases for which ROU assets have been recognized as well as short-term leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At September 30, 2024, the Company has a total operating lease liability of \$556,000, of which \$163,000 was classified as operating lease liabilities, short-term and \$393,000 was classified as operating lease liabilities, net of current portion, on the condensed consolidated balance sheet. At December 31, 2023, the Company's total operating lease liability was \$668,000, of which \$151,000 was classified as operating lease liabilities, short-term and \$517,000 was classified as operating lease liabilities, net of current portion, on the condensed consolidated balance sheet. Operating ROU assets as of September 30, 2024 and December 31, 2023 were \$531,000 and \$640,000, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For each of the three and nine months ended September 30, 2024, cash paid for amounts included in the measurement of lease liabilities in operating cash flows from operating leases was \$51,000 and \$153,000, respectively, and \$50,000 and \$150,000 for the three and nine months ended September 30, 2023, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The weighted average remaining lease term as of September 30, 2024 and 2023 was 3.0 and 4.1 years, respectively, and the weighted average discount rate for operating leases was 9% at September 30, 2024 and 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024, maturities of lease liabilities were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 89%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024 (excluding the nine months ended September 30, 2024)</span></td><td style="width: 1%"></td><td style="width: 1%"></td><td style="width: 1%"></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr></table>

[illegible]